

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

INDEX

VOLUME 24
2004

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

VOLUME 24

2004

Editorial Board

F. A. Anderer	Friedrich-Miescher-Laboratorium der Max-Planck-Gesellschaft, Tübingen, Germany
J. P. Armand	Institut Gustav-Roussy, Villejuif, France
D. Assimakopoulos	Dept. Otorhinolaryngology, Medical School, University of Ioannina, Greece
V. I. Avramis	Div. Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
R. C. Bast	Dept. of Translational Research, Univ. of Texas M.D. Anderson Cancer Ctr., Houston, TX, USA
G. Bauer	Abteilung Virologie, Inst. f. Med. Microbiol. u. Hygiene, Freiburg, Germany
E. E. Baulieu	Département de Chimie Biologique, Université de Paris Sud, Bicetre, France
Y. Becker	Department of Molecular Virology, Hebrew University of Jerusalem, Israel
J. Bergh	Dept. of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Inst., Stockholm, Sweden
J. L. Biedler	Memorial Sloan-Kettering Cancer Center, New York, NY, USA
D. D. Bigner	Department of Pathology, Duke University Medical Center, Durham, NC, USA
A. Böcking	Institute for Cytopathology, University of Düsseldorf, Germany
G. Bonadonna	Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
G. Bounous	Montreal General Hospital, Montreal, Québec, Canada
G. Broich	ASL Lodi, Lodi, Italy
J. M. Brown	Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA
Ø. S. Bruland	Dept. Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cardinal Bernardin Cancer Ctr, Loyola Univ. Medical Center, Maywood, IL, USA
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Dept. Oncology, London Regional Cancer Center, London, Ont., Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
C. A. Cudennec	Laboratoires Jacques Logeais, Issy-Les-Moulineaux, France
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. De Loecker	Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
P.H.M. De Mulder	Department of Medical Oncology, University Medical Center, Nijmegen, The Netherlands
W. Den Otter	Div. of Cell Biology and Histology, Dept. of Biochemistry, Utrecht University, The Netherlands
E.P. Diamandis	Dept. of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto Ont., Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
W. Ebert	Thoraxclinic HD-Rohrbach, Heidelberg, Germany
U. Eppenberger	Laboratory of Biochemistry/Endocrinology, University Clinic, Basel, Switzerland
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	M. D. Anderson Hospital and Tumor Institute, Texas Medical Center, Houston, TX, USA
W. Fiers	Institute of Biotechnology, Flanders Interuniversity, University of Gent, Belgium
N. E. Fusenig	Institut für Biochemie, Deutsches Krebsforschungszentrum, Heidelberg, Germany
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
A. F. Gazdar	Hamon Ctr for Therapeutic Oncology Research, Univ. of Texas Southeastern Medical Center, Dallas, TX, USA
A. Giordano	Sbarro Inst. for Cancer Research, Temple Univ., Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
R. H. Goldfarb	Sopherion Therapeutics, Inc., New Haven, CT, USA
J. W. Gorrod	Toxicology Unit, University of Essex, UK
S. Hammarström	Department of Immunology, University of Umeå, Sweden
I. Hellström	Pacific Northwest Research Institute, Seattle, WA, USA
L. Helson	Department of Experimental Therapeutics, New York Medical College, Valhalla, NY, USA
R. B. Herberman	Pittsburgh Cancer Institute, Pittsburgh, PA, USA
R. M. Hoffman	Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA

- C. G. Ioannides** Department of Gynecology, M. D. Anderson Cancer Center, Houston, TX, USA
- M. Ishizuka** Institute of Cancer Research, Shizuoka, Japan
- S. C. Jhanwar** Lab. of Solid Tumor Genetics, Dept. of Medicine, Memorial Sloan-Kettering Cancer Ctr, New York, NY, USA
- J. V. Johannessen** Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
- B. Kaina** Institute of Toxicology, University of Mainz, Germany
- H. E. Kaiser** Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
- B. K. Keppler** School of Medicine, University of Vienna, Austria
- D. G. Kieback** Department of Gynecology and Obstetrics, Academisch Ziekenhuis Maastricht, The Netherlands
- J. Kieler** The Fibiger Institute, Copenhagen, Denmark
- R. Klapdor** Medical Clinic, University of Hamburg, Germany
- U. R. Kleeberg** Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany
- P. Kleihues** International Agency for Research on Cancer, Lyon, France
- E. Klein** Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
- S. von Kleist** Institut für Immunologie der Universität der Freiburg, Germany
- S. Kobayashi** Aichi Sannomaru Hospital, Nagoya, Japan
- A. Koestner** Dept. of Veterinary Pathobiology, Col. of Veterinary Medicine, Ohio State Univ., Columbus, OH, USA
- S. D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- G. R. F. Krueger** Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
- D. W. Kufe** Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
- Pat Kumar** Dept. of Biological Sciences, Manchester Metropolitan Univ., Manchester, UK
- Shant Kumar** Dept. Pathology, University of Manchester Medical School, Manchester, UK
- O. D. Laerum** Department of Pathology, The Gade Institute, University of Bergen, Norway
- F. J. Lejeune** Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
- C. J. Link** Human Gene Therapy Research Institute, Des Moines, IA, USA
- L. A. Liotta** Dept. of Pathology and Lab. Medicine, Div. of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD, USA
- G. Litwack** Jefferson Cancer Institute, Philadelphia, PA, USA
- L. F. Liu** Dept. Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
- D. M. Lopez** Dept. of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
- E. Lundgren** Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
- H. T. Lynch** Dept. of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA
- J. Mark** Department of Pathology, Kärnshjukhuset, Skövde, Sweden
- D. Medina** Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA
- S. Mitra** Sealy Center for Molecular Science, Univ. of Texas Medical Branch, Galveston, TX, USA
- F. M. Muggia** New York University Cancer Institute, School of Medicine, NY, USA
- M. J. Murphy Jr** Hipple Cancer Research Center, Dayton, OH, USA
- R. Narayanan** Dept. Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- K. Nilsson** Department of Pathology, The Wallenberg Laboratory, University of Uppsala, Sweden
- J. F. Novak** Department of Biology, Bucknell University, Lewisburg, PA, USA
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- S. Pestka** Dept. of Molecular Genetics and Microbiology, Univ. of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
- A. Pihl** Department of Biochemistry, Norsk Hydro's Institute for Cancer Research, Oslo, Norway
- G. J. Pilkington** Dept. Cellular & Molec. Neurooncology, School of Pharmacy and Biomedical Sciences, Univ. of Portsmouth, UK
- C.D. Platsoucas** Dept. of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA, USA
- F. Podo** Laboratory of Cell Biology, Istituto Superiore di Sanità, Rome, Italy
- A. Polliack** Department of Hematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- N. Prajda** National Institute of Oncology, Budapest, Hungary
- M. F. Rajewsky** Institut für Zellbiologie, Universität St Essen, Germany

G. Rebel	IRCAD, Hopitaux Universitaires, Strasbourg, France
M. Rigaud	Lab. Biochimie et Génétique Molec., Fac. Médecine de Limoges, France
U. Ringborg	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
M. Roselli	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
F. P. Rossini	Department of Oncology, San Giovanni Hospital, Torino, Italy
G. F. Saunders	Department of Biochemistry and Molecular Biology, University of Texas, Houston, TX, USA
A. Schauer	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
M. Schneider	Dept. of Organic Chemistry, Bergische Univ., Wuppertal, Germany
A. Seth	Lab. of Molec. Pathology, Sunnybrook and Women's College, Health Science Ctr, Toronto, Ont., Canada
A. K. M. Shamsuddin	Dept. of Pathology, University of Maryland Medical School, Baltimore, MD, USA
G. V. Sherbet	Cancer Research Unit, University of Newcastle upon Tyne, UK
G. -I. Soma	Institute for Health Sciences, Tokushima Bunri Univ., Tokushima, Japan
G. S. Stein	Department of Cell Biology, University of Massachusetts Medical Center, Worcester, MA, USA
K. Takagi	Kennan Takagi Clinic, Kumamoto, Japan
H. Tanaka	Department of Biophysics, Institute for Virus Research, Kyoto, Japan
D. Tarin	Univ. of California at San Diego, Cancer Center, La Jolla, CA, USA
G. B. de Thé	Institut Pasteur, Paris, France
T. M. Theophanides	Department of Chemistry, Technical University of Athens, Greece
B. Toth	The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
E. Trelle	Dept. of General Practice and Primary Care, Faculty of Health Sciences, University of Linköping, Sweden
G.P. Tryfiates	Department of Biochemistry, W. Virginia University, Morgantown, WV, USA
P. M. Ueland	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
P.T. Vihko	Department of Clinical Chemistry, University of Oulu, Finland
M. Volm	German Cancer Research Center, Heidelberg, Germany
G. Weber	Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA
I. B. Weinstein	Herbert Irving Comprehensive Cancer Ctr., Columbia University College of Physicians and Surgeons, New York, NY, USA
B. Westermark	Rudbecklaboratoriet, Dept. of Genetics and Pathology, University of Uppsala, Sweden
S. Zimmer	Department of Microbiology and Immunology, University of Kentucky Medical Ctr., Lexington, KY, USA
B. Zumoff	Div. Endocrinology & Metabolism, Beth Israel Medical Center, New York, NY, USA

Acknowledgements

The following Organisations supported many of the works published in Anticancer Research, Volume 24, 2004.

Aarke Cancer Foundation, Tromso, Norway
 Academy of Finland
 ACS Career Development Award
 Agence Nationale pour la Valorisation de la Recherche (ANVAR), France
 Ake Wibergs Stiftelse, Sweden
 Akiben Foundation, USA
 Alexander von Humboldt Foundation, Germany
 Alma Toorock Memorial for Cancer Research, USA
 American Association for Cancer Research AstraZeneca Cancer Research and Prevention Foundation, USA
 American Brain Tumor Association, USA
 American Cancer Society, USA
 American Foundation and Pharmaceutical Education, USA
 American Society of Clinical Oncology, USA
 Antorchas Foundation, Argentina
 APERS, France
 Apotekerfonden af 1991
 Arbeitsgemeinschaft fuer Regionale Tumortherapie, Germany
 Arjay and Frances Miller Brain Tumor Research Fund, USA
 Arvid Nielsson's Fond, Denmark
 Association for Research of Childhood Cancer, USA
 Association pour la Recherche contre le Cancer, France
 Associazione Italiana Ricerca sul Cancro (AIRC), Italy
 AstraZeneca Cancer Research and Prevention Foundation, USA
 Atlantic Philanthropies, Ireland
 Austrian Cancer Aid/Styria
 Austrian National Bank Fund, Austria
 Aventis
 Aventis Pharmaceuticals, Germany
 Aventis Pharmaceuticals, USA
 Awa Bank Foundation for Promotion of Science and Culture, Japan

Basel Cancer League, Switzerland
 Bavarian State Ministry of the Environment, Public Health and Consumer Protection, Munich, Germany
 Bayer Health Care
 Baystate/UMASS Collaborative Research Center, USA
 Beckam Foundation
 Belgian-Hungarian Bilateral (International) Scientific and Technological Cooperation
 Bilkent University, Turkey
 Bioalliance Pharma, France

Bioresearch Ierland and Enterprice, Ireland
 Board for International Higher Education and Research (STINT), Sweden
 Bonner CF-Studie, Germany
 British Medical Association Research Award, UK

Caisse Nationale d' Assurance Maladie des Travailleurs Salaries, France
 California Breast Cancer Research Program, USA
 Canadian Institutes of Health Research, Canada
 Cancer and Allergy Foundation, Sweden
 Cancer Association of South Africa, (CANSA)
 Cancer Council of South Australia
 Cancer Council of Western Australia
 Cancer Leagues of Switzerland
 Cancer Research Institute, Seoul National University College of Medicine, Korea
 Cancer Research, Ireland
 Cancer Research, UK
 Cancer Society of Finland
 Cancer Society of New Zealand
 Cancer Society of North Finland
 Cancer Society of Stockholm, Sweden
 Cancerfoereningen I Stockholm, Sweden
 Cantons of Fribourg and Bern, Switzerland
 CaP CURE
 Catalonia's TV3 Foundation, Spain
 China Medical University Hospital, Taiwan
 China Medical University, Taiwan, ROC
 Chinese State Key Basic Research Project, China
 Civillingenior Bent Bogh og hustru Inge Bogh Fond, Denmark
 Clayton Foundation for Research, USA
 CNR, Italy
 Compagnia di S. Paolo, Italy
 County Council of Jönköping, Sweden
 Cretan Association for Biomedical Research (CABR), Greece

Danish Cancer Society, Denmark
 Danish Hospital Foundation for Medical Research, Denmark
 Danish Kidney Foundation, Denmark
 Danish Medical Research Council, Denmark
 Department of Defense US Army Breast Cancer Research Program, USA
 Department of Health, Executive Yuan, Republic of China

- Department of Veterans Affairs, USA
 Deutsche Forschungsgemeinschaft, Germany
 Deutsche Krebshilfe Dr. Mildred Scheel Foundation, Germany
 Dr. Mildred Scheel Foundation for Cancer Research, Bonn, Germany
 DRRC Saint Etienne, France
 Dublin City University Educational Trust, Ireland
 Dust Diseases Board, Australia
- ECS Brain Tumor Research Fund, USA
 Education and Research Fund of the Department of Cell and Development Biology, State University of New York, USA
 Eli Lilly, Nieuwegein, The Netherlands
 Elsa U. Pardee Foundation
 Else Kroener-Fresenius-Foundation, Bad Homburg v.h. Hoehe, Germany
 Enterprice, Ireland
 Erich-und-Gertrud-Roggenbuck-Stiftung, Germany
 Erik Horslev og hustru Birgit Horslevs Fond, Denmark
 ETT, Hungary
 EU Commission
 Eva and Henry Fraenkel's Memorial Foundation, Denmark
- Faculty of Engineering of the University of Tokushima, Japan
 Faculty of Medicine of the University of Munich, Germany
 Family Planning's Fund, Sweden
 Faroe Islands and Greenland, Denmark
 FCT, Portugal
 FEBS Fellowship
 Federal Ministry for Social Security and Generation, Austria
 Federation Nationale de Lutte contre le Cancer, Comites de l'Herault et de l'Ardeche, France
 Finnish Breast Cancer Group, Finland
 Finnish Cancer Society, Finland
 FKFP, Hungary
 Flinders Technologies Pty. Ltd., Australia
 Fondazione Cassa di Risparmio in Bologna, Italy
 Fondo de Investigacion Sanitaria, Spain
 Fonds de la Recherche Scientifique Medicale, Belgium
 Fonds der Chemischen Industrie, Germany
 Food Animal and Disease Research Program at Auburn University, College of Veterinary Medicine, USA
 Foundation for the Development of the Community, Tochigi, Japan
 Foundation pour la Recherche Medicale du Languedoc Roussillon, France
 FoU-radet, Sweden
 Frances and Augustus Newman Foundation, UK
- Franz Lanyar Foundation, Graz, Austria
 Freda and David Becker Trust, USA
 French Ministry of Research, France
 Fritz-Bender-Stiftung, Germany
 Fukuoka Cancer Society, Japan
 Functional Foods for Health Program, University of Illinois, USA
 FUTURA-Onlus
- G. Nilson Foundation, Sweden
 Gaspar de Portola Program, Spain
 German Cancer Research Foundation DFG, Germany
 Gorthon Fund and Thelma Zoega Foundation, Sweden
 Graduate School of Medical Sciences, Kitasato University, Japan
 Greek Anticancer Institute, Greece
 Greek General Secretary for Research and Technology, Greece
 Groningen University Institute for Drug Exploration (GUIDE), The Netherlands
 Groupement des Entreprises Francaises dans la Lutte contre le Cancer, Grenoble, Dauphine-Savoie, France
 Gustav-Spierling-Stiftung, Germany
- H. Lee Moffitt Cancer Center and Research Institute, USA
 H.W. & J. Hector Stiftung Weinheim, Germany
 Hamburger Stiftung fuer Krebsforschung, Germany
 Harboe Fonden, Denmark
 HEA, Ireland
 Health Research Board of Ireland
 Health Research Council in the South-East Sweden
 Health Research Council of New Zealand
 Health Science Foundation of the Medical University of South Carolina, USA
 Helsinki University Central Hospital, Finland
 Hogskolan i Kristianstad, Sweden
 Houansa Foundation, Japan
 Hungarian Academy of Sciences, Hungary
- I.S.S.C.O
 IBEX Technologies
 Icelandic Cancer Society
 Immune System Disease Research Center of Tokyo Mecal University, Japan
 Inamori Foundation, Japan
 Indiana Clarian Health Value Fund Grant, USA
 International Agency for Research on Cancer
 IRCCS Mondino Institute, Pavia, Italy
 Italian Ministry for Education, University and Research (MIUR), Italy
 Italian Ministry for Instruction, University and Research, (MIUR), Italy
 Italian Ministry for Scientific Research (MURST), Italy

- Japan China Medical Association
 Japan Orthopaedics and Traumatology Foundation Inc.,
 Japan
 Japan Society for the Promotion of Science, Japan
 Josai University, Japan
 Josef-Freitag-Stiftung, Paderborn, Germany
 Junta de Andalucia, Spain
- Karolinska Institute and Hospital, Stockholm, Sweden
 Kentucky Lung Cancer Fund, USA
 King Gustav V Jubilee Fund, Sweden
 Korea Research Foundation
 Korea Science & Engineering Foundation, Korea
 Korean Ministry of Health and Welfare, Seoul, Korea
 Korean Research Foundation, Korea
 Kuopio University Hospital, Finland
- L' Association de la Recherche, contre le Cancer,
 Villejuif, France
 La Ligue Nationale Francaise de Lutte Contre le Cancer,
 France
 La Region Ile de France
 Landeskliniken Salzburg, Austria
 Le Comite du Puy-de-Dome, France
 Leonard S. Lovullo Memorial Fund, USA
 Leopold Kronenberg Foundation, Poland
 Leukemia and Lymphoma Society, USA
 Ligue Departementale contre le Cancer de la Marne, France
 Ligue Nationale de Lutte contre le Cancer, France
 Ligues contre le Cancer de la Marne et des Ardennes,
 France
- MADAUS AG, Cologne, Germany
 Marie Curie Fellowship from the European Union
 Maxim Pharmaceuticals Inc., San Diego, CA, USA
 Medical College of Georgia Research Institute, USA
 Medical Faculty Charite, Humboldt-University Berlin,
 Germany
 Medical University of Warsaw, Poland
 Medizinische Forschungsgesellschaft Salzburg, Austria
 Megumi Medical Foundation, Kanazawa, Japan
 Memorial Fund of Bergthora Magnusdottir and Jakob
 Bjarnason
 MGH Department of Radiation Oncology Alumni Scholar
 Award, USA
 Ministere d' Education Nationale, de la Recherche et de
 la Technologie, France
 Ministerium fuer Umwelt und Forsten/Mainz, Germany
 Ministero dell' Istruzione dell'Universita e della Ricerca,
 Italy
 Ministero della Salute, Italy
 Ministero dell'Universita e della Ricerca Scientifica
 (MURST, COFIN), Italy
- Ministry of Agriculture, Forestry and Fisheries, Japan
 Ministry of Economy, Trade and Technology of Japan
 Ministry of Education, Culture, Sports, Science and
 Technology of Japan
 Ministry of Education, Science and Sport of the Republic
 of Slovenia
 Ministry of Health, Italy
 Ministry of Health, Labour and Welfare for Cancer
 Research, Japan
 Ministry of Health, Social and Family Affairs, Hungary
 Ministry of Science and Technology, Korea
 Ministry of University and Research, Fondo Investimenti
 Ricerca Base (FIRB), Italy
 MIUR-COFIN 2002
 A.P. Moller and Chastine Mc-Kinney Moller Foundation
- National Cancer Institute CA, USA
 National Cancer Institute of Canada
 National Consortium of Oncology, Hungary
 National Foundation for Cancer Research-Center for
 Metastasis Research, USA
 National Health Research Institute of Taiwan, ROC
 National Institute of General Medical Sciences, USA
 National Institute of Health, USA
 National Institutes of Environmental Health Sciences,
 USA
 National Natural Science Foundation of China
 National Research Council, Italy
 National Research Foundation of South Africa
 National Science Council of Taiwan, ROC
 NATO
 Natural Science and Engineering Research Council of
 Canada
 Natural Science Foundation of Guangxi, China
 NeoPharm Inc., USA
 Netherlands Organisation for Scientific Research, (NOW),
 The Netherlands
 Niedersaechsische Krebshilfe, Germany
 NIEHS, USA
 NIH-AIAA, USA
 NIH-CAM, USA
 Nilssons Cancerstiftelse, Sweden
 NKFP, Hungary
 Norwegian Cancer Society
 Norwegian Research Council, Norway
 NSW, Australia
 Numico Research, The Netherlands
- Oesterreichische Krebshilfe, Salzburg, Austria
 Oncogene Science/Bayer Diagnostics, Germany
 Oncogene Science/Bayer Diagnostics, MA, USA
 Oncology Research Foundation of the Greenville
 Hospital System, SC, USA

- Osaka City University Medical Research Foundation,
Japan
- OTKA, Hungary
- Otsuka Pharmaceutical Co., Ltd., Japan
- Overlaege Johan Boserup og Lise Boserups Legat,
Denmark
- Parent's Association Grant of Kitasato University, School
of Medicine, Japan
- Pfizer, USA
- Pharmaceutical Research and Manufacturers of America
- Pharmacia and Astrazeneca, Sweden
- Plant Diversity Research Center of the 21st Century
Frontier Program, Korea
- Polish State Committee for Science, Poland
- PRODEP, Portugal
- Programme for Research in Third Level Institutions,
Ireland
- Quilmes National University, Argentina
- RCSI Research Committee, Ireland
- Region Champagne-Ardenne, France
- Region of Copenhagen, Denmark
- Region Wallonne, Belgium
- Research Council of Norway
- Research Fund of the Faculty of Medicine Mannheim,
Germany
- Research Section of Chung Shan Medical University,
Taiwan, ROC
- Research Section of the China Medical College, Taiwan,
ROC
- Rhone-Poulenc Rorer, USA
- Riley Children's Foundation
- Robert Bosch Foundation, Stuttgart, Germany
- Roche Pharmaceuticals, Austria
- Roswell Park Cancer Center, USA
- Royal Victoria Eye and Ear Hospital, Ireland
- SAMUR (Advanced Studies Urologic Diseases), Italy
- Sanofi-Synthelabo GmbH, Germany
- Science Foundation of the Ministry of Health, P.R. China
- Second-Term Comprehensive 10-year Strategy of Cancer
Control, Japan
- Seidel Family Trust, USA
- Selander's and Family Planning's Foundation in Uppsala,
Sweden
- Selanders Fund, Sweden
- Sigma Xi Grand-in-Aid, USA
- Sigrid Juselius Foundation, Finland
- Special Research Account of the University of Athens,
Greece
- State Committee for Scientific Research of Poland
- State Key Basic Research Program Fundamental
Investigation on Human Carcinogenesis by the Ministry
of Science and Technology of China
- Stavros Niarchos Foundation for Charity, Greece
- Stockholm Cancer Society, Sweden
- Stockholm City Council, Sweden
- Swedish Academy of Science, Sweden
- Swedish Cancer Foundation, Sweden
- Swedish Cancer Society, Sweden
- Swedish Heart and Lung Foundation, Sweden
- Swedish Medical Research Council, Sweden
- Swedish Society of Medicine, Sweden
- Swiss Foundation for Cancer Research, Switzerland
- Swiss Science National Foundation, Switzerland
- Szeged Foundation of Cancer Research, Hungary
- T.J. Martell Foundation for Cancer and AIDS Research,
USA
- Taipei Veterans General Hospital, Taipei, Taiwan, ROC
- Takeda Science Foundation, Japan
- The Baxter Foundation, USA
- The Clinical Institute, University of Aarhus, Denmark
- The Community Trust of Wellington, New Zealand
- The Finnish Cancer Foundation, Finland
- The Foundation of Guangdong Science and Technology
Committee, China
- The Foundation of Guangzhou Science and Technology
Committee, China
- The Irish Higher Education Authority's Program and
Research Foundation, Ireland
- The King Gustav V Jubilee Fund, Stockholm, Sweden
- The Mary and Robert Gade Foundation, Gainesville, FL,
USA
- The National Natural Science Fund, China
- The Nordic Cancer Union
- The Research and Development Office, Northern Ireland
- The Research Council of Iceland
- The Riviera Country Club, France
- The Scientific and Technical Research Council of Turkey
- The Susan G. Komen Breast Cancer Foundation, USA
- The University of Otago, New Zealand
- The Wellington Medical Research Foundation, New
Zealand
- Tobacco-Related Disease Research Program, University of
California, USA
- Tokyo Metropolitan Small Business Promotion Agency,
Japan
- Torsten and Ragnar Soederberg Foundation, Sweden
- Tumorzentrum Heidelberg/Mannheim, Germany
- Turku University Central Hospital, Finland
- U.S. Public Health Service, USA
- Uehara Memorial Foundation, Japan

Ulster Cancer Foundation, Ireland	UNLV Planning Initiative Award
United States Army Medical Research and Material Command	US Army Concept Award, USA
United States Department of Energy, USA	USPNS, USA
University of Bologna, Italy	Vehicle Racing Commemorative Foundation, Japan
University of California Breast Cancer Research Program, USA	Vereinigung Nordwestdeutscher Chirurgen, Germany
University of Heidelberg, Germany	Wadsworth Memorial Trust, USA
University of Iceland	Weinberg Foundation, USA
University of Lund, Sweden	Wellington Medical Research Foundation, New Zealand
University of North Dakota, School of Medicine, USA	Wellington School of Medicine Surgical Research Trust, New Zealand
University of Occupational and Environmental Health Research Grant for the Promotion of Occupational Health, Japan	Y. Boel Foundation, Belgium
University of Tuebingen, Germany	Yamagiwa-Yoshida Foundation, Japan

Contents, Volume 24, 2004

Number 1A

Experimental Studies

Effects of Tumor Suppressor Gene (p53) on Brain Tumor Angiogenesis and Expression of Angiogenic Modulators. V. TSE, Y. YUNG, J.G. SANTARELLI, D. JUAN, M. HSIAO, M. HAAS, G. HARSH IV, G. SILVERBERG (<i>Stanford; San Jose; San Diego, CA, USA; Kaohsiung, Taiwan</i>)	1
Activated Akt Expression has Significant Correlation with EGFR and TGF- α Expressions in Stage I NSCLC. T. MUKOHARA, S. KUDOH, K. MATSUURA, S. YAMAUCHI, T. KIMURA, N. YOSHIMURA, H. KANAZAWA, K. HIRATA, K. INOUE, H. WANIBUCHI, S. FUKUSHIMA, J. YOSHIKAWA (<i>Osaka, Japan</i>)	11
CGH Analysis Shows Genetic Similarities and Differences in Atypical Fibroxanthoma and Undifferentiated High Grade Pleomorphic Sarcoma. D. MIHIC-PROBST, J. ZHAO, P. SAREMASLANI, A. BAER, C. OEHLSCHEGEL, B. PAREDES, P. KOMMINOTH, P.U. HEITZ (<i>Zürich; St. Gallen; Bern, Switzerland</i>)	19
Paclitaxel-induced Apoptosis May Occur without a Prior G2/M-Phase Arrest. J.M. DZIADYK, M. SUI, X. ZHU, W. FAN (<i>Charleston, SC, USA</i>)	27
Immune Cell Infiltration of Intrinsic and Metastatic Intracranial Tumours. H.M. STRIK, M. STOLL, R. MEYERMANN (<i>Tübingen, Germany</i>)	37
In-silico Analysis of Kallikrein Gene Expression in Pancreatic and Colon Cancers. G.M. YOUSEF, C.A. BORGONO, C. POPALIS, G.M. YACoub, M.-E. POLYMERIS, A. SOOSAIPILLAI, E.P. DIAMANDIS (<i>Toronto, Ont., Canada; Roanoke, VA, USA</i>)	43
Spontaneous Apoptosis in the Intra-Ductal Component's Stroma of Breast Invasive Carcinoma. C. ROULEAU-DUBOIS, M. CUNY, G. FERRIERES, J. S.-LAFONTAINE, P. ROUANET, J. GRENIER, P. JEANTEUR, P. BALDET, C. ESCOT (<i>Montpellier, France</i>)	53
Activity of Irofulven against Human Pancreatic Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . E.S. VAN LAAR, S. ROTH, S. WEITMAN, J.R. MACDONALD, S.J. WATERS (<i>Bloomington, MN; San Antonio, TX, USA</i>)	59
BZLF1 Controlled by Family Repeat Domain Induces Lytic Cytotoxicity in Epstein-Barr Virus Positive Tumor Cells. H. WANG, Y. ZHAO, L. ZENG, M. TANG, A. EL-DEEB, J.J. LI, Y. CAO (<i>Hunan, China; Duarte, CA, USA</i>)	67
Activation of Expression of p15, p73 and E-Cadherin in Leukemic Cells by Different Concentrations of 5-Aza-2'-Deoxycytidine (Decitabine). N.J. FARINHA, S. SHAKER, M. LEMAIRE, L. MOMPARDLER, M. BERNSTEIN, R.L. MOMPARDLER (<i>Montréal, Québec, Canada; Porto, Portugal</i>)	75
Expression of Interleukin-21 and -23 in Human Esophageal Tumors Produced Antitumor Effects in Nude Mice. B. SHAN, L. YU, O. SHIMOZATO, Q. LI, M. TAGAWA (<i>Chiba, Japan; Hebei, China</i>)	79
PCR and Flow Cytometric Analysis of Paclitaxel-inhibited Arylamine N-Acetyltransferase Activity and Gene Expression in Human Osteogenic Sarcoma Cells (U-2 OS). K.-H. LU, D.-Y. WANG, K.-H. LUE, Y.-M. HSIAO, M.-C. CHOU, Y.-S. CHEN, J.-G. CHUNG (<i>Taichung, Taiwan</i>)	83
The Inhibitory Effects of Gossypol on Human Prostate Cancer Cells-PC3 are Associated with Transforming Growth Factor Beta ₁ (TGF β_1) Signal Transduction Pathway. J. JIANG, Y. SUGIMOTO, S. LIU, H.-L. CHANG, K.-Y. PARK, S.K. KULP, Y.C. LIN (<i>Columbus, OH, USA</i>)	91

Thorium and Actinium Polyphosphonate Compounds as Bone-seeking Alpha Particle-emitting Agents. G. HENRIKSEN, Ø. S.BRULAND, R.H. LARSEN (<i>Oslo, Norway</i>)	101
Transitional Increase in Growth Fraction Estimated by Ki-67 Index After Irradiation to Human Tumor in Xenograft. T. TAKAHASHI, T. NAKANO, K. OKA, K. ANDO (<i>Saitama; Gunma; Mito; Chiba, Japan</i>)....	107
Numerical Aberrations of Chromosome 17 and the p53 Locus in Small Hepatocellular Carcinomas. H. YANO, A. NANASHIMA, S. HIDAKA, M. HASEBA, K. TANAKA, H. YAMAGUCHI, T. NAKAGOE, Y. TAGAWA, T. NAGAYASU (<i>Nagasaki, Japan</i>)	111
Repair of Short Oligodeoxyribonucleotides Containing a Stable Adduct and an Apurinic Site by Extracts of MCF-10A1 Cells. K.A. CHAPMAN, E.L. CAVALIERI, E.G. ROGAN (<i>Omaha, NE, USA</i>)	117
A P-glycoprotein- and MRP1-independent Doxorubicin-resistant Variant of the MCF-7 Breast Cancer Cell Line with Defects in Caspase-6, -7, -8, -9 and -10 Activation Pathways. S.-J. PARK, C.-H. WU, A.R. SAFA (<i>Indianapolis, IN, USA</i>)	123
Modulation of the Constitutive Activated STAT3 Transcription Factor in Pancreatic Cancer Prevention: Effects of Indole-3-Carbinol (I3C) and Genistein. J.P. LIAN, B. WORD, S. TAYLOR, G.J. HAMMONS, B.D. LYN-COOK (<i>Jefferson, AR, USA</i>)	133
β -Galactosidase and α -Mannosidase Inhibit Formation of Multicellular Nodules in Breast Cancer Cell Cultures. K.F. ARCARO, J. WANG, C.N. OTIS, B.M. ZUCKERMAN (<i>Amherst; Springfield, MA, USA</i>)	139
Drug-induced Caspase-3 Activation in a Ewing Tumor Cell Line and Primary Ewing Tumor Cells. C. MAUZ-KÖRHOLZ, M. KACHEL, B. HARMS-SCHIRRA, A. KLEIN-VEHNE, P.-U. TUNN, D. KÖRHOLZ (<i>Leipzig; Erkrath; Berlin-Buch, Germany</i>).....	145
Genomic Imbalance and Onco-protein Expression of Ovarian Endometrioid Adenocarcinoma Arisen in an Endometriotic Cyst. F. NOACK, H. SCHMIDT, O. BUCHWEITZ, E. MALIK, H.-P. HORNY (<i>Lübeck; Halle; Münster; Aachen, Germany</i>)	151
Numerical Aberrations of Chromosome 8 in Gastric Cancer Detected by Fluorescence <i>In Situ</i> Hybridisation. A.D. PANANI, A.D. FERTI, A. AVGERINOS, S.A. RAPTIS (<i>Athens, Greece</i>)	155
Synthesis and Evaluation of a Hematoporphyrin Derivative in a Folate Receptor-targeted Solid-Lipid Nanoparticle Formulation. P.J. STEVENS, M. SEKIDO, R.J. LEE (<i>Columbus, OH, USA</i>).....	161
HIF Transcription Factor Expression and Induction of Hypoxic Response Genes in a Retroperitoneal Angiosarcoma. W.K. RATHMELL, G. ACS, M.C. SIMON, D.J. VAUGHN (<i>Chapell Hill, NC; Philadelphia, PA, USA</i>).....	167
IFN- γ Responses in Peptide-treated Melanoma Patients Measured by an ELISPOT Assay Using Allogeneic Dendritic Cells. S. GABRIELSSON, V. BRICHARD, O. DHELLIN, T. DORVAL, C. BONNEROT (<i>Paris; Evry, France; Rixensart, Belgium; Stockholm, Sweden</i>)	171
Abilities of 3,4-Diarylfuran-2-one Analogs of Combretastatin A-4 to Inhibit Both Proliferation of Tumor Cell Lines and Growth of Relevant Tumors in Nude Mice. L. SUN, N.I. VASILEVICH, J.A. FUSELIER, D.H. COY (<i>New Orleans, LA, USA</i>)	179
Computational Simulation of Chronic Persistent Virus Infection: Factors Determining Differences in Clinical Outcome of HHV-6, HIV-1 and HTLV-1 Infections Including Aplastic, Hyperplastic and Neoplastic Responses. G.R.F. KRUEGER, M.E. BRANDT, G. WANG, L.M. BUJA (<i>Houston, TX, USA</i>).....	187

The Matrix Metalloproteinase-21 Gene 572C/T Polymorphism and the Risk of Breast Cancer. E.I. SHAGISULTANOVA, I.A. NOVIKOVA, Y.S. SIDORENKO, G.N. MARCHENKO, A.Y. STRONGIN S.R. MALKHOSYAN (<i>La Jolla, CA, USA; Rostov-on-Don, Russia</i>)	199
Potential Antitumor Agents. 34.(1) Synthesis and Antitumor Activity of Guanylhydrazones from Imidazo[2,1- <i>b</i>]thiazoles and from Diimidazo[1,2- <i>a</i> :1,2- <i>c</i>]pyrimidine. A. ANDREANI, M. GRANAIOLA, A. LEONI, A. LOCATELLI, R. MORIGI, M. RAMBALDI, G. GIORGI, V. GARALIENE (<i>Bologna; Siena, Italy; Kaunas, Lithuania</i>)	203
Simultaneous Targeting of VEGF Message and VEGF Receptor Signaling as a Therapeutic Anticancer Approach. W. SHI, D.W. SIEMANN (<i>Gainesville, FL, USA</i>)	213
Apoptosis Induced by Oxaliplatin in Human Colon Cancer HCT15 Cell Line. P. MARCHETTI, D.A.P. GALLA, F.P. RUSSO, E. RICEVUTO, V. FLATI, G. PORZIO, C. FICORELLA, M.G. CIFONE (<i>L'Aquila, Italy</i>)	219
Effects of the <i>Medicago scutellata</i> Trypsin Inhibitor (MsTI) on Cisplatin-induced Cytotoxicity in Human Breast and Cervical Cancer Cells. A. LANZA, A. TAVA, M. CATALANO, L. RAGONA, I. SINGUAROLI, F.S. ROBUSTELLI DELLA CUNA, G. ROBUSTELLI DELLA CUNA (<i>Pavia; Lodi; Milano; Montescano, Italy</i>)	227
YY1 Transcription Factor is not Responsible for the Negative Regulation of Hamster <i>Muc1</i> Transcription. A. HISATSUNE, S.W. HYUN, I.J. LEE, S. GEORAS, K.C. KIM (<i>Baltimore, MD, USA</i>)	235
Clinical Studies	
Increased Plasma Levels of Serine Proteinase Inhibitors in Lung Cancer Patients. I. ZELVYTE, A. WALLMARK, E. PIITULAINEN, U. WESTIN, S. JANCIAUSKIENE (<i>Malmö, Sweden</i>)	241
Orbital Rhabdomyosarcoma: Relationship Between DNA Ploidy, P53, Bcl-2, MDR-1 and Ki67 (MIB1) Expression and Clinical Behavior. S. STAIBANO, R. FRANCO, F. TRANFA, E. MEZZA, L. LO MUZIO, D. STRIANESE, M.E. ERRICO, P. BUFO, G. FERRARA, P. SOMMA, G. MANSUETO, I. GRECO, A. FIORILLO, G. BONAVOLONTÀ, G. DE ROSA (<i>Naples; Ancona; Foggia; Benevento; L'Aquila, Italy</i>).....	249
Polo-like Kinase 1 (PLK1) Expression is Associated with Cell Proliferative Activity and Cdc2 Expression in Malignant Lymphoma of the Thyroid. Y. ITO, H. YOSHIDA, F. MATSUZUKA, N. MATSUURA, Y. NAKAMURA, H. NAKAMINE, K. KAKUDO, K. KUMA, A. MIYAUCHI (<i>Kobe; Osaka; Wakayama, Japan</i>)	259
Palliative Management of Malignant Rectosigmoidal Obstruction. Colostomy vs. Endoscopic Stenting. A Randomized Prospective Trial. E. FIORI, A. LAMAZZA, A. DE CESARE, M. BONONI, P. VOLPINO, A. SCHILLACI, A. CAVALLARO, V. CANGEMI (<i>Rome, Italy</i>).....	265
Palliative Management of Malignant Antro-pyloric Strictures. Gastroenterostomy vs. Endoscopic Stenting. A Randomized Prospective Trial. E. FIORI, A. LAMAZZA, P. VOLPINO, A. BURZA, C. PAPARELLI, G. CAVALLARO, A. SCHILLACI, V. CANGEMI (<i>Rome, Italy</i>)	269
Immunohistochemical Dihydropyrimidine Dehydrogenase Expression is a Good Prognostic Indicator for Patients with Dukes' C Colorectal Cancer. K. OI, M. MAKINO, M. OZAKI, H. TAKEMOTO, N. YAMANE, S. NAKAMURA, M. IKEGUCHI, N. KAIBARA (<i>Yonago, Japan</i>)	273
Loss of BRCA2 Correlates with Reduced Long-term Survival of Sporadic Breast Cancer Patients. J.A. HAMPL, M. HAMPL, G. REIß, R. KOCH, H.-D. SAEGER, H.K. SCHACKERT (<i>Cologne; Düsseldorf; Dresden, Germany</i>)	281

Multidrug Resistance Proteins in Primary and Metastatic Soft-tissue Sarcomas: Down-regulation of P-glycoprotein During Metastatic Progression. R. KOMDEUR, W.M. MOLENAAR, N. ZWART, H.J. HOEKSTRA, E. VAN DEN BERG, W.T.A. VAN DER GRAAF (<i>Groningen, The Netherlands</i>).....	291
Clinical and Immunohistochemical Analysis of Patients with Unknown Primary Tumour. A Search for Prognostic Factors in UPT. A.J. VAN DE WOUW, R.L.H. JANSEN, A.W. GRIFFIOEN, H.F.P. HILLEN (<i>Maastricht, The Netherlands</i>).....	297
Impact of Complementary Mistletoe Extract Treatment on Quality of Life in Breast, Ovarian and Non-small Cell Lung Cancer Patients. A Prospective Randomized Controlled Clinical Trial. B.K. PIAO, Y.X. WANG, G.R. XIE, U. MANSMANN, H. MATTHES, J. BEUTH, H. S. LIN (<i>Beijing; Shenyang; Tainjin, China; Heidelberg; Berlin; Köln, Germany</i>).....	303
Catestatin—A Novel Neuropeptide in Carcinoid Tumors of the Appendix. R. PROMMEGGER, C. ENSINGER, C. ADLASSNIG, S. VAINGANKAR, S.K. MAHATA, J. MARKSTEINER, R. MARGREITER (<i>Innsbruck, Austria; San Diego, CA, USA</i>).....	311
Complete Response of Severe Symptomatic Bone Marrow Metastases from Heavily Pretreated Breast Cancer with a 3-Weekly Trastuzumab Schedule. A Clinical Case. A. ROSSI, G. COLANTUONI, N. CANTORE, L. PANICO, G. DE CHIARA, U. FERBO, C. GRIDELLI (<i>Avellino, Italy</i>).....	317
Differential Expressions of BRCA1 and BRCA2 in Infantile Gynecomastia. D.J. BERNARD-GALLON, P.J. DECHELOTTE, L. LE CORRE, N. CHALABI, C. VISSAC-SABATIER, Y.-J. BIGNON (<i>Clermont-Ferrand, France</i>).....	321
The Impact of Stromal Cell Contamination on Chemosensitivity Testing of Head and Neck Carcinoma. R. DOLLNER, C. GRANZOW, B.M. HELMKE, A. RUESS, A. SCHAD, A. DIETZ (<i>Heidelberg, Germany</i>).....	325
Immunohistochemical Detection of HER-2/ <i>neu</i> , c-Kit (CD117) and Vascular Endothelial Growth Factor (VEGF) Overexpression in Soft Tissue Sarcomas. A. POTTI, A.K. GANTI, H. FOSTER, S. KNOX, B.J. HEBERT, K. TENDULKAR, K. SHOLES, M. KOCH, S. KARGAS (<i>Fargo, ND; Los Angeles, CA, USA</i>).....	333
Pulmonary Radiofrequency Ablation – An International Study Survey. K. STEINKE, P.E. SEWELL, D. DUPUY, R. LENCIONI, T. HELMBERGER, S.T. KEE, A.L. JACOB, D.W. GLENN, J. KING, D.L. MORRIS (<i>Sydney, Australia; Jackson, MS; Providence, RI; Stanford, CA, USA; Pisa, Italy; München, Germany; Basel, Switzerland</i>).....	339
Paclitaxel and Carboplatin Concurrent with Radiotherapy for Primary Cervical Cancer. F.Y.F.L. DE VOS, A.M.E. BOS, J.A. GIETEMA, E. PRAS, A.G.J. VAN DER ZEE, E.G.E. DE VRIES, P.H.B. WILLEMSE (<i>Groningen, The Netherlands</i>).....	345
Radiotherapy in the Treatment of Stage III-IV Hypopharyngeal Carcinoma. V. TOMBOLINI, M. SANTARELLI, N. RAFFETTO, V. DONATO, M. VALERIANI, A. FERRETTI, R. M. ENRICI (<i>L'Aquila; Rome, Italy</i>).....	349
Phase II Study of Weekly Oxaliplatin and High-dose Infusional 5-Fluorouracil plus Leucovorin in Pretreated Patients with Metastatic Colorectal Cancer. S. CHIARA, M.T. NOBILE, A. GOZZA, P. TAVEGGIA, A. HEOUAINE, I. PASTRONE, P.L. PERCIVALE, R. LIONETTO, O. SANGUINETI, R. ROSSO (<i>Genova, Italy</i>).....	355
Molecular and Clinicopathological Analysis of Ovarian Carcinomas With and Without Microsatellite Instability. A. DELLAS, A. PUHL, P. SCHRAML, S.E. THOMKE, J. RÜSCHOFF, M.J. MIHATSCH, H. MOCH (<i>Basel, Switzerland; Kassel, Germany</i>).....	361
Assessment of Microvessel Density in Core Needle Biopsy Specimen in Breast Cancer. L. RYDÉN, P. BOIESEN, P.-E. JÖNSSON (<i>Helsingborg, Sweden</i>).....	371

Yearly Alterations in Prognostic Factors in Gastric Cancer During the Post-operative Period. C. KUNISAKI, H. SHIMADA, H. AKIYAMA, M. NOMURA, G. MATSUDA, Y. OTSUKA, H. ONO (Yokohama, Japan)	377
Palliative Second-line Treatment with Weekly High-dose 5-Fluorouracil as 24-hour Infusion and Folinic Acid (AIO) plus Oxaliplatin after Pre-treatment with the AIO-Regimen in Colorectal Cancer (CRC). K. LINK, K. HAPPICH, I. SCHIRNER, B. JÜNGERT, V. BRÜCKL, G. MÄNNLEIN, W.M. BRÜCKL, S. MERKEL, J. GÖHL, W. HOHENBERGER, E.G. HAHN, A. WEIN (Erlangen, Germany)	385
Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung. T. KOZUKI, K. KIURA, H. UEOKA, M. TABATA, H. DATE, S. HAMAZAKI, A. BESSHO, M. TANIMOTO (Okayama; Matsuyama, Japan)	393

Number 2A

Biotechnology, Cancer and Drug Resistance Special Issue, Edited by Lorraine O'Driscoll, Robert O'Connor, Martin Clynes

* Antivascular and Antitumor Activities of Liposome-associated Drugs. R.M. STRAUBINGER, R.D. ARNOLD, R. ZHOU, R. MAZURCHUK, J.E. SLACK (Amherst; Buffalo, NY, USA)	397
Adriamycin Alters the Expression of Drug Efflux Pumps and Confers Amphotericin B Tolerance in <i>Candida albicans</i> . J. O'KEEFFE, K. KAVANAGH (Kildare, Ireland)	405
Structure-activity Analysis of Taxane-based Broad-spectrum Multidrug Resistance Modulators. T.A. BROOKS, D.R. KENNEDY, D.J. GRUOL, I. OJIMA, M.R. BAER, R.J. BERNACKI (Buffalo; Stony Brook, NY; San Diego, CA, USA)	409
5-Fluorouracil: Identification of Novel Downstream Mediators of Tumour Response. J. BOYER, P.J. MAXWELL, D.B. LONGLEY, P.G. JOHNSTON (Belfast, N. Ireland)	417
Construction and Transfection of a Ribozyme Targeting Human Caspase-3. D. CRONIN, C. DALY, T. O'DOHERTY, M. HEENAN, K.J. SCANLON, M. CLYNES (Dublin, Ireland; Claremont, CA, USA)	425
Two-deoxyglucose as an Anti-metabolite in Human Carcinoma Cell Line RPMI-2650 and Drug-resistant Variants. J. KEENAN, Y. LIANG, M. CLYNES (Dublin, Ireland)	433
Microarrays in Cancer Research. G.M. GRANT, A. FORTNEY, F. GORRETA, M. ESTEP, L. DEL GIACCO, A. VAN METER, A. CHRISTENSEN, L. APPALLA, C. NAOUAR, C. JAMISON, A. AL-TIMIMI, J. DONOVAN, J. COOPER, C. GARRETT, V. CHANDHOKE (Manassas; Falls Church; Richmond, VA, USA)	441
Functional Studies on the MRP1 Multidrug Transporter: Characterization of ABC-signature Mutant Variants. ZS. SZENTPÉTERY, B. SARKADI, É. BAKOS, A. VÁRADI (Budapest, Hungary)	449
Increased Anti-tumour Efficacy of Doxorubicin when Combined with Sulindac in a Xenograft Model of an MRP-1-positive Human Lung Cancer. R. O'CONNOR, M. HEENAN, L. CONNOLLY, A.-M. LARKIN, M. CLYNES (Dublin, Ireland)	457
Cellular Models of Drug- and Radiation-resistant Small Cell Lung Cancer. R.A. DAVEY, V.L. LOCKE, S. HENNESS, R.M. HARVIE, M.W. DAVEY (St. Leonards; Gore Hill, NSW, Australia)	465

Expression and Prognostic Relevance of Mcl-1 in Breast Cancer. L. O'DRISCOLL, D. CRONIN, S.M. KENNEDY, R. PURCELL, R. LINEHAN, S. GLYNN, A. LARKIN, K. SCANLON, E.W. MCDERMOTT, A.D. HILL, N.J. O'HIGGINS, M. PARKINSON, M. CLYNES (<i>Dublin, Ireland; Claremont, CA, USA</i>).....	473
A Novel Gene Delivery System for Mammalian Cells. B. GIBSON, A.M. DUFFY, S. GOULD FOGERITE, S. KRAUSE-ELSMORE, R. LU, G. SHANG, Z.-W. CHEN, R.J. MANNINO, D.J. BOUCHIER-HAYES, J.H. HARMEY (<i>Dublin, Ireland; Newark, NJ, USA</i>)	483
Increased Invasion and Expression of MMP-9 in Human Colorectal Cell Lines by a CD44-dependent Mechanism. D. MURRAY, M. MORRIN, S. MCDONNELL (<i>Limerick; Dublin, Ireland</i>)	489
Activity of Novel Plant Extracts Against Medullary Thyroid Carcinoma Cells. B. RINNER, V. SIEGL, P. PÜRSTNER, T. EFFERTH, B. BREM, H. GREGER, R. PFRAGNER (<i>Graz; Vienna, Austria; Heidelberg, Germany</i>)	495
* Cancer Gene Therapy: Challenges and Opportunities. K.J. SCANLON (<i>Claremont, CA, USA</i>)	501
Abstracts of the International Conference "Biotechnology, Cancer and Drug Resistance: New Targets, New Diagnosis and New Treatments for Tumours Resistant to Current Therapies" 7-8 July 2003, Clontarf Castle, Dublin, Ireland.....	505
Reviews (pp 397, 501)	

Number 2B

Experimental Studies

Histone Deacetylase Inhibitors Enhance Paclitaxel-induced Cell Death in Ovarian Cancer Cell Lines Independent of p53 Status. N.H. CHOBANIAN, V.L. GREENBERG, J.M. GASS, C.P. DESIMONE, J.R. VAN NAGELL, STEPHEN G. ZIMMER (<i>Lexington, KY, USA</i>)	539
Overexpression of the Neuropilin 1 (NRP1) Gene Correlated with Poor Prognosis in Human Glioma. H. OSADA, T. TOKUNAGA, M. NISHI, H. HATANAKA, Y. ABE, A. TSUGU, H. KIJIMA, H. YAMAZAKI, Y. UEYAMA, M. NAKAMURA (<i>Kanagawa, Japan</i>).....	547
* Molecular Pathogenesis and Prevention of Prostate Cancer. G. BOUNOUS, D. BEER (<i>Vaudreuil-Dorion, Quebec, Canada</i>)	553
Ionizing Radiation Inhibits the PLK Cell Cycle Gene in a G ₂ Checkpoint-dependent Manner. A.H. REE, Å. BRATLAND, K. SOLBERG LANDSVERK, Ø. FODSTAD (<i>Oslo, Norway</i>).....	555
Cytotoxicity, ROS-generation Activity and Radical-scavenging Activity of Curcumin and Related Compounds. S. FUJISAWA, T. ATSUMI, M. ISHIHARA, Y. KADOMA (<i>Saitama; Tokyo, Japan</i>).....	563
Cytotoxic T Cell Induction against Human Malignant Melanoma Cells Using HLA-A24-restricted Melanoma Peptide Cocktail. Y. AKIYAMA, K. MARUYAMA, N. NARA, T. MOCHIZUKI, A. YAMAMOTO, N. YAMAZAKI, I. KAWASHIMA, I. NUKAYA, K. TAKESAKO, K. YAMAGUCHI (<i>Tokyo; Shizuoka; Shiga, Japan</i>).....	571
Cellular Parameters Predictive of the Clinical Response of Colorectal Cancers to Irinotecan. A Preliminary Study. V. PAVILLARD, V. CHARASSON, A. LAROCHE-CLARY, I. SOUBEYRAN, J. ROBERT (<i>Bordeaux, France</i>)	579

The Colon Mitosis Inhibitor Pyroglutamyl-histidyl-glycine Inhibits Growth of Non-tumorigenic Colonic Epithelial Cells. W.H. REICHEL, P.M. DE ANGELIS, H.K. KNUTSEN, T. HUSØY, K. ELGJO, K.L. REICHEL (Oslo, Norway).....	587
Overlapping Functions of Ras and Rac GTPases in Regulating Cancer Cell Proliferation and Invasion. D.L. CROWE (Los Angeles, CA, USA)	593
Expression of Hyaluronan Synthases and Hyaluronan in Malignant Mesothelioma Cells. Z. LIU, K. DOBRA, D. HAUZENBERGER, J. KLOMINEK (Stockholm, Sweden).....	599
Suppression of Lewis Lung Tumor Development in Alpha 1,3 Galactosyltransferase Knock-Out Mice. K.J. POSEKANY, H.K. PITTMAN, M.S. SWANSON, C.E. HAISCH, K.M. VERBANAC (Greenville, NC, USA)....	605
Comparison of Human Tumour Cell Responses to Cisplatin and ZD0473 with and without Irradiation. G.P. RAAPHORST, D.P. YANG, L.F. LI, S. MALONE (Ottawa, Ontario, Canada)	613
Effects of Oral Squamous Cell Carcinoma-derived TGF-β1 on CD26/DPPIV Expression in T Cells. T.UEMATSU, H. TANAKA, M. YAMAOKA, K. FURUSAWA (Nagano, Japan).....	619
Preliminary Study of the Optimal Dosing Schedule for Oral UFT/Leucovorin Chemotherapy. S. SADAHIRO, T. SUZUKI, K. ISHIKAWA, T. NAKAMURA, T. SAGUCHI, A. KAMIJO, S. YASUDA, H. MAKUUCHI, C. MURAYAMA (Tokai, Japan)	625
Taurolidine-Fibrin-Sealant-Matrix Using Spray Application for Local Treatment of Brain Tumors. R. STENDEL, L. SCHEURER, K. SCHLATTERER, R. GMINSKI, H. MÖHLER (Berlin, Germany; Zurich, Switzerland).....	631
Enhancing Effect of PS-K on IL-2-induced Lymphocyte Activation: Possible Involvement of Antagonistic Action Against TGF-beta. Y. YAMAGUCHI, K. MINAMI, A. OHSHITA, Y. KAWABUCHI, K. NOMA, T. TOGE (Hiroshima, Japan)	639
The Association Between Methylenetetrahydrofolate Reductase Polymorphism and Promoter Methylation in Proximal Colon Cancer. K. OYAMA, K. KAWAKAMI, K. MAEDA, K. ISHIGURO, G. WATANABE (Kanazawa, Japan)	649
Apoptosis-inducing Activity of Cisplatin (CDDP) against Human Hepatoma and Oral Squamous Cell Carcinoma Cell Lines. M. OKAMURA, K. HASHIMOTO, J. SHIMADA, H. SAKAGAMI (Saitama, Japan).....	655
Efficient Targeting of Gastric Cancer Cells using Radiolabeled Anti-carcinoembryonic Antigen-specific T84.66 Fragments in Experimental Radioimmunoguided Surgery. J.C. KIM, H.K. HONG, S.A. ROH, K.H. KOO, I.H. KA, H. NAMGUNG, K.H. LEE, J.H. RYU, C.S. YU, S.J. OH, J.S. RYU, J.S. KIM, H.C. KIM (Seoul, Korea)	663
Different Expression of Cyclooxygenase-2 in Biliary Epithelia of Bile Duct Cancer with or without Pancreaticobiliary Maljunction. O. WATANABE, K. YOSHIMATSU, S. SHIOZAWA, A. TSUCHIYA, N. OSHIBE, M. AIBA, K. OGAWA (Tokyo, Japan).....	671
Increased Nuclear Factor-κB Activation in Human Colorectal Carcinoma and its Correlation with Tumor Progression. M. KOJIMA, T. MORISAKI, N. SASAKI, K. NAKANO, R. MIBU, M. TANAKA, M. KATANO (Fukuoka, Japan).....	675
Relationship between Differentiation-inducing Activity and Hypercalcemic Activity of Hexafluorotrihydroxyvitamin D ₃ Derivatives. S. UNTEN, M. ISHIHARA, H. SAKAGAMI (Saitama, Japan).....	683

CD40 Ligand Stimulation Inhibits the Proliferation of Mantle Cell Lymphoma Lines. Z. JIN, N. TERAMOTO, K. HAYASHI, Y.-X. LIU, G. JIN, T. OKA, K. TAKAHASHI, T. YOSHINO, T. AKAGI (Okayama, Japan; Stockholm, Sweden)	691
Increased Tyrosine Kinase Activities May Lead to the Phenotypic Differences of Gastric Cancer Cells. H. ONO, Y. TAKEUCHI, J.-I. UKEGAWA, S. KUSAYANAGI, K. MITAMURA, M. IMAWARI (Tokyo, Japan)	699
Expression Pattern of the <i>HMGB1</i> Gene in Sarcomas of the Dog. B. MEYER, H. MURUA ESCOBAR, S. HAUKE, A. RICHTER, S. WINKLER, P. ROGALLA, A.M. FLOHR, J. BULLERDIEK, I. NOLTE (Bremen; Hannover, Germany)	707
Induction of Apoptosis by β -Diketones in Human Tumor Cells. K. NAKANO, T. NAKAYACHI, E. YASUMOTO, S. REZA M.D. MORSHED, K. HASHIMOTO, H. KIKUCHI, H. NISHIKAWA, K. SUGIYAMA, O. AMANO, M. KAWASE, H. SAKAGAMI (Saitama, Japan)	711
Green Fluorescent Protein Expression and Visualization of Mediastinal Lymph Node Metastasis of Human Lung Cancer Cell Line Using Orthotopic Implantation. H. ISHIKURA, K. KONDO, T. MIYOSHI, Y. TAKAHASHI, H. FUJINO, Y. MONDEN (Tokushima, Japan)	719
Fluorescence-based Assessment of LRP Activity: A Comparative Study. M. DURDUX, D. GRUNWALD, T. GAUTIER, X. RONOT, J. BOUTONNAT (La Tronche; Grenoble, France)	725
Antitumor Effects of Lipoxygenase Inhibitors on Murine Bladder Cancer Cell Line (MBT-2). S. IKEMOTO, K. SUGIMURA, K. KURATUKURI, T. NAKATANI (Osaka, Japan)	733
Structure-Activity Relationships of α , β -Unsaturated Ketones as Assessed by their Cytotoxicity against Oral Tumor Cells. T. NAKAYACHI, E. YASUMOTO, K. NAKANO, S. REZA MD. MORSHED, K. HASHIMOTO, H. KIKUCHI, H. NISHIKAWA, M. KAWASE, H. SAKAGAMI (Saitama, Japan)	737
Plant Phenolics Protect from Bleomycin-induced Oxidative Stress and Mutagenicity in <i>Salmonella typhimurium</i> TA102. D. STAGOS, S. KOURIS, D. KOURETAS (Larissa, Greece)	743
EGCG Blocks Tumor Promoter-induced MMP-9 Expression <i>Via</i> Suppression of MAPK and AP-1 Activation in Human Gastric AGS Cells. H.S. KIM, M.H. KIM, M. JEONG, Y.S. HWANG, S.H. LIM, B.A. SHIN, B.W. AHN, Y.D. JUNG (Kwangju, Korea)	747
Cytotoxic Activity of Deferiprone, Maltol and Related Hydroxyketones against Human Tumor Cell Lines. E. YASUMOTO, K. NAKANO, T. NAKAYACHI, S. REZA MD. MORSHED, K. HASHIMOTO, H. KIKUCHI, H. NISHIKAWA, M. KAWASE, H. SAKAGAMI (Saitama, Japan)	755
Cytotoxicity and Cell Death Pathways Invoked by Two New Rhodium-Ferrocene Complexes in Benign and Malignant Prostatic Cell Lines. B. WEBER, A. SERAFIN, J. MICHIE, C. VAN RENSBURG, J.C. SWARTS, L. BOHM (Tygerberg; Pretoria; Bloemfontein, South Africa)	763
Cytokeratin 17 and p63 are Markers of the HPV Target Cell, the Cervical Stem Cell. J.E. MARTENS, J. ARENDS, P.J.Q. VAN DER LINDEN, B.A.G. DE BOER, T.J.M. HELMERHORST (Deventer; Rotterdam, The Netherlands)	771
Inverse Correlation Between Expression Levels of p27 and the Ubiquitin Ligase Subunit Skp2 in Early Esophageal Squamous Cell Carcinoma. M. FUKUCHI, N. MASUDA, M. NAKAJIMA, Y. FUKAI, T. MIYAZAKI, H. KATO, H. KUWANO (Maebashi, Japan)	777
Lack of Preventive Efficacy of FK228, a Histone Deacetylase Inhibitor, Against <i>N</i> -butyl- <i>N</i> -(4-hydroxybutyl) Nitrosamine-induced Urinary Bladder Carcinogenesis in p53 ^{+/-} and p53 ^{+/+} Mice. M. WEI, H. WANIBUCHI, K. MORIMURA, E.I. SALIM, M. MOKU, K. DOI, M. MITSUHASHI, C. MASUDA, J. SHEN, A. KINOSHITA, S. FUKUSHIMA (Osaka, Japan)	785

Variations of Telomerase Activity in Cultured Mouse Fibroblasts upon Proliferation of Polyomavirus. D. PASTORE, A. IACOANGELI, G. GALATI, L. IZZO, E. FIORI, A. GIULIANI, M. CASTELLI, G. RISULEO (<i>Rome, Italy; Brooklyn, NY, USA</i>).....	791
Inhibitory Effect of Genistein and Daidzein on Ovarian Cancer Cell Growth. C. GERCEL-TAYLOR, A.K. FEITELSON, D.D. TAYLOR (<i>Louisville, KY, USA</i>)	795
Glutamyl- but Not Aspartyl- Aminopeptidase Activity is Modified in Serum of N-Methyl Nitrosourea-induced Rat Mammary Tumours. M.P. CARRERA, M.J. RAMNREZ-EXPÓSITO, M.T. VALENZUELA, M.J. GARCÍA, M.D. MAYAS, J.M. MARTÍNEZ-MARTOS (<i>Jaén; Granada, Spain</i>).....	801
All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner. Z. FALUHELYI, I. RODLER, A. CSEJTEY, S.K. TYRING, I.A. EMBER, I. ARANY (<i>Pécs; Budapest; Szombathely, Hungary; Galveston, TX, USA</i>)	807
Selective Inhibition of Survival Signal Transduction Pathways Enhanced Radiosensitivity in Human Esophageal Cancer Cell Lines <i>In Vitro</i> . T. AKIMOTO, T. NONAKA, K. HARASHIMA, H. ISHIKAWA, H. SAKURAI, N. MITSUHASHI (<i>Gunma; Tokyo, Japan</i>).....	811
Down-regulation of the Human Tumor Antigen Mucin by Gemcitabine on the Pancreatic Cancer Cell Line Capan-2. D.C. DORN, U. HARNACK, G. PECHER (<i>Berlin, Germany</i>).....	821
Resistance Developing after Long-term Ganciclovir Prodrug Treatment in a Preclinical Model of NSCLC. R. KURDOW, B. SCHNIEWIND, A.S. BOEHLE, S. HAYE, L. BOENICKE, P. DOHRMANN, H. KALTHOFF (<i>Kiel, Germany</i>).....	827
Effect of Octreotide on Apoptosis-related Proteins in Rat Kupffer Cells: A Possible Anti-tumour Mechanism. C. XIDAKIS, G. KOLIOS, V. VALATAS, G. NOTAS, I. MOUZAS, E. KOUROUMALIS (<i>Heraklion, Greece</i>)	833
Effects of Dietary Anticarcinogens and Nonsteroidal Anti-inflammatory Drugs on Rat Gastrointestinal UDP-Glucuronosyltransferases. E.M.J. VAN DER LOGT, H.M.J. ROELOFS, E.M.M. VAN LIESHOUT, F.M. NAGENGAST, W.H.M. PETERS (<i>Nijmegen, The Netherlands</i>).....	843
Resistance to Gemcitabine in a Lymphoma Cell Line Resistant to Fas-mediated Apoptosis. M. MELI, M. TOLOMEO, N. D'ALESSANDRO, S. GRIMAUDO, M. NOTARBARTOLO, G. PAPOFF, G. RUBERTI, L. RAUSA, L. DUSONCHET (<i>Palermo; Rome, Italy</i>).....	851
Effect of Cycloartanes on Reversal of Multidrug Resistance and Apoptosis Induction on Mouse Lymphoma Cells. A.M. MADUREIRA, G. SPENGLER, A. MOLNAR, A. VARGA, J. MOLNAR, P.M. ABREU, M.-J.U. FERREIRA (<i>Lisboa; Caparica, Portugal; Berlin, Germany; Szeged, Hungary</i>)	859
New Silicon Compounds as Resistance Modifiers against Multidrug-resistant Cancer Cells. J. MOLNAR, I. MUCSI, J. NACSA, A. HEVÉR, N. GYÉMÁNT, K. UGOCSAI, P. HEGYES, ST. KIESSIG, D. GAAL, H. LAGE, A. VARGA (<i>Szeged; Budapest, Hungary; Berlin; Heidelberg, Germany</i>).....	865
Induction of Apoptosis and G2/M Arrest by 2-Methoxyestradiol in Human Cervical Cancer HeLaS3 Cells. L. LI, S. BU, T. BÄCKSTRÖM, M. LANDSTRÖM, U. ULMSTEN, X. FU (<i>Uppsala; Umea, Sweden; Shijiazhuang, China</i>)	873
Overexpression of Id-1 in Gastric Adenocarcinoma: Implication for a Novel Diagnostic Marker. Q. WANG, S.W. TSAO, S. FU, W. XUE, X. MENG, H. FENG, Y.C. WONG, X. WANG (<i>Harbin; Hong Kong, China</i>).....	881
Antitumour Effects of a Bispecific Trivalent Antibody in Multicellular Tumour Spheroids. A. WALZ, B. MACK, B. SCHMITT, O. GIRES, B. WOLLENBERG, R. ZEIDLER (<i>Munich; Lübeck, Germany</i>).....	887

Serum HER-2/neu as a Prediction and Monitoring Parameter in a Phase II Study with Weekly Paclitaxel in Metastatic Breast Cancer. D. LÜFTNER, P. HENSCHKE, B. FLATH, C. AKRIVAKIS, S. SCHNABEL, B. PRINZ, R. GEPPERT, K.-D. WERNECKE, K. POSSINGER (<i>Berlin, Germany</i>).....	895
Antitumor Activity of Imidazothioxanthenes in Murine and Human Tumor Models <i>In Vitro</i> and <i>In Vivo</i> . A. VARVARESOU, K. IAKOVOU, E. GIKAS, I. FICHTNER, H.H. FIEBIG, L.R. KELLAND, J.A. DOUBLE, M.C. BIBBY, H.R. HENDRIKS (<i>Amsterdam, The Netherlands; Athens, Greece; Berlin; Freiburg, Germany; Sutton; Bradford, United Kingdom</i>).....	907
Focal Adhesion Kinase Interacts with the Transcriptional Coactivator FHL2 and Both are Overexpressed in Epithelial Ovarian Cancer. B. GABRIEL, S. MILDENBERGER, C.W. WEISSER, E. METZGER, G. GITSCH, R. SCHÜLE, J.M. MÜLLER (<i>Freiburg, Germany</i>).....	921
Electrofusion Generates Diverse DC-tumour Cell Hybrids for Cancer Immunotherapy. J.B. WEISE, F. HILPERT, A. HEISER, T. GÖRÖGH, J.E. MEYER, J. WEIMER, C. KRÜGER, A. ROSENAU, W. WIECKHORST, N. ARNOLD, J. PFISTERER, D. KABELITZ, S. MAUNE (<i>Kiel, Germany</i>).....	929
Three-dimensional Culture and Multidrug Resistance: Effects on Immune Reactivity of MCF-7 Cells by Monocytes. L. MOUGEL, M. TARPIN, P. ALBERT, R. LE NAOUR, J. DEVY, H. KAPLAN, L. VENTÉO, A. CARLIER, C. MADOULET (<i>Reims, France</i>)	935
Structure-Activity Relationships of Synthetic Analogs of (-)-Epigallocatechin-3-Gallate as Proteasome Inhibitors. A. KAZI, Z. WANG, N. KUMAR, S.C. FALSETTI, T.-H. CHAN, Q. PING DOU (<i>Tampa, FL, USA; Montreal, Quebec, Canada</i>)	943
Expression and Localization of Homeodomain Proteins <i>DLX4</i> , <i>HB9</i> and <i>HB24</i> in Malignant and Benign Human Colorectal Tissues. P. HOLLINGTON, P. NEUFING, B. KALIONIS, P. WARING, J. BENTEL, D. WATTCHOW, W.D. TILLEY (<i>Adelaide; Bedford Park, SA; Carlton; Melbourne, VIC; Perth, Australia</i>).....	955
Simultaneous Measurement of Nucleolin and Estrogen Receptor in Breast Cancer Cells by Laser Scanning Cytometry. M. MASIUK, E. URASINSKA, W. DOMAGALA (<i>Szczecin, Poland</i>).....	963
Activation of Metalloproteinases-2 and -9 by Interleukin-1 α in S100A4-positive Liposarcoma Cell Line: Correlation with Cell Invasiveness. L. PAZZAGLIA, F. PONTICELLI, G. MAGAGNOLI, G. MAGAGNOLI, G. GAMBERI, P. RAGAZZINI, A. BALLADELLI, P. PICCI, M. BENASSI (<i>Bologna, Italy</i>).....	967
Comparison of Surface HLA Class I Levels in Squamous Cell Carcinoma Cell Lines of the Head and Neck. R. MANDIC, A. LIEDER, M. SADOWSKI, R. PELDSZUS, J.A. WERNER (<i>Marburg, Germany</i>)	973
Altered Expression and New Mutations in DNA Mismatch Repair Genes <i>MLH1</i> and <i>MSH2</i> in Melanoma Brain Metastases. M. KORABIOWSKA, F. KÖNIG, R. VERHEGGEN, T. SCHLOTT, C. CORDON-CARDO, B. ROMEIKE, U. BRINCK (<i>Göttingen; Homburg/Saar, Germany; New York, NY, USA</i>).....	981
Curcumin and Resveratrol Induce Apoptosis and Nuclear Translocation and Activation of p53 in Human Neuroblastoma. A. LIONTAS, H. YEGER (<i>Toronto, Ontario, Canada</i>).....	987
The 3,4-Dihydroxyl Groups are Important for <i>trans</i> -Resveratrol Analogs to Exhibit Enhanced Antioxidant and Apoptotic Activities. Y.-J. CAI, Q.-Y. WEI, J.-G. FANG, L. YANG, Z.-L. LIU, J.H. WYCHE, Z. HAN (<i>Gansu, China; Coral Gables, FL, USA</i>).....	999
Capsaicin-mediated Denervation of Sensory Neurons Promotes Mammary Tumor Metastasis to Lung and Heart. N. ERIN, P.J. BOYER, R.H. BONNEAU, G.A. CLAWSON, D.R. WELCH (<i>Hershey, PA; Dallas, TX; Birmingham, AL, USA</i>).....	1003

Altered mRNA Expression of the Rb and p16 Tumor Suppressor Genes and of CDK4 in Transitional Cell Carcinomas of the Urinary Bladder Associated with Tumor Progression. T. QUENTIN, C. HENKE, M. KORABIOWSKA, T. SCHLOTT, B. ZIMMERMAN, E. KUNZE (<i>Göttingen, Germany</i>).....	1011
Human Beta-Defensin-2 in Oral Cancer with Opportunistic <i>Candida</i> Infection. J.E. MEYER, J. HARDER, T. GÖRÖGH, J.B WEISE, S. SCHUBERT, D. JANSSEN, S. MAUNE (<i>Kiel, Germany</i>)	1025
Review (page 553)	

Number 2C

Clinical Studies

Haptoglobin α -Subunit and Hepatocyte Growth Factor can Potentially Serve as Serum Tumor Biomarkers in Small Cell Lung Cancer. A. BHARTI, P.C. MA, G. MAULIK, R. SINGH, E. KHAN, A.T. SKARIN, R. SALGIA (<i>Boston, MA; Chicago, IL, USA</i>)	1031
Well-differentiated Liposarcoma Associated with Benign Lipoma. H. HATANO, T. MORITA, A. OGOSE, T. HOTTA, H. KOBAYASHI, K. HONMA (<i>Niigata, Japan</i>)	1039
Expression of Copper-transporting P-type Adenosine Triphosphatase(ATP7B) in Human Hepatocellular Carcinoma. H. SUGENO, Y. TAKEBAYASHI, M. HIGASHIMOTO, Y. OGURA, G. SHIBUKAWA, A. KANZAKI, K. TERADA, T. SUGIYAMA, K. WATANABE, R. KATOH, Y. NITTA, T. FUKUSHIMA, Y. KOYAMA, N. INOUE, K. SEKIKAWA, K. OGAWA, Y. SATO, S. TAKENOSHITA (<i>Fukushima; Tokyo; Kagoshima; Sendai; Akita; Chiba, Japan</i>)	1045
Neuroendocrine Tumors and Second Primary Malignancy-A Relationship with Clinical Impact? R. PROMMEGGER, C. ENSINGER, P. STEINER, T. SAUPER, C. PROFANTER, R. MARGREITER (<i>Innsbruck, Austria</i>)	1049
CD44s Expression is Associated with Improved Survival in Soft Tissue Sarcoma. M. PEIPER, T. SATO, D. ZURAKOWSKI, C. EISENBERGER, A. HEINECKE, S. HOSCH, W.T. KNOEFEL (<i>Hamburg; Düsseldorf, Germany; Boston, MA, USA</i>)	1053
Comparison of Carboxyterminal Telopeptide of Type I Collagen (ICTP) and CA 125 as Predictors of Prognosis in Ovarian Cancer. M. SANTALA, J. RISTELI, A. KAUPPILA (<i>Oulu, Finland</i>).....	1057
Scatter Factor Receptor (c-Met) as Possible Prognostic Factor in Patients with Oral Squamous Cell Carcinoma. L. LO MUZIO, R. LEONARDI, M.D. MIGNOGNA, G. PANNONE, C. RUBINI, T. PIERAMICI, L. TREVISIOL, F. FERRARI, R. SERPICO, N. TESTA, G. DE ROSA, S. STAIBANO (<i>Ancona; Catania; Naples; Verona; Bari, Italy</i>)	1063
Nuclear Factor- κ B p65 is a Prognostic Indicator in Gastric Carcinoma. N. YAMANAKA, N. SASAKI, A. TASAKI, H. NAKASHIMA, M. KUBO, T. MORISAKI, H. NOSHIRO, T. YAO, M. TSUNEYOSHI, M. TANAKA, M. KATANO (<i>Fukuoka, Japan</i>)	1071
Male Breast Adenocarcinoma in a Prostate Cancer Patient Following Prolonged Anti-androgen Monotherapy. P. KARAMANAKOS, C.S. MITSIADES, P. LEMBESSIS, M. KONTOS, D. TRAFALIS, M. KOUTSILIERIS (<i>Athens, Greece; Boston, MA, USA</i>)	1077
Longitudinal Changes in Serum HER-2/ <i>neu</i> Oncoprotein Levels in Trastuzumab-treated Metastatic Breast Cancer Patients. A. BETHUNE-VOLTERS, M. LABROQUERE, S. GUEPRATTE, K. HACENE, R. NEUMANN, W. CARNEY, M.-F. PICHON (<i>Saint-Cloud, France; Leverkusen, Germany; Cambridge, MA, USA</i>)	1083

Dehydropyrimidine Dehydrogenase Deficiency in a Cancer Patient Undergoing 5-Fluorouracil Chemotherapy. H.B. SCHNEIDER, H. BECKER (<i>Göttingen, Germany</i>)	1091
Testis Metastasis as an Initial Manifestation of an Occult Gastrointestinal Cancer. N. SALESI, A. FABI, B. DI COCCO, F. MARANDINO, G. PIZZI, A. VECCHIONE, F. COGNETTI (<i>Rome, Italy</i>)	1093
Expression and Prognostic Value of the Lung Resistance-related Protein (LRP) in Germ Cell Testicular Tumors. L. MÁNDOKY, L. GÉCZI, Z. DOLESCHALL, I. BODROGI, O. CSUKA, M. KÁSLER, M. BAK (<i>Budapest, Hungary</i>)	1097
Primitive Neuroectodermal Tumor (PNET) Treated with Interferon- β after Surgical Removal and Irradiation: Case Report. K.C. PARK, S. TOYONAGA, H. NAKABAYASHI, H. MIZOBUCHI, E. NAKAI, N. IKAWA, K. SHIMIZU (<i>Kochi, Japan</i>)	1105
Galectin-3 Immunodetection May Improve Cytological Diagnosis of Occult Papillary Thyroid Carcinoma. T. PISANI, A. VECCHIONE, M.R. GIOVAGNOLI (<i>Rome, Italy</i>)	1111
Combination of L-3-phosphoserine Phosphatase and CEA Using Real-time RT-PCR Improves Accuracy in Detection of Peritoneal Micrometastasis of Gastric Cancer. K. SHIMOMURA, C. SAKAKURA, M. TAKEMURA, T. TAKAGI, K. FUKUDA, S. KIN, Y. NAKASE, K. MIYAGAWA, M. OHGAKI, J. FUJIYAMA, Y. FUJITA, M. NAKANISHI, A. HAGIWARA, M. SHIRANE, Y. OKAZAKI, Y. HAYASHIZAKI, H. YAMAGISHI (<i>Kyoto; Kanagawa; Yokohama; Japan</i>)	1113
Deamination of Glutamine is a Prerequisite for Optimal Asparagine Deamination by Asparaginases <i>In Vivo</i> (CCG-1961). E.H. PANOSYAN, R.S. GRIGORYAN, I.A. AVRAMIS, N.L. SEIBEL, P.S. GAYNON, S.E. SIEGEL, H.J. FINGERT, V.I. AVRAMIS (<i>Los Angeles; Arcadia, CA; Washington, DC; Collegeville, PA, USA</i>)	1121
Monitoring of Serum Her-2/ <i>neu</i> Predicts Histopathological Response to Neoadjuvant Trastuzumab-based Therapy for Breast Cancer. W.J. KÖSTLER, G.G. STEGER, A. SOLEIMAN, B. SCHWAB, C.F. SINGER, S. TOMEK, T. BRODOWICZ, M. KRAINER, C. WILTSCHKE, R. HORVAT, R. JAKESZ, C.C. ZIELINSKI (<i>Vienna, Austria</i>)	1127
Prophylactic Efficacy of Allopurinol Ice Ball for Leucovorin/5-Fluorouracil Therapy-induced Stomatitis. H. YOKOMIZO, K. YOSHIMATSU, M. HASHIMOTO, K. ISHIBASHI, A. UMEHARA, K. YOSHIDA, T. FUJIMOTO, K. WATANABE, K. OGAWA (<i>Tokyo, Japan</i>)	1131
Stevens-Johnson Syndrome Induced by Paclitaxel in a Patient with Squamous Cell Carcinoma of the Lung: A Case Report. A. HIRAKI, K. AOE, T. MURAKAMI, T. MAEDA, R. EDA, H. TAKEYAMA (<i>Yamaguchi, Japan</i>)	1135
Activity and Toxicity of Oxaliplatin Plus Raltitrexed in 5-Fluorouracil Refractory Metastatic Colorectal Adeno-Carcinoma. A. LAUDANI, V. GEBBIA, V. LEONARDI, G. SAVIO, N. BORSELLINO, M.P. CUSIMANO, C. CALABRIA, R. STEFANO, B. AGOSTARA (<i>Palermo, Italy</i>)	1139
Treatment of Glioblastoma with Intravenous Taurolidine. First Clinical Experience. R. STENDEL, T. PICT, A. SCHILLING, J. HEIDENREICH, C. LODDENKEMPER, W. JÄNISCH, M. BROCK (<i>Berlin, Germany</i>)	1143
Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from Patients with Ovarian Carcinoma. A. HARLOZIŃSKA, P. SEDLACZEK, J. KULPA, M. GRYBOS, E. WÓJCIK, A. VAN DALEN, R. EINARSSON (<i>Wroclaw; Cracow, Poland; Gouda, The Netherlands; Stockholm, Sweden</i>)	1149

A Protein Chip System for Parallel Analysis of Multi-tumor Markers and its Application in Cancer Detection. Z. SUN, X. FU, L. ZHANG, X. YANG, F. LIU, G. HU (<i>Shanghai, China</i>)	1159
Local Excision of Rectal Cancer with Transanal Endoscopic Microsurgery (TEM). F. STIPA, G. LUCANDRI, M. FERRI, G. CASULA, V. ZIPARO (<i>Rome; Cagliari, Italy</i>)	1167
The Dissociated Expression of Protein and Messenger RNA of DPC4 in Human Invasive Ductal Carcinoma of the Pancreas and their Implication for Patient Outcome. T. TOGA, Y. NIO, K. HASHIMOTO, T. HIGAMI, R. MARUYAMA (<i>Izumo, Japan</i>)	1173
Detectable Serum PSA After Radical Prostatectomy. Clinical and Pathological Relevance of Perianastomotic Biopsies. D. MINARDI, A.B. GALOSI, L. DELL'ATTI, M. YEHIA, G. MUZZONIGRO (<i>Ancona, Italy</i>)	1179
Impact of Mistletoe Lectin Binding in Breast Cancer. P. FRITZ, J. DIPPON, T. KIERSCHKE, I. SIEGLE, A. MÖHRING, A. MOISA, T.E. MÜRDTER (<i>Stuttgart; Tübingen, Germany</i>)	1187
Host-oriented Peptide Evaluation Using Whole Blood Assay for Generating Antigen-specific Cytotoxic T Lymphocytes. Y. KAWABUCHI, Y. YAMAGUCHI, A. OHSHITA, K. MINAMI, T. TOGE (<i>Hiroshima, Japan</i>)	1193
p53 Analysis in Gallbladder Cancer: Comparison of Gene Analysis Versus Immunohistochemistry. H. PUHALLA, D. KANDIOLER, C. LUDWIG, M. FILIPITS, F. WRBA, F. LAENGLE, R. JAKESZ, T. GRUENBERGER (<i>Vienna, Austria</i>)	1201
Prevalence of <i>Chlamydia pneumoniae</i> Infection in Squamous Cell Carcinoma of the Head and Neck. K. MOUTEL, J.-C. MEROL, A. PREVOST, F. EB, J.-F. LEFEBVRE, P. CONINX, F. LIAUTAUD-ROGER (<i>Reims; Amiens, France</i>)	1207
Weekly Docetaxel as Second-line Chemotherapy in Advanced Non-small Cell Lung Cancer: Phase II Trial. M. SERKE, N. SCHOENFEL, R. LODDENKEMPER (<i>Berlin, Germany</i>)	1211
Molecular Prognostic Factors in Locally Irresectable Rectal Cancer Treated Preoperatively by Chemoradiotherapy. O. REERINK, A. KARRENBELD, J.T.M. PLUKKER, R.C.J. VERSCHUEREN, B.G. SZABZ M, W.J. SLUITER, G.A.P. HOSPERS, N.H. MULDER (<i>Groningen, The Netherlands</i>)	1217
Granulosa Cell Tumor of the Ovary: 10 Years Follow-up Data of 65 Patients. J. SEHOULI, F.S. DRESCHER, A. MUSTEA, D. ELLING, W. FRIEDMANN, W. KÜHN, M. NEHMZOW, F. OPRI, P. KLARE, M. DIETEL, W. LICHTENEGGER (<i>Berlin; Bremerhaven; Greifswald, Germany</i>)	1223
Cellular Immunomodulation and Safety of Standardized Aqueous Mistletoe Extract PS76A2 in Tumor Patients Treated for 48 Weeks. W. DOHMEN, M. BREIER, U. MENGES (<i>Aachen; Cologne, Germany</i>)	1231
Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma: A Phase II Study. M. JAHANZEB, G. SARNA, R. HIRSCH, P. RADICE, A. KOLETSKY, M. MARTINEZ, E. KRUGLYAK, E. WOLIN, E. CAMACHO, L. KRONISH, S. MOTL (<i>Memphis, TN; Boca Raton, Aventura, FL; Los Angeles; Palm Springs, CA; USA</i>)	1239
Prognostic Significance of Soluble Adhesion Molecules in Hodgkin's Disease. K.N. SYRIGOS, E. SALGAMI, A.J. KARAYIANNAKIS, N. KATIRTZOGLU, E. SEKARA, P. ROUSSOU (<i>Athens, Greece</i>)	1243
Pre-irradiation Chemotherapy for Newly Diagnosed High Grade Astrocytoma. N.T. MATHIEU, D. GENET, F. LABROUSSE, P. BOUILLET, S. L. DENES, J. MARTIN, J.L. LABOUREY, L. VENAT, P. CLAVERE, J.J. MOREAU (<i>Limoges, France</i>)	1249

Treatment with All-trans Retinoic Acid Plus Tamoxifen and Vitamin E in Advanced Hepatocellular Carcinoma. C. CLERICI, D. CASTELLANI, G. RUSSO, S. FIORUCCI, G. SABATINO, V. GIULIANO, G. GENTILI, O. MORELLI, P. RAFFO, M. BALDONI, A. MORELLI, S. TOMA (<i>Perugia; San Giovanni Rotondo, Italy</i>)	1255
Serum Levels of HER2 ECD Can Determine the Response Rate to Low Dose Oral Cyclophosphamide and Methotrexate in Patients with Advanced Stage Breast Carcinoma. M.T. SANDRI, H. JOHANSSON, M. COLLEONI, L. ZORZINO, R. PASSERINI, L. ORLANDO, G. VIALE (<i>Milan, Italy</i>)	1261
Topotecan as a Continuous Infusion Over 14 Days in Recurrent Ovarian Cancer Patients. D. DENSLAG, D. WATERMANN, K. HÖRIG, C. KISSEL, C. TEMPFER, G. GITSCH (<i>Freiburg, Germany</i>)	1267
Serum Bone Markers in Breast Cancer Patients During 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy. M.E.H. KAILAJÄRVI, E.K. SALMINEN, O.M.M. PAIJA, A.M. VIRTANEN, A.E. LEINO, K.A. IRJALA (<i>Turku, Finland</i>)	1271
Fulvestrant for the Treatment of Advanced Breast Cancer in Postmenopausal Women: A Japanese Study. T. WATANABE, M. SANO, S. OHNO, H. INAJI, R. NISHIMURA, E. SHIN, Y. NOMURA, C. MORRIS (<i>Tokyo; Niigata; Fukuoka; Osaka; Kumamoto; Japan; Wilmington, DE, USA</i>)	1275
Value of Multilevel Sectioning for Improved Detection of Micrometastases in Sentinel Lymph Nodes in Invasive Squamous Cell Carcinoma of the Vulva. A. HAKAM, A. NASIR, R. RAGHUWANSHI, P.V. SMITH, S. CRAWLEY, H. E. KAISER, E. GRENDYS, J.F. FIORICA (<i>Tampa, FL; Silver Spring, MD, USA</i>)	1281
* Alfa-epoietin and Anaemia in Gynaecological Cancer. B. DI COCCO, N. SALESI, A. FABI, C. NARDONI, G. FERRETTI, G. BOSSONE, M. CICCARESE, A. SAVARESE, A. VECCHIONE, F. COGNETTI (<i>Rome, Italy</i>)	1287
The Standardised Mistletoe Extract PS76A2 Improves QoL in Patients with Breast Cancer Receiving Adjuvant CMF Chemotherapy: A Randomised, Placebo-controlled, Double-blind, Multicentre Clinical Trial. V.F. SEMIGLASOV, V.V. STEPULA, A. DUDOV, W. LEHMACHER, U. MENGES (<i>St. Petersburg, Russia; Odessa, Ukraine; Cologne, Germany</i>)	1293
Local Recurrence in Breast Cancer after Conservative Surgery: Timing of Radiotherapy and Sequencing of Chemotherapy. V. DONATO, A. MONACO, F. MESSINA, V. DE SANCTIS, D. MESSINEO, E. BANELLI, R. MAURIZI ENRICI (<i>Rome, Italy</i>)	1303
Amphiregulin and Epidermal Growth Factor Receptor Expression in Human Malignant Fibrous Histiocytoma of Soft Tissues. T. YAMAMOTO, I. FUJITA, T. AKISUE, T. MARUI, T. NAKATANI, T. KAWAMOTO, T. HITORA, K. NAGIRA, K. MATSUMOTO, M. KUROSAKA (<i>Kobe; Akashi, Japan</i>)	1307
The Interleukin-6 ⁻¹⁷⁴ Promoter Polymorphism is Associated with a Risk of Development of Kaposi's Sarcoma in Renal Transplant Recipients. M. GAZOULI, G. ZAVOS, I. PAPAConstantinou, J.C. LUKAS, A. ZOGRAFIDIS, J. BOLETIS, A. KOSTAKIS (<i>Athens, Greece</i>)	1311
Anastrozole as Neoadjuvant Therapy for Patients with Hormone-dependent, Locally-advanced Breast Cancer. A. MILLA-SANTOS, L. MILLA, N. CALVO, J. PORTELLA, L RALLO, J.M. CASANOVAS, M. PONS, J. RODES (<i>Barcelona; Tarragona, Italy</i>)	1315
Human Papillomavirus DNA and Protein in Tissue Samples of Oesophageal Cancer, Barrett's Oesophagus and Oesophagitis. E. ACEVEDO-NUNO, A. GONZÁLEZ-OJEDA, G. VÁZQUEZ-CAMACHO, A. BALDERAS-PENA LUZ MA, H.MORENO-VILLA, H. MONTOYA-FUENTES (<i>Jalisco, México</i>)	1319

Errata Volume 24, Number 1	1325
Review (page1287)	

Number 3A

Experimental Studies

Cytotoxic Activity of the Recombinant Anti-mesothelin Immunotoxin, SS1(dsFv)PE38, Towards Tumor Cell Lines Established from Ascites of Patients with Peritoneal Mesotheliomas. Q. LI, C.F. VERSCHRAEGEN, J. MENDOZA, R. HASSAN (<i>Oklahoma City, OK; Albuquerque, NM; Houston, TX; Bethesda, MD, USA</i>)	1327
CD105 Inhibits Transforming Growth Factor- β -Smad3 Signalling. B. GUO, M. SLEVIN, C. LI, S.PARAMESHWAR, D. LIU, P. KUMAR, C. BERNABEU, S. KUMAR (<i>Manchester, UK</i>)	1337
Charge-dependent Targeting: Results in Six Tumor Cell Lines. M. MÁRQUEZ, S. NILSSON, L. LENNARTSSON, Z. LIU, T. TAMMELA, M. RAITANEN, A.R. HOLMBERG (<i>Stockholm, Sweden; Tampere, Seinäjoki, Finland; Jinan, China</i>)	1347
Oral 5-FU is a More Effective Antimetastatic Agent than UFT. J.WANG, M. YANG, S. YAGI, R.M. HOFFMAN (<i>San Diego, California, USA</i>)	1353
Bone Sialoprotein Promotes Bone Metastasis of a Non-bone-seeking Clone of Human Breast Cancer Cells. J.H. ZHANG, J. WANG, J. TANG, B. BARNETT, J. DICKSON, N. HAHSIMOTO, P. WILLIAMS, W. MA, W. ZHENG, T. YONEDA, S. PAGEAU, J. CHEN (<i>Boston, MA, San Antonio, TX, USA</i>)	1361
Biochemical Analysis and Subcellular Distribution of E-Cadherin-Catenin in Adenocarcinomas of the Gastro-Oesophageal Junction. B.P.L. WIJNHOFEN, E.T. TUCKER, W.N.M. DINJENS, H.W. TILANUS, M. PIGNATELLI (<i>Rotterdam, The Netherlands; Bristol, UK</i>)	1369
Caspase-1 Enhances the Apoptotic Response of Prostate Cancer Cells to Ionizing Radiation. R.N. WINTER, J.G. RHEE, N. KYPRIANOU (<i>Baltimore, MD; Lexington, KY, USA</i>)	1377
PHGPx Overexpression Induces an Increase in COX-2 Activity in Colon Carcinoma Cells. G. BARRIÈRE, H. RABINOVITCH-CHABLE, J. COOK-MOREAU, K. FAUCHER, M. RIGAUD, F. STURTZ (<i>Limoges Cedex, France</i>)	1387
Extracellular Expression of Cytosine Deaminase Results in Increased 5-FU Production for Enhanced Enzyme/Prodrug Therapy. A. REHEMTULLA, D.A. HAMSTRA, E. KIEVIT, M.A. DAVIS, E.Y. NG, K. DORNFELD, T.S. LAWRENCE (<i>Ann Arbor, MI, USA</i>)	1393
Selenium Compounds Regulate p53 by Common, Distinctive Mechanisms. M.L. SMITH, J.K. LANCIA, T.I. MERCER, C. IP (<i>Indianapolis, IN; Buffalo, NY, USA</i>)	1401
The Ligands of Peroxisome Proliferator-activated Receptor (PPAR) Gamma Inhibit Growth of Human Esophageal Carcinoma Cells through Induction of Apoptosis and Cell Cycle Arrest. D. FUJII, K. YOSHIDA, K. TANABE, J. HIHARA, T. TOGE (<i>Hiroshima, Japan</i>)	1409
Analysis of Scellin (SCEL) as a Candidate Gene in Esophageal Squamous Cell Carcinoma. W. CORONA, D.J. KARKERA, R.H. PATTERSON, N. SAINI, G. D. TRACHIOTIS, L.Y. KORMAN, B. LIU, E.P. ALEXANDER, A.S. DE LA PENNA, A.B. MARCELO, R. WADLEIGH (<i>Washington, DC, USA; Manila, Philippines</i>)	1417

Correlation of Circulating Tumor Cells with Tumor Size and Metastatic Load in a Spontaneous Lung Metastasis Model. M. KATOH, M. NEUMAIER, R. NEZAM, J.R. IZBICKI, U. SCHUMACHER (<i>Hamburg, Germany</i>).....	1421
A Synthetic Peptide Derived from the Human Eosinophil-derived Neurotoxin Induces Apoptosis in Kaposi's Sarcoma Cells. A. DRICU, S.-B. CATRINA, K. BRISMAR, P. BIBERFELD, L.C. ANDERSSON (<i>Stockholm, Sweden; Helsinki, Finland</i>).....	1427
Dydrogesterone (Duphaston®) and its 20-Dihydro-derivative as Selective Estrogen Enzyme Modulators in Human Breast Cancer Cell Lines. Effect on Sulfatase and on 17β-Hydroxysteroid Dehydrogenase (17β-HSD) Activity. G.S. CHETRITTE, H.H. THOLE, J.-C. PHILIPPE, J.R. PASQUALINI (<i>Paris, France; Hannover, Germany</i>)	1433
Cyclooxygenase-2 Expression in Human Gastric Tubular Adenomas and Carcinomas; Correlation with Intratumoral Microvessel Density and Apoptotic Index . S. HONJO, S. KASE, M. OSAKI, T.D. ARDYANTO, N. KAIBARA, H. ITO (<i>Tottori, Japan</i>).....	1439
STI571 as a Potent Inhibitor of Growth and Invasiveness of Human Epithelial Breast Cancer Cells. A.E. ROUSSIDIS, T.N. MITROPOULOU, A.D. THEOCHARIS, C. KIAMOURIS, S. PAPAPOPOULOS, D. KLETSAS, N.K. KARAMANOS (<i>Patras; Athens, Greece</i>).....	1445
Vitamins A, E, Microelements and Membrane Lipid Peroxidation in Patients with Neoplastic Disease Treated with Calcium Antagonists and Antagonists of Receptors H ₂ . F. DELLA ROVERE, A. GRANATA, R. PAVIA, A. TOMAINO, A. ZIRILLI, F. MONACO, D. FAMILIARI, A. LA ROCCA, R. IENTILE, B. MONDELLO, G. BASILE, M. MONACO (<i>Messina, Italy</i>).....	1449
Induction of Apoptosis in Breast Cancer Cells by <i>Saccharomyces Cerevisiae</i> , the Baker's Yeast, <i>In Vitro</i> . M. GHONEUM, S. GOLLAPUDI (<i>Los Angeles, CA; Irvine, CA; USA</i>)	1455
Pyroglutamyl-histidyl-glycine, the Endogenous Colon Mitosis Inhibitor, Regulates Cyclic AMP Level in Non-tumorigenic Colonic Epithelial Cells . W.H. REICHELT, J.-G.H. IVERSEN, J.E. PAULSEN, K. ELGJO, K.L. REICHELT (<i>Oslo, Norway</i>)	1465
Characterization of the CDP-Like/CTAS-1 Binding Site in the Okadaic Acid Response Element (OARE) of the Human CDK1(p34 ^{cdc2}) Promoter. R. CURTIS BIRD, P. DEINNOCENTES (<i>Auburn, AL, USA</i>).....	1469
Cytotoxicity and Radical Modulating Activity of Isoflavones and Isoflavanones from <i>Sophora</i> Species. Y. SHIRATAKI, M. WAKAE, Y. YAMAMOTO, K. HASHIMOTO, K. SATOH, M. ISHIHARA, H. KIKUCHI, H. NISHIKAWA, K. MINAGAWA, N. MOTOHASHI, H. SAKAGAMI (<i>Saitama; Kiyose; Tokyo; Japan</i>)	1481
Suppression of Proline-directed Protein Kinase F _A Inhibits the Malignant Growth of Human Pancreatic Ductal Adenocarcinoma. H.-H. FU, S.-D. YANG (<i>Hsinchu, Taiwan</i>)	1489
Nuclear Methylation Levels in Normal and Cancerous Thyroid Cells. A. DE CAPOA, C. GRAPPELLI, P. VOLPINO, M. BONONI, A. MUSOLINO, A. CIARDI, A. CAVALLARO, V. CANGEMI (<i>Rome, Italy</i>).....	1495
N-Acetyltransferase Activity is Involved in Paclitaxel-induced N-Acetylation of 2-Aminofluorene in Human Bladder Cancer Cells (T24). C.-C. YANG, J.-H. YANG, H.-F. LU, S.-Y. CHEN, S.-Y. LIN, J.-G. CHUNG (<i>Taichung; Taipei, Taiwan</i>).....	1501
Differential Expression of the Prion-like Protein Doppel Gene (PRND) in Astrocytomas: A New Molecular Marker Potentially Involved in Tumor Progression. S. COMINCINI, A. FACOETTI, I. DEL VECCHIO, K. PEOC'H, J.-L. LAPLANCHE, L. MAGRASSI, M. CERONI, L. FERRETTI, R. NANO (<i>Paris, France; Pavia; Monza, Italy</i>).....	1507
Id3-mediated Enhancement of Cisplatin-induced Apoptosis in a Sarcoma Cell Line MG-63. T.KOYAMA, H. SUZUKI, A. IMAKIIRE, N. YANASE, K. HATA, J. MIZUGUCHI (<i>Tokyo, Japan</i>).....	1519

High Frequency of Allele-specific Down-regulation of HLA class I Expression in Lung Cancer Cell Lines. A. HIRAKI, N. FUJII, T. MURAKAMI, K. KIURA, K. AOE, H. YAMANE, K. MASUDA, T. MAEDA, K. SUGI, Z. DARZYNKIEWICZ, M. TANIMOTO, M. HARADA (<i>Ube, Okayama, Japan; NewYork, NY, USA</i>).....	1525
* Metals and Metal Compounds in Cancer Treatment. B. DESOIZE (<i>Reims, France</i>).....	1529
A Novel Quantitative Chick Embryo Assay as an Angiogenesis Model Using Digital Image Analysis. C. PEIFER, G. DANNHARDT (<i>Mainz, Germany</i>).....	1545
Ultrastructure of Sarcoma 180 Cells After Ultrasound Irradiation in the Presence of Sparfloxacin. D. HUANG, K. OKADA, C. KOMORI, E. ITOI, K. KAWAMURA, T. SUZUKI (<i>Akita, Japan</i>).....	1553
A Microplate Assay for Selective Measurement of Growth of Epithelial Tumor Cells in Direct Coculture with Stromal Cells. M. KAWADA, Y. YOSHIMOTO, K. MINAMIGUCHI, H. KUMAGAI, T. SOMENO, T. MASUDA, M. ISHIZUKA, D. IKEDA (<i>Shizuoka, Japan</i>).....	1561
The Breakdown of Apoptotic Mechanism in the Development and Progression of Colorectal Carcinoma. S. OGAWA, M. NAGAO, H. KANEHIRO, M. HISANAGA, S. KO, N. IKEDA, Y. NAKAJIMA (<i>Nara, Japan</i>).....	1569
mRNA Expression of the Angiogenesis Markers VEGF and CD105 (Endoglin) in Human Breast Cancer. F. GÓMEZ-ESQUER, D. AGUDO, F. MARTÍNEZ-ARRIBAS, M.-J. NUNEZ-VILLAR, J. SCHNEIDER (<i>Madrid, Spain</i>).....	1581
Shikonin Inhibits the Growth and N-acetylation of 2-Aminofluorene in <i>Helicobacter pylori</i> from Ulcer Patients. H.-M. KUO, T.-C. HSIA, Y.-C. CHUANG, H.-F. LU, S.-Y. LIN, J.-G. CHUNG (<i>Taichung, Taiwan</i>).....	1587
Procarbazine Radiolysis and Experiments <i>In Vitro</i> . A. DELIPETAR-GRUDL, N. GETOFF (<i>Wien, Austria</i>).....	1593
Human Herpesvirus Type 8 Genotypes in Iatrogenic, Classic and AIDS-associated Kaposi's Sarcoma from Greece. M. GAZOULI, I. PAPACONSTANTINO, G. ZAVOS, V. METAXA-MARIATOU, G. NASIOULAS, J. BOLETIS, P. ARAPADONI-DADIOTI, K. GIASLAKIOTIS, A. ZOGRAFIDIS, A. KOSTAKIS (<i>Pireaus, Athens, Greece</i>).....	1597
Alteration of E-Cadherin Expression in Gastric Mucosa: Role of Intestinal Metaplasia and <i>Helicobacter pylori</i> Infection. A. ZULLO, A. ROMITI, F. BORRINI, C. HASSAN, F. STELLA, I. SARCINA, M.E. MARTINI, S. TOMAO, S. MORINI, P. MINGAZZINI (<i>Rome, Italy</i>).....	1603
Granulocyte/Macrophage Colony-stimulating Factor and Interleukin-4-induced Dendritic Cells. H. HIKINO, K. KASONO, M. KANZAKI, T. KAI, F. KONISHI, M. KAWAKAMI (<i>Saitama, Japan</i>).....	1609
Effects of Clodronate on Cancer Growth and Ca ²⁺ Signaling of Human Thyroid Carcinoma Cell Lines. D.-M. YANG, C.-W. CHI, H.-M. CHANG, L.-H. WU, T.-K. LEE, J.-D. LIN, S.-T. CHEN, C.-H. LEE (<i>Taoyuan; Taipei, Taiwan</i>).....	1617
Chemotaxis and Chemokinesis of Malignant Mesothelioma Cells to Multiple Growth Factors. Z. LIU, J. KLOMINEK (<i>Stockholm, Sweden</i>).....	1625
Synthesis and Multidrug Resistance Reversal Activity of 1,2-Disubstituted Tetrahydroisoquinoline Derivatives. A. MIHÁLYI, R. GÁSPÁR, Z. ZALÁN, L. LÁZÁR, F. FÜLÖP, P.A.M. DE WITTE (<i>Szeged, Hungary; Leuven, Belgium</i>).....	1631
Changed Adhesion Molecule Profile of Ewing Tumor Cell Lines and Xenografts under the Influence of Ionizing Radiation. S. KÖNEMANN, J. MALATH, T. BÖLLING, A. KOLKMEYER, K. JANKE, D. RIESENBECK, S. HESSELMANN, T.P. NGUYEN, R. DIALLO, J. VORMOOR, N. WILLICH, A. SCHUCK (<i>Düsseldorf, Münster, Germany</i>).....	1637
Promoter CpG Methylation of Caveolin-1 in Sporadic Colorectal Cancer. S.-Y. LIN, K.-T. YEH, W.T.-L. CHEN, H.-C. CHEN, S.-T. CHEN, J.-G. CHANG (<i>Taipei, Changhua, Taichung, Taiwan</i>).....	1645

Expression of Different Vascular Endothelial Markers in Prostate Cancer and BPH Tissue: An Immunohistochemical and Clinical Evaluation. L. TROJAN, D. THOMAS, D. FRIEDRICH, R. GROBHOLZ, T. KNOLL, P. ALKEN, M.S. MICHEL (<i>Mannheim, Germany</i>).....	1651
Retinoic Acid Enhances Histamine Content and H1 Receptor Expression in Human Neuroblastoma Cell Line Paju. H. HEGYESI, ZS. DARVAS, V. LÁSZLÓ, Z. PÓS, É. PÁLLINGER, K. HIRSCHBERG, P. KOVÁCS, A. FALUS (<i>Budapest, Hungary</i>)	1657
CD44s Expression, in Benign, Borderline and Malignant Tumors of Ovarian Surface Epithelium. Correlation with p53, Steroid Receptor Status, Proliferative Indices (PCNA, MIB1) and Survival. N. ZAGORIANAKOU, D. STEFANO, G. MAKRYDIMAS, P. ZAGORIANAKOU, E. BRIASOULIS, B. KARAVASILIS, N.J. AGNANTIS (<i>Ioannina, Greece</i>)	1665
Expression of L-type Amino Acid Transporter 1 (LAT1) and 4F2 Heavy Chain (4F2hc) in Oral Squamous Cell Carcinoma and its Precursor Lesions. D.K. KIM, S.G. AHN, J.C. PARK, Y. KANAI, H. ENDOU, J.H. YOON (<i>Gwangju, Korea; Tokyo, Japan</i>)	1671
N-Ethylphenyl Acetamide (EPA) Inhibits DNA Synthesis and N-Acetylation of 2-Aminofluorene in Human Colon Tumor Cells (colo 205). W.-C. LIN, C. SHUN, L.-J. HUANG, S.-C. KUO, C.-S. YU, J.-G. CHUNG (<i>Taichung, Taiwan</i>)	1677
Induction of Apoptosis by Tocotrienol in Rat Hepatoma dRLh-84 Cells. M. SAKAI, M. OKABE, M. YAMASAKI, H. TACHIBANA, K. YAMADA (<i>Fukuoka, Japan</i>).....	1683
A Simple Model to Simulate Cellular Changes in the T Cell System Following HIV-1 Infection. G. WANG, G.R.F. KRUEGER, L. M. BUJA (<i>Houston, TX, USA</i>)	1689
Stealth Liposomal 5-Fluorouracil With or Without Degradable Starch Microspheres for Hepatic Arterial Infusion in the Treatment of Liver Metastases. An Animal Study in VX-2 Liver Tumor-bearing Rabbits. U. POHLEN, R. RESZKA, P. SCHNEIDER, H.J. BUHR, G. BERGER (<i>Berlin, Germany</i>).....	1699
Isolation and Characterization of a New Cell Line from a Renal Carcinoma Bone Metastasis. S. AVNET, E. CENNI, D. GRANCHI, F. PERUT, I. AMATO, L. BATTISTELLI, M.L BRANDI, A. GIUNTI, N. BALDINI (<i>Florence, Italy</i>)	1705
Selected Cyclic Dipeptides Inhibit Cancer Cell Growth and Induce Apoptosis in HT-29 Colon Cancer Cells. S.C. BRAUNS, P. MILNE, R. NAUDÉ, M. VAN DE VENTER (<i>Port Elizabeth, South Africa</i>)	1713
Comparative Genomic Hybridization in Cartilaginous Tumors. T. OZAKI, D. WAI, K.-L. SCHÄFER, N. LINDNER, W. BÖCKER, W. WINKELMANN, B. DOCKHORN-DWORNICZAK, C. POREMBA (<i>Münster; Kempten, Germany</i>).....	1721
Luteinizing Hormone-releasing Hormone (LHRH) Inhibits Apoptosis Induced by Cytotoxic Agent and UV-light but not Apoptosis Mediated Through CD95 in Human Ovarian and Endometrial Cancer Cells. A.R. GÜNTHER, C. GRÜNDKER, B. BÖTTCHER, G. EMONS (<i>Göttingen, Germany</i>)	1727
New Evaluation of Plasma DNA Microsatellite Analysis in Patients with TCC of the Urinary Bladder. D. FORNARI, K. STEVEN, A.B. HANSEN, H. VIBITS, J.V. JEPSEN, A.L. POULSEN, M. SCHWARTZ, T. HORN (<i>Herlev; Copenhagen, Denmark</i>)	1733
Role of Protein Kinase C-dependent Signaling Pathways in the Antiangiogenic Properties of Nafoxidine. M.S. DE LORENZO, H.G. FARINA, D.F. ALONSO, D.E. GOMEZ (<i>Buenos Aires, Argentina</i>)	1737
Topotecan-induced Alterations in the Amount and Stability of Human DNA Topoisomerase I in Solid Tumor Cell Lines. J. DEVY, R. WARGNIER, M. PLUOT, I. NABIEV, A. SUKHANOVA (<i>Reims, France</i>)	1745

Mitochondrial DNA Mutations in Light-associated Skin Tumors. J.-H. YANG, H.-C. LEE, J.-G. CHUNG, Y.H. WEI (<i>Taichung, Taipei, Taiwan</i>)	1753
Antiangiogenic Potency of Various Chemotherapeutic Drugs for Metronomic Chemotherapy. J. DREVS, J. FAKLER, S. EISELE, M. MEDINGER, G. BING, N. ESSER, D. MARMÉ, C. UNGER (<i>Freiburg, Germany</i>).....	1759
Histological Changes Pertinent to Local Tumor Progression in Hereditary Nonpolyposis Colorectal Cancer (HNPCC). A Preliminary Report. C.A. RUBIO and A. LINDBLOM (<i>Stockholm, Sweden</i>)	1765
Selective Induction of G2/M Arrest and Apoptosis in HL-60 by a Potent Anticancer Agent, HMJ-38. J.-S. YANG, M.-J. HOUR, S.-C. KUO, L.-J. HUANG, M.-R. LEE (<i>Taichung, Taiwan</i>).....	1769
Retinoids and Cancer: Antitumor Effect of ATRA and of a New Derivative of Retinoic Acid, IIF, on Colon Carcinoma Cell Lines CaCo-2 and HT-29 . G. BARTOLINI, K. AMMAR, B. MANTOVANI, F. SCANABISSI, A.M. FERRERI, P. ROCCHI, M. ORLANDI (<i>Bologna, Italy</i>)	1779
Intravenous Chemotherapy with Cisplatin for Regional Lymph Node Metastases of Auricular VX2 Carcinoma . A.A. DÜNNE, C. KUROPKAT, N. SAPUNDZHIEV, A. RAMASWAMY, A. SESTERHENN, S. SCHULZ, J.A. WERNER (<i>Marburg, Germany</i>).....	1785
ProteinChip® Array Analysis of Microdissected Colorectal Carcinoma and Associated Tumor Stroma Shows Specific Protein Bands in the 3.4 to 3.6 kDa Range. R.C. KRIEG, F. FOGT, T. BRAUNSCHWEIG, P.C. HERRMANN, V. WOLLSCHIEDT, A. WELLMANN (<i>Aachen, Germany; Philadelphia, PA, USA; Bonn, Bernried, Germany; Bethesda, MD, USA</i>)	1791
Expression of bFGF, VEGF and c-met and their Correlation with Microvessel Density and Progression in Prostate Carcinoma. D. STROHMEYER, F. STRAUß, C. RÖSSING, C. ROBERTS, O. KAUFMANN, G. BARTSCH, P. EFFERT (<i>Innsbruck, Austria; Berlin, Germany; Milan, Italy; Aachen, Germany</i>).....	1797
Combinatorial Chemoprevention: Efficacy of Lovostatin and Exisulind on the Formation and Progression of Aberrant Crypt Foci. K.P. KIM, C. WHITEHEAD, G. PIAZZA, M.J. WARGOVICH (<i>Columbia, SC; Birmingham, AL; Horsham, PA; USA</i>)	1805
A Continuous Model Studying T Cell Differentiation and Lymphomagenesis and its Distinction with Discrete Models. G. WANG, G.R.F. KRUEGER, L.M. BUJA (<i>Houston, TX, USA</i>).....	1813
Mevastatin-induced Apoptosis and Growth Suppression in U266 Myeloma Cells. J. JÁNOSI, A. SEBESTYÉN, J. BOCSI, G. BARNA, K. NAGY, I. VÁLYI-NAGY, L. KOPPER (<i>Budapest, Hungary</i>).....	1817
Profile of Cytokines Produced in Tumor Tissue after Administration of Cyclophosphamide in a Combination Therapy with Tumor Necrosis Factor. K. TAKIGUCHI, T. NAKAMOTO, H. INAGAWA, C. KOHCHI, T. NISHIZAWA, N. NAGASUE, G.-I. SOMA (<i>Nagoya; Shimane; Yamaguchi; Tokushima; Japan</i>)	1823
Review (page 1529)	

Number 3B

Clinical Studies

* Presence of Human Papillomavirus in Tonsillar Cancer Is a Favourable Prognostic Factor for Clinical Outcome. H. DAHLSTRAND (MELLIN), L. DAHLGREN, D. LINDQUIST, E. MUNCK-WIKLAND, T. DALIANIS (<i>Stockholm, Sweden</i>)	1829
Combined Treatment with Histamine Dihydrochloride, Interleukin-2 and Interferon- α in Patients with Metastatic Melanoma. P. LINDNÉR, M. RIZELL, J. MATTSSON, K. HELLSTRAND, P. NAREDI (<i>Göteborg; Umea, Sweden</i>)	1837

Phase I Study of Combination Therapy with S-1, Docetaxel (TXT) for Advanced or Recurrent Gastric Cancer. K. YOSHIDA, N. HIRABAYASHI, W. TAKIYAMA, M. NINOMIYA, N. TAKAKURA, J. SAKAMOTO, M. NISHIYAMA, T. TOGE (<i>Hiroshima; Kyoto, Japan</i>).....	1843
Neoangiogenesis in Patients with Gastric Carcinoma in Relation to the Expression of Vascular Endothelial Growth Factor and Thymidine Phosphorylase. S. TSUJITANI, H. SAITO, Y. MAETA, K. YAMAGUCHI, S. TATEBE, A. KONDO, N. KAIBARA (<i>Yonago, Japan</i>).....	1853
Autologous Natural Killer Cell Therapy for Human Recurrent Malignant Glioma. E. ISHIKAWA, K. TSUBOI, K. SAJO, H. HARADA, S. TAKANO, T. NOSE, T. OHNO (<i>Ibaraki, Japan</i>).....	1861
Gefitinib as Salvage Therapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer. Data from a Compassionate Use Program. C. GRIDELLI, A. ROSSI, P. MAIONE, C. GUERRIERO, G. AIROMA, G. COLANTUONI, M.L. BARZELLONI (<i>Avellino, Italy</i>).....	1873
A Randomized Consent Design Trial of Neoadjuvant Chemotherapy with Tegafur Plus Uracil (UFT) for Gastric Cancer – A Single Institute Study. Y. NIO, M. KOIKE, H. OMORI, K. HASHIMOTO, M. ITAKURA, S. YANO, T. HIGAMI, R. MARUYAMA (<i>Shimane, Japan</i>).....	1879
Acetabular Osteosarcoma Treated by Irradiation-vascularized Hybrid Bone Graft. T. KUBO, T. SUGITA, S. SHIMOSE, H. TANAKA, H. NOBUTO, K. TANAKA, M. OCHI (<i>Hiroshima, Japan</i>).....	1889
Histological Findings in a Human Autogenous Pasteurized Bone Graft. T. KUBO, T. SUGITA, S. SHIMOSE, K. ARIHIRO, H. TANAKA, H. NOBUTO, K. TANAKA, M. OCHI (<i>Hiroshima, Japan</i>).....	1893
Kaposi's Sarcoma of the Tongue Associated with Median Rhomboid Glossitis in a Non-AIDS Patient. A Case Report. R. ROSSIELLO, G. COLELLA, R.A. SATRIANO, A. VOZZA, L. ROSSIELLO (<i>Napoli, Italy</i>).....	1897
Long-term Survival over 28 Years of a Patient with Metastatic Adrenal Cortical Carcinoma – Case Report. A. MEYER, M. BEHREND (<i>Hannover; Deggendorf, Germany</i>).....	1901
Primary Choriocarcinoma of the Lung. Y. UMEMORI, A. HIRAKI, K. AOE, T. MURAKAMI, T. MAEDA, E. MATSUDA, H. TAKEYAMA (<i>Yamaguchi, Japan</i>).....	1905
Validation of the Limited-sampling Models for Carboplatin AUC in Combination Chemotherapy with Taxanes. M. MIYAZAKI, T. OGURI, T. KURATA, T. TAKAHASHI, H. DAGA, K. FUJITAKA, T. ISOBE, M. NAKAJIMA, Y. FUJIWARA, N. KOHNO (<i>Hiroshima, Japan</i>).....	1911
A Retrospective Study Focusing on Clinical Predictive Factors in 126 Patients with Oesophageal Carcinoma. M. DREILICH, S. BERGSTRÖM, G. WAGENIUS, D. BRATTSTRÖM, M. BERGOVIST (<i>Uppsala, Sweden</i>).....	1915
Significance of T Stadium and Grading as Prognostic Factors in Transitional Cell Carcinoma of the Ureter. E. FIORI, G. CAVALLARO, C. PAPARELLI, A. DECESARE, M. BONONI, G. GALATI, G. TIZIANO, A. CAVALLARO, V. CANGEMI (<i>Rome, Italy</i>).....	1921
Bcl-2 Protein Expression Correlates with Better Prognosis in Patients with Advanced Non-small Cell Lung Cancer. Y. SHIBATA, S. HIDAKA, Y. TAGAWA, T. NAGAYASU (<i>Nagasaki, Japan</i>).....	1925
Preoperative Chemolipiodolization of the Whole Liver for Hepatocellular Carcinoma. M. KAIBORI, N. TANIGAWA, Y. MATSUI, A.-H. KWON, S. SAWADA, Y. KAMIYAMA (<i>Osaka, Japan</i>).....	1929
Oxaliplatin Fractionated Over Two Days with Bimonthly Leucovorin and 5-Fluorouracil in Metastatic Colorectal Cancer. F. RECCHIA, S. REA, A. NUZZO, A. LALLI, L. DI LULLO, S. DE FILIPPIS, G. SAGGIO, E. BIONDI, E. MASSA, G. MANTOVANI (<i>L'Aquila; Cagliari, Italy</i>).....	1935
The Prognostic Value of Both Neuron-specific Enolase (NSE) and Cyfra21-1 in Small Cell Lung Cancer. S. ANDO, M. SUZUKI, N. YAMAMOTO, T. IIDA, H. KIMURA (<i>Chiba, Japan</i>).....	1941

Tolerability of Adjuvant High-dose Interferon Alfa-2b: 1 Month <i>Versus</i> 1 Year—A Hellenic Cooperative Oncology Group Study. H. GOGAS, D. BAFALOUKOS, J. IOANNOVICH, D. SKARLOS, A. POLYZOS, G. FOUNTZILAS, H.P. KALOFONOS, G. ARAVANTINOS, D. TSOUTSOS, P. PANAGIOTOU, K. FRANGIA, T. PETRAKOPOULOU, D. PECTASIDES (<i>Athens; Piraeus; Thessaloniki; Patras, Greece</i>)	1947
CYFRA 21-1 and CEA are Independent Prognostic Factors in 153 Operated Stage I NSCLC Patients. T. MULEY, H. DIENEMANN, W. EBERT (<i>Heidelberg, Germany</i>)	1953
Epoetin Beta (NeoRecormon) Corrects Anaemia in Patients with Hormone-refractory Prostate Cancer and Bone Metastases. J. BOGDANOS, D. KARAMANOLAKIS, K. MILATHIANAKIS, P. REPOUSIS, A. CHLORAKI-BOBOTA, H. MAJED, E. PAGALOU-THOUA, A. TSINTAVIS, M. KOUTSILIERIS (<i>Athens; Piraeus, Greece</i>).....	1957
Epirubicin Plus Docetaxel in Metastatic Breast Cancer: Escalating Dose does not Improve Efficacy. A Phase II Study. A. FABI, P. PAPALDO, M.S. PINO, G. FERRETTI, P. CARLINI, U. PACETTI, S. DI COSIMO, C. NARDONI, D. GIANNARELLI, I. SACCHI, F. COGNETTI (<i>Rome, Italy</i>).....	1963
5FU and Oxaliplatin-containing Chemotherapy in Two Dihydropyrimidine Dehydrogenase-deficient Patients. O. REERINK, N.H. MULDER, B.G. SZABO, G.A.P. HOSPERS (<i>Groningen, The Netherlands</i>).....	1969
Correlation of Serum VEGF Levels with Clinical Stage, Therapy Efficacy, Tumor Metastasis and Patient Survival in Ovarian Cancer. L. LI, L. WANG, W. ZHANG, B. TANG, J. ZHANG, H. SONG, D. YAO, Y. TANG, X. CHEN, Z. YANG, G. WANG, X. LI, J. ZHAO, H. DING, E. REED, Q.Q. LI (<i>Nanning; Beijing, China; Morgantown, WV, USA</i>)	1973
The Prognostic Value of Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Stage III Ovarian Cancer Patients. F.D. BEGUM, C.K. HØGDALL, S.K. KJAER, L. CHRISTENSEN, J. BLAAKAER, J.E. BOCK, E. GLUD, G. HØYER-HANSEN, H. RING-LARSEN, E.V.S. HØGDALL (<i>Copenhagen; Skejby, Denmark</i>).....	1981
Prognostic Significance of Serum HER2 and CA 15-3 at the Time of Diagnosis of Metastatic Breast Cancer. T. FEHM, W. JÄGER, S. KRÄMER, C. SOHN, E. SOLOMAYER, D. WALLWIENER, G. GEBAUER (<i>Tuebingen; Nuremberg; Hannover, Germany</i>)	1987
Peroxisome Proliferator Activated Receptor Gamma Immunohistochemical Expression in Human Papillary Thyroid Carcinoma Tissues. Possible Relationship to Lymph Node Metastasis. B. GALUSCA, J.M. DUMOLLARD, M.L. CHAMBONNIERE, N. GERMAIN, J.M. PRADES, M. PÉOC'H, B. ESTOUR (<i>Saint-Etienne, France</i>)	1993
99m-Tc-MDP-Scintimammography in the Evaluation of Breast Masses or Tumor Angiogenesis. N.S. TURHAL, F. DANE, F. DEDE, M. GUMUS, P. FULDEN YUMUK, F. CAKALAGA OGLU, D. SAVCI, M. KARAMAN, B. GULLU OGLU, H. TURGUT TUROGLU (<i>Istanbul, Turkey</i>)	1999
Expression of Betacellulin, Heparin-binding Epidermal Growth Factor and Epiregulin in Human Malignant Fibrous Histiocytoma. T. YAMAMOTO, T. AKISUE, T. MARUI, T. NAKATANI, T. KAWAMOTO, T. HITORA, K. NAGIRA, I. FUJITA, K. MATSUMOTO, M. KUROSAKA (<i>Kob, Akashi, Japan</i>).....	2007
Decrease in Specific Micronutrient Intake in Colorectal Cancer Patients with Tumors Presenting <i>Ki-ras</i> Mutation. N. LASO, S. MAS, M. JOSE LAFUENTE, X. CASTERAD, M. TRIAS, A. BALLESTA, R. MOLINA, J. SALAS, C. ASCASO, S. ZHENG, J.K. WIENCKE, A. LAFUENTE (<i>Barcelona; Reus, Spain; San Francisco, CA USA</i>).....	2011
Single Nucleotide Polymorphisms in <i>MMP1</i> and <i>MMP3</i> Gene Promoters as Risk Factor in Head and Neck Squamous Cell Carcinoma. F. ZINZINDOHOUE, H. BLONS, S. HANS, M.-A. LORIOT, A.-M. HOULLIER, D. BRASNU, O. LACCOURREYE, D.-A. TREGOUET, I. STUCKER, P. LAURENT-PUIG (<i>Paris; Villejuif, France</i>).....	2021
Circulating Soluble E-Cadherin Levels are of Prognostic Significance in Patients with Multiple Myeloma. K.N. SYRIGOS, K. J. HARRINGTON, A.J. KARAYIANNAKIS, N. BAIBAS, N. KATIRTZOGLU, P. ROUSSOU (<i>Athens, Greece; London, UK</i>)	2027

Possible Mechanism Pertinent to Mucosal Invasion in Sporadic Colonic Adenomas. C.A. RUBIO (<i>Stockholm, Sweden</i>)	2033
Efficacy of Infusional Biomodulated 5-Fluorouracil in Metastatic Colorectal Cancer after Raltitrexed Failure. L. DECOSTER, B. NEYNS, H. AKOUAOUACH, C. FONTAINE, D. SCHALLIER, J.L.P. DE GREVE (<i>Brussels, Belgium</i>)	2037
Pharmacokinetics of Cisplatin in Semi-closed Hyperthermic Peritoneal Perfusion (HPP) for Treatment of Peritoneal Carcinomatosis. L. CATTEL, M. DE SIMONE, R. PASSERA, M.C. VERLENGO, L. DELPRINO (<i>Torino; Empoli, Italy</i>).....	2041
Alterations of the K-ras, p53 Genes and Microsatellite Instability in Sporadic Colorectal Carcinomas. A. HASEGAWA, T. FUKUSHIMA, M. MASHIKO, K. NAKANO, S. SUZUKI, Y. ENDO, S. OHKI, Y. HATAKEYAMA, Y. KOYAMA, N. INOUE, Y. TAKEBAYASHI, K. SEKIKAWA, S.-I. TAKENOSHITA (<i>Fukushima, Japan</i>).....	2047
* Thrombocytosis in Gynecologic Malignancies. F. GÜCER, K. TAMUSSINO, F. KEIL, P. BALKANLIKAPLAN, M.A. YÜCE (<i>Edirne, Turkey; Graz; Vienna, Austria</i>)	2053
Tumor Histology and Stage but not p53, Her2-neu or Cathepsin-D Expression are Independent Prognostic Factors in Breast Cancer Patients . D.P. KORKOLIS, E. TSOLI, D. FOUSKAKIS, J. YIOTIS, G.J. KOULLIAS, D. GIANNOPOULOS, E. PAPALAMBROS, N.I. NIKITEAS, E. PATSOURIS, P. ASIMACOPOULOS, V.G. GORGOLIS (<i>Athens, Greece; Houston, TX, USA</i>).....	2061
Demographic and Clinical Factors as Determinants of Serum Levels of Prostate Specific Antigen and its Derivatives. M.A. GRAY, B. DELAHUNT, J.R. FOWLES, P. WEINSTEIN, R.R. COOKE, J.N. NACEY (<i>Wellington, New Zealand</i>).....	2069
Prognostic Value of Pelvic Lymphadenectomy in Surgical Treatment of Apparent Stage I Endometrial Cancer. M. CECCARONI, L. SAVELLI, A. BOVICELLI, C. ALBONI, M. CECCARINI, A. FARINA, L. BOVICELLI (<i>Bologna, Italy; Philadelphia, PA, USA</i>).....	2073
Cardiotoxicity in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum and Non-platinum Based Combinations as First-line Treatment. F.M. WACHTERS, W.T.A. VAN DER GRAAF, H.J.M. GROEN (<i>Groningen, The Netherlands</i>).....	2079
Combination Chemotherapy with Docetaxel and Doxifluridine showed a Beneficial Outcome in Advanced or Recurrent Breast Cancer Patients with Longer Disease-free Interval. R. NISHIMURA, T. TOMINAGA, S. MITSUYAMA, H. AOYAMA, T. ASAGA, S. OHNO, N. OKUYAMA, M. KIMURA, H. IWASE, K. KANDA, T. KOGA, E. SHIBA, T. IKEDA (<i>Kumamoto; Tokyo; Fukuoka; Nagoya; Yokohama; Gunma; Osaka, Japan</i>)	2085
Oxaliplatin Hepatic Arterial Infusion Chemotherapy for Hepatic Metastases from Colorectal Cancer: A Phase I-II Clinical Study. G. FIORENTINI, S. ROSSI, P. DENTICO, F. MEUCCI, F. BONECHI, P. BERNARDESCHI, M. CANTORE, S. GUADAGNI, M. DE SIMONE (<i>Empoli; Massa-Carrara; L'Aquila, Italy</i>).....	2093
Ten-year Disease-free Survival of a Small Cell Lung Cancer Patient with Brain Metastasis Treated with Chemoradiotherapy. Y. NIIBE, K. KARASAWA, K. HAYAKAWA (<i>Tokyo; Kanagawa, Japan</i>).....	2097
Prognostic Impact of Tissue Inhibitor of Matrix Metalloproteinase- 1 in Plasma of Patients with Colorectal Cancer. N. YUKAWA, T. YOSHIKAWA, M. AKAIKE, Y. SUGIMASA, S. TAKEMIYA, S. YANOMA, T. IMADA, Y. NOGUCHI (<i>Yokohama, Japan</i>).....	2101
Gemcitabine and Continuous Infusion of 5-Fluorouracil in Locally Advanced and Metastatic Pancreatic Cancer: A Phase I-II Study. C. OLIANI, M. PADOVANI, P. MANNO, D. BARANA, M. FALCONI, C. BASSI, G. CAVALLINI, P. PEDERZOLI, G.L. CETTO (<i>Verona, Italy</i>).....	2107

Serrated Adenomas of the Cardia. C.A. RUBIO, J. LAGERGREN (<i>Stockholm, Sweden</i>).....	2113
* Instruments for Quality of Life Assessment in Patients with Gastrointestinal Cancer. A.G. PALLIS, I.A. MOUZAS (<i>Heraklion, Greece</i>)	2117
CD3 ζ Expression of Regional Lymph Node and Peripheral Blood Lymphocytes in Gastric Cancer. S. ISHIGAMI, S. NATSUGOE, F. MIYAZONO, K. TOKUDA, A. NAKAJO, M. MATSUMOTO, H. OKUMURA, S. NAKASHIMA, S. HOKITA, I. MARUYAMA, T. AIKOU (<i>Kagoshima, Japan</i>)	2123
Review (pages 1829, 2053, 2117)	

Number 4

Experimental Studies

Inhibition of the Human Apurinic/Apyrimidinic Endonuclease (Ape1) Repair Activity and Sensitization of Breast Cancer Cells to DNA Alkylating Agents with Lucanthone. M. LUO, M.R. KELLEY (<i>Indianapolis, Indiana, USA</i>).....	2127
Androgen Withdrawal Inhibits Tumor Growth and is Associated with Decrease in Angiogenesis and VEGF Expression in Androgen-Independent CWR22Rv1 Human Prostate Cancer Model. L. CHENG, S. ZHANG, C.J. SWEENEY, C. KAO, T.A GARDNER, J.N. EBLE (<i>Indianapolis, Indiana, USA</i>)	2135
<i>In Vitro</i> Generation of Cytolytic T Cells Against Human Melanoma Cells Overexpressing HDM2. A. SORURI, A. FAYYAZI, S. GANGL, C. GRIESINGER, C.A. ALBRECHT, T. SCHLOTT (<i>Goettingen; Langen, Germany</i>)	2141
Artemisinin: An Alternative Treatment for Oral Squamous Cell Carcinoma. E. YAMACHIKA, T. HABTE, D. ODA (<i>Seattle, WA, USA; Okayama City, Japan</i>)	2153
S19-mRNA Expression in Squamous Cell Carcinomas of the Upper Aerodigestive Tract. V. SENGPIEL, T. ROST, T. GÖRÖGH, I.O. RATHCKE, J.A. WERNER (<i>Marburg; Kiel, Germany</i>)	2161
Three-dimensional Culture System as a Model for Studying Cancer Cell Invasion Capacity and Anticancer Drug Sensitivity. C.J. DOILLON, E. GAGNON, R. PARADIS, M. KOUTSILIERIS (<i>Quebec, Canada; Athens, Greece</i>)	2169
Targeting Chemotherapy-induced VEGF Up-regulation by VEGF Antisense Oligonucleotides in HNSCC Cell Lines. F. RIEDEL, K. GÖTTE, U. GOESSLER, H. SADICK, K. HÖRMANN (<i>Mannheim, Germany</i>)	2179
Cyclin D1 Expression in Endometrioid-type Endometrial Adenocarcinoma is Correlated with Histological Grade and Proliferative Activity, but not with Prognosis. Y. NISHIMURA, J. WATANABE, T. JOBO, N. KATO, T. FUJISAWA, Y. KAMATA, H. KURAMOTO (<i>Kanagawa, Japan</i>)	2185
Low Renal Toxicity of Lipoplatin Compared to Cisplatin in Animals. P. DEVARAJAN, R. TARABISHI, J. MISHRA, Q. MA, A. KOURVETARIS, M. VOUGIOUKA, T. BOULIKAS (<i>Cincinnati, OH; Mountain View, VA, USA; Athens, Greece</i>).....	2193
TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply. N. HASHIGUCHI, T. KUBOTA, J.-I. KOH, Y. YAMADA, Y. SAIKAWA, Y. OTANI, M. WATANABE, K. KUMAI, M. KITAJIMA, J.-I. WATANABE, M. KOBAYASHI (<i>Tokyo; Saitama; Kanagawa, Japan</i>)	2201

Probucol, a Hypocholesterolemic Agent, Prevents the Development of Uterine Adenomyosis Induced by Pituitary Grafting in Mice. Y.-F. ZHOU, T. MORI, H. NAGASAWA, T. NAKAYAMA, T. KUBOTA, S. SAKAMOTO (<i>Beijing, China; Chiba; Kanagawa; Tokyo, Japan</i>)	2209
Growth-inhibitory Effects of the Ketone Body, Monoacetoacetin, on Human Gastric Cancer Cells with Succinyl-CoA: 3-Oxoacid CoA-Transferase (SCOT) Deficiency. M. SAWAI, M. YASHIRO, Y. NISHIGUCHI, M. OHIRA, K. HIRAKAWA (<i>Osaka, Japan</i>)	2213
Clinical Relevance of HER-2/neu Expression in Germ-cell Testicular Tumors. L. MÁNDOKY, L. GÉCZI, I. BODROGI, J. TÓTH, O. CSUKA, M. KÁSLER, M. BAK (<i>Budapest, Hungary</i>)	2219
Antineoplastic Effect of Immunostimulatory DNA (CpG-ODN) in a Murine C57-BL6 / MB-49 Transitional Cell Carcinoma Model. A. HEGELE, A. DALPKE, P. BARTH, Z. VARGA, K. HEEG, R. HOFMANN, P. OLBERT (<i>Marburg, Germany</i>)	2225
Effective Knock Down of Very High ABCG2 Expression by a Hammerhead Ribozyme. P. KOWALSKI, K.M. FARLEY, H. LAGE, E. SCHNEIDER (<i>Albany, NY, USA; Berlin, Germany</i>)	2231
Diffuse Growth Pattern Affects E-Cadherin Expression in Invasive Breast Cancer. U. BRINCK, S. JACOBS, M. NEUSS, K. TORY, W. RATH, B. KULLE, L. FÜZESI (<i>Göttingen; Aachen, Germany</i>)	2237
* Involvement of Endothelial Monocyte Activating Polypeptide II in Tumor Necrosis Factor-alpha-based Anti-cancer Therapy. T.E. LANS, R. VAN HORSSSEN, A.M.M. EGGERMONT, T.L.M. TEN HAGEN (<i>Rotterdam, The Netherlands</i>)	2243
Chemoimmunotherapy of Murine Mammary Adenocarcinomas. I.H. AMES (<i>Syracuse, NY, USA</i>)	2249
Perivascular Mast Cells in Advanced Gastric Adenocarcinomas: An Electron Microscopic Study. R.A. CARUSO, A. IENI, V. FABIANO, G. BASILE, C. INFERRERA (<i>Messina, Italy</i>)	2257
Pre-clinical Immunogenicity and Anti-tumour Efficacy of a Deleted Recombinant Human Papillomavirus Type 16 E7 Protein. S. HALLEZ, J.-M. BRULET, C. VANDOOREN, F. MAUDOUX, S. THOMAS, M. HEINDERICKX, A. BOLLEN, R. WATTIEZ, A. JACQUET (<i>Gosselies; Mons, Belgium</i>)	2265
Artemisinin Induces Apoptosis in Human Cancer Cells. N.P. SINGH, H.C. LAI (<i>Seattle, WA, USA</i>)	2277
Effects of the Polyacetylene Capillin on Human Tumour Cell Lines. L.C. WHELAN, M.F. RYAN (<i>Dublin, Ireland</i>)	2281
Involvement of Pattern Recognition Receptors in the Induction of Cytokines and Reactive Oxygen Intermediates Production by Human Monocytes/Macrophages Stimulated with Tumour Cells. B. MYTAR, M. WOLOSZYN, A. MACURA-BIEGUN, B. HAJTO, I. RUGGIERO, B. PIEKARSKA, M. ZEMBALA (<i>Cracow; Poland</i>)	2287
Isolated Limb Perfusion Based Anti-p21ras Gene Therapy in a Rat Rhabdomyosarcoma. B. VAN ETTEN, S.T. VAN TIEL, G. AMBAGTSHEER, A.M.M. EGGERMONT, T.L.M. TEN HAGEN (<i>Rotterdam, The Netherlands</i>)	2295
Acoustic Energy: A New Transfection Method for Cancer of the Prostate, Cancer of the Bladder and Benign Kidney Cells. M.S. MICHEL, P. ERBEN, L. TROJAN, A. SCHAAF, K. KIKNAVELIDZE, T. KNOLL, P. ALKEN (<i>Mannheim, Germany</i>)	2303
Epstein-Barr Virus LMP1 Status in Relation to Apoptosis, P53 Expression and Leucocyte Infiltration in Nasopharyngeal Carcinoma. J.-Y. SHAO, I. ERNBERG, P. BIBERFELD, T. HEIDEN, Y.-X. ZENG, L.-F. HU (<i>Stockholm, Sweden; Guangzhou, China</i>)	2309
Can Recurrence of Meningiomas be Predicted? J.-P. KALALA, D. BENOIT, L. DE RIDDER (<i>Ghent, Belgium</i>)	2319

Erythroid Differentiation in K562 Chronic Myelogenous Cells Induced by Crambescidin 800, a Pentacyclic Guanidine Alkaloid. S. AOKI, D. KONG, K. MATSUI, M. KOBAYASHI (<i>Osaka, Japan</i>)	2325
Somatostatin Controls LFA-1 Gene Expression by Altering Neuraminidase Expression in Spleen Cells. W.-K. YOON, H.-J. KIM, H.-Y. SON, K.-S. JEONG, S.-J. PARK, T.-H. KIM, S.-H. KIM, S.-R. KIM, S.-Y. RYU (<i>Daejeon; Daegu; Kwangju, South Korea</i>)	2331
Amifostine Protects Against Chemotherapy-induced Neurotoxicity: An <i>In Vitro</i> Investigation. C.C.P. VERSTAPPEN, T.J. POSTMA, A.A. GELDOF, J.J. HEIMANS (<i>Amsterdam, The Netherlands</i>)	2337
Antitumour Effectiveness of Hyperthermia is Potentiated by Local Application of Electric Pulses to LPB Tumours in Mice. K.B. KARNER, H. LESNICAR, M. CEMAZAR, G. SERSA (<i>Ljubljana, Slovenia</i>)	2343
Elevated Cyclooxygenase-2 Expression Correlates with Distant Metastases in Breast Cancer. G.S. RANGER, V. THOMAS, A. JEWELL, K. MOKBEL (<i>London, UK</i>)	2349
Changes in Serum Soluble VEGFR-1 and Tie-2 Receptors in Colorectal Cancer Patients Following Surgical Resections. K.-F. CHIN, J. GREENMAN, P. REUSCH, E. GARDINER, D. MARME, J. MONSON (<i>Hull, UK; Freiburg, Germany</i>)	2353
Clinical Studies	
Correlation of FDG-PET Interpretation with Survival in a Cohort of Glioma Patients. F.S. PARDO, H.J. ARONEN, M. FITZEK, D.N. KENNEDY, J. EFIRD, B.R. ROSEN, A.J. FISCHMAN (<i>Boston, MA; La Jolla; Palo Alto, CA; Helsinki, Finland; Berlin, Germany</i>)	2359
Survival in Small Cell Lung Cancer is Independent of Tumor Expression of VEGF and COX-2. J.E. DOWELL, R.H. AMIRKHAN, W.S. LAI, W.H. FRAWLEY, J.D. MINNA (<i>Dallas, TX, USA</i>)	2367
Spectrum of Cytokeratin-positive Cells in the Bone Marrows of Colorectal Carcinoma Patients. J.D. SHETYE, M.L. LILJEFORS, S.O. EMDIN, J.-E. FRÖDIN, K. STRIGÅRD, H.T. MELLSTEDT, A. PORWIT (<i>Stockholm; Umea, Sweden</i>)	2375
Case Report: A Young Woman with Advanced Esophageal Cancer Showing Pathological Complete Response to Neoadjuvant Chemotherapy (CDDP, 5-FU and ADM). Y. NARITAKA, K. OGAWA, T. SHIMAKAWA, Y. WAGATSUMA, K. HAMAGUCHI, S. KONNO, T. KATŠUBE, H. YAGAWA, M. AIBA, H. IDE (<i>Tokyo, Japan</i>)	2385
LEA-135 Expression: Its Association with a Lower Risk of Recurrence and Increased Overall Survival of Patients with Lymph Node-positive Primary Invasive Breast Cancer. B. SAHA, N. ZHANG, W.Y. NARITOKU, D.D. TSAO-WEI, S.L. GROSHEN, G. CARLSSON, L. LARSSON, B. GUSTAVSSON, B. CHAIWUN, C.R. TAYLOR, S.A. IMAM (<i>Pasadena; Los Angeles, CA; Göteborg, Sweden; Chiangmai, Thailand</i>)	2391
Evaluation of the Clinical Significance of HER2 Amplification by Chromogenic <i>In Situ</i> Hybridisation in Patients with Primary Breast Cancer. N. DANDACHI, O. DIETZE, C. HAUSER-KRONBERGER (<i>Salzburg; Graz, Austria</i>)	2401
The Expression and Prognostic Value of α -, β - and γ -Catenins in Renal Cell Carcinoma. S. AALTOMAA, P. LIPPONEN, V. KÄRJÄ, S. LUNDSTEDT, J. LAPPI, V.-M. KOSMA (<i>Kuopio; Jyväskylä; Tampere, Finland</i>)	2407
Absence of BRAF Gene Mutations Differentiates Spitz Nevi from Malignant Melanoma. D. MIHIC-PROBST, A. PERREN, S. SCHMID, P. SAREMASLANI, P. KOMMINOTH, P.U. HEITZ (<i>Baden, Switzerland</i>)	2415

Radiofrequency Ablation Combined with Percutaneous Ethanol Injection in the Treatment of Hepatocellular Carcinoma and Portal Vein Neoplastic Thrombosis. G. POGGI, C. GATTI, C. TERAGNI, ANGELO DELMONTE, GIOVANNI BERNARDO (<i>Pavia, Italy</i>)	2419
Long-term Intravenous Administration of Activated Autologous Lymphocytes for Cancer Patients does not Induce Antinuclear Antibody and Rheumatoid Factor. T. YAMAGUCHI, K. BAMBA, A. KITAYAMA, Y. KUROIWA, K. YOSHIMATSU, T. SHIMAKAWA, K. OGAWA, T. SEKINE, N. SHIMIZU, K. YAMAMOTO (<i>Tokyo, Japan</i>)	2423
Genetic Polymorphisms of Hormone-related Genes and Prostate Cancer Risk in the Japanese Population. T. FUKATSU, Y. HIROKAWA, T. ARAKI, T. HIOKI, T. MURATA, H. SUZUKI, T. ICHIKAWA, H. TSUKINO, D. QIU, T. KATOH, Y. SUGIMURA, R. YATANI, T. SHIRAISHI, M. WATANABE (<i>Tsu; Matsusaka; Suzuka; Chiba; Miyazaki; Yokohama, Japan</i>)	2431
Lymph Node Dissection in Papillary or Follicular Thyroid Carcinoma. M. BONONI, A. TOCCHI, V. CANGEMI, A. VECCHIONE, M.R. GIOVAGNOLI, A. DE CESARE, E. FIORI, P. VOLPINO, S. BROZZETTI, M. MEUCCI, S. SCOZZAFAVA, A. CAVALLARO (<i>Rome, Italy</i>)	2439
* Boosting the Immune Response: An Alternative Combination Therapy for Cancer Patients. G. THYPHRONITIS, M. KOUTSILIERIS (<i>Athens, Greece</i>)	2443
Thymidylate Synthetase (TS) Genotype and TS/dihydropyrimidine Dehydrogenase mRNA Level as an Indicator in Determining Chemosensitivity to 5-Fluorouracil in Advanced Gastric Carcinoma. F. TORIUMI, T. KUBOTA, Y. SAIKAWA, M. YOSHIDA, Y. OTANI, M. WATANABE, K. KUMAI, M. KITAJIMA (<i>Tokyo, Japan</i>)	2455
Randomized Phase II Study Comparing Mitomycin, Cisplatin Plus Doxifluridine with Cisplatin Plus Doxifluridine in Advanced Unresectable Gastric Cancer. W. KOIZUMI, Y. FUKUYAMA, T. FUKUDA, T. AKIYA, K. HASEGAWA, Y. KOJIMA, N. OHNO, M. KURIHARA (<i>Kanagawa; Chiba; Gunma; Fukushima, Tokyo Japan</i>)	2465
Association of K-ras Mutations with Liver Metastases from Colorectal Carcinoma. A. TSUNODA, T. IIJIMA, Y. TSUNODA, K. NAKAO, M. MIYAKI, M. KUSANO (<i>Tokyo, Japan</i>)	2471
Detection of Aberrant Methylation as a Tumor Marker in Serum of Patients with Gastric Cancer. D. ICHIKAWA, H. KOIKE, H. IKOMA, D. IKOMA, N. TANI, E. OTSUJI, K. KITAMURA, H. YAMAGISHI (<i>Kyoto, Japan</i>)	2477
Efficacy and Toxicities of Concurrent Chemoradiation for Elderly Patients with Esophageal Cancer. T. UNO, K. ISOBE, H. KAWAKAMI, N. UENO, H. KOBAYASHI, H. SHIMADA, H. MASTUBARA, S. OKAZUMI, Y. NABEYA, T. SHIRATORI, T. OCHIAI, T. KAWATA, H. ITO (<i>Chiba, Japan</i>)	2483
Tumor Shrinkage Evaluation During and After Preoperative Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients with Breast Cancer. F. PUGLISI, M. MANSUTTI, G. APRILE, A.M. MINISINI, C. DI LORETO, M. BAZZOCCHI, V. LONDERO, C. CEDOLINI, G. GENTILE, S. PIZZOLITTO, A. PIGA, A. SOBRERO (<i>Udine; Genoa, Italy</i>)	2487
Expression of Dihydropyrimidine Dehydrogenase in Cancer Cells but not in Stromal Cells Predicts the Efficacy of Fluorouracil Treatment in Patients with Gastric Carcinoma. K. HISAMITSU, S. TSUJITANI, K. YAMAGUCHI, K. FUKUDA, I. KONISHI, N. KAIBARA (<i>Yonago, Japan</i>)	2495
Oncogenes Modulate Cell Sensitivity to Apoptosis Induced by Glucose Deprivation. M. KANSARA, M.V. BERRIDGE (<i>South Wellington, New Zealand</i>)	2503

Serum Levels of S-100B Protein and Neuron-specific Enolase in Glioma Patients: A Pilot Study. M.J. VOS, T.J. POSTMA, F. MARTENS, B.M.J. UITDEHAAG, M.A. BLANKENSTEIN, W.P. VANDERTOP, B.J. SLOTMAN, J.J. HEIMANS (<i>Amsterdam, The Netherlands</i>)	2511
Pancreatic Polypeptide is Increased in Patients with Advanced Malignant Disease. A. HJALMARSEN, R.M. BREMNES, U. AASEBØ, R. JORDE (<i>Tromsø, Norway</i>)	2515
* Prognostic and Predictive Molecular Markers in Colorectal Carcinoma. R. BENDARDAF, H. LAMLUM, S. PYRHÖNEN (<i>Turku, Finland</i>)	2519
Usefulness of ^{99m} Tc-pertechnetate Scintigraphy and Fine-needle Aspiration Cytology in Patients with Solitary Thyroid Nodules and Thyroid Cancer. F. LUMACHI, L. VAROTTO, S. BORSATO, A. TREGNAGHI, P. ZUCCHETTA, M.C. MARZOLA, D. CECCHIN, F. BUI (<i>Padova, Italy</i>).....	2531
Interphase FISH for Follow-up of Philadelphia Chromosome-positive Chronic Myeloid Leukemia Treatment. N. DOUET-GUILBERT, F. MOREL, T. LE CHARPENTIER, M.-J. LE BRIS, A. HERRY, P. MORICE, P. BOURQUARD, J.F. ABGRALL, C. BERTHOU, M. DE BRAEKELEER (<i>Brest, France</i>)	2535
Differences in Prognosis of Colorectal Cancer Patients Based on the Expression of Sialyl Lewis ^a , Sialyl Lewis ^x and Sialyl Tn Antigens in Serum and Tumor Tissue. S. AKAMINE, T. NAKAGOE, T. SAWAI, T. TSUJI, K. TANAKA, S. HIDAKA, S.-I. SHIBASAKI, A. NANASHIMA, H.YAMAGUCHI, T. NAGAYASU, T. YASUTAKE (<i>Nagasaki, Japan</i>)	2541
Lack of Association Between <i>RNASEL</i> Arg462Gln Variant and the Risk of Breast Cancer. A. SEVINÇ, D. YANNOUKAKOS, I. KONSTANTOPOULOU, E. MANGUOGLU, G. LÜLECI, T. ÇOLAK, C. AKYERLI, G. ÇOLAKOGLU, M. TEZ, I. SAYEK, G. VOUSINAS, G. NASIOULAS, E. PAPAPOPOULOU, L. FLORENTIN, E. KONTOGIANNI, B. BOZKURT, N.A. KOCABAS, A.E. KARAKAYA, I.G. YULUG, T. ÖZÇELİK (<i>Ankara; Istanbul, Turkey; Athens, Greece</i>)	2547
Ethnic Differences in Diet and Associations with Clinical Markers of Prostate Disease in New Zealand Men. A. HARRIS, M.A. GRAY, D.P. SLANEY, M.L.TURLEY, J.R. FOWLES, P. WEINSTEIN (<i>Wellington, New Zealand; Perth, WA, Australia</i>).....	2551
Failure of Alkylating Agents to Improve Induction Chemotherapy of Oropharyngeal Squamous Cell Cancer. L. OLASZ, Z. NYÁRÁDY, Á. NÉMETH, L. KIRÁLYFALVI, I. EMBER (<i>Pécs, Hungary</i>)	2557
Bone Metastasis from Glioblastoma Multiforme without Central Nervous System Relapse: A Case Report. A. FABI, A. VIDIRI, C. CARAPPELLA, A. PACE, E. OCCHIPINTI, F. CAROLI, A. MIRRI, P. CARLINI, F. COGNETTI (<i>Rome, Italy</i>).....	2563
A Phase II Trial of Weekly Paclitaxel and Gemcitabine in Non-small Cell Lung Cancer Patients Previously Treated with Platinum and Vinorelbine. V. DONGIOVANNI, A. ADDEO, A. BERRUTI, L. BUFFONI, D. DONGIOVANNI, M.A. POLIMENI, C. FISSORE, C. BARONE, O. BERTETTO (<i>Torino; Orbassano, Italy</i>)	2567
Serum Level of Cathepsin B and its Density in Men with Prostate Cancer as Novel Markers of Disease Progression. H. MIYAKE, I. HARA, H. ETO (<i>Akashi; Kobe, Japan</i>)	2573
Predictive Effect of p53 and p21 Alteration on Chemotherapy Response and Survival in Locally Advanced Adenocarcinoma of the Esophagus. P.A.M. HEEREN, F.W.H. KLOPPENBERG, H. HOLLEMA, N.H. MULDER, R.E. NAP, J.TH.M. PLUKKER (<i>Groningen, The Netherlands</i>)	2579

* Review (pages 2243, 2443, 2519)

Number 5A

Experimental Studies

- Interaction Between the Pura and E2F-1 Transcription Factors. N. DARBINIAN, M.K. WHITE, G.L. GALLIA, S. AMINI, J. RAPPAPORT, K. KHALILI (*Philadelphia, PA; Baltimore, MD, USA*)..... 2585
- Loss of Heterozygosity and Nonsense Mutation in *Apc* in Azoxymethane-induced Colonic Tumours in *Min* Mice. L. MØLLERSEN, J.E. PAULSEN, J. ALEXANDER (*Oslo, Norway*) 2595
- Acute Changes in U937 Nuclear Ca²⁺ Preceding Type 1 "Apoptotic" Programmed Cell Death due to MK 886. K.M. ANDERSON, M. RUBENSTEIN, W.A. ALREFAI, P. DUDEJA, P. TSUI, J.E. HARRIS (*Chicago, IL, USA*)..... 2601
- An Effective *In Vitro* Antitumor Response Against Human Pancreatic Carcinoma with Paclitaxel and Daunorubicin by Induction of Both Necrosis and Apoptosis. J.E. GERVASONI JR, A.A. HINDENBURG, M.P. VEZERIDIS, S. SCHULZE, H.J. WANEBO, S. MEHTA (*Trenton, NJ; Mineola, NY; Lowell, MA, USA*) 2617
- Effect of Confluence State and Passaging on Global Cancer Gene Expression Pattern in Oral Carcinoma Cell Lines. M. RUUTU, B. JOHANSSON, R. GRENMAN, K. SYRJÄNEN, S. SYRJÄNEN (*Turku, Finland; Rome, Italy*)..... 2627
- Treatment with IL-2 and IL-12 Inhibits Tumour Cell Division in SL2 Lymphoma. A. MASZTALERZ, M. VAN LUYN, N. WERNER, G. MOLEMA, L.A. EVERSE, W. DEN OTTER (*Utrecht; Groningen, The Netherlands*)..... 2633
- pAkt, Cyclin D1 and p27/Kip.1 in Glioblastomas With and Without EGFR Amplification and PTEN Mutation. V. FIANO, C. GHIMENTI, S. IMARISIO, L. SILENGO, D. SCHIFFER (*Monza; Turin, Italy*)..... 2643
- Apoptosis in Cervical Cancer Cells: Implications for Adjunct Anti-Estrogen Therapy for Cervical Cancer. D. CHEN, T.H. CARTER, K.J. AUBORN (*Manhasset; Jamaica; New Hyde Park, NY, USA*)..... 2649
- Response of *Cyclin B1* to Ionizing Radiation: Regulation by NF- κ B and Mitochondrial Antioxidant Enzyme MnSOD. M. OZEKI, D. TAMAE, D.-X. HOU, T. WANG, T. LEBON, D.R. SPITZ, J.J. LI (*Duarte, CA; Iowa, IA, USA; Kagoshima, Japan*) 2657
- Generation of a Humanized Monoclonal Antibody Against Human Parathyroid Hormone-related Protein and its Efficacy Against Humoral Hypercalcemia of Malignancy. E. ONUMA, K. SATO, H. SAITO, T. TSUNENARI, K. ISHII, K. ESAKI, N. YABUTA, Y. WAKAHARA, H. YAMADA-OKABE, E. OGATA (*Kanagawa; Tokyo, Japan*)..... 2665
- Inhibitory Effect of STI571 on Cell Proliferation of Human Malignant Fibrous Histiocytoma Cell Lines. T. KAWAMOTO, T. AKISUE, T. MARUI, T. NAKATANI, T. HITORA, I. FUJITA, M. KUROSAKA, T. YAMAMOTO (*Hyogo, Japan*) 2675
- Deletions on Chromosome 4 in Sporadic and BRCA Mutated Tumors and Association with Pathological Variables. H.K. JOHANNSDOTTIR, G. JOHANNESDOTTIR, B.A. AGNARSSON, H. EEROLA, A. ARASON, O.T. JOHANSSON, P. HEIKKILÄ, V. EGILSSON, H. OLSSON, Å. BORG, H. NEVANLINNA, R.B. BARKARDOTTIR (*Reykjavik, Iceland; Helsinki, Finland; Lund, Sweden*)..... 2681
- In Vivo* Adriamycin-induced Apoptosis in Peritoneal Murine Macrophages: Partial Participation of a Caspase Cascade. J.R. DOMÍNGUEZ-RODRÍGUEZ, V. CHAPARRO-HUERTA, G. HERNÁNDEZ-FLORES, P.C. GÓMEZ-CONTRERAS, J.M. LERMA-DÍAZ, P.C. ORTIZ-LAZARENO, R. CERVANTES-MUNGUÍA, S. ORBACH ARBOUYS, D. SCOTT-ALGARA, A. BRAVO CUELLAR (*Jalisco, México; Paris, France*) 2689

Rapamycin Inhibits Akt-Mediated Oncogenic Transformation and Tumor Growth. X. LIU, J. POWLAS, Y. SHI, A.X. OLEKSIJEW, A.R. SHOEMAKER, R. DE JONG, T. OLTERS DORF, V.L. GIRANDA, Y. LUO (<i>Abbott Park, IL; Diego, CA, USA</i>).....	2697
Depsipeptide Enhances Imatinib Mesylate-induced Apoptosis of Bcr-Abl-positive Cells and Ectopic Expression of Cyclin D1, c-Myc or Active MEK Abrogates this Effect. T. KAWANO, J. HORIGUCHI-YAMADA, S. IWASE, M. AKIYAMA, Y. FURUKAWA, Y. KANO, H. YAMADA (<i>Tokyo; Tochigi, Japan</i>)	2705
Expression of CD40 Ligand in CD40-positive Murine Tumors Activates Transcription of the Interleukin-23 Subunit Genes and Produces Antitumor Responses. A. WADA, Y. TADA, O. SHIMOZATO, Y. TAKIGUCHI, K. TATSUMI, T. KURIYAMA, M. TAGAWA (<i>Chiba, Japan</i>).....	2713
Inhibition or Promotion of Tumor Growth by Granulocyte-Macrophage Colony Stimulating Factor Derived from Engineered Tumor Cells is Dose-dependent. J. LI, H. BOUTON-VERVILLE, L.M. HOLMES, K.E. BURGİN, S. JAKUBCHAK, X. YU, T.E. WAGNER, Y. WEI (<i>Clemson, SC, USA</i>)	2717
Cyclooxygenase-2 Gene Induction Causes CDDP Resistance in Colon Cancer Cell Line, HCT-15. Y. SAIKAWA, T. SUGIURA, F. TORIUMI, T. KUBOTA, K. SUGANUMA, S. ISSHIKI, Y. OTANI, K. KUMAI, M. KITAJIMA (<i>Tokyo; Kanagawa, Japan</i>).....	2723
Apoptosis-related Gene Expression Affected by a GnRH Analogue Without Induction of Programmed Cell Death in LNCaP Cells. C. ANGELUCCI, F. IACOPINO, G. LAMA, S. CAPUCCI, G. ZELANO, M. BOCA, A. PISTILLI, G. SICA (<i>Rome; Perugia, Italy</i>)	2729
Role of Enzymatically Inactive Procathepsin D in Lung Cancer. V. VETVICKA, J. VETVICKOVA, P. BENES (<i>Louisville, KY, USA; Brno, Czech Republic</i>)	2739
Alteration of the Vascular Endothelial Growth Factor and Angiopoietins-1 and -2 Pathways in Transitional Cell Carcinomas of the Urinary Bladder Associated with Tumor Progression. T. QUENTIN, T. SCHLOTT, M. KORABIEWSKA, N. KÄTHE, G. ZÖLLER, F. GLASER, E. KUNZE (<i>Göttingen; Göttingen-Weende, Germany</i>)	2745
A New Method of Thermoablation with Hot Water Vapour for Localized Tumours. E. HILTBRAND, J. BELENGER, T. BINZONI, F. BUCHEGGER, M. COSTA, H. MEHIER (<i>Geneva, Switzerland; Archamps, France</i>)	2757
Inhibition of Cell Proliferation by Potential Peroxisome Proliferator-activated Receptor (PPAR) Gamma Agonists and Antagonists. M.A. LEA, M. SURA, C. DESBORDES (<i>Newark, NJ; Brooklyn, NY, USA</i>).....	2765
Activated Akt-1 in Specific Cell Populations During Multi-stage Skin Carcinogenesis. N.I. AFFARA, B.L. SCHANBACHER, M.J. MIHM, A.C. COOK, P. PEI, S.R. MALLERY, C.S. TREMPUS, J.A. BAUER, F.M. ROBERTSON (<i>Columbus, OH; Triangle Park, NC, USA</i>)	2773
* Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies. B.B. AGGARWAL, A. BHARDWAJ, R.S. AGGARWAL, N.P. SEERAM, S. SHISHODIA, Y. TAKADA (<i>Houston, TX; Los Angeles, CA, USA</i>)	2783
Re-distribution of Tenascin-C in the Parotid Acinar Cells. An Early Marker of Radiation-induced Damage of Salivary Glands? S.G. HAKIM, I. LAUER, R. NADROWITZ, A. BERNDT, H. KOSMEHL, P. SIEG (<i>Luebeck; Jena; Erfurt, Germany</i>)	2841
Activity of Cathepsin B and D in Colorectal Cancer: Relationships with Tumour Budding. K. GUZIŃSKA-USTYMOWICZ, B. ZALEWSKI, I. KASACKA, Z. PIOTROWSKI, E. SKRZYDLEWSKA (<i>Białystok, Poland</i>)	2847

Immunocytochemical and Pharmacological Characterisation of P2-purinoceptor-mediated Cell Growth and Death in PC-3 Hormone Refractory Prostate Cancer Cells. R.C. CALVERT, M. SHABBIR, C.S. THOMPSON, D.P. MIKHAILIDIS, R.J. MORGAN, G. BURNSTOCK (<i>London, UK</i>).....	2853
Immunotherapy by Gene Transfer with Plasmids Encoding IL-12/IL-18 is Superior to IL-23/IL-18 Gene Transfer in a Rat Osteosarcoma Model. C. LIEBAU, C. ROESEL, S. SCHMIDT, C. KARREMAN, J.B. PRISACK, H. BOJAR, H. MERK, N. WOLFRAM, A.W.A. BALTZER (<i>Bad Harzburg; Düsseldorf; Magdeburg, Germany</i>)	2861
Carboxyamido-triazole (CAI), a Signal Transduction Inhibitor Induces Growth Inhibition and Apoptosis in Bladder Cancer Cells by Modulation of Bcl-2. F.G.E. PERABO, A. WIRGER, S. KAMP, H. LINDNER, D.H. SCHMIDT, S.C. MÜLLER, E.C. KOHN (<i>Luebeck, Germany; Bethesda, MD, USA</i>)	2869
Sasa Health Exerts a Protective Effect on Her2/NeuN Mammary Tumorigenesis. M. REN, R.T. REILLY, N. SACCHI (<i>Buffalo, NY; Baltimore, MD, USA</i>)	2879
EGF-Receptor Related Protein Causes Cell Cycle Arrest and Induces Apoptosis of Colon Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> . E. LEVI, R. MOHAMMAD, U. KODALI, D. MARCINIAK, S. REDDY, A. ABOUKAMEEL, F.H. SARKAR, O. KUCUK, A.K. RISHI, A.P.N. MAJUMDAR (<i>Detroit, MI, USA</i>)	2885
UGT1A10 is Responsible for SN-38 Glucuronidation and its Expression in Human Lung Cancers. T. OGURI, T. TAKAHASHI, M. MIYAZAKI, T. ISOBE, N. KOHNO, P.I. MACKENZIE, Y. FUJIWARA (<i>Nagoya; Hiroshima, Japan; Bedford Park, SA, Australia</i>).....	2893
High Efficacy of Docetaxel with and without Androgen Deprivation and Estramustine in Preclinical Models of Advanced Prostate Cancer. K. FIZAZI, C.R. SIKES, J. KIM, J. YANG, L.A. MARTINEZ, M.C. OLIVE, C.J. LOGOTHETIS, N.M. NAVONE (<i>Villejuif, France; Houston, TX, USA</i>)	2897
Combination Study of 1,24(S)-Dihydroxyvitamin D ₂ and Chemotherapeutic Agents on Human Breast and Prostate Cancer Cell Lines. D.P. WIGINGTON, C.M. URBEN, S.A. STRUGNELL, J.C. KNUTSON (<i>Middleton, WI, USA</i>).....	2905
Selenium Influences the Radiation Sensitivity of C6 Rat Glioma Cells. P. SCHUELLER, S. PUETTMANN, O. MICKE, V. SENNER, U. SCHAEFER, N. WILLICH (<i>Muenster, Germany</i>)	2913
Expression of Estrogen Receptor-Beta Isoforms in Barrett's Metaplasia, Dysplasia and Esophageal Adenocarcinoma. L. LIU, M. CHIRALA, M. YOUNES (<i>Houston, TX, USA</i>).....	2919
Methotrexate as a Photosensitiser. M.L. PASCU, A. STAIKU, L. VOICU, M. BREZEANU, B. CARSTOCEA, R. PASCU, D. GAZDARU (<i>Bucharest – Magurele, Romania</i>).....	2925
Multidrug Resistance Associated Genes MRP1, MRP2 and MRP3 in Primary and Anthracycline Exposed Breast Cancer. I.F. FANEYTE, P.M.P. KRISTEL, M.J. VAN DE VIJVER (<i>Amsterdam, The Netherlands</i>).....	2931
X-rays Affect the Expression of Genes Involved in Angiogenesis. C. POLYTARCHOU, T. GLIGORIS, D. KARDAMAKIS, E. KOTSAKI, E. PAPADIMITRIOU (<i>Patras, Greece</i>).....	2941
<i>Ex Vivo</i> Responsiveness of Head and Neck Squamous Cell Carcinoma to Glufosfamide, a Novel Alkylating Agent. R. DOLLNER, A. DIETZ, M. KOPUN, M. HELBIG, F. WALLNER, C. GRANZOW (<i>Leipzig; Heidelberg, Germany</i>)	2947
* IGF-I in Mammary Tumorigenesis and Diabetes. C. COCCA, M. NUNEZ, A. GUTIÉRREZ, G. MARTÍN, G. CRICCO, V. MEDINA, N. MOHAMAD, E. RIVERA, R. BERGOC (<i>Buenos Aires, Argentina</i>).....	2953

Novel Recurrent Structural Chromosomal Aberrations in Primary Bladder Cancer. A.D. PANANI, A.D. FERTI, S.A. RAPTIS, C. ROUSSOS (<i>Athens, Greece</i>).....	2967
Applicability of the 2-Nitroimidazole-sodium Borocaptate- ¹⁰ B Conjugate, TX-2060, as a ¹⁰ B-carrier in Boron Neutron Capture Therapy. S.-I. MASUNAGA, H. NAGASAWA, M. HIRAOKA, Y. SAKURAI, Y. UTO, H. HORI, K. NAGATA, M. SUZUKI, A. MARUHASHI, Y. KINASHI, K. ONO (<i>Osaka; Tokushima, Japan</i>)	2975
Does the Sequence of Gemcitabine and Vinorelbine Affect their Efficacy in Non-small Cell Lung Cancer <i>In Vitro</i> ? A. DE LUCA, M. GRASSI, M.R. MAIELLO, M. DI MAIO, M. MANCINO, E. DE MAIO, C. GRIDELLI, F. PERRONE, N. NORMANNO (<i>Naples; Avellino, Italy</i>)	2985
Down-regulation of Cyclin E Expression by Caffeine Promotes Cancer Cell Entry into the S-phase of the Cell Cycle. J. QIN, D. TAO, X. CHEN, Y. FENG, J. HU, E. REED, Q.Q. LI, J. GONG (<i>Wuhan, China; Morgantown, WV, USA</i>)	2991
Gene Therapy of Prostate Xenograft Tumors with a p75 ^{NTR} Lipoplex. J. ALLEN, F. KHWAJA, D. DJAKIEW (<i>Washington, DC, USA</i>)	2997
Penetration into Solid Tumor Tissue of Fluorescent Latex Microspheres: A Mimic of Liposome Particles. X.Q. PAN, R.J. LEE, M. RATNAM (<i>Columbus; Toledo, OH, USA</i>).....	3005
VGA1155, a Novel Binding Antagonist of VEGF, Inhibits Angiogenesis <i>In Vitro</i> and <i>In Vivo</i> . Y. UEDA, T. YAMAGISHI, H. IKEYA, N. HIRAYAMA, T. ITOKAWA, Y. AOZUKA, K. SAMATA, S. NAKAIKE, M. TANAKA, M. ONO, I. SAIKI (<i>Saitama; Fukuoka; Toyama, Japan</i>).....	3009
Kinetic Radical Scavenging Activity and Cytotoxicity of 2-Methoxy- and 2-t-Butyl-substituted Phenols and their Dimers. S. FUJISAWA, T. ATSUMI, Y. KADOMA, M. ISHIHARA, S. ITO, I. YOKOE (<i>Saitama; Tokyo, Japan</i>).....	3019
Absence of Ras-gene Hot-spot Mutations in Canine Fibrosarcomas and Melanomas. H.M. ESCOBAR, K. GÜNTHER, A. RICHTER, J.T. SOLLER, S. WINKLER, I. NOLTE, J. BULLERDIEK (<i>Bremen; Hanover, Germany</i>).....	3027
The Role of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 in Human Esophageal Cancer. M. SOHDA, H. KATO, T. MIYAZAKI, M. NAKAJIMA, M. FUKUCHI, R. MANDA, Y. FUKAI, N. MASUDA, H. KUWANO (<i>Maebashi, Japan</i>)	3029
Doxorubicin Activates Hepatitis B Virus (HBV) Replication in HBV-harboring Hepatoblastoma Cells. A Possible Novel Mechanism of HBV Reactivation in HBV Carriers Receiving Systemic Chemotherapy. C.-H. HSU, H.-C. HSU, H.-L. CHEN, M. GAO, P.-Y. YEH, P.-J. CHEN, A.-L. CHENG (<i>Taipei, Taiwan</i>).....	3035
E2F-1 Transcription Factor Immunoexpression is Inversely Associated with Tumor Growth in Colon Adenocarcinomas. J. BRAMIS, P. ZACHARATOS, I. PAPAConstantinou, A. KOTSINAS, F. SIGALA, D.P. KORKOLIS, N. NIKITEAS, A. PAZAITI, C. KITTAS, E. BASTOUNIS, V.G. GORGOULIS (<i>Athens, Greece</i>)	3041
Efficacy of Garbanzo and Soybean Flour in Suppression of Aberrant Crypt Foci in the Colons of CF-1 Mice. G. MURILLO, J.K. CHOI, O. PAN, A.I. CONSTANTINOU, R.G. MEHTA (<i>Chicago, IL, USA</i>).....	3049
Expression of Glucose Transporter 1 (Glut-1) in Cell Lines and Clinical Specimens from Human Prostate Adenocarcinoma. P. EFFERT, A.J. BENIERS, Y. TAMIMI, S. HANDT, G. JAKSE (<i>Aachen, Germany; Nijmegen, The Netherlands</i>)	3057

Protective Effects of EGCG on Salivary Gland Cells Treated with γ -Radiation or Cis-platinum(II)Diammine Dichloride. T. YAMAMOTO, J. STAPLES, J. WATAHA, J. LEWIS, P. LOCKWOOD, P. SCHOENLEIN, S. RAO, T. OSAKI, D. DICKINSON, T. KAMATANI, G. SCHUSTER, S. HSU (<i>Augusta, GA, USA; Kochi, Japan</i>).....	3065
Gene Therapy in Colon Cancer Cells with a Fiber-modified Adenovector Expressing the TRAIL Gene Driven by the hTERT Promoter. D. JACOB, M. BAHRA, G. SCHUMACHER, P. NEUHAUS, B. FANG (<i>Berlin, Germany; Houston, TX, USA</i>).....	3075
Cluster Analysis of Apoptosis-Associated bcl2 Family Proteins in Diffuse Large B-cell Lymphomas. Relations with the Apoptotic Index, the Proliferation Profile and the B-cell Differentiation Immunophenotypes. M. BAI, A. SKYRLAS, N.J. AGNANTIS, S. KAMINA, P. KITSOULIS, P. KANAVAROS (<i>Ioannina, Greece</i>)	3081
Monoterpenes Enhanced the Sensitivity of Head and Neck Cancer Cells to Radiation Treatment <i>In Vitro</i> . D. SAMAILA, B.J. TOY, R.C. WANG, J. ABIODUN ELEGBEDE (<i>Las Vegas, NV, USA</i>).....	3089
Reviews (pages 2783, 2953)	

Number 5B

Clinical Studies

A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma. M.G. HURTUK, M. CARBONE (<i>Maywood, IL, USA</i>)	3097
Overexpression of the Wilms' Tumor Gene <i>WT1</i> in Esophageal Cancer. Y. OJI, M. YANO, Y. NAKANO, S. ABENO, S.-I. NAKATSUKA, A. IKEBA, T. YASUDA, Y. FUJIWARA, S. TAKIGUCHI, H. YAMAMOTO, S. FUJITA, K. KANATO, K. ITO, T. JOMGEOW, M. KAWAKAMI, A. TSUBOI, T. SHIRAKATA, S. NISHIDA, N. HOSEN, Y. OKA, K. AOZASA, M. MONDEN, H. SUGIYAMA (<i>Osaka, Japan</i>).....	3103
The γ 2 Chain of Laminin-5 as an Indicator of Increased Risk for Recurrence in T1 Stage Tongue Cancer. P. STOLTZFUS, A. HÖGMO, J. LINDHOLM, U. ASPENBLAD, G. AUER, E. MUNCK-WIKLAND (<i>Stockholm, Sweden</i>)	3109
Hypertension and Risk of Brain Metastasis from Small Cell Lung Cancer: A Retrospective Follow-up Study. A. E. SAHMOUN, L. D. CASE, S. CHAVOUR, S. KAREEM, G.G. SCHWARTZ (<i>Fargo, ND; Winston-Salem, NC, USA</i>)	3115
Ursodeoxycholic Acid Treatment in IBD-patients with Colorectal Dysplasia and/or DNA-aneuploidy: a Prospective, Double-blind, Randomized Controlled Pilot Study. U. SJÖQVIST, B. TRIBUKAIT, Å. ÖST, C. EINARSSON, L. OXELMARK, R. LÖFBERG (<i>Stockholm, Sweden</i>).....	3121
Radiofrequency Heat Ablation and Vertebroplasty in the Treatment of Neoplastic Vertebral Body Fractures. S. MASALA, M. ROSELLI, F. MASSARI, R. FIORI, A. URSONE, E. FOSSILE, A. LAUDISI, G. SIMONETTI (<i>Rome, Italy</i>).....	3129
Changes in Serum IgG Oligosaccharide Chains with Prostate Cancer Progression. Y. KANO, T. MASHIKO, M. DANBARA, Y. TAKAYAMA, S. OHTANI, S. EGAWA, S. BABA, T. AKAHOSHI (<i>Kanagawa, Japan</i>)	3135
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan. K. NAKAMURA, T. TESHIMA, Y. TAKAHASHI, A. IMAI, M. KOIZUMI, N. MITSUHASHI, Y. SHIOYAMA, T. INOUE, JAPANESE PCS WORKING SUBGROUP OF PROSTATE CANCER (<i>Fukuoka; Osaka; Tokyo, Japan</i>)	3141

PET Scanning Evaluation of Response to Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor (GIST) Patients. A. GELIBTER, M. MILELLA, A. CERIBELLI, M. ZEULI, V. FERRARESI, A. VECCHIONE, F. COGNETTI (<i>Rome, Italy</i>).....	3147
Malignant Intestinal Obstruction: Useful Technical Advice in Self-expanding Metallic Stent Placement. E. FIORI, A. LAMAZZA, A. BURZA, M. MEUCCI, G. CAVALLARO, L. IZZO, A. SCHILLACI, V. CANGEMI (<i>Rome, Italy</i>).....	3153
Pleomorphic Lipoma: A Definite Histopathological Entity. P. PERSICHETTI, F. DI LELLA, G.F. MARANGI, B. CAGLI, P. SIMONE, S. TENNA, C. RABITTI, R. CASSANDRO, V. ESPOSITO, A.M. GROEGER, A. BALDI (<i>Rome; Naples, Italy; Silver Spring, MD, USA; Vienna, Austria</i>).....	3157
Microsatellite Status and Cell Cycle Associated Markers in Rectal Cancer Patients Undergoing a Combined Regimen of 5-FU and CPT-11 Chemotherapy and Radiotherapy. M. CHARARA, T. BOCKER EDMONSTON, S. BURKHOLDER, R. WALTERS, P. ANNE, E. MITCHELL, R. FRY, B. BOMAN, D. ROSE, R. FISHEL, W. CURRAN, J. PALAZZO (<i>Philadelphia, PA, USA</i>).....	3161
Surgical Outcome of Serosa-negative Advanced Gastric Carcinoma. C. KUNISAKI, H. SHIMADA, M. NOMURA, G. MATSUDA, Y. OTSUKA, H. ONO, H. AKIYAMA (<i>Yokohama, Japan</i>).....	3169
Aspirin Use and Mortality from Cancer in a Prospective Cohort Study. L. D. RATNASINGHE, B.I. GRAUBARD, L. KAHLE, J.A. TANGREA, P.R. TAYLOR, E. HAWK (<i>Little Rock, AR; Bethesda; Silver Spring, MD, USA</i>).....	3177
Extended Intestinal Metaplasia. A Survey of 1392 Gastrectomies from Dwellers of the Pacific Basin. C.A. RUBIO, T. HIROTA, M. ITABASHI, K. MANDAI, A. YANAGISAWA, T. KITAGAWA, H. SUGANO, Y. KATO (<i>Stockholm, Sweden; Tokyo; Matsuyama, Japan</i>).....	3185
Comparison of Bone Scintigraphy with Bone Markers in the Diagnosis of Bone Metastasis in Lung Carcinoma Patients. W. EBERT, TH. MULEY, K.P. HERB, H. SCHMIDT-GAYK (<i>Heidelberg, Germany</i>).....	3193
Cytokeratin Positivity in Paraffin-embedded Malignant Melanomas: Comparative Study of KL1, A4 and Lu5 Antibodies. M. KORABIOWSKA, G. FISCHER, A. STEINACKER, J. STACHURA, C. CORDON-CARDO, U. BRINCK (<i>Göttingen; Wilhelmshaven, Germany; Krakow, Poland; New York, NY, USA</i>).....	3203
Effect of Primary Anthracycline-based Chemotherapy on Disseminated Tumor Cells in Locally Advanced Breast Cancer. C. JÄGER, A. KAFKA, S. BOSSERT, R. GRUNDMANN, J. WINDISCH, R. KREIENBERG, V. HEILMANN (<i>Ulm, Germany</i>).....	3209
Methylenetetrahydrofolate Reductase and Thymidylate Synthase Polymorphisms are not Associated with Breast Cancer Risk or Phenotype. F. GRIEU, B. POWELL, J. BEILBY, B. IACOPETTA (<i>Nedlands; Crawley, Australia</i>).....	3215
Relationship Between Tumor Markers CEA and CA 15-3, TNM Staging, Estrogen Receptor Rate and MIB-1 Index in Patients with pT1-2 Breast Cancer. F. LUMACHI, S.M.M. BASSO, A.A. BRANDES, D. PAGANO, M. ERMANI (<i>Padova, Italy</i>).....	3221
P21 ^{WAF1/CIP1} Protein and Tongue Cancer Prognosis. M.A. GONZALEZ-MOLES, I. RUIZ-AVILA, J.A. FERNÁNDEZ MARTINEZ, J.A. GIL-MONTOYA, F. ESTEBAN, S. GONZALEZ-MOLES, M. BRAVO-PEREZ, A. BASCONES (<i>Granada; Jaen; Seville, Madrid, Spain</i>).....	3225
Lack of HER-2/neu Overexpression in Non-Hodgkin's Lymphoma. D. LÜFTNER, I. GENVRESSE, R. GEPPERT, O. KAUFMANN, M. DIETEL, K. POSSINGER (<i>Berlin, Germany</i>).....	3233

Conformal Hypofractionated and Accelerated Radiotherapy with Cytoprotection (HypoARC) for High Risk Prostatic Carcinoma: Rationale, Technique and Early Experience. M. I. KOUKOURAKIS, S. TOULOUPIDIS, J. MANAVIS, I. ABATZOGLOU, K. SISMANIDOU, L. SIVRIDIS (Alexandroupolis, Greece).....	3239
Serum Markers as Predictors of Esophageal Squamous Dysplasia and Early Cancer. W. CHEN, C. C. ABNET, W.-Q. WEI, M.J. ROTH, N. LU, P.R. TAYLOR, Q.-J. PAN, X.-M. LUO, S.M. DAWSEY, Y.-L. QIAO (Beijing, China; Bethesda, MD, USA)	3245
Immunocompetence in Non-seminomatous Testicular Cancer Patients Before any Treatment and One Year After Completion of Therapy. Ž. KAŠTELAN, J. PASINI, D. DEREŽIĆ, J. LUKAČ, Z. KUSIĆ, D. MRAZOVAC, H. ŠOŠIĆ, M. KAŠTELAN (Zagreb, Croatia)	3251
Long-survival in Responding Patients with Metastatic Breast Cancer Treated with Doxorubicin-Docetaxel Combination. A Multicentre Phase II Trial. R. MATTIOLI, P. LIPPE, C. MASSACESI, C. CAPPELLETTI, D. NACCIARRITI, R. BISONNI, F. GRAZIANO, E.T. MENICHETTI, L. IMPERATORI, E. TESTA, G. LAICI, A. BALLETTA, R.R. SILVA (Fano, Italy)	3257
Outcome of Local Application of Amifostine (WR-1065) on Epirubicin-induced Oral Mucositis. A Phase II Study. M.A. STOKMAN, F.M. WACHTERS, P. KOOPMANS, J.G.M. BURGERHOF, H.J.M. GROEN, F.K.L. SPIJKERVET, D.R.A. UGES, G.A.P. HOSPERS (Groningen, The Netherlands).....	3263
* Centrosomes – Their Role in Tumors and Cancer Therapy. S. RO, L.-X. YANG (San Francisco, CA, USA).....	3269
Multicenter Pilot Study of 5-Fluorouracil, Folinic Acid, Interferon Alpha-2b and Degradable Starch Microspheres <i>Via</i> Hepatic Arterial Infusion in Patients with Nonresectable Colorectal Liver Metastases. U. POHLEN, U. MANSMANN, G. BERGER, C.T. GERMER, U. GALLKOWSKI, J. BOESE-LANDGRAF, H.J. BUHR (Heidelberg; Chemnitz, Germany)	3275
Analysis of Correlation Between Mitotic Index, MIB1 Score and S-phase Fraction as Proliferation Markers in Invasive Breast Carcinoma. Methodological Aspects and Prognostic Value in a Series of 257 Cases. M. CALY, P. GENIN, A. AL GHUZLAN, C. ELIE, P. FRÉNEAUX, J. KLIJANIENKO, C. ROSTY, B. SIGAL-ZAFRANI, A. VINCENT-SALOMON, A. DOUGGAZ, M. ZIDANE, X. SASTRE-GARAU (Paris, France)	3283
Review (page 3269)	

Number 5C

Proceedings of the Joint Meeting of the 7th Annual Meeting of the Society of Biotherapeutic Approaches and the 2nd Annual Meeting of the Japan Research Association for Immunotherapeutics Special Issue Edited by S. Goto, M. Kuroki, T. Fukushima, H. Okada and G.-I. Soma

Relationships Between Local and Systemic Expression of Interleukin-12 and Plasma Levels of Vascular Endothelial Growth Factor in Patients with Gastric Cancer. Y. NAKAYAMA, Y. INOUE, N. NAGASHIMA, T. KATSUKI, K. MATSUMOTO, K. SHIBAO, K. TSURUDOME, K. HIRATA, T. SAKO, N. NAGATA, H. ITOH (Kita-Kyushu, Japan)	3289
* Biological Effect of OK-432 (Picibanil) and Possible Application to Dendritic Cell Therapy. Y. RYOMA, Y. MORIYA, M. OKAMOTO, I. KANAYA, M. SAITO, M. SATO (Tokyo; Tokushima, Japan)	3295
A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate. T. KANEKO, S. GOTO, Y. KUSHIMA, Y. MIYAMOTO, M. ERIGUCHI, M. NIEDA, K. EGAWA (Kanagawa; Tokyo; Miyazaki, Japan)	3303

* Utilization of Macrophages in Anticancer Therapy: The Macrophage Network Theory. C. KOHCHI, H. INAGAWA, M. HINO, M. ODA, K. NAKATA, A. YOSHIDA, H. HORI, H. TERADA, K. MAKINO, K. TAKIGUCHI, G.-I. SOMA (<i>Tokushima-shi; Noda-shi; Shimonoseki-shi; Nagoya-shi, Japan</i>).....	3311
* Immuno-cell Therapy of Cancer in Japan. K. EGAWA (<i>Tokyo, Japan</i>)	3321
Mature Dendritic Cells are Superior to Immature Dendritic Cells in Expanding Antigen-specific Naive and Memory CD8+ T Cells. M. TOMIYAMA, M. TAKAHARA, K. EGAWA, M. NIEDA (<i>Yokohama; Tokyo, Japan</i>)	3327
Correlation of Histological Localization of Tumor-associated Macrophages with Clinicopathological Features in Endometrial Cancer. S. OHNO, Y. OHNO, N. SUZUKI, T. KAMEI, K. KOIKE, H. INAGAWA, C. KOHCHI, G.-I. SOMA, M. INOUE (<i>Ishikawa; Yamaguchi; Tokushima; Chiba, Japan</i>).....	3335
Structural Analysis of Human Specific Cytolysin Intermedilysin Aiming Application to Cancer Immunotherapy. K. OHKURA, H. NAGAMYUNE, H. KOURAI (<i>Tokushima; Aichi, Japan</i>).....	3343
Cloning and Sequencing of Variable Region cDNAs of a Novel Human Monoclonal Antibody to Carcinoembryonic Antigen, and Generation of a Single Chain Variable Fragmented Antibody. H. SHIBAGUCHI, MASAHIDE KUROKI, MOTOMU KUROKI, A. BADRAN, K. HACHIMINE, T. KINUGASA (<i>Fukuoka, Japan</i>).....	3355
Association of the Macrophage Activating Factor (MAF) Precursor Activity with Polymorphism in Vitamin D-binding Protein. H. NAGASAWA, H. SASAKI, Y. UTO, S. KUBO, H. HORI (<i>Tokushima, Japan</i>)	3361
A Cell Membrane Modification Technique Using Domain 4 of Intermedilysin for Immunotherapy Against Cancer. H. NAGAMUNE, K. OHKURA, K. UMEZU, H. SHOUJI, H. KOURAI (<i>Tokushima; Nagoya; Naruto, Japan</i>)	3367
* Tumor-targeting Viral Vectors for Cancer Gene Therapy by Using Antibodies or their Genes against Tumor-associated Antigens. MASAHIDE KUROKI, MOTOMU KUROKI, H. SHIBAGUCHI, K. HACHIMINE, T. KINUGASA, A. BADRAN (<i>Fukuoka, Japan</i>).....	3373
Tumor-Cell-specific Transcription of a Murine Histocompatibility Class Ib Q5 Gene. K. NOGUCHI, E. KUWADA, S. GOTO, K. EGAWA (<i>Tokyo, Japan</i>)	3379
Detection of Anti-HLA-F Antibodies in Sera from Cancer Patients. K. NOGUCHI, M. ISOGAI, E. KUWADA, A. NOGUCHI, S. GOTO, K. EGAWA (<i>Tokyo, Japan</i>)	3387
Reviews (pages 3295, 3311, 3321, 3373)	

Number 5D

Abstracts of the Seventh International Conference of Anticancer Research October 25 - 30, 2004, Corfu, Greece	3393-3698
--	-----------

Number 6

Experimental Studies

Visualizing Portal Vein Metastatic Trafficking to the Liver with Green Fluorescent Protein-expressing Tumor Cells. J. WANG, M. YANG, R.M. HOFFMAN (<i>San Diego, CA, USA</i>)	3699
	4317

Prognostic Value of the Expression of Smad6 and Smad7, as Inhibitory Smads of the TGF- β Superfamily, in Esophageal Squamous Cell Carcinoma. H. OSAWA, M. NAKAJIMA, H. KATO, M. FUKUCHI, H. KUWANO (<i>Maebashi, Japan</i>)	3703
Expression of Chemokine Receptor CXCR6 in Human Colorectal Adenocarcinomas. D. WÅGSÄTER, J. DIMBERG (<i>Örebro; Jönköping, Sweden</i>)	3711
Targeted Gene Expression Using a 1.1 Kilobase Promoter Fragment of the Tumour-associated Antigen EpCAM. O. GIRES, S. PÖCKL, R.D. CHAPMAN, M. MÜNZ (<i>Munich, Germany</i>).....	3715
Antibiotics Directly Induce Apoptosis in B Cell Lymphoma Cells Derived from BALB/c Mice. T. OHARA, T. MORISHITA, H. SUZUKI, T. MASAOKA, H. ISHII, T. HIBI (<i>Chiba; Tokyo, Japan</i>)	3723
Plasminogen Activator Inhibitor-1 is a Downstream Mediator of the PGP9.5-related Oncogenic Pathway in Esophageal Squamous Cell Carcinoma. K. HIBI, Y. KODERA, K. ITO, S. AKIYAMA, M. SHIRANE, A. NAKAO (<i>Nagoya; Kanagawa, Japan</i>).....	3731
Growth Hormone Receptor Antagonist Administration Inhibits Growth of Human Colorectal Carcinoma in Nude Mice. F. DAGNAES-HANSEN, H. DUAN, L.M. RASMUSSEN, K.E. FRIEND, A. FLYVBJERG (<i>Aarhus, Denmark; Houston, TX, USA</i>).....	3735
Characterization of Osteosarcoma Cell Lines MG-63, Saos-2 and U-2 OS in Comparison to Human Osteoblasts. C. PAUTKE, M. SCHIEKER, T. TISCHER, A. KOLK, P. NETH, W. MUTSCHLER, S. MILZ (<i>Munich, Germany</i>).....	3743
Non-genomic Cell Growth Inhibition by Progesterone. Cell Cycle Retardation and Induction of Cell Death. E.L. BERTELSEN, P.C. ENDRESEN, A. ØRBO, G. SAGER (<i>Tromsø, Norway</i>)	3749
The Preventive Effect of Green Tea on the Gap Junction Intercellular Communication in Renal Epithelial Cells Treated with a Renal Carcinogen. H. TAKAHASHI, K. NOMATA, K.-I. MORI, M. MATSUO, T. MIYAGUCHI, M. NOGUCHI. H. KANETAKE (<i>Nagasaki, Japan</i>).....	3757
Antitumor Effects Produced by Transduction of Dendritic Cells-derived Heterodimeric Cytokine Genes in Murine Colon Carcinoma Cells. M. CHIYO, O. SHIMOZATO, T. IIZASA, T. FUJISAWA, M. TAGAWA (<i>Chiba, Japan</i>)	3763
Head and Neck Squamous Cell Carcinoma Cell Lines are Highly Sensitive to the New Taxanes, BMS-184476, BMS-188797, <i>In Vitro</i> . M. RAITANEN, J. PULKKINEN, J. KULMALA, R. GRÉNMAN (<i>Turku, Finland</i>)	3769
Synthesis and Antiproliferative Activity of [1,2,4]Triazino[4,3- α]indoles. P. BARRAJA, P. DIANA, A. LAURIA, A. MONTALBANO, A.M. ALMERICO, G. DATTOLO, G. CIRRINCIONE (<i>Palermo, Italy</i>)	3775
Quantification of the Expression of Multidrug Resistance-related Genes in Human Tumour Cell Lines Grown with Free Doxorubicin or Doxorubicin Encapsulated in Polyisohexylcyanoacrylate Nanospheres. A. LAURAND, A. LAROCHE-CLARY, A. LARRUE, S. HUET, I. SOMA, J. BONNET, J. ROBERT (<i>Bordeaux; Châtenay-Malabry, France</i>)	3781
Effect of Cyclooxygenase-2 Antisense Oligodeoxyribonucleotides in A-549 Lung Cancer Cells. U. WINDHÖVEL, C. HAASPER, M. DUCHROW, H.-P. BRUCH, R. BROLL (<i>Lübeck, Germany</i>).....	3789
Cellular and Molecular Effects of α -Tocopheryloxybutyrate: Lessons for the Design of Vitamin E Analog for Cancer Prevention. Y. WU, K. ZU, J. NI, S. YEY, D. KASI, N.S. JAMES, S. CHEMLER, C. IP (<i>Buffalo; Rochester, NY, USA</i>)	3795

Prevention of Radiation-induced Central Nervous System Toxicity: A Role for Amifostine? C. NIEDER, N.H. ANDRATSCHKE, N. WIEDENMANN, M. MOLLS (<i>Munich, Germany</i>)	3803
Expression of the <i>Drosophila melanogaster</i> S3 Ribosomal/Repair Protein in T24 Human Bladder Cells. M. ROPOLO, A. GEROLDI, O. ROSSI, P. DEGAN, S. ZUPO, A. POGGI, G. FROSINA (<i>Genova, Italy</i>)....	3811
Analysis of Central Regulatory Pathways in p53-deficient Primary Cultures of Malignant Fibrous Histiocytoma Exposed to Ifosfamide. T. SCHLOTT, H. TAUBERT, A. FAYYAZI, S. SCHWEYER, F. BARTEL, M. KORABIOWSKA, U. BRINCK (<i>Goettingen; Halle-Wittenberg, Germany</i>)	3819
Effect of Lactoferrin on the Methotrexate-induced Suppression of the Cellular and Humoral Immune Response in Mice. J. ARTYM, M. ZIMECKI, M.L. KRUZEL (<i>Houston, TX, USA</i>)	3831
Up-regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Activity in Left-sided Human Colon Cancer. M. NOTARNICOLA, C. MESSA, M. PRICCI, V. GUERRA, D.F. ALTOMARE, S. MONTEMURRO, M.G. CARUSO (<i>Bari, Italy</i>)	3837
Immunohistochemical Expression of E-cadherin and β -catenin in the Normal and Malignant Human Endometrium: An Inverse Correlation Between E-cadherin and Nuclear β -catenin Expression. H.-C. SHIH, T. SHIOZAWA, T. MIYAMOTO, H. KASHIMA, Y.-Z. FENG, M. KURAI, I. KONISHI (<i>Matsumoto, Japan</i>).....	3843
Expression of Twist and Wnt in Human Breast Cancer. O. WATANABE, H. IMAMURA, T. SHIMIZU, J. KINOSHITA, T. OKABE, A. HIRANO, K. YOSHIMATSU, S. KONNO, M. AIBA, K. OGAWA (<i>Tokyo, Japan</i>)	3851
Numerical Aberrations of Chromosomes 9 and 11 Detected by FISH in Greek Bladder Cancer Patients. A.D. PANANI, A. BABANARAKI, E. MALIANGA, CH. ROUSSOS (<i>Athens, Greece</i>)	3857
The <i>MTHFR</i> C677T Polymorphism, Estrogen Exposure and Breast Cancer Risk: A Nested Case-control Study in Taiwan. W.-Y. LIN, Y.-C. CHOU, M.-H. WU, H.-B. HUANG, Y.-L. JENG, C.-C. WU, C.-P. YU, J.-C. YU, S.-L. YOU, T.-Y. CHU, C.-J. CHEN, C.-A. SUN (<i>Taipei; Taiwan</i>).....	3863
Change of Zinc Uptake under Growth Arrest and Apoptosis. A. TAKEDA, H. TAMANO, Y. IBUKI (<i>Shizuoka, Japan</i>)	3869
Thymidylate Synthase Gene Promoter Polymorphisms are Associated With TSmRNA Expressions But Not With Microsatellite Instability in Colorectal Cancer. A. CALASCIBETTA, D. CABIBI, A. MARTORANA, G. SANGUEDOLCE, L. RAUSA, S. FEO, G. DARDANONI, R. SANGUEDOLCE (<i>Palermo, Italy</i>).....	3875
STAT 3 Activation in Head and Neck Squamous Cell Carcinomas is Controlled by the EGFR. M. HAMBEK, M. BAGHI, K. STREBHARD, A. MAY, O. ADUNKA, W. GSTOTTNER, R. KNECHT (<i>Frankfurt, Germany</i>)	3881
Sp1 Regulates Cathepsin B Transcription and Invasiveness in Murine B16 Melanoma Cells. A.M. SZPADERSKA, S. SILBERMAN, Y. AHMED, A. FRANKFATER (<i>Maywood, IL, USA</i>)	3887
Cisplatin Down-regulates Topoisomerase I Activity in Lung Cancer Cell Lines. K. AOE, K. KIURA, H. UEOKA, M. TABATA, M. CHIKAMORI, H. KOHARA, M. HARADA, M. TANIMOTO (<i>Okayama; Yamaguchi, Japan</i>)	3893
Functional Analysis of Focal Adhesion Kinase (FAK) Reduction by Small Inhibitory RNAs. E. K.-H. HAN, T. MCGONIGAL, J. WANG, V.L. GIRANDA, Y. LUO (<i>Abbott Park, IL, USA</i>).....	3899
Chk1 Binds and Phosphorylates BAD Protein. E. K.-H. HAN, C. BUTLER, H. ZHANG, S. ROSENBERG, V.L. GIRANDA, S.-C. NG, Y. LUO (<i>Abbott Park, IL, USA</i>).....	3907

Establishment of a 7-Ethyl-10-hydroxy-camptothecin-resistant Small Cell Lung Cancer Cell Line. M. CHIKAMORI, N. TAKIGAWA, K. KIURA, M. TABATA, T. SHIBAYAMA, Y. SEGAWA, H. UEOKA, T. OHNOSHI, M. TANIMOTO (<i>Okayama, Japan</i>).....	3911
Inhibition of LPS-stimulated NO Production in Mouse Macrophage-like Cells by Tropolones. K. YOKOYAMA, K. HASHIBA, H. WAKABAYASHI, K. HASHIMOTO, K. SATOH, T. KURIHARA, N. MOTOHASHI, H. SAKAGAMI (<i>Saitama; Tokyo, Japan</i>).....	3917
Characterization of the Glutamatergic System in MG-63 Osteoblast-like Osteosarcoma Cells. N. KALARITI, P. LEMBESSIS, M. KOUTSILIERIS (<i>Athens, Greece</i>)	3923
Kinetic Studies of the Radical-scavenging Activity of Estrogens and Antiestrogens. S. FUJISAWA, Y. KADOMA (<i>Saitama; Tokyo, Japan</i>)	3931
Inhibition of LPS-stimulated NO Production in Mouse Macrophage-like Cells by Azulenes K. HASHIBA, K. YOKOYAMA, H. WAKABAYASHI, K. HASHIMOTO, K. SATOH, T. KURIHARA, N. MOTOHASHI, H. SAKAGAMI (<i>Saitama; Tokyo, Japan</i>)	3939
Conventional Cytogenetics and Fluorescence <i>In Situ</i> Hybridization in Persistent Cytopenias and Myelodysplastic Syndromes in Childhood. V. TOULIATOU, A. KOLIALEXI, G.TH. TSANGARIS, M. MOSCHOVI, S. POLYCHRONOPOULOU, A. MAVROU (<i>Athens, Greece</i>)	3945
* Over-expression of RNA Helicases in Cancer. M. ABDELHALEEM (<i>Toronto, Ontario, Canada</i>)	3951
Checkpoint Effectors CDKN1A and Gadd45 correlate with Oxidative DNA Damage in Human Prostate Carcinoma. C. GIOVANNINI, P. CHIECO, A. BERTACCINI, L. GRAMANTIERI, M. LACCHINI, G. MARTORANA (<i>Bologna, Italy</i>).....	3955
Effect of Estrogen, Tamoxifen and Epidermal Growth Factor on the Transcriptional Regulation of Vascular Endothelial Growth Factor in Breast Cancer Cells. J.E. LEE, K.-W. CHUNG, W. HAN, S.-W. KIM, S.W. KIM, H.J. SHIN, J.Y. BAE, D.-Y. NOH (<i>Seoul; Gyeonggi-do, Korea</i>).....	3961
Polymorphisms of Glutathione-S-Transferase and Arylamine N-Acetyltransferase Enzymes and Susceptibility to Colorectal Cancer. I. KISS, A. NÉMETH, B. BOGNER, G. PAJKOS, Z. ORSÓS, J. SÁNDOR, A. CSEJTEY, Z. FALUHELYI, I. RODLER, I. EMBER (<i>Pécs; Budapest; Szombathely, Hungary</i>)	3965
Action and Efficacy of p-[¹³¹ I]Iodo-L-phenylalanine on Primary Human Glioma Cell Cultures and Rats with C6-gliomas. B.F.M. ROMEIKE, D. HELLWIG, A. HEIMANN, O. KEMPSKI, W. FEIDEN, C.-M. KIRSCH, S. SAMNICK (<i>Homburg; Mainz, Germany</i>)	3971
Is Troponin I Gene Therapy Effective for Osteosarcoma Treatment? Study on a Human-like Orthotopic Rat Model. A. DUTOUR, H. RABINOVICH-CHABLE, C. KALETTA, U. MICHAELIS, F. FIORENZA, F. STURTZ, M. RIGAUD (<i>Limoges, France; Neuried, Germany</i>).....	3977
Induction of Apoptosis or Necrosis in Human Endometrial Carcinoma Cells by 2-Methoxyestradiol. L. LI, N.-E. HELDIN, J. GRAWÉ, U. ULMSTEN, X. FU (<i>Uppsala, Sweden; Shijiazhuang, China</i>).....	3983
Anticancer Activity of Bacteriophage T4 and its Mutant HAP1 in Mouse Experimental Tumour Models. K. DABROWSKA, A. OPOLSKI, J. WIETRZYK, K. SWITALA-JELEN, J. GODLEWSKA, J. BORATYNSKI, D. SYPER, B. WEBER-DABROWSKA, A. GORSKI (<i>Wroclaw; Warsaw; Czestochowa, Poland</i>)	3991
Early Effects of Transplatin on Oncogene Activation <i>In Vivo</i> . Á. NÉMETH, E. NÁDASI, A. BERÓ, L. OLASZ, Á. EMBER, A. KVARDA, L. BUJDOSÓ, I. ARANY, A. CSEJTEI, ZS. FALUHELYI, I. EMBER (<i>Pécs; Zala; Veszprém; Szombathely, Hungary; Little Rock, AR, USA</i>)	3997

Identification of Calretinin and the Alternatively Spliced form Calretinin-22k in Primary Pleural Mesotheliomas and in Their Metastases. B. SCHWALLER, M.R. CELIO, C. DOGLIONI (<i>Fribourg, Switzerland; Belluno, Italy</i>).....	4003
Transendothelial Migration of Two Metastatic Breast Carcinoma Cells Depend on the SDF-1 α -CXCR4 Complexes. T. LECHERTIER, M. BERARD, R. VASSY, M-A. HERVE, M. CREPIN (<i>Bobigny, France</i>).....	4011
Histone Deacetylase Inhibitors Enhance Retinoid Response in Human Breast Cancer Cell Lines. L. EMIONITE, F. GALMOZZI, M. GRATAROLA, F. BOCCARDO, L. VERGANI, S. TOMA (<i>Genova, Italy</i>).....	4019
Expression of MMPs and TIMPs Genes in Human Breast Cancer Epithelial Cells Depends on Cell Culture Conditions and is Associated with their Invasive Potential. O. CH. KOUSIDOU, A. E. ROUSSIDIS, A. D. THEOCHARIS, N. K. KARAMANOS (<i>Patras, Greece</i>).....	4025
Vitamin B2 (Riboflavin) and a Mixture of Vitamin B2 and C Affects MMC Efficiency in Aerated Media Under Irradiation. L. FUGA, M. KRAGL, N. GETOFF (<i>Vienna, Austria</i>).....	4031
Targeting Against Epidermal Growth Factor Receptors. Cellular Processing of Astatinated EGF After Binding to Cultured Carcinoma Cells. A. ORLOVA, A. SJÖSTRÖM, O. LEBEDA, H. LUNDQVIST, J. CARLSSON, V. TOLMACHEV (<i>Uppsala, Sweden; Rez, Czech Republic</i>).....	4035
Clinical Studies	
Intermediate Stage Hodgkin's Disease: Preliminary Results on 210 Patients Treated with Four ABVD Chemotherapy Cycles Plus Extended versus Involved Field Radiotherapy. A.P. ANSELMO, E. CAVALIERI, F.M. OSTI, M. CANTONETTI, V. DE SANCTIS, M. ALFO', S. AMADORI, R. MAURIZI ENRICI (<i>Roma, Italy</i>)....	4045
Elevated Serum β -Defensins Concentrations in Patients with Lung Cancer. Y. ARIMURA, J.-I. ASHITANI, S. YANAGI, M. TOKOJIMA, K. ABE, H. MUKAE, M. NAKAZATO (<i>Miyazaki; Nagasaki, Japan</i>).....	4051
Comparison of Epstein-Barr Virus DNA Level in Plasma, Peripheral Blood Cell and Tumor Tissue in Nasopharyngeal Carcinoma. J.-Y. SHAO, Y. ZHANG, Y.-H. LI, H.-Y. GAO, H.-X. FENG, Q.-L. WU, N.-J. CUI, G. CHENG, B. HU, L.-F. HU, I. ERNBERG, Y.-X. ZENG (<i>Guangzhou, China; Stockholm, Sweden</i>).....	4059
Color Coding Cancer Cells with Fluorescent Proteins to Visualize <i>In Vivo</i> Cellular Interaction in Metastatic Colonies. N. YAMAMOTO, M. YANG, P. JIANG, M. XU, K. YAMAUCHI, H. TSUCHIYA, K. TOMITA, A.R. MOOSSA, R. M. HOFFMAN (<i>San Diego, CA, USA; Ishikawa, Japan</i>).....	4067
Bronchoscopic Treatment with Argon Plasma Coagulation for Recurrent Typical Carcinoids: Report of a Case. K. ORINO, H. KAWAI, J. OGAWA (<i>Akita, Japan</i>).....	4073
Correlation Between the Histological Grade of Chondrosarcoma and the Expression of MMPs, ADAMTSs and TIMPs. H. SUGITA, S. OSAKA, M. TORIYAMA, E. OSAKA, Y. YOSHIDA, J. RYU, M. SANO, M. SUGITANI, N. NEMOTO (<i>Tokyo, Japan</i>).....	4079
Imbalance in Expression Levels of Insulin-like Growth Factor 2 and H19 Transcripts Linked to Progression of Hepatocellular Carcinoma. N. IIZUKA, M. OKA, T. TAMESA, Y. HAMAMOTO, H. YAMADA-OKABE (<i>Yamaguchi; Kanagawa, Japan</i>).....	4085
The Effectiveness of Planned Esophagectomy after Neoadjuvant Chemoradiotherapy for Advanced Esophageal Carcinomas. H. KATO, M. FUKUCHI, R. MANDA, A. FARIED, J. TAKITA, M. NAKAJIMA, T. MIYAZAKI, M. SOHDA, Y. FUKAI, N. MASUDA, K. TSUKADA, H. KUWANO (<i>Maebashi, Japan</i>).....	4091
MRI Diagnosis of Mesorectal Lymph Node Metastasis in Patients with Rectal Carcinoma. What is the Optimal Criterion? H. MATSUOKA, A. NAKAMURA, M. SUGIYAMA, J. HACHIYA, Y. ATOMI, T. MASAKI (<i>Tokyo, Japan</i>).....	4097

Application of PET and PET/CT Imaging for Cancer Screening. Y.-K. CHEN, H.-J. DING, C.-T. SU, Y.-Y. SHEN, L.-K. CHEN, A. C. LIAO, T.-Z. HUNG, F.-L. HU, C.-H. KAO (<i>Taipei; Kaohsiung; Taichung, Taiwan</i>)..	4103
Sedation in Gynaecologic Oncology Day Surgery. M.C. PACE, A. PALAGIANO, L. PACE, M.B. PASSAVANTI, M. IANNOTTI, R. SORRENTINO, C. AURILIO (<i>Naples, Italy</i>)	4109
Masaoka Staging is of Prognostic Relevance in Type B3 / C Thymomas. T. LUEBKE, K.T.E. BECKURTS, C. WICKENHAUSER, P. SCHNEIDER, A. H. HOELSCHER, S.P. MOENIG (<i>Cologne, Germany</i>)	4113
Clinical Response Following Adjuvant Temozolomide in a Patient with Primary Cerebral Lymphoma. H. M. STRIK, A. SPREER, H. NAGEL, S. JACOB, W. JUNG, B. KITZE, M. BÄHR (<i>Göttingen, Germany</i>)	4121
Molecular Markers for Human Colon Cancer in Stool and Blood Identified by RT-PCR. F.E. AHMED, P. VOS (<i>Greenville, NC, USA</i>)	4127
Concurrent Chemoradiotherapy with Cisplatin and Docetaxel for Advanced Head and Neck Cancer. A Phase I Study. H. INOHARA, T. INOUE, S. AKAHANI, Y. YAMAMOTO, Y. TAKENAKA, T. NAKAGAWA, F. ISOHASHI, T. KUBO (<i>Osaka, Japan</i>)	4135
Cathepsin B, Plasminogenactivator-inhibitor (PAI-1) and Plasminogenactivator-receptor (uPAR) are Prognostic Factors for Patients with Non-small Cell Lung Cancer. B. WERLE, M. KOTZSCH, T.T. LAH, J. KOS, D. GABRIJELCIC-GEIGER, E. SPIESS, J. SCHIRREN, W. EBERT, W. FIEHN, T. LUTHER, V. MAGDOLEN, M. SCHMITT, N. HARBECK (<i>Heidelberg; Dresden; München; Wiesbaden, Germany; Ljubljana, Slovenia</i>).....	4141
Cytogenetic Data as a Prognostic Factor in Multiple Myeloma Patients: Involvement of 1p12 Region an Adverse Prognostic Factor. A.D. PANANI, A.D. FERTI, C. PAPAXOINIS, S.A. RAPTIS, CH. ROUSSOS (<i>Athens, Greece</i>)	4147
Role of Endoscopic Clipping for Determining the Resection Line for Tumors Located in the Middle or Upper Corpus of the Stomach: Experience with 100 Gastrectomies for Early Gastric Cancer. S. KIKUCHI, K. HIRAI, S. KUROYAMA, N. KATADA, S. SAKURAMOTO, N. KOBAYASHI, H. SHIMAO, M. WATANABE, H. MITOMI, T. MIKAMI (<i>Kanagawa, Japan</i>)	4163
Fatty Acid Synthase (FAS) is a Marker of Increased Risk of Recurrence in Lung Carcinoma. P. VISCA, V. SEBASTIANI, C. BOTTI, M.G. DIODORO, R.P. LASAGNI, F. ROMAGNOLI, A. BRENNNA, B.C. DE JOANNON, R. PERRONE DONNORSO, G. LOMBARDI, P.L. ALO (<i>Rome, Italy</i>).....	4169
Correlation of Diffusion-weighted MR Imaging with Cellularity of Renal Tumours. E. SQUILLACI, G. MANENTI, M. COVA, M. DI ROMA, R. MIANO, G. PALMIERI, G. SIMONETTI (<i>Rome; Trieste, Italy</i>)	4175
Complexed Prostate-specific Antigen for the Detection of Prostate Cancer. X. FILELLA, D. TRUAN, J. ALCOVER, R. GUTIERREZ, R. MOLINA, F. COCA, A.M. BALLESTA (<i>Barcelona, Spain</i>)	4181
Paneth Cell Adenoma of the Ileum. C. A. RUBIO (<i>Stockholm, Sweden</i>).....	4187
Application of New Ploidy-related Parameters for the Diagnosis of Ovarian Tumours. M. KORABIOWSKA, U. BRINCK, J. SKUBIS, B. SATTLER, G. FISCHER (<i>Wilhelmshaven; Leer; Göttingen, Germany</i>).....	4191
High-dose Tamoxifen Treatment Increases the Incidence of Multifocal Tumor Recurrences in Glioblastoma Patients. M.J.A. PUCHNER, A. GIESE, F. LOHMANN, L. CRISTANTE (<i>Bielefeld; Lubeck; Saarbrücken; Hamburg, Germany; Manitoba, Winnipeg, Canada</i>)	4195
Changes of Serum HER2 Status during Clinical Course of Metastatic Breast Cancer Patients. T. FEHM, W. JAGER, S. KRAEMER, C. SOHN, G. SOLOMAYER-MEYBERG, EF. SOLOMAYER, R. KUREK, D. WALLWIENER, G. GEBAUER (<i>Tuebingen; Nuremberg; Hannover, Germany</i>)	4205

Influence of Tumor Biological Factors on Tumor Cell Dissemination in Primary Breast Cancer. T. FEHM, S. BECKER, G. PERGOLA-BECKER, B. KRAMER, I. GRUBER, K. SOTLAR, R. KUREK, D. WALLWIENER, E. SOLOMAYER (<i>Tuebingen, Germany</i>).....	4211
A Dose Escalation Study of Leucovorin (LV) and 48-hour Continuous Infusion of 5-Fluorouracil in Combination with Cyclophosphamide and Vinorelbine in Pretreated Patients with Metastatic Breast Cancer. C. KOUROUSSIS, K. KALBAKIS, N. ANDROULAKIS, S. AGELAKI, L. VAMVAKAS, K. MALAS, J. SOUGLAKOS, N. VARDAKIS, V. GEORGOULIAS (<i>Heraklion, Greece</i>)	4217
Enhancement of the Efficacy of Weekly Low-dose Taxotere by the Long Acting Anti-prolactinemic Drug Cabergoline in Pretreated Metastatic Breast Cancer. L. FRONTINI, P. LISSONI, M. VAGHI, M.S. PEREGO, S. PESCIA, A. ARDIZZOIA, G. GARDANI (<i>Milan, Italy</i>)	4223
Cisplatin and Vinorelbine Remains a Valid Option for the Front-line Chemotherapy Treatment of NSCLC. G. BUCCHERI, D. FERRIGNO, C. GIORDANO (<i>Cuneo, Italy</i>)	4227
Circulating Vascular Endothelial Growth Factor During the Normal Menstrual Cycle. Y.H. KUSUMANTO, G.A.P. HOSPERS, W.J. SLUITER, W.A. DAM, C. MEIJER, N.H. MULDER (<i>Groningen, The Netherlands</i>) ...	4237
Imbalance of Cell Proliferation and Apoptosis During Progression of Lung Carcinomas. J. MATTERN, M. VOLM (<i>Heidelberg, Germany</i>)	4243
Matrix Metalloproteinase-9 (MMP-9) Immunoreactive Protein has Modest Prognostic Value in Locally Advanced Breast Carcinoma Patients Treated with an Adjuvant Antiestrogen Therapy. E. RAHKO, A. JUKKOLA, J. MELKKO, P. PAAVO, R. BLOIGU, A. TALVENSAARI-MATTILA, T. TURPEENNIEMI-HUJANEN (<i>Oulu, Finland</i>)	4247
Prognostic Value of Serum VEGF in Melanoma Patients: a Pilot Study. P.A. ASCIERTO, E. LEONARDI, A. OTTAIANO, M. NAPOLITANO, S. SCALA, G. CASTELLO (<i>Naples, Italy</i>)	4255
Loss of Heterozygosity at Chromosomes 3p and 17p in Primary Non-small Cell Lung Cancer. M. CHMARA, A. WOZNIAK, K. OCHMAN, G. KOBIERSKA, R. DZIADZIUSZKO, K. SOSINSKA-MIELCAREK, E. JASSEM, J. SKOKOWSKI, J. JASSEM, J. LIMON (<i>Gdansk, Poland</i>)	4259
Abstracts of the 7th International Conference of Anticancer Research	4265
* Review (page 3951)	

Subject Index

(Figures refer to page numbers)

- A-431 cells, 211
 At-para-astato-benzoate, 125I-para-iodo-benzoate, EGF, intracellular retention, 4035
 A-549, cyclooxygenase-2, antisense oligonucleotides, lung cancer cells, 3789
 ABC-ABC structure, MRP1, multidrug resistance, ATP-binding cassette, ABC-signature, nucleotide trapping, 449
 ABC-signature, MRP1, multidrug resistance, ATP-binding cassette, nucleotide trapping, ABC-ABC structure, 449
 ABCG2, ribozyme, multidrug resistance, 2231
 Aberrant crypt foci, chemoprevention, lovostatin, exisulind, 1805
 Abl, glucose deprivation, oncogenes, src, ras, bcr-abl, bcl-2, IL-3, apoptosis, 2503
 Acetabular osteosarcoma, pelvic reconstruction, vascularized fibula graft, irradiated osteoarticular graft, 1889
 N-Acetyl-2-aminofluorene, N-acetyltransferase, 2-aminofluorene, shikonin, Helicobacter pylori, gastric cancer, 1587
 N-Acetyltransferase (NAT), N-ethylphenyl acetamide (EPA), 2-aminofluorene (AF), colon tumor cells, 1677
 N-Acetyltransferase, 2-aminofluorene, N-acetyl-2-aminofluorene, shikonin, Helicobacter pylori, gastric cancer, 1587
 N-Acetyltransferase, colorectal cancer, metabolizing enzymes, cancer susceptibility, glutathione-S-transferase, 3965
 N-Acetyltransferase, paclitaxel, 2-aminofluorene-DNA adduct, osteogenic sarcoma, 83
 N-Acetyltransferase, paclitaxel, bladder cancer cell line (T24), 2-aminofluorene, flow cytometry, cDNA microarray, 1501
 ACF, colon cancer, soybean flour, garbanzo beans, CF-1 mice, 3049
 Acoustic energy, gene therapy, transfection, 2303
 Across-platform, microarray, cancer, genomics, 441
 Actinic keratosis, mitochondrial DNA deletion, tandem duplication, basal cell carcinoma, squamous cell carcinoma, 1753
 Actinium, thorium, α -particles, osseous neoplasms, 101
 Adenocarcinoma, E-cadherin-catenin, gastro-oesophageal junction, 1369
 Adenocarcinoma, UPT, prognostic factors, 297
 Adenoma, Paneth cells, ileum, 4187
 Adenoma, serrated, gastric, 2113
 Adenomas, colon, tumor progression, 2033
 Adenomatous polyposis coli, azoxymethane, Min mice, β -catenin, LOH, 2595
 Adenovirus, isolated perfusion, ras-oncogene, rhabdomyosarcoma, gene therapy, 2295
 Adhesion molecule, E-cadherin, breast cancer, growth pattern, 2237
 Adhesion molecules, apoptosis, ionizing radiation, multiparametric flow cytometry, Ewing tumors, 1637
 Adhesion, E-cadherin, prognosis, multiple myeloma, 2027
 Adhesion, focal adhesion kinase, extracellular matrix, 3899
 Adjuvant chemotherapy, 5-fluorouracil, postoperative survival, dihydropyrimidine dehydrogenase, gastric carcinoma, 2495
 Adjuvant chemotherapy, pancreatic cancer, SMAD-4, DPC4, 1173
 Adjuvant therapy, rectal cancer, transanal endoscopic microsurgery, 1167
 Adoptive immunotherapy, autologous activated lymphocyte, antinuclear antibody, rheumatoid factor, autoimmune disease, 2423
 Adoptive immunotherapy, immuno-cell therapy, immunotherapy, LAK, CD3-LAK, review, 3321
 Adoptive immunotherapy, malignant brain tumor, therapeutic activity, 1861
 Adrenal cortical carcinoma, recurrence, repeat surgical resection, survival, 1901
 Adriamycin, apoptosis, macrophages, caspases, p38 MAPK, 2689
 Advanced colorectal cancer, chemotherapy, oxaliplatin, leucovorin, 5-fluorouracil, 1935
 Advanced gastric carcinoma, mast cells, microvasculature, dispersed fibrous long-spacing collagen, angiogenesis, electron microscopy, 2257
 Advanced stage, hypopharyngeal cancer, exclusive radiotherapy, 349
 AIDS, Kaposi's sarcoma, hCG, apoptosis, human eosinophil-derived neurotoxin, 1427
 Akt, EGFR, HER-2, NSCLC, TGF- α , immunohistochemistry, 11
 Akt, glioblastoma, PTEN, EGFR, 2643
 Akt, PKB, p70 S6 kinase, phosphatidylinositol 3-kinase, rapamycin, 2697
 Akt, α -tocopheryloxybutyrate, α -tocopheryl succinate, prostate cancer, apoptosis, 3795
 Akt-1, protein kinase B, inositolphosphate-3-kinase, IP3-K, multi-stage skin carcinogenesis, epidermal keratinocytes, cell survival, mast cells, papilloma, image analysis, 2773
 Alkylating drugs, induction chemotherapy, head and neck cancer, oropharyngeal cancer, 2557
 Allopurinol-cryotherapy, cancer chemotherapy, stomatitis, LV/5-FU, 1131
 Alternative splicing, calretinin, calcium-binding proteins, EF-hand, mesothelioma, tumor marker, differential expression, 4003

- Ames test, Salmonella typhimurium, oxidative stress, mutagenicity, plant phenolics, bleomycin, antioxidant, antimutagenicity, caffeic acid, 743
- Amifostine, central nervous system, brain, spinal cord, radiation therapy, 3803
- Amifostine, chemotherapy, neurotoxicity, in vitro study, 2337
- Amifostine, mucositis, WR-1065, cytoprotection, 3263
- Amifostine, prostate cancer, radiotherapy, hypofractionation, 3239
- 2-Aminofluorene (AF), N-Ethylphenyl acetamide (EPA), N-acetyltransferase (NAT), colon tumor cells, 1677
- 2-Aminofluorene, N-acetyltransferase, N-acetyl-2-aminofluorene, shikonin, helicobacter pylori, gastric cancer, 1587
- 2-Aminofluorene, N-acetyltransferase, paclitaxel, bladder cancer cell line (T24), flow cytometry, cDNA microarray, 1501
- 2-Aminofluorene-DNA adduct, paclitaxel, N-acetyltransferase, osteogenic sarcoma, 83
- Aminopeptidase A, breast cancer, angiotensin, N-methylnitrosourea, 801
- Amphiregulin, malignant fibrous histiocytoma, soft tissue, immuno-histochemistry, epidermal growth factor receptor, 1307
- Amphotericin B, anti-fungal, Candida, CDR 1, drug resistance, 405
- Anaemia, alfa-erythropoietin, gynaecological cancer, 1287
- Anaemia, hormone-refractory prostate cancer, metastatic prostate cancer, epoetin beta, 1957
- Anastrozole, breast cancer, postmenopausal, hormone-dependent tumors, 1315
- Androgen independent, prostate, animal models, CWR22, angiogenesis, VEGF, 2135
- Aneuploidy, chromosomal instability, centriole, aurora A, tumorigenesis, review, 3269
- Angiogenesis inhibition, chick embryo assay, digital image analysis, antiangiogenic compounds, 1545
- Angiogenesis, bone metastasis, renal cell carcinoma, osteolysis, 1705
- Angiogenesis, breast cancer, VEGF, CD105, endoglin, 1581
- Angiogenesis, colorectal carcinoma, prognostic markers, review, genomic instability, invasion, circulating cells, 2519
- Angiogenesis, COX-2, gastric carcinoma, tubular adenoma, apoptosis, 1439
- Angiogenesis, lung neoplasms, prognosis, 2367
- Angiogenesis, mast cells, microvasculature, dispersed fibrous long-spacing collagen, electron microscopy, advanced gastric carcinoma, 2257
- Angiogenesis, nafoxidine, antiestrogens, metalloproteinases, 1737
- Angiogenesis, prostate cancer, bFGF, VEGF, c-met, progression, 1797
- Angiogenesis, prostate, animal models, CWR22, androgen independent, VEGF, 2135
- Angiogenesis, prostatic neoplasms, von Willebrand factor, CD34, CD31, endothelial cells, endothelial marker, 1651
- Angiogenesis, urinary bladder, transitional cell carcinomas, real-time RT-PCR, vascular endothelial growth factor, angiopoietins-1 and -2, 2745
- Angiogenesis, vascular endothelial growth factor (VEGF), antisense, chemotherapy, head and neck cancer, 2179
- Angiogenesis, vascular endothelial growth factor, antisense oligodeoxynucleotides, receptor tyrosine kinase inhibitor, renal cell carcinoma, 213
- Angiogenesis, VEGF1155, VEGF, KDR/Flk-1, Flt-1, endothelial cell, 3009
- Angiogenesis, X-rays, vascular endothelial growth factor, heparin affn regulatory peptide, nitric oxide synthase, 2941
- Angiopoietins, p53, gene therapy, glioma, retrovirus, VEGF, 1
- Angiopoietins-1 and -2, Urinary bladder, transitional cell carcinomas, angiogenesis, real-time RT-PCR, vascular endothelial growth factor, 2745
- Angiosarcoma, VEGF, vascular endothelial growth factor, endothelium, retroperitoneal mass, HIF1, HIF2, hypoxia inducible factor, VHL, von Hippel-Lindau, 167
- Angiotensin, aminopeptidase A, breast cancer, N-methylnitrosourea, 801
- Animal model, VX2 carcinoma, lymph node metastasis, intravenous cisplatin therapy, 1785
- Animal models, prostate, CWR22, androgen independent, angiogenesis, VEGF, 2135
- Animal tumour model, electroporation, hyperthermia, tumour perfusion, 2343
- Anthracycline-based chemotherapy, breast cancer, disseminated tumor cells, 3209
- Anthracyclines, cardiotoxicity, cisplatin, epirubicin, gemcitabine, left ventricular ejection fraction, non-small cell lung cancer, radionuclide ventriculography, 2079
- Anthracyclines, endothelial cell proliferation, paclitaxel, 5-FU, etoposide, 1759
- Anthracyclines, multidrug resistance, real-time reverse transcriptase polymerase chain reaction, 2931
- Anti-androgen monotherapy, prostate cancer, male breast cancer, 1077
- Anti-angiogenic gene therapy, cationic liposomes, osteosarcoma, human-like orthotopic model, 3977
- Anti-angiogenic treatment, malignant glioma, brain tumor, local treatment, glioblastoma, 631
- Anti-cancer drugs, arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, gallium, platinum, review, 1529

- Anti-fungal, amphotericin B, *Candida*, CDR 1, drug resistance, 405
- Anti-hypersensitivity prophylaxis failure, Stevens-Johnson syndrome, paclitaxel, lung squamous cell carcinoma, 1135
- Anti- α Gal antibodies, immunotherapy, tumor antigens, alpha 1, 3 galactosyltransferase, 605
- Antiangiogenic compounds, angiogenesis inhibition, chick embryo assay, digital image analysis, 1545
- Anticancer drug screening, fibrin/collagen gel, 3-D culture systems, cancer cell invasion, colony formation, cancer assessment, 2169
- Anticarcinogens, UDP-glucuronosyltransferases, NSAIDs, chemoprevention, Wistar rat, 843
- Antichymotrypsin, antitrypsin, secretory leukocyte proteinase inhibitor, lung tumor, inflammation, 241
- Anti-estrogen therapy, Breast carcinoma, MMP-9, 4247
- Anti-estrogens, angiogenesis, nafoxidine, metalloproteinases, 1737
- Anti-estrogens, estrogens, stoichiometric factor, inhibition rate constants, 3931
- Antimicrobial peptide, β -defensin, lung cancer, immunohistochemistry, tumour marker, 4051
- Antimicrobial peptides, hBD-2, innate immunity, cancer, *Candida*, defensin, 1025
- Antimony, anti-cancer drugs, arsenic, bismuth, gold, vanadium, iron, rhodium, titanium, gallium, platinum, review, 1529
- Antimutagenicity, *Salmonella typhimurium*, Ames test, oxidative stress, mutagenicity, plant phenolics, bleomycin, antioxidant, caffeic acid, 743
- Antinuclear antibody, adoptive immunotherapy, autologous activated lymphocyte, rheumatoid factor, autoimmune disease, 2423
- Antioestrogen, fulvestrant, 'Faslodex', breast cancer, ER antagonist, 1275
- Antioxidant, resveratrol, apoptosis, 999
- Antioxidant, *Salmonella typhimurium*, Ames test, oxidative stress, mutagenicity, plant phenolics, bleomycin, antimutagenicity, caffeic acid, 743
- Antioxidant, whey protein, cysteine, glutathione, prostate, breast cancer, oxidant, 553
- Antiproliferation, cancer, vitamin D, 1, 24(OH)2D2, isobologram, 2905
- Antiproliferative activity, 2-diazoindoles, triazinoindoles, 3775
- Antisense oligodeoxynucleotides, vascular endothelial growth factor, angiogenesis, receptor tyrosine kinase inhibitor, renal cell carcinoma, 213
- Antisense oligonucleotides, cyclooxygenase-2, lung cancer cells, A-549, 3789
- Antisense, vascular endothelial growth factor (VEGF), angiogenesis, chemotherapy, head and neck cancer, 2179
- Antitrypsin, antichymotrypsin, secretory leukocyte proteinase inhibitor, lung tumor, inflammation, 241
- Antitumor activity, imidazothioxanones, cytotoxicity, human tumor xenografts, murine tumors, molecular modeling-docking, 907
- Antitumor activity, imidazo[2, 1-b]thiazole, diimidazo[1, 2-a:1, 2-c]pyrimidine, guanylhydrazones, 203
- Antitumor drugs, prostate cancer, stromal cells, tumor-stromal cell interaction, fibroblast, 1561
- AP-1, EGCG, MMP-9, MAPK, gastric cancer, 747
- APE1, ref-1, base excision repair, lucanthon, breast cancer, 2127
- Apoptosis induction, cycloartane triterpenes, *Euphorbia*, multidrug resistance, mouse lymphoma cell line, 859
- Apoptosis, 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone, HL-60, PBMC, cell cycle, G2/M arrest, ERK, 1769
- Apoptosis, 2-methoxyestradiol, endometrium carcinoma cells, HEC-1-A, RL-95-2, cell cycle, necrosis, iNOS, caspases, STAT1, 3983
- Apoptosis, adhesion molecules, ionizing radiation, multiparametric flow cytometry, Ewing tumors, 1637
- Apoptosis, artemisinin, cancer cells, 2277
- Apoptosis, bcl-2, breast cancer, disease/relapse-free survival, immunohistochemistry, mcl-1, overall survival, prognostic indicator, reverse-transcriptase polymerase chain reaction, 473
- Apoptosis, bladder cancer, carboxyamido-triazole (CAI), signal transduction inhibition, bcl-2, calcium, 2869
- Apoptosis, caspase-1, radiation, prostate cancer, 1377
- Apoptosis, cervical cancer, estrogen, indole-3-carbinol, 2649
- Apoptosis, cervical cells, HeLaS3 cells, 2-methoxyestradiol, cell cycle, 873
- Apoptosis, chronic myeloid leukemia, imatinib mesylate, histone deacetylase inhibitor, depsipeptide, cyclin D1, MEK, c-myc, 2705
- Apoptosis, cisplatin (CDDP), hepatoma, oral carcinoma, DNA fragmentation, caspase, 655
- Apoptosis, COX-2, gastric carcinoma, tubular adenoma, angiogenesis, 1439
- Apoptosis, cyclic dipeptides, HT-29, 1713
- Apoptosis, diffuse large B-cell lymphomas, cluster analysis, 3081
- Apoptosis, DNA fragmentation, breast ductal carcinoma, tumor stroma, lymph node invasion, steroid hormone, 53
- Apoptosis, E2F-1, proliferation, colon cancer, 3041
- Apoptosis, epidermal growth factor receptor, colon cancer, ERFP, scid mouse tumor xenograft, 2885
- Apoptosis, eradication therapy of *H.pylori*, B cell lymphoma, 3723
- Apoptosis, esophageal cancer, PPAR, molecular targeting, cell cycle regulator, 1409

- Apoptosis, gemcitabine, drug resistance, Fas/FasL system, caspases, 851
- Apoptosis, gene therapy, colon carcinoma, RGD, fiber modifications, 3075
- Apoptosis, glioblastoma, taurolidine, 1143
- Apoptosis, glucose deprivation, oncogenes, src, ras, abl, bcr-abl, bcl-2, IL-3, 2503
- Apoptosis, HMGCoA reductase, cell proliferation, colon cancer, 3837
- Apoptosis, Kaposi's sarcoma, AIDS, hCG, human eosinophil-derived neurotoxin, 1427
- Apoptosis, Kupffer cells, LPS, octreotide, 833
- Apoptosis, lung cancer, cell proliferation, 4243
- Apoptosis, luteinizing hormone-releasing hormone, LHRH, ovarian cancer, endometrial cancer, 1727
- Apoptosis, macrophages, adriamycin, caspases, p38 MAPK, 2689
- Apoptosis, MBT-2, lipoxygenase, baicalein, 733
- Apoptosis, medullary thyroid carcinoma, drug resistance, plant - based drugs, 495
- Apoptosis, mevastatin, multiple myeloma, caspase, 1817
- Apoptosis, MK 886, U937 nuclear Ca²⁺, 2601
- Apoptosis, nasopharyngeal carcinoma, EBV LMP1, infiltrating leucocytes, p53, 2309
- Apoptosis, neuroblastoma, p53, curcumin, resveratrol, 987
- Apoptosis, ovarian cancer, paclitaxel, histone deacetylase inhibitor, p53, 539
- Apoptosis, oxaliplatin, colon cancer cells, 219
- Apoptosis, paclitaxel, NF- κ B, I κ B- α , mitotic arrest, 27
- Apoptosis, pancreatic carcinoma cells, paclitaxel, daunorubicin, necrosis, 2617
- Apoptosis, pEHG, proliferation, cell cycle, colonic epithelial cells, 587
- Apoptosis, phagocytosis, breast cancer cells, 1455
- Apoptosis, prostate cancer cell lines, rhodium ferrocene complexes, 763
- Apoptosis, resveratrol, antioxidant, 999
- Apoptosis, resveratrol, cell signaling, chemoprevention, metastasis, transformation, invasion, tumorigenesis, review, 2783
- Apoptosis, sarcoma, CDDP, Id, caspase, 1519
- Apoptosis, taxol, caspases, mitochondria, cytochrome c, leukemia, death receptors, 123
- Apoptosis, tocotrienol, tocopherol, hepatoma, 1683
- Apoptosis, viral infection, telomerase activity, polyomavirus, 791
- Apoptosis, zinc, tumor imaging, 3869
- Apoptosis, α -tocopheryloxybutyrate, α -tocopheryl succinate, prostate cancer, Akt, 3795
- Apoptosis, β -diketone, cytotoxic activity, oral tumor cells, 711
- Apoptosis-related genes, leuprorelin acetate, dihydrotestosterone, cyproterone acetate, prostate cancer, 2729
- Apoptotic markers, esophageal carcinoma, chemotherapy response, 2579
- Appendix, carcinoid, catestatin, immunohistochemistry, Western blot, 311
- Apurinic sites, base excision repair, DNA adducts, DNA repair, human breast cell extracts, nucleotide excision repair, 117
- Archival breast cancer, Her2/neu, oncogene, chromogenic in situ hybridisation, prognostic significance, 2401
- Argon plasma coagulation, bronchopulmonary carcinoid, bronchoscopic treatment, 4073
- Array, SELDI, proteinChip, proteome, protein, colorectal cancer, carcinoma, 1791
- Arsenic, anti-cancer drugs, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, gallium, platinum, review, 1529
- Artemisia species, capillin, polyacetylenes, 2281
- Artemisinin, cancer cells, apoptosis, 2277
- Artemisinin, oral squamous cell carcinoma, 2153
- Artificial intelligence, microarray, cancer screen, 1159
- Ascites, VEGF, cyst fluid, ovarian carcinoma, 1149
- Asparaginase, asparagine, glutamine, deamination, 1121
- Asparagine, asparaginase, glutamine, deamination, 1121
- Aspirin, NSAIDs, cancer, cardiovascular disease, NHANES, cohort study, 3177
- Astrocytomas, malignant glioma, extracranial metastases, glioblastomas, 2563
- 211At-para-astato-benzoate, 125I-para-iodo-benzoate, EGF, A-431 cells, intracellular retention, 4035
- ATP-binding cassette, MRP1, multidrug resistance, ABC-signature, nucleotide trapping, ABC-ABC structure, 449
- ATP7B, cisplatin, hepatocellular carcinoma, 1045
- Atypical fibroxanthoma, undifferentiated high grade pleomorphic sarcoma, pleomorphic malignant fibrous histiocytoma, comparative genomic hybridization, 19
- AUC, carboplatin, taxane, limited-sampling model, 1911
- Aurora A, chromosomal instability, aneuploidy, centriole, tumorigenesis, review, 3269
- Autograft, pasteurized bone graft, chondrosarcoma, 1893
- Autoimmune disease, adoptive immunotherapy, autologous activated lymphocyte, antinuclear antibody, rheumatoid factor, 2423
- Autologous activated lymphocyte, adoptive immunotherapy, antinuclear antibody, rheumatoid factor, autoimmune disease, 2423
- 5-Aza-2'-deoxycytidine, leukemia, methylation, p15CDKN2B, E-cadherin, p73, 75
- Azoxymethane, min mice, adenomatous polyposis coli, β -catenin, LOH, 2595
- Azulenes, Raw 264.7 cells, NO, iNOS, ESR, radical, 3939
- B cell lymphoma, eradication therapy of *H.pylori*, apoptosis, 3723
- Bacteriophages, purified bacteriophages, melanoma, 3991

- BAD, Chk1, cell cycle, DNA damage, 3907
- Baicalein, MBT-2, lipoxygenase, apoptosis, 733
- Bamboo grass leaves, chemoprevention, Her2/NeuN, mammary tumor, Sasa Health, 2879
- Barrett's metaplasia, estrogen receptor beta, esophagus cancer, 2919
- Barrett's oesophagus, human papillomavirus, oesophageal cancer, oesophagitis, 1319
- Basal cell carcinoma, mitochondrial DNA deletion, tandem duplication, actinic keratosis, squamous cell carcinoma, 1753
- Base excision repair, APE1, ref-1, lucanthone, breast cancer, 2127
- Base excision repair, apurinic sites, DNA adducts, DNA repair, human breast cell extracts, nucleotide excision repair, 117
- Bcl-2, apoptosis, breast cancer, disease/relapse-free survival, immunohistochemistry, mcl-1, overall survival, prognostic indicator, reverse-transcriptase polymerase chain reaction, 473
- Bcl-2, bladder cancer, carboxyamido-triazole (CAI), signal transduction inhibition, apoptosis, calcium, 2869
- Bcl-2, glucose deprivation, oncogenes, src, ras, abl, bcr-abl, IL-3, apoptosis, 2503
- Bcl-2, p53, non-small cell lung cancer, 1925
- Bcl-2, p53, p21waf1, myc, drug resistance, radiation resistance, paclitaxel, SCLC cells, 465
- Bcl-2, tumor cell dissemination, breast cancer, HER2, p53, Ki-67, hormone receptor, 4211
- Bcl2, orbital rhabdomyosarcoma, p53, MDR-1, Ki67 (MIB1), DNA ploidy, prognosis, 249
- Bcr-abl, chronic myeloid leukemia, FISH, 2535
- Bcr-abl, glucose deprivation, oncogenes, src, ras, abl, bcl-2, IL-3, apoptosis, 2503
- Betacellulin, malignant fibrous histiocytoma, immunohistochemistry, heparin-binding epidermal growth factor, epiregulin, 2007
- BFGF, prostate cancer, angiogenesis, VEGF, c-met, progression, 1797
- Bile duct cancer, cyclooxygenase-2, pancreaticobiliary maljunction, 671
- Biochemical failure, prostate specific antigen, radical prostatectomy, perianastomotic biopsies, intraprostatic surgical margin, 1179
- Biological therapy, drug toxicity, interferon alpha, melanoma, 1947
- Bismuth, anti-cancer drugs, arsenic, antimony, gold, vanadium, iron, rhodium, titanium, gallium, platinum, review, 1529
- Bispecific trivalent antibody, multicellular tumour spheroids, 887
- Bisphosphonates, clodronate, thyroid cancer cells, growth inhibition, calcium signaling, 1617
- Bladder cancer cell line (T24), N-acetyltransferase, paclitaxel, 2-aminofluorene, flow cytometry, cDNA microarray, 1501
- Bladder cancer, carboxyamido-triazole (CAI), signal transduction inhibition, apoptosis, bcl-2, calcium, 2869
- Bladder cancer, fluorescence in situ hybridization, chromosome 9 and 11 numerical aberrations, interphase cytogenetics, 3857
- Bladder cancer, G-banding, chromosomes, 2967
- Bladder cells, Drosophila melanogaster S3, ribosomal/repair protein, dS3, oxidative DNA damage, 3811
- Bladder neoplasm, immunotherapy, subcutaneous animal model, CpG-ODN, 2225
- Bladder, plasma, microsatellites, LOH, MSI, 1733
- Bleomycin, Salmonella typhimurium, Ames test, oxidative stress, mutagenicity, plant phenolics, antioxidant, antimutagenicity, caffeic acid, 743
- Bone markers, bone scintigraphy, bone metastasis, lung carcinoma, 3193
- Bone marrow metastases, trastuzumab, metastatic breast cancer, 317
- Bone marrow micrometastases, colorectal carcinoma, immunohistochemistry, cytokeratin, p53, Ki67, 2375
- Bone metabolism markers, breast cancer, chemotherapy, 5-fluorouracil, epirubicin, cyclophosphamide, 1271
- Bone metastasis, bone scintigraphy, bone markers, lung carcinoma, 3193
- Bone metastasis, renal cell carcinoma, osteolysis, angiogenesis, 1705
- Bone scintigraphy, bone markers, bone metastasis, lung carcinoma, 3193
- Bone sialoprotein (BSP), bone, breast cancer, metastasis, 1361
- Bone, bone sialoprotein (BSP), breast cancer, metastasis, 1361
- Boron neutron capture therapy, sodium borocaptate-10B, 2-nitroimidazole, quiescent cell, thermal neutrons, γ -rays, 2975
- BRAF gene, spitz nevus, malignant melanoma, 2415
- Brain cancer, experimental treatment, glioma therapy, iodine-131-labelled amino acid, preclinical study, 3971
- Brain imaging, glioma, central nervous system, tumor progression, 2359
- Brain metastasis, small cell lung cancer, radiation therapy, chemotherapy, 2097
- Brain tumor, malignant glioma, local treatment, glioblastoma, anti-angiogenic treatment, 631
- Brain tumors, melanoma brain metastases, DNA-repair, mutations, immunohistochemistry, 981
- Brain, central nervous system, spinal cord, radiation therapy, amifostine, 3803
- Brain, metastasis, small cell lung cancer, hypertension, 3115

- BRCA1, BRCA2, p53, LOH analysis, long-term survival, prognostic marker, sporadic breast cancer, 281
- BRCA1, breast cancer, BRCA2, loss of heterozygosity, 2681
- BRCA1, infantile gynecomastia, BRCA2, immunohistochemistry, 321
- BRCA2, BRCA1, p53, LOH analysis, long-term survival, prognostic marker, sporadic breast cancer, 281
- BRCA2, breast cancer, BRCA1, loss of heterozygosity, 2681
- BRCA2, infantile gynecomastia, BRCA1, immunohistochemistry, 321
- Breast cancer cells, dydrogesterone, progestins, sulfatase, 17 β -hydroxysteroid dehydrogenase, 1433
- Breast cancer cells, phagocytosis, apoptosis, 1455Luteinizing hormone-releasing hormone, LHRH, apoptosis, ovarian cancer, endometrial cancer, 1727
- Breast cancer patients, mistletoe extract, mistletoe lectin, immunomodulation, 1293
- Breast cancer resistance protein, multidrug resistance, doxorubicin, drug encapsulation, gene expression, topoisomerase II, P-glycoprotein, 3781
- Breast cancer resistance protein, multidrug resistance, P-glycoprotein, multidrug resistance protein, modulation, taxane, structure-activity analysis, 409
- Breast cancer, aminopeptidase A, angiotensin, N-methylnitrosourea, 801
- Breast cancer, anastrozole, postmenopausal, hormone-dependent tumors, 1315
- Breast cancer, APE1, ref-1, base excision repair, lucanthone, 2127
- Breast cancer, apoptosis, bcl-2, disease/relapse-free survival, immunohistochemistry, mcl-1, overall survival, prognostic indicator, reverse-transcriptase polymerase chain reaction, 473
- Breast cancer, bone sialoprotein (BSP), bone, metastasis, 1361
- Breast cancer, BRCA1, BRCA2, loss of heterozygosity, 2681
- Breast cancer, CEA, CA 15-3, MIB-1, hormone receptor, 3221
- Breast cancer, cells, STI571 (Glivec®), 1445
- Breast cancer, chemotherapy, bone metabolism markers, 5-fluorouracil, epirubicin, cyclophosphamide, 1271
- Breast cancer, chemotherapy, HER2, predictive value, tumor marker, 1261
- Breast cancer, core needle biopsy, microvessel density, vascular endothelial growth factor, 371
- Breast cancer, cyclooxygenase-2, metastases, 2349
- Breast cancer, disseminated tumor cells, anthracycline-based chemotherapy, 3209
- Breast cancer, doxorubicin, cyclophosphamide, docetaxel, 2487
- Breast cancer, E-cadherin, growth pattern, adhesion molecule, 2237
- Breast cancer, estrogen exposure, MTHFR, polymorphism, 3863
- Breast cancer, extracellular domain, c-erbB2, trastuzumab, 1127
- Breast cancer, folate, polymorphism, MTHFR, TS, 3215
- Breast cancer, fulvestrant, 'Faslodex', ER antagonist, antioestrogen, 1275
- Breast cancer, mammography, technetium Tc-99m-medronate, VEGF, 1999
- Breast cancer, matrix metalloproteinases, MMP-21, polymorphism, 199
- Breast cancer, MCF-7, MB-MDA-231, estrogen receptor (ER), estrogen, tamoxifen, VEGF, 3961
- Breast cancer, MCF-7, β -galactosidase, α -mannosidase, fluorescent-lectin conjugates, membrane receptors, 139
- Breast cancer, MDA-MB-231, MDA-MB-435, SDF-1 α , CXCR4, chemotaxis, transendothelial migration, 4011
- Breast cancer, MIB1, mitotic index, S-phase fraction, 3283
- Breast cancer, mistletoe lectin, 1187
- Breast cancer, MMPs, TIMPs, genistein, cell growth, invasion, 4025
- Breast cancer, multidrug resistance, MCF-7, monocyte, cytokine, 935
- Breast cancer, p53, Her2-neu, cathepsin D, survival, 2061
- Breast cancer, Polo-like kinase 1, cell cycle checkpoints, ionizing radiation, 555
- Breast cancer, radiotherapy, 1303
- Breast cancer, retinoids, histone deacetylase inhibitors, 4019
- Breast cancer, RNASEL, 2547
- Breast cancer, salvage chemotherapy, cyclophosphamide, 5-fluorouracil, leucovorin, vinorelbine, 4217
- Breast cancer, salvage chemotherapy, cyclophosphamide, 5-fluorouracil, leucovorin, vinorelbine, 4223
- Breast cancer, serum HER2, CA 15-3, prognosis, survival, metastasis, 1987
- Breast cancer, tumor cell dissemination, HER2, p53, bcl-2, Ki-67, hormone receptor, 4211
- Breast cancer, Twist, Wnt, 3851
- Breast cancer, TZT-1027, nude mouse, vascular flow, 2201
- Breast cancer, VEGF, CD105, endoglin, angiogenesis, 1581
- Breast cancer, whey protein, cysteine, glutathione, prostate, oxidant, antioxidant, 553
- Breast carcinoma, MMP-9, antiestrogen therapy, 4247
- Breast carcinoma, nucleolin, estrogen receptor, nucleolus, 963
- Breast carcinoma, prognosis, LEA-135, 2391
- Breast ductal carcinoma, apoptosis, DNA fragmentation, tumor stroma, lymph node invasion, steroid hormone, 53
- Breast neoplasms, HER-2/neu, serum, trastuzumab, 1083
- Bronchopulmonary carcinoid, bronchoscopic treatment, argon plasma coagulation, 4073

- Bronchoscopic treatment, bronchopulmonary carcinoid, argon plasma coagulation, 4073
- Butyl-substituted phenols, 2-methoxyphenols, orthobisphenols, 3019
- BZLF1, gene therapy, Epstein-Barr virus, lytic replication, 67
- CA 125, collagen metabolism, epithelial ovarian cancer, ICTP, prognosis, tumor markers, 1057
- CA 15-3, breast cancer, CEA, MIB-1, hormone receptor, 3221
- CA 15-3, serum HER2, breast cancer, prognosis, survival, metastasis, 1987
- CA-074, cancer, invasion, Sp1 transcription factor, cathepsin B, matrigel, 3887
- CA-4, 3, 4-diarylfuran-2-one, tumors, tubulin polymerization, MTT assay, cell cycle, 179
- 3, CA-4, 4-diarylfuran-2-one, tumors, tubulin polymerization, MTT assay, cell cycle, 179
- Ca²⁺, pEHG, cAMP, colonic epithelial cells, 1465
- CaCo-2, retinoids, colon cancer, HT-29, IIF, cell differentiation, 1779
- E-Cadherin, 5-aza-2'-deoxycytidine, leukemia, methylation, p15CDKN2B, p73, 75
- E-Cadherin, adhesion, prognosis, multiple myeloma, 2027
- E-Cadherin, breast cancer, growth pattern, adhesion molecule, 2237
- E-Cadherin, catenin, cell adhesion, gastric cancer, 699
- E-Cadherin, intestinal metaplasia, Helicobacter pylori, gastritis, 1603
- E-Cadherin, β -catenin, endometrium, endometrial carcinoma, immunohistochemistry, 3843
- E-Cadherin-catenin, adenocarcinoma, gastro-oesophageal junction, 1369
- Caffeic acid, Salmonella typhimurium, Ames test, oxidative stress, mutagenicity, plant phenolics, bleomycin, antioxidant, antimutagenicity, 743
- Caffeine, cell cycle, cyclin E, flow cytometry, cell proliferation, MOLT-4 cells, 2991
- Calcium signaling, Clodronate, bisphosphonates, thyroid cancer cells, growth inhibition, 1617
- Calcium, bladder cancer, carboxyamido-triazole (CAI), signal transduction inhibition, apoptosis, bcl-2, 2869
- Calcium-binding proteins, calretinin, EF-hand, mesothelioma, tumor marker, differential expression, alternative splicing, 4003
- Calretinin, calcium-binding proteins, EF-hand, mesothelioma, tumor marker, differential expression, alternative splicing, 4003
- Calretinin, sarcomatoid malignant mesothelioma, cytokeratin, mesothelioma, 3097
- CAMP, pEHG, Ca²⁺, colonic epithelial cells, 1465
- Cancer assessment, Fibrin/collagen gel, 3-D culture systems, cancer cell invasion, colony formation, anticancer drug screening, 2169
- Cancer cell invasion, Fibrin/collagen gel, 3-D culture systems, colony formation, cancer assessment, anticancer drug screening, 2169
- Cancer cells, artemisinin, apoptosis, 2277
- Cancer chemotherapy, drug delivery, paclitaxel, doxorubicin, liposomes, physiological modeling, 397
- Cancer chemotherapy, stomatitis, allopurinol-cryotherapy, LV/5-FU, 1131
- Cancer gene therapy, viral vector, tumor-targeting, tumor-associated antigen, 3373
- Cancer genes, kallikreins, pancreatic cancer, colon cancer, serine proteases, SAGE, tumor markers, digital differential display, X-profiler, in-silico analysis, 43
- Cancer patients, mistletoe extract, quality of life, randomized controlled trial, 303
- Cancer screen, microarray, artificial intelligence, 1159
- Cancer screening, FDG, PET, PET/CT, 4103
- Cancer susceptibility, colorectal cancer, metabolizing enzymes, N-acetyltransferase, glutathione-S-transferase, 3965
- Cancer, aspirin, NSAIDs, cardiovascular disease, NHANES, cohort study, 3177
- Cancer, dehydropyrimidine dehydrogenase, 5-fluorouracil chemotherapy, 1091
- Cancer, dendritic cells, electrofusion, vaccine, immunotherapy, 929
- Cancer, gene therapy, delivery systems, stem cells, 501
- Cancer, hBD-2, antimicrobial peptides, innate immunity, Candida, defensin, 1025
- Cancer, HLA antibody, 3387
- Cancer, invasion, Sp1 transcription factor, cathepsin B, matrigel, CA-074, 3887
- Cancer, microarray, genomics, across-platform, 441
- Cancer, RNA helicases, review, 3951
- Cancer, vitamin D, 1, 24(OH)2D2, antiproliferation, isobologram, 2905
- Cancer, vitamins, microelements, oxidative stress, lipoperoxidation, free radical scavengers, 1449
- Cancer-chemoprevention, DNA repair, field-effect, selenium compounds, 1401
- Candida, anti-fungal, amphotericin B, CDR 1, drug resistance, 405
- Candida, hBD-2, antimicrobial peptides, innate immunity, cancer, defensin, 1025
- Canis familiaris, fibrosarcoma, hot-spot mutations, melanoma, ras genes, 3027
- Capillin, artemisia species, polyacetylenes, 2281
- Capsaicin, denervation, sensory neurons, mammary tumor, metastasis, 1003
- Carbohydrate processing, vitamin D-binding protein, Gc protein, macrophage activating factor (MAF), Gc typing, GalNAc, 3361
- Carboplatin, AUC, taxane, limited-sampling model, 1911

- Carboplatin, cervical carcinoma, chemoradiation, paclitaxel, 345
- Carboplatin, docetaxel, non-small cell lung cancer, 1239
- Carboxyamido-triazole (CAI), bladder cancer, signal transduction inhibition, apoptosis, bcl-2, calcium, 2869
- Carboxylesterase, irinotecan, colon cancer, topoisomerase I, clinical response, 579
- Carcinoembryonic antigen (CEA), metastasis model, PCR, colon cancer cell line HT29, severe-combined-immunodeficient (scid) mouse, circulating tumor cells, 1421
- Carcinoembryonic antigen (CEA), radioimmunoguided surgery (RIGS), gastric carcinoma, T84.66, F(ab')₂, Fab', 663
- Carcinoembryonic antigen, monoclonal antibody, scFv, 3355
- Carcinogenesis, Fas, FasL, colorectal carcinoma, metastasis, 1569
- Carcinoid, appendix, catestatin, immunohistochemistry, Western blot, 311
- Carcinoma, fatty acid synthase, lung, prognosis, 4169
- Carcinoma, SELDI, ProteinChip, proteome, protein, array, colorectal cancer, 1791
- Cardiotoxicity, anthracyclines, cisplatin, epirubicin, gemcitabine, left ventricular ejection fraction, non-small cell lung cancer, radionuclide ventriculography, 2079
- Cardiovascular disease, aspirin, NSAIDs, cancer, NHANES, cohort study, 3177
- Cardiovascular tests, malignant disease, pancreatic polypeptide, 2515
- Cartilaginous tumors, genomic hybridization, chondrosarcomas, 1721
- CAS200, ovarian tumours, image cytophotometry, 4191
- Case control study, MMP1, MMP3, head and neck cancer, haplotype, 2021
- Caspase, cisplatin (CDDP), hepatoma, oral carcinoma, apoptosis, DNA fragmentation, 655
- Caspase, mevastatin, multiple myeloma, apoptosis, 1817
- Caspase, sarcoma, apoptosis, CDDP, Id, 1519
- Caspase-1, apoptosis, radiation, prostate cancer, 1377
- Caspase-3 activation, drug-induced apoptosis, Ewing tumor, drug sensitivity testing, 145
- Caspase-3, ribozyme, 425
- Caspases, 2-methoxyestradiol, endometrium carcinoma cells, HEC-1-A, RL-95-2, cell cycle, apoptosis, necrosis, iNOS, STAT1, 3983
- Caspases, apoptosis, macrophages, adriamycin, p38 MAPK, 2689
- Caspases, gemcitabine, apoptosis, drug resistance, Fas/FasL system, 851
- Caspases, Taxol, apoptosis, mitochondria, cytochrome c, leukemia, death receptors, 123
- Catenin, E-cadherin, cell adhesion, gastric cancer, 699
- β -Catenin, azoxymethane, min mice, adenomatous polyposis coli, LOH, 2595
- β -Catenin, E-cadherin, endometrium, endometrial carcinoma, immunohistochemistry, 3843
- Catenin, renal cell carcinoma, 2407
- Catestatin, appendix, carcinoid, immunohistochemistry, Western blot, 311
- Cathepsin B (cath B), plasminogen activator-inhibitor (PAI-1), plasminogen activator-receptor (uPAR), prognosis, non-small cell lung cancer (NSCLC), 4147
- Cathepsin B, cancer, invasion, Sp1 transcription factor, matrigel, CA-074, 3887
- Cathepsin B, prostate cancer, serum, prostate volume, 2573
- Cathepsin B, tumour budding, cathepsin D, colorectal cancer, 2847
- Cathepsin D, breast cancer, p53, Her2-neu, survival, 2061
- Cathepsin D, tumour budding, cathepsin B, colorectal cancer, 2847
- Cationic dextran, sialic acid, growth inhibition, 1347
- Cationic dextran, sialic acid, growth inhibition, 1347
- Cationic liposomes, anti-angiogenic gene therapy, osteosarcoma, human-like orthotopic model, 3977
- Caveolin-1 gene, colorectal cancer, methylation specific PCR, 1645
- CD105, breast cancer, VEGF, endoglin, angiogenesis, 1581
- CD105, Smad, endoglin, TGF- β 1, 1337
- CD26, tumor marker, squamous cell carcinoma, TGF- β 1, p27kip, 619
- CD3 ζ chain, gastric cancer, lymph node, 2123
- CD3-LAK, immuno-cell therapy, immunotherapy, adoptive immunotherapy, LAK, review, 3321
- CD31, prostatic neoplasms, angiogenesis, von Willebrand factor, CD34, endothelial cells, endothelial marker, 1651
- CD34, prostatic neoplasms, angiogenesis, von Willebrand factor, CD31, endothelial cells, endothelial marker, 1651
- CD40 ligand, CD40, IL-23, 2713
- CD40 ligand, Mantle cell lymphoma, CD40, IL-10, 691
- CD40, CD40 ligand, IL-23, 2713
- CD40, mantle cell lymphoma, CD40 ligand, IL-10, 691
- CD44, MMP-9, invasion, migration, colon tumour cell lines, 489
- CD44s, ovarian cancer, ER, PR, p53, PCNA, MIB1, 1665
- CD44s, soft tissue sarcoma, tumor prognosis, survival, 1053
- CDDP, sarcoma, apoptosis, Id, caspase, 1519
- CDK1, enhancer, transcription, cell cycle, proliferation, gene expression, 1469
- CDKN1A, checkpoints, Gadd45, human, oxidative stress, prostate cancer, DNA repair, 3955
- CDNA microarray, 5-fluorouracil, tomudex, oxaliplatin, CPT-11, 417
- CDNA microarray, N-acetyltransferase, paclitaxel, bladder cancer cell line (T24), 2-aminofluorene, flow cytometry, 1501

- CDR 1, anti-fungal, amphotericin B, *Candida*, drug resistance, 405
- CEA, breast cancer, CA 15-3, MIB-1, hormone receptor, 3221
- CEA, NSCLC, CYFRA 21-1, 1953
- Cell adhesion, E-cadherin, catenin, gastric cancer, 699
- Cell cycle checkpoints, Polo-like kinase 1, ionizing radiation, breast cancer, 555
- Cell cycle proteins, rectal cancer, microsatellite instability, neoadjuvant therapy, irinotecan, 3161
- Cell cycle regulator, esophageal cancer, PPAR, molecular targeting, apoptosis, 1409
- Cell cycle, (-)-EGCG, green tea, organic synthesis, proteasome inhibitors, growth inhibition, 943
- Cell cycle, 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone, HL-60, PBMC, apoptosis, G2/M arrest, ERK, 1769
- Cell cycle, 2-methoxyestradiol, endometrium carcinoma cells, HEC-1-A, RL-95-2, apoptosis, necrosis, iNOS, caspases, STAT1, 3983
- Cell cycle, CA-4, 3, 4-diarylfuran-2-one, tumors, tubulin polymerization, MTT assay, 179
- Cell cycle, caffeine, cyclin E, flow cytometry, cell proliferation, MOLT-4 cells, 2991
- Cell cycle, CDK1, enhancer, transcription, proliferation, gene expression, 1469
- Cell cycle, cervical cells, HeLaS3 cells, 2-methoxyestradiol, apoptosis, 873
- Cell cycle, Chk1, BAD, DNA damage, 3907
- Cell cycle, cyclin D1, endometrial adenocarcinoma, 2185
- Cell cycle, mitogen activated protein kinase, growth factor, signal transduction, migration, 593
- Cell cycle, pEHG, proliferation, apoptosis, colonic epithelial cells, 587
- Cell cycle, PLK1, thyroid malignant lymphoma, immunohistochemistry, 259
- Cell cycle, progesterone, non-genomic cell growth inhibition, 3749
- Cell cycle, Puro α , E2F1, growth inhibition, RNA association, 2585
- Cell differentiation, retinoids, colon cancer, CaCo-2, HT-29, IIF, 1779
- Cell growth, MMPs, TIMPs, genistein, breast cancer, invasion, 4025
- Cell proliferation, caffeine, cell cycle, cyclin E, flow cytometry, MOLT-4 cells, 2991
- Cell proliferation, HMGCoA reductase, apoptosis, colon cancer, 3837
- Cell proliferation, lung cancer, apoptosis, 4243
- Cell signaling, resveratrol, chemoprevention, metastasis, transformation, invasion, tumorigenesis, apoptosis, review, 2783
- Cell survival, Akt-1, protein kinase B, inositolphosphate-3-kinase, IP3-K, multi-stage skin carcinogenesis, epidermal keratinocytes, mast cells, papilloma, image analysis, 2773
- Central nervous system, brain, spinal cord, radiation therapy, amifostine, 3803
- Central nervous system, glioma, tumor progression, brain imaging, 2359
- Centriole, chromosomal instability, aneuploidy, aurora A, tumorigenesis, review, 3269
- Cervical cancer, estrogen, apoptosis, indole-3-carbinol, 2649
- Cervical carcinoma, carboplatin, chemoradiation, paclitaxel, 345
- Cervical carcinoma, platelet count, thrombocytosis, endometrial carcinoma, ovarian cancer, 2053
- Cervical cells, HeLaS3 cells, 2-methoxyestradiol, apoptosis, cell cycle, 873
- CF-1 mice, colon cancer, soybean flour, garbanzo beans, ACF, 3049
- Checkpoints, CDKN1A, Gadd45, human, oxidative stress, prostate cancer, DNA repair, 3955
- Chemo-lipiodolization, hepatocellular carcinoma, hepatectomy, 1929
- Chemo-radiation, monoterpenes, head and neck cancer, 3089
- Chemoimmunotherapy, mouse mammary tumors, 2249
- Chemokinesis, malignant mesothelioma, chemotaxis, growth factors, 1625
- Chemoprevention, bamboo grass leaves, Her2/NeuN, mammary tumor, Sasa Health, 2879
- Chemoprevention, lovostatin, exisulind, aberrant crypt foci, 1805
- Chemoprevention, resveratrol, cell signaling, metastasis, transformation, invasion, tumorigenesis, apoptosis, review, 2783
- Chemoprevention, UDP-glucuronosyltransferases, NSAIDs, anticarcinogens, Wistar rat, 843
- Chemoradiation, carboplatin, cervical carcinoma, paclitaxel, 345
- Chemoradiotherapy, esophageal carcinoma, neoadjuvant therapy, esophagectomy, 4091
- Chemosensitivity testing, head and neck carcinoma, HNSCC, tumor stroma, ex vivo culture, 325
- Chemosensitivity, 5-fluorouracil, thymidylate synthetase, dihydropyrimidine dehydrogenase, tandem repeat, gastric cancer, 2455
- Chemosensitivity, glufosfamide, head and neck carcinoma, HNSCC, glufosfamide, 2947
- Chemosensitivity, taxane analogues, paclitaxel, head and neck squamous cell carcinoma, clonogenic assay, 3769
- Chemotaxis, breast cancer, MDA-MB-231, MDA-MB-435, SDF-1 α , CXCR4, transendothelial migration, 4011

- Chemotaxis, malignant mesothelioma, chemokinesis, growth factors, 1625
- Chemotherapy response, esophageal carcinoma, apoptotic markers, 2579
- Chemotherapy, advanced colorectal cancer, oxaliplatin, leucovorin, 5-fluorouracil, 1935
- Chemotherapy, breast cancer, bone metabolism markers, 5-fluorouracil, epirubicin, cyclophosphamide, 1271
- Chemotherapy, breast cancer, HER2, predictive value, tumor marker, 1261
- Chemotherapy, docetaxel, second-line, non-small cell lung cancer, taxane, 1211
- Chemotherapy, esophageal cancer, elderly, radiotherapy, 2483
- Chemotherapy, gastric carcinoma, phase I study, S-1, docetaxel, 1843
- Chemotherapy, neurotoxicity, amifostine, in vitro study, 2337
- Chemotherapy, primary cerebral tumor, glioblastoma, 1249
- Chemotherapy, small cell lung cancer, brain metastasis, radiation therapy, 2097
- Chemotherapy, vascular endothelial growth factor (VEGF), angiogenesis, antisense, head and neck cancer, 2179
- Chick embryo assay, angiogenesis inhibition, digital image analysis, antiangiogenic compounds, 1545
- Childhood, persistent cytopenia, myelodysplastic syndrome, chromosome aberrations, conventional, cytogenetic analysis, fluorescence in situ hybridization, 3945
- Chk1, BAD, cell cycle, DNA damage, 3907
- Chlamydia pneumoniae, head and neck neoplasms, squamous cell carcinoma, 1207
- Cholesterol, cytolysin, intermedilysin, immunotherapy, 3343
- Chondrosarcoma, matrix metalloproteinase, tissue inhibitor of metalloproteinase, α disintegrin and metalloproteinase, immunohistochemistry, histological grade, 4079
- Chondrosarcoma, pasteurized bone graft, autograft, 1893
- Chondrosarcomas, genomic hybridization, cartilaginous tumors, 1721
- Choriocarcinoma, chorionic gonadotropin, lung tumor, 1905
- Chorionic gonadotropin, choriocarcinoma, lung tumor, 1905
- Chromogenic in situ hybridisation, Her2/neu, oncogene, archival breast cancer, prognostic significance, 2401
- Chromosomal abnormalities, multiple myeloma, conventional cytogenetics, involvement of 1p12, prognosis, 4141
- Chromosomal instability, aneuploidy, centriole, aurora A, tumorigenesis, review, 3269
- Chromosome 17, p53 locus, small hepatocellular carcinoma, dual-color fluorescence in situ hybridization, 111
- Chromosome 17p, non-small cell lung cancer, loss of heterozygosity, chromosome 3p, 4259
- Chromosome 3p, non-small cell lung cancer, loss of heterozygosity, chromosome 17p, 4259
- Chromosome 8 aberrations, fluorescence in situ hybridization, gastric cancer, interphase cytogenetics, 155
- Chromosome 9 and 11 numerical aberrations, fluorescence in situ hybridization, bladder cancer, interphase cytogenetics, 3857
- Chromosome aberrations, persistent cytopenia, myelodysplastic syndrome, conventional, cytogenetic analysis, fluorescence in situ hybridization, childhood, 3945
- Chromosomes, G-banding, bladder cancer, 2967
- Chronic myeloid leukemia, bcr-abl, FISH, 2535
- Chronic myeloid leukemia, imatinib mesylate, histone deacetylase inhibitor, depsipeptide, apoptosis, cyclin D1, MEK, c-myc, 2705
- Circulating cells, colorectal carcinoma, prognostic markers, review, angiogenesis, genomic instability, invasion, 2519
- Circulating tumor cells, metastasis model, PCR, colon cancer cell line HT29, severe-combined-immunodeficient (scid) mouse, carcinoembryonic antigen (CEA), 1421
- Cisplatin (CDDP), hepatoma, oral carcinoma, apoptosis, DNA fragmentation, caspase, 655
- Cisplatin, anthracyclines, cardiotoxicity, epirubicin, gemcitabine, left ventricular ejection fraction, non-small cell lung cancer, radionuclide ventriculography, 2079
- Cisplatin, ATP7B, hepatocellular carcinoma, 1045
- Cisplatin, colon cancer cell, cyclooxygenase-2, MDR-1, MRP-1, 2723
- Cisplatin, concurrent chemoradiation, head and neck cancer, docetaxel, 4135
- Cisplatin, hyperthermia, intraperitoneal perfusion, 2041
- Cisplatin, lipoplatin, nephrotoxicity, 2193
- Cisplatin, mitomycin, doxifluridine, gastric cancer, inoperable, combination therapy, 2465
- Cisplatin, non-small cell lung cancer, vinorelbine, 4227
- Cisplatin, osteosarcoma, HMGB1 expression, semi-quantitative RT-PCR, 707
- Cisplatin, radiosensitization, ZD0473, human tumour cells, 613
- Cisplatin, topoisomerase I, irinotecan, lung cancer, 3893
- CK17, p63, stem cell, uterine cervix, reserve cell, HPV, 771
- Clodronate, bisphosphonates, thyroid cancer cells, growth inhibition, calcium signaling, 1617
- Clonogenic assay, taxane analogues, paclitaxel, head and neck squamous cell carcinoma, chemosensitivity, 3769
- Cluster analysis, apoptosis, diffuse large B-cell lymphomas, 3081
- CNS-lymphoma, temozolomide, CSF, 4121
- Cochleate, gene therapy, macrophage, transgene, tumour cell, 483

- Cohort study, aspirin, NSAIDs, cancer, cardiovascular disease, NHANES, 3177
- Collagen metabolism, CA 125, epithelial ovarian cancer, ICTP, prognosis, tumor markers, 1057
- Colon cancer cell line HT29, metastasis model, PCR, severe-combined-immunodeficient (scid) mouse, carcinoembryonic antigen (CEA), circulating tumor cells, 1421
- Colon cancer cell, cisplatin, cyclooxygenase-2, MDR-1, MRP-1, 2723
- Colon cancer cells, oxaliplatin, apoptosis, 219
- Colon cancer cells, PHGPx, GPx4, cyclooxygenase, 1387
- Colon cancer, E2F-1, proliferation, apoptosis, 3041
- Colon cancer, epidermal growth factor receptor, ERFP, apoptosis, scid mouse tumor xenograft, 2885
- Colon cancer, HMGCoA reductase, cell proliferation, apoptosis, 3837
- Colon cancer, irinotecan, topoisomerase I, carboxylesterase, clinical response, 579
- Colon cancer, kallikreins, pancreatic cancer, serine proteases, cancer genes, SAGE, tumor markers, digital differential display, X-profiler, in-silico analysis, 43
- Colon cancer, molecular markers, RT-PCR, 4127
- Colon cancer, retinoids, CaCo-2, HT-29, IIF, cell differentiation, 1779
- Colon cancer, soybean flour, garbanzo beans, ACF, CF-1 mice, 3049
- Colon carcinoma, apoptosis, gene therapy, RGD, fiber modifications, 3075
- Colon tumor cells, N-ethylphenyl acetamide (EPA), 2-aminofluorene (AF), N-acetyltransferase (NAT), 1677
- Colon tumour cell lines, MMP-9, CD44, invasion, migration, 489
- Colon, adenomas, tumor progression, 2033
- Colonic epithelial cells, pEHG, cAMP, Ca²⁺, 1465
- Colonic epithelial cells, pEHG, proliferation, apoptosis, cell cycle, 587
- Colony formation, fibrin/collagen gel, 3-D culture systems, cancer cell invasion, cancer assessment, anticancer drug screening, 2169
- Colorectal cancer risk, Ki-ras, diet, vitamin A, thiamine, vitamin D, iron, 2011
- Colorectal cancer, caveolin-1 gene, methylation specific PCR, 1645
- Colorectal cancer, cross-resistance, 5-fluorouracil, raltitrexed, 2037
- Colorectal cancer, dihydropyrimidine dehydrogenase, enzymatic activity, immunohistochemical expression, disease-free survival, 273
- Colorectal cancer, HNPCC, tumor progression, 1765
- Colorectal cancer, homeodomain, immunohistochemistry, 955
- Colorectal cancer, metabolizing enzymes, cancer susceptibility, N-acetyltransferase, glutathione-S-transferase, 3965
- Colorectal cancer, metastases, raltitrexed, oxaliplatin, 1139
- Colorectal cancer, MTHFR polymorphism, DNA methylation, methylator phenotype, 649
- Colorectal cancer, palliative first- and second-line treatment, weekly high-dose 5-FU as 24-hour infusion and folinic acid, oxaliplatin, 385
- Colorectal cancer, phase II, dose-intensity, oxaliplatin, 5-fluorouracil, 355
- Colorectal cancer, quality of life, gastrointestinal, oesophageal, gastric, pancreatic, 2117
- Colorectal cancer, SELDI, proteinChip, proteome, protein, array, carcinoma, 1791
- Colorectal cancer, thymidylate synthase, pharmacogenomic, microsatellite instability, polymorphism, molecular therapeutic, 3875
- Colorectal cancer, tumour budding, cathepsin D, cathepsin B, 2847
- Colorectal cancer, tumour marker, 2353
- Colorectal carcinoma, bone marrow micrometastases, immunohistochemistry, cytokeratin, p53, Ki67, 2375
- Colorectal carcinoma, Fas, FasL, carcinogenesis, metastasis, 1569
- Colorectal carcinoma, K-ras mutation, liver metastases, 2471
- Colorectal carcinoma, microsatellite instability, K-ras, p53, 2047
- Colorectal carcinoma, nuclear factor-kB, electrophoretic mobility shift assay, tumor progression, 675
- Colorectal carcinoma, prognostic markers, review, angiogenesis, genomic instability, invasion, circulating cells, 2519
- Colorectal carcinoma, tissue inhibitor of matrix metalloproteinase-1, plasma, prognostic value, 2101
- Colorectal liver metastases, hepatic arterial infusion, interferon, 5-fluorouracil, starch microspheres, 3275
- Colostomy, self-expanding, metallic stent, rectosigmoidal obstruction, 265
- Combination chemotherapy, multiple drug resistance, MRP-1, MDR, sulindac, resistance modulation, resistance circumvention, NCI H460, 457
- Combination therapy, mitomycin, cisplatin, doxifluridine, gastric cancer, inoperable, 2465
- Comparative genomic hybridisation, endometrioid adenocarcinoma, endometriosis, ovary, onco-protein, 151
- Comparative genomic hybridization, atypical fibroxanthoma, undifferentiated high grade pleomorphic sarcoma, pleomorphic malignant fibrous histiocytoma, 19
- Computational simulation, infection, HHV-6, HIV, HTLV-1, clinical course, 187
- Confluence, oral carcinoma cell lines, gene expression, 2627
- Confocal laser scanning microscopy, multidrug resistance, LRP, flow cytometry, fluorescence correlation spectroscopy, 725

- Confrontation culture, meningiomas, proliferation markers, 2319
- Connexin, green tea, gap junction, renal cell carcinoma, 3757
- Conventional cytogenetics, multiple myeloma, chromosomal abnormalities, involvement of 1p12, prognosis, 4141
- Conventional, persistent cytopenia, myelodysplastic syndrome, chromosome aberrations, cytogenetic analysis, fluorescence in situ hybridization, childhood, 3945
- Core needle biopsy, breast cancer, microvessel density, vascular endothelial growth factor, 371
- COX-2, gastric carcinoma, tubular adenoma, angiogenesis, apoptosis, 1439
- CpG-ODN, immunotherapy, bladder neoplasm, subcutaneous animal model, 2225
- CPSA, PSA, free PSA, prostate cancer, 4181
- CPT-11, 5-fluorouracil, tomudex, oxaliplatin, cDNA microarray, 417
- CPT-11, UGT, SN-38, lung cancer, 2893
- Crambescidin 800, erythroid differentiation, K562 cells, guanidine alkaloid, p21, Neuro 2A cells, neurite outgrowth, 2325
- Crohn's disease, ursodeoxycholic acid, inflammatory bowel diseases, ulcerative colitis, dysplasia, DNA-aneuploidy, 3121
- Cross-resistance, colorectal cancer, 5-fluorouracil, raltitrexed, 2037
- CSF, temozolomide, CNS-lymphoma, 4121
- CTL epitope, metastatic melanoma, cytotoxic T cell (CTL), HLA-A24 motif, HLA-A*2402-restricted peptide cocktail, 571
- CTL, MHC, SCCHN, FACS, 973
- 3-D Culture systems, fibrin/collagen gel, cancer cell invasion, colony formation, cancer assessment, anticancer drug screening, 2169
- Curcumin, cytotoxicity, ROS, stoichiometric factor, inhibition rate constants, DPPH, PM3, 563
- Curcumin, neuroblastoma, p53, resveratrol, apoptosis, 987
- CWR22, prostate, animal models, androgen independent, angiogenesis, VEGF, 2135
- CXCR4, breast cancer, MDA-MB-231, MDA-MB-435, SDF-1 α , chemotaxis, transendothelial migration, 4011
- CXCR6, protein expression, rectal cancer, macrophages, T cells, epithelial cells, 3711
- Cyclic dipeptides, HT-29, apoptosis, 1713
- Cyclin B1, ionizing radiation, NF- κ B, mitochondrial antioxidant enzyme, MnSOD, 2657
- Cyclin D-dependent kinase 4, transitional cell carcinomas, urinary bladder, RT-PCR, mRNA, retinoblastoma gene, p16 gene, LOH, lifestyle and occupational risk factors, 1011
- Cyclin D1, chronic myeloid leukemia, imatinib mesylate, histone deacetylase inhibitor, depsipeptide, apoptosis, MEK, c-Myc, 2705
- Cyclin D1, endometrial adenocarcinoma, cell cycle, 2185
- Cyclin D1, gossypol, DNA synthesis, TGF β 1, PC3, 91
- Cyclin E, caffeine, cell cycle, flow cytometry, cell proliferation, MOLT-4 cells, 2991
- Cycloartane triterpenes, euphorbia, apoptosis induction, multidrug resistance, mouse lymphoma cell line, 859
- Cyclooxygenase, PHGPx, GPx4, colon cancer cells, 1387
- Cyclooxygenase-2, antisense oligonucleotides, lung cancer cells, A-549, 3789
- Cyclooxygenase-2, bile duct cancer, pancreaticobiliary maljunction, 671
- Cyclooxygenase-2, breast cancer, metastases, 2349
- Cyclooxygenase-2, colon cancer cell, cisplatin, MDR-1, MRP-1, 2723
- Cyclophosphamide, breast cancer, chemotherapy, bone metabolism markers, 5-fluorouracil, epirubicin, 1271
- Cyclophosphamide, breast cancer, doxorubicin, docetaxel, 2487
- Cyclophosphamide, breast cancer, salvage chemotherapy, 5-fluorouracil, leucovorin, vinorelbine, 4217
- Cyclophosphamide, breast cancer, salvage chemotherapy, 5-fluorouracil, leucovorin, vinorelbine, 4223
- Cyclophosphamide, ONO-4007, IL-12, isolation perfusion, TNF, 1823
- CYFRA 21-1, NSCLC, CEA, 1953
- Cyfra21-1, NSE, multiple tumour markers, small cell lung cancer, prognosis, 1941
- Cyproterone acetate, leuprorelin acetate, dihydrotestosterone, apoptosis-related genes, prostate cancer, 2729
- Cyst fluid, VEGF, ascites, ovarian carcinoma, 1149
- Cysteine, whey protein, glutathione, prostate, breast cancer, oxidant, antioxidant, 553
- Cytochrome c, taxol, apoptosis, caspases, mitochondria, leukemia, death receptors, 123
- Cytogenetic analysis, persistent cytopenia, myelodysplastic syndrome, chromosome aberrations, conventional, fluorescence in situ hybridization, childhood, 3945
- Cytokeratin, bone marrow micrometastases, colorectal carcinoma, immunohistochemistry, p53, Ki67, 2375
- Cytokeratin, malignant melanoma, 3203
- Cytokeratin, sarcomatoid malignant mesothelioma, calretinin, mesothelioma, 3097
- Cytokine gene therapy, IL-12, IL-23, IL-27, 3763
- Cytokine, multidrug resistance, MCF-7, breast cancer, monocyte, 935
- Cytokines, scavenger receptors, mannose receptors, monocytes, tumour cells, 2287
- Cytolysin, cholesterol, intermedilysin, immunotherapy, 3343
- Cytoprotection, mucositis, amifostine, WR-1065, 3263
- Cytosine deaminase, enzyme/prodrug therapy, 5-fluorouracil, gene therapy, protein secretion, 1393

- Cytotoxic activity, deferiprone, maltol, hydroxyketones, oral tumor cells, 755
- Cytotoxic activity, α , β -unsaturated ketone, oral tumor cells, structure-activity, 737
- Cytotoxic activity, β -diketone, apoptosis, oral tumor cells, 711
- Cytotoxic T cell (CTL), metastatic melanoma, CTL epitope, HLA-A24 motif, HLA-A*2402-restricted peptide cocktail, 571
- Cytotoxic T lymphocytes, peptide, interferon-gamma, ELISA, 1193
- Cytotoxic, HMAF, MiaPaCa, 59
- Cytotoxicity, curcumin, ROS, stoichiometric factor, inhibition rate constants, DPPH, PM3, 563
- Cytotoxicity, imidazothioxanones, antitumor activity, human tumor xenografts, murine tumors, molecular modeling-docking, 907
- Cytotoxicity, serine protease inhibitor, medicago scutellata, 227
- Daidzein, ovarian cancer cell, genistein, 795
- Daunorubicin, pancreatic carcinoma cells, paclitaxel, apoptosis, necrosis, 2617
- DC maturation, DCs, tumor-antigen specific CTL, regulatory T cells, 3327
- DCs, DC maturation, tumor-antigen specific CTL, regulatory T cells, 3327
- Deamination, asparaginase, asparagine, glutamine, 1121
- Death receptors, taxol, apoptosis, caspases, mitochondria, cytochrome c, leukemia, 123
- Defensin, hBD-2, antimicrobial peptides, innate immunity, cancer, Candida, 1025
- β -Defensin, lung cancer, immunohistochemistry, tumour marker, antimicrobial peptide, 4051
- Deferiprone, maltol, hydroxyketones, cytotoxic activity, oral tumor cells, 755
- Dehydroypyrimidine dehydrogenase, 5-fluorouracil chemotherapy, cancer, 1091
- Delay differential equation, immune system modeling, HIV infection, 1689
- Delayed type hypersensitivity, methotrexate, lactoferrin, humoral immune response, mice, 3831
- Deleted E7 protein, HPV, therapeutic vaccine, tumour, Pichia pastoris, 2265
- Delivery systems, cancer, gene therapy, stem cells, 501
- Dendritic cell, GM-CSF, IL-4, immunotherapy, 1609
- Dendritic cell, OK-432, immunotherapy, toll-like receptor, review, 3295
- Dendritic cells, electrofusion, cancer, vaccine, immunotherapy, 929
- Dendritic cells, ELISPOT, interferon- γ , melanoma, T cell, 171
- Dendritic cells, HDM2, melanoma, 2141
- Denervation, capsaicin, sensory neurons, mammary tumor, metastasis, 1003
- Depsipeptide, chronic myeloid leukemia, imatinib mesylate, histone deacetylase inhibitor, apoptosis, cyclin D1, MEK, c-Myc, 2705
- 2-DG uptake, altered glucose metabolism, drug-resistance, 433
- Diabetes, mammary carcinogenesis, insulin-growth factor-I, insulin-growth factor-I receptor, rats, 2953
- 4-Diarylfuran-2-one, CA-4, 3, tumors, tubulin polymerization, MTT assay, cell cycle, 179
- 2-Diazaindoles, triazaindoles, antiproliferative activity, 3775
- Diet, colorectal cancer risk, Ki-ras, vitamin A, thiamine, vitamin D, iron, 2011
- Diet, prostate cancer, ethnic differences, 2551
- Differential expression, calretinin, calcium-binding proteins, EF-hand, mesothelioma, tumor marker, alternative splicing, 4003
- Differentiation, hexafluorotrihydroxyvitamin D3 derivatives, hypercalcemic activity, structure-activity relationship, log P, hydrophobicity, 683
- Diffuse large B-cell lymphomas, apoptosis, cluster analysis, 3081
- Diffuse large cell lymphoma, non-Hodgkin's lymphoma, HER-2/neu, 3233
- Digital differential display, kallikreins, pancreatic cancer, colon cancer, serine proteases, cancer genes, SAGE, tumor markers, X-profiler, in-silico analysis, 43
- Digital image analysis, angiogenesis inhibition, chick embryo assay, antiangiogenic compounds, 1545
- Dihydropyrimidine dehydrogenase, 5-fluorouracil, adjuvant chemotherapy, postoperative survival, gastric carcinoma, 2495
- Dihydropyrimidine dehydrogenase, 5-fluorouracil, chemosensitivity, thymidylate synthetase, tandem repeat, gastric cancer, 2455
- Dihydropyrimidine dehydrogenase, colorectal cancer, enzymatic activity, immunohistochemical expression, disease-free survival, 273
- Dihydrotestosterone, leuprorelin acetate, cyproterone acetate, apoptosis-related genes, prostate cancer, 2729
- Diimidazo[1, imidazo[2, 1-b]thiazole, 2-a:1, 2-c]pyrimidine, guanylhydrazones, antitumor activity, 203
- β -Diketone, apoptosis, cytotoxic activity, oral tumor cells, 711
- Disease-free survival, colorectal cancer, dihydropyrimidine dehydrogenase, enzymatic activity, immunohistochemical expression, 273
- Disease/relapse-free survival, apoptosis, bcl-2, breast cancer, immunohistochemistry, mcl-1, overall survival, prognostic indicator, reverse-transcriptase polymerase chain reaction, 473
- A-Disintegrin and metalloproteinase, chondrosarcoma, matrix metalloproteinase, tissue inhibitor of metalloproteinase, immunohistochemistry, histological grade, 4079

- Dispersed fibrous long-spacing collagen, mast cells, microvasculature, angiogenesis, electron microscopy, advanced gastric carcinoma, 2257
- Disseminated tumor cells, breast cancer, anthracycline-based chemotherapy, 3209
- DNA adducts, apurinic sites, base excision repair, DNA repair, human breast cell extracts, nucleotide excision repair, 117
- DNA damage, Chk1, BAD, cell cycle, 3907
- DNA fragmentation, apoptosis, breast ductal carcinoma, tumor stroma, lymph node invasion, steroid hormone, 53
- DNA fragmentation, cisplatin (CDDP), hepatoma, oral carcinoma, apoptosis, caspase, 655
- DNA methylation, MTHFR polymorphism, methylator phenotype, colorectal cancer, 649
- DNA ploidy, orbital rhabdomyosarcoma, p53, bcl2, MDR-1, Ki67 (MIB1), prognosis, 249
- DNA repair, apurinic sites, base excision repair, DNA adducts, human breast cell extracts, nucleotide excision repair, 117
- DNA repair, cancer-chemoprevention, field-effect, selenium compounds, 1401
- DNA repair, checkpoints, CDKN1A, Gadd45, human, oxidative stress, prostate cancer, 3955
- DNA synthesis, gossypol, cyclin D1, TGF β 1, PC3, 91
- DNA topoisomerase I, topotecan, down-regulation, solid tumor cell lines, 1745
- DNA-aneuploidy, ursodeoxycholic acid, inflammatory bowel diseases, ulcerative colitis, Crohn's disease, dysplasia, 3121
- DNA-repair, melanoma brain metastases, brain tumors, mutations, immunohistochemistry, 981
- Docetaxel, breast cancer, doxorubicin, cyclophosphamide, 2487
- Docetaxel, carboplatin, non-small cell lung cancer, 1239
- Docetaxel, chemotherapy, second-line, non-small cell lung cancer, taxane, 1211
- Docetaxel, concurrent chemoradiation, head and neck cancer, cisplatin, 4135
- Docetaxel, doxorubicin, metastatic breast cancer, 3257
- Docetaxel, epirubicin, metastatic breast cancer, epirubicin dose, 1963
- Docetaxel, gastric carcinoma, chemotherapy, phase I study, S-1, 1843
- Docetaxel, prostate cancer, estramustine, hormone, metastases, 2897
- Docetaxel, recurrent, doxifluridine, 2085
- Doppel gene expression, prion, glioblastoma multiforme, 1507
- Dose-intensity, colorectal cancer, phase II, oxaliplatin, 5-fluorouracil, 355
- Down-regulation, DNA topoisomerase I, topotecan, solid tumor cell lines, 1745
- Doxifluridine, mitomycin, cisplatin, gastric cancer, inoperable, combination therapy, 2465
- Doxifluridine, recurrent, docetaxel, 2085
- Doxorubicin, breast cancer, cyclophosphamide, docetaxel, 2487
- Doxorubicin, docetaxel, metastatic breast cancer, 3257
- Doxorubicin, drug delivery, paclitaxel, liposomes, physiological modeling, cancer chemotherapy, 397
- Doxorubicin, hepatitis B virus (HBV), viral reactivation, lamivudine, 3035
- Doxorubicin, multidrug resistance, drug encapsulation, gene expression, topoisomerase II, P-glycoprotein, breast cancer resistance protein, 3781
- DPC4, pancreatic cancer, SMAD-4, adjuvant chemotherapy, 1173
- DPD deficiency, 5FU, oxaliplatin, 1969
- DPPH, curcumin, cytotoxicity, ROS, stoichiometric factor, inhibition rate constants, PM3, 563
- Drosophila melanogaster S3, ribosomal/repair protein, bladder cells, dS3, oxidative DNA damage, 3811
- Drug delivery, paclitaxel, doxorubicin, liposomes, physiological modeling, cancer chemotherapy, 397
- Drug encapsulation, multidrug resistance, doxorubicin, gene expression, topoisomerase II, P-glycoprotein, breast cancer resistance protein, 3781
- Drug resistance, anti-fungal, amphotericin B, Candida, CDR 1, 405
- Drug resistance, Bcl-2, p53, p21waf1, myc, radiation resistance, paclitaxel, SCLC cells, 465
- Drug resistance, gemcitabine, apoptosis, Fas/FasL system, caspases, 851
- Drug resistance, glioblastoma, glioma, tamoxifen, 4195
- Drug resistance, glioblastoma, glioma, tamoxifen, 4205
- Drug resistance, irinotecan, small cell lung cancer, topoisomerase, 3911
- Drug resistance, medullary thyroid carcinoma, apoptosis, plant - based drugs, 495
- Drug sensitivity testing, drug-induced apoptosis, caspase-3 activation, Ewing tumor, 145
- Drug toxicity, biological therapy, interferon alpha, melanoma, 1947
- Drug-induced apoptosis, caspase-3 activation, Ewing tumor, drug sensitivity testing, 145
- Drug-resistance, 2-DG uptake, altered glucose metabolism, 433
- DS3, Drosophila melanogaster S3, ribosomal/repair protein, bladder cells, oxidative DNA damage, 3811
- Dual-color fluorescence in situ hybridization, p53 locus, small hepatocellular carcinoma, chromosome 17, 111
- Dydrogesterone, progestins, breast cancer cells, sulfatase, 17 β -hydroxysteroid dehydrogenase, 1433
- Dysfunction, irradiation, salivary glands, tenascin-C, 2841
- Dysplasia, esophagus, MMP-9, 3245

- Dysplasia, ursodeoxycholic acid, inflammatory bowel diseases, ulcerative colitis, Crohn's disease, DNA-aneuploidy, 3121
- E2F-1, proliferation, apoptosis, colon cancer, 3041
- E2F1, Pura, growth inhibition, cell cycle, RNA association, 2585
- E7, retinoids, HPV16, transcription, inhibition, 807
- Early gastric cancer, endoscopic clipping, surgery, 4163
- EBV LMP1, nasopharyngeal carcinoma, infiltrating leucocytes, apoptosis, p53, 2309
- Edothelial marker, prostatic neoplasms, angiogenesis, von Willebrand factor, CD34, CD31, endothelial cells, 1651
- EF-hand, calretinin, calcium-binding proteins, mesothelioma, tumor marker, differential expression, alternative splicing, 4003
- (-)-EGCG, green tea, organic synthesis, proteasome inhibitors, cell cycle, growth inhibition, 943
- EGCG, MMP-9, AP-1, MAPK, gastric cancer, 747
- EGCG, xerostomia, tea, salivary gland, oral carcinomas, 3065
- EGF, 211At-para-astato-benzoate, 125I-para-iodo-benzoate, A-431 cells, intracellular retention, 4035
- EGFR, Akt, HER-2, NSCLC, TGF- α , immunohistochemistry, 11
- EGFR, glioblastoma, Akt, PTEN, 2643
- EGFR, NSCLC, squamous, EGFR-TKI, gefitinib, ZD1839, 393
- EGFR, STAT 3, head and neck squamous cell carcinoma, 3881
- EGFR-TKI, NSCLC, squamous, EGFR, gefitinib, ZD1839, 393
- Elderly, esophageal cancer, radiotherapy, chemotherapy, 2483
- Electrofusion, dendritic cells, cancer, vaccine, immunotherapy, 929
- Electron microscopy, mast cells, microvasculature, dispersed fibrous long-spacing collagen, angiogenesis, advanced gastric carcinoma, 2257
- Electrophoretic mobility shift assay, nuclear factor-kB, colorectal carcinoma, tumor progression, 675
- Electroporation, hyperthermia, tumour perfusion, animal tumour model, 2343
- ELISA, IGF-1, IGFBP-3, esophageal carcinoma, 3029
- ELISA, peptide, cytotoxic T lymphocytes, interferon-gamma, 1193
- ELISA, suPAR, ovarian cancer, prognostic factors, 1981
- ELISPOT, interferon- γ , dendritic cells, melanoma, T cell, 171
- Endoglin, breast cancer, VEGF, CD105, angiogenesis, 1581
- Endoglin, CD105, Smad, TGF- β 1, 1337
- Endometrial adenocarcinoma, cyclin D1, cell cycle, 2185
- Endometrial cancer, luteinizing hormone-releasing hormone, LHRH, apoptosis, ovarian cancer, 1727
- Endometrial cancer, pelvic lymphadenectomy, staging, prognostic value, surgery, hysterectomy, 2073
- Endometrial cancer, tumor-associated macrophage, 3335
- Endometrial carcinoma, E-cadherin, β -catenin, endometrium, immunohistochemistry, 3843
- Endometrial carcinoma, platelet count, thrombocytosis, cervical carcinoma, ovarian cancer, 2053
- Endometrioid adenocarcinoma, endometriosis, ovary, onco-protein, comparative genomic hybridisation, 151
- Endometriosis, endometrioid adenocarcinoma, ovary, onco-protein, comparative genomic hybridisation, 151
- Endometrium carcinoma cells, 2-Methoxyestradiol, HEC-1-A, RL-95-2, cell cycle, apoptosis, necrosis, iNOS, caspases, STAT1, 3983
- Endometrium, E-cadherin, β -catenin, endometrial carcinoma, immunohistochemistry, 3843
- Endoscopic clipping, early gastric cancer, surgery, 4163
- Endothelial cell proliferation, anthracyclines, paclitaxel, 5-FU, etoposide, 1759
- Endothelial cell, VEGF, VEGF, angiogenesis, KDR/Flk-1, Flt-1, 3009
- Endothelial monocyte activating polypeptide II (EMAP II), tumor necrosis factor-alpha, review, 2243
- Endothelium, VEGF, vascular endothelial growth factor, angiosarcoma, retroperitoneal mass, HIF1, HIF2, hypoxia inducible factor, VHL, von Hippel-Lindau, 167
- Enhancer, CDK1, transcription, cell cycle, proliferation, gene expression, 1469
- Endothelial cells, prostatic neoplasms, angiogenesis, von Willebrand factor, CD34, CD31, endothelial marker, 1651
- Enzymatic activity, colorectal cancer, dihydropyrimidine dehydrogenase, immunohistochemical expression, disease-free survival, 273
- Enzyme/prodrug therapy, cytosine deaminase, 5-fluorouracil, gene therapy, protein secretion, 1393
- EpCAM, promoter, targeted gene expression, HSV1-TK, GFP, 3715
- Epidermal growth factor receptor, colon cancer, ERFP, apoptosis, scid mouse tumor xenograft, 2885
- Epidermal growth factor receptor, malignant fibrous histiocytoma, soft tissue, immuno-histochemistry, amphiregulin, 1307
- Epidermal keratinocytes, Akt-1, protein kinase B, inositolphosphate-3-kinase, IP3-K, multi-stage skin carcinogenesis, cell survival, mast cells, papilloma, image analysis, 2773
- Epiregulin, malignant fibrous histiocytoma, immunohistochemistry, betacellulin, heparin-binding epidermal growth factor, 2007
- Epirubicin dose, epirubicin, docetaxel, metastatic breast cancer, 1963

- Epirubicin, anthracyclines, cardiotoxicity, cisplatin, gemcitabine, left ventricular ejection fraction, non-small cell lung cancer, radionuclide ventriculography, 2079
- Epirubicin, breast cancer, chemotherapy, bone metabolism markers, 5-fluorouracil, cyclophosphamide, 1271
- Epirubicin, docetaxel, metastatic breast cancer, epirubicin dose, 1963
- Epithelial cells, CXCR6, protein expression, rectal cancer, macrophages, T cells, 3711
- Epithelial ovarian cancer, CA 125, collagen metabolism, ICTP, prognosis, tumor markers, 1057
- Epithelial ovarian cancer, FHL2, focal adhesion kinase (pp125FAK), protein interaction, ovary, 921
- Epitope, humanized monoclonal antibody, parathyroid hormone-related protein, hypercalcemia, 2665
- Epoetin beta, hormone-refractory prostate cancer, metastatic prostate cancer, anaemia, 1957
- Epstein-Barr virus, gene therapy, BZLF1, lytic replication, 67
- Epstein-Barr virus, real-time PCR, nasopharyngeal carcinoma, 4059
- ER antagonist, fulvestrant, 'Faslodex', breast cancer, antioestrogen, 1275
- ER, CD44s, ovarian cancer, PR, p53, PCNA, MIB1, 1665
- Eradication therapy of *H.pylori*, apoptosis, B cell lymphoma, 3723
- C-ErbB2, extracellular domain, trastuzumab, breast cancer, 1127
- ERK, 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone, HL-60, PBMC, apoptosis, cell cycle, G2/M arrest, 1769
- ERRP, epidermal growth factor receptor, colon cancer, apoptosis, scid mouse tumor xenograft, 2885
- Erythroid differentiation, crambescidin 800, K562 cells, guanidine alkaloid, p21, Neuro 2A cells, neurite outgrowth, 2325
- Alfa-Erythropoietin, gynaecological cancer, anaemia, 1287
- Esophageal cancer, elderly, radiotherapy, chemotherapy, 2483
- Esophageal cancer, neoadjuvant chemotherapy, 2385
- Esophageal cancer, PPAR, molecular targeting, cell cycle regulator, apoptosis, 1409
- Esophageal cancer, Wilms' tumor gene, WT1, esophageal dysplasia, 3103
- Esophageal carcinoma, chemotherapy response, apoptotic markers, 2579
- Esophageal carcinoma, IGF-1, IGFBP-3, ELISA, 3029
- Esophageal carcinoma, neoadjuvant therapy, chemoradiotherapy, esophagectomy, 4091
- Esophageal dysplasia, Wilms' tumor gene, WT1, esophageal cancer, 3103
- Esophageal neoplasms, genes, squamous cell, 1417
- Esophageal squamous cell carcinoma, plasminogen activator inhibitor-1, PGP9.5, 3731
- Esophageal squamous cell carcinoma, Skp2, p27, immunohistochemistry, Western blotting, 777
- Esophageal squamous cell carcinoma, TGF- β , Smad6, Smad7, immunohistochemistry, 3703
- Esophageal tumors, IL-21, IL-23, gene therapy, 79
- Esophagectomy, esophageal carcinoma, neoadjuvant therapy, chemoradiotherapy, 4091
- Esophagus cancer, estrogen receptor beta, Barrett's metaplasia, 2919
- Esophagus, dysplasia, MMP-9, 3245
- ESR, azulenes, Raw 264.7 cells, NO, iNOS, radical, 3939
- ESR, tropolones, Raw 264.7 cells, NO, iNOS, radical, 3917
- Estramustine, prostate cancer, docetaxel, hormone, metastases, 2897
- Estrogen exposure, breast cancer, MTHFR, polymorphism, 3863
- Estrogen receptor (ER), breast cancer, MCF-7, MB-MDA-231, estrogen, tamoxifen, VEGF, 3961
- Estrogen receptor beta, esophagus cancer, Barrett's metaplasia, 2919
- Estrogen receptor, nucleolin, nucleolus, breast carcinoma, 963
- Estrogen, breast cancer, MCF-7, MB-MDA-231, estrogen receptor (ER), tamoxifen, VEGF, 3961
- Estrogen, cervical cancer, apoptosis, indole-3-carbinol, 2649
- Estrogens, antiestrogens, stoichiometric factor, inhibition rate constants, 3931
- Ethanol injection, hepatocellular carcinoma, portal vein thrombosis, radiofrequency, thermal ablation, 2419
- Ethnic differences, prostate cancer, diet, 2551
- N-Ethylphenyl acetamide (EPA), 2-aminofluorene (AF), N-acetyltransferase (NAT), colon tumor cells, 1677
- Etoposide, endothelial cell proliferation, anthracyclines, paclitaxel, 5-FU, 1759
- Euphorbia, cycloartane triterpenes, apoptosis induction, multidrug resistance, mouse lymphoma cell line, 859
- Ewing tumor, drug-induced apoptosis, caspase-3 activation, drug sensitivity testing, 145
- Ewing tumors, adhesion molecules, apoptosis, ionizing radiation, multiparametric flow cytometry, 1637
- Ex vivo culture, head and neck carcinoma, HNSCC, chemosensitivity testing, tumor stroma, 325
- Exclusive radiotherapy, hypopharyngeal cancer, advanced stage, 349
- Exisulind, chemoprevention, lovostatin, aberrant crypt foci, 1805
- Experimental treatment, brain cancer, glioma therapy, iodine-131-labelled amino acid, preclinical study, 3971
- Extended field radiotherapy, Hodgkin's disease, intermediate stage HD, involved field radiotherapy, radiotherapy, 4045
- Extracellular domain, c-erbB2, trastuzumab, breast cancer, 1127

- Extracellular matrix, focal adhesion kinase, adhesion, 3899
- Extracellular matrix, morphometry, proliferation kinetic, osteoblastic marker, immunocytochemistry, 3743
- Extracellular matrix, S100A4 protein, metalloproteinases, liposarcoma cells, 967
- Extracranial metastases, malignant glioma, astrocytomas, glioblastomas, 2563
- F(ab')₂, radioimmunoguided surgery (RIGS), gastric carcinoma, carcinoembryonic antigen (CEA), T84.66, Fab', 663
- Fab', radioimmunoguided surgery (RIGS), gastric carcinoma, carcinoembryonic antigen (CEA), T84.66, F(ab')₂, 663
- FACS, MHC, CTL, SCCHN, 973
- Fas, FasL, colorectal carcinoma, carcinogenesis, metastasis, 1569
- Fas/FasL system, gemcitabine, apoptosis, drug resistance, caspases, 851
- FasL, Fas, colorectal carcinoma, carcinogenesis, metastasis, 1569
- 'Faslodex', fulvestrant, breast cancer, ER antagonist, antioestrogen, 1275
- Fatty acid synthase, lung, carcinoma, prognosis, 4169
- FDG, cancer screening, PET, PET/CT, 4103
- (18)F-FDG PET, GIST, imatinib, 3147
- FHL2, focal adhesion kinase (pp125FAK), protein interaction, ovary, epithelial ovarian cancer, 921
- Fiber modifications, apoptosis, gene therapy, colon carcinoma, RGD, 3075
- Fibrin/collagen gel, 3-D culture systems, cancer cell invasion, colony formation, cancer assessment, anticancer drug screening, 2169
- Fibroblast, prostate cancer, stromal cells, tumor-stromal cell interaction, antitumor drugs, 1561
- Fibrosarcoma, Canis familiaris, hot-spot mutations, melanoma, ras genes, 3027
- Field-effect, DNA repair, cancer-chemoprevention, selenium compounds, 1401
- Fine-needle aspiration cytology, thyroid cancer, thyroid nodule, thyroid scintigraphy, FNAB, 2531
- FISH, chronic myeloid leukemia, bcr-abl, 2535
- FISH, HER-2/neu, germ-cell testicular tumors, 2219
- FK228, histone deacetylase inhibitor, urinary bladder carcinogenesis, 785
- Flow cytometry, caffeine, cell cycle, cyclin E, cell proliferation, MOLT-4 cells, 2991
- Flow cytometry, multidrug resistance, LRP, confocal laser scanning microscopy, fluorescence correlation spectroscopy, 725
- Flow cytometry, N-acetyltransferase, paclitaxel, bladder cancer cell line (T24), 2-aminofluorene, cDNA microarray, 1501
- Flt-1, neuropilin 1, glioma, VEGF, KDR, prognosis, 547
- Flt-1, VEGF, angiogenesis, KDR/Flk-1, endothelial cell, 3009
- Fluorescence in situ hybridization, chromosome 9 and 11 numerical aberrations, bladder cancer, interphase cytogenetics, 3857
- Fluorescence correlation spectroscopy, multidrug resistance, LRP, flow cytometry, confocal laser scanning microscopy, 725
- Fluorescence in situ hybridization, chromosome 8 aberrations, gastric cancer, interphase cytogenetics, 155
- Fluorescence in situ hybridization, persistent cytopenia, myelodysplastic syndrome, chromosome aberrations, conventional, cytogenetic analysis, childhood, 3945
- Fluorescent latex microspheres, liposome, solid tumor, 3005
- Fluorescent-lectin conjugates, breast cancer, MCF-7, β -galactosidase, α -mannosidase, membrane receptors, 139
- 5-Fluorouracil chemotherapy, dehydroypyrimidine dehydrogenase, cancer, 1091
- 5-Fluorouracil, adjuvant chemotherapy, postoperative survival, dihydropyrimidine dehydrogenase, gastric carcinoma, 2495
- 5-Fluorouracil, advanced colorectal cancer, chemotherapy, oxaliplatin, leucovorin, 1935
- 5-Fluorouracil, breast cancer, chemotherapy, bone metabolism markers, epirubicin, cyclophosphamide, 1271
- 5-Fluorouracil, breast cancer, salvage chemotherapy, cyclophosphamide, leucovorin, vinorelbine, 4217
- 5-Fluorouracil, breast cancer, salvage chemotherapy, cyclophosphamide, leucovorin, vinorelbine, 4223
- 5-Fluorouracil, chemosensitivity, thymidylate synthetase, dihydropyrimidine dehydrogenase, tandem repeat, gastric cancer, 2455
- 5-Fluorouracil, colorectal cancer, cross-resistance, raltitrexed, 2037
- 5-Fluorouracil, colorectal cancer, phase II, dose-intensity, oxaliplatin, 355
- 5-Fluorouracil, colorectal liver metastases, hepatic arterial infusion, interferon, starch microspheres, 3275
- 5-Fluorouracil, enzyme/prodrug therapy, cytosine deaminase, gene therapy, protein secretion, 1393
- 5-Fluorouracil, gemcitabine, pancreatic cancer, 2107
- 5-Fluorouracil, metastasis, imaging, GFP, UFT, 1353
- 5-Fluorouracil, oxaliplatin, DPD deficiency, 1969
- 5-Fluorouracil, Stealth liposomes, PEG liposomes, locoregional chemotherapy, 1699
- 5-Fluorouracil, tomudex, oxaliplatin, CPT-11, cDNA microarray, 417
- FNAB, thyroid cancer, thyroid nodule, thyroid scintigraphy, fine-needle aspiration cytology, 2531
- FNAC, occult papillary carcinoma, immunocytochemistry, galectin-3, 1111
- Focal adhesion kinase (pp125FAK), FHL2, protein interaction, ovary, epithelial ovarian cancer, 921

- Focal adhesion kinase, extracellular matrix, adhesion, 3899
- Folate receptor, hematoporphyrin, photodynamic therapy, targeted solid-lipid nanoparticle, 161
- Folate, breast cancer, polymorphism, MTHFR, TS, 3215
- Follicular thyroid carcinoma, papillary thyroid carcinoma, lymphadenectomy, 2439
- Fractionated paclitaxel, serum HER-2/neu, predictive markers, monitoring, metastatic breast cancer, 895
- Free PSA, PSA, cPSA, prostate cancer, 4181
- Free radical scavengers, cancer, vitamins, microelements, oxidative stress, lipoperoxidation, 1449
- Fulvestrant, 'Faslodex', breast cancer, ER antagonist, antioestrogen, 1275
- G-banding, chromosomes, bladder cancer, 2967
- G2/M arrest, 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone, HL-60, PBMC, apoptosis, cell cycle, ERK, 1769
- Gadd45, checkpoints, CDKN1A, human, oxidative stress, prostate cancer, DNA repair, 3955
- β -Galactosidase, breast cancer, MCF-7, α -mannosidase, fluorescent-lectin conjugates, membrane receptors, 139
- 3 Galactosyltransferase, immunotherapy, tumor antigens, alpha 1, anti- α Gal antibodies, 605
- Galectin-3, occult papillary carcinoma, FNAC, immunocytochemistry, 1111
- Gallbladder cancer, p53, immunohistochemistry, 1201
- Gallium, anti-cancer drugs, arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, platinum, review, 1529
- GalNAc, vitamin D-binding protein, Gc protein, macrophage activating factor (MAF), Gc typing, carbohydrate processing, 3361
- Gap junction, green tea, renal cell carcinoma, connexin, 3757
- Garbanzo beans, colon cancer, soybean flour, ACF, CF-1 mice, 3049
- Gastrectomy, gastric, intestinal metaplasia, 3185
- Gastric cancer, 5-fluorouracil, chemosensitivity, thymidylate synthetase, dihydropyrimidine dehydrogenase, tandem repeat, 2455
- Gastric cancer, CD3 ζ chain, lymph node, 2123
- Gastric cancer, E-cadherin, catenin, cell adhesion, 699
- Gastric cancer, EGCG, MMP-9, AP-1, MAPK, 747
- Gastric cancer, fluorescence in situ hybridization, chromosome 8 aberrations, interphase cytogenetics, 155
- Gastric cancer, hypermethylation, methylation-specific polymerase chain reaction, tumor marker, 2477
- Gastric cancer, Id-1, up-regulation, 881
- Gastric cancer, interleukin-12, vascular endothelial growth factor, 3289
- Gastric cancer, ketone body, monoacetoacetin, succinyl-CoA transferase, 2213
- Gastric cancer, mitomycin, cisplatin, doxifluridine, inoperable, combination therapy, 2465
- Gastric cancer, N-acetyltransferase, 2-aminofluorene, N-acetyl-2-aminofluorene, shikonin, Helicobacter pylori, 1587
- Gastric cancer, neoadjuvant chemotherapy, UFT, randomized consent design trial, 1879
- Gastric cancer, peritoneal dissemination, real-time RT-PCR, 1113
- Gastric cancer, prognostic factors, 377
- Gastric carcinoma, 5-fluorouracil, adjuvant chemotherapy, postoperative survival, dihydropyrimidine dehydrogenase, 2495
- Gastric carcinoma, chemotherapy, phase I study, S-1, docetaxel, 1843
- Gastric carcinoma, COX-2, tubular adenoma, angiogenesis, apoptosis, 1439
- Gastric carcinoma, radioimmunoguided surgery (RIGS), carcinoembryonic antigen (CEA), T84.66, F(ab')₂, Fab', 663
- Gastric carcinoma, vascular endothelial growth factor, thymidine phosphorylase, microvessel density, 1853
- Gastric outlet obstruction, self-expanding, metallic stent, gastroenterostomy, 269
- Gastric, adenoma, serrated, 2113
- Gastric, intestinal metaplasia, gastrectomy, 3185
- Gastric, quality of life, gastrointestinal, oesophageal, pancreatic, colorectal cancer, 2117
- Gastritis, E-cadherin, intestinal metaplasia, Helicobacter pylori, 1603
- Gastro-oesophageal junction, E-cadherin-catenin, adenocarcinoma, 1369
- Gastroenterostomy, self-expanding, metallic stent, gastric outlet obstruction, 269
- Gastrointestinal cancer, testicular metastasis, occult cancer, 1093
- Gastrointestinal, quality of life, oesophageal, gastric, pancreatic, colorectal cancer, 2117
- Gc protein, vitamin D-binding protein, macrophage activating factor (MAF), Gc typing, carbohydrate processing, GalNAc, 3361
- Gc typing, vitamin D-binding protein, Gc protein, macrophage activating factor (MAF), carbohydrate processing, GalNAc, 3361
- Gefitinib, NSCLC, salvage therapy, 1873
- Gefitinib, NSCLC, squamous, EGFR, EGFR-TKI, ZD1839, 393
- Gemcitabine, 5-fluorouracil, pancreatic cancer, 2107
- Gemcitabine, anthracyclines, cardiotoxicity, cisplatin, epirubicin, left ventricular ejection fraction, non-small cell lung cancer, radionuclide ventriculography, 2079
- Gemcitabine, apoptosis, drug resistance, Fas/FasL system, caspases, 851
- Gemcitabine, lung cancer, vinorelbine, 2985
- Gemcitabine, mucin, tumor antigen, 821

- Gemcitabine, non-small cell lung cancer, weekly paclitaxel, second-line chemotherapy, 2567
- Gene expression, CDK1, enhancer, transcription, cell cycle, proliferation, 1469
- Gene expression, confluence, oral carcinoma cell lines, 2627
- Gene expression, multidrug resistance, doxorubicin, drug encapsulation, topoisomerase II, P-glycoprotein, breast cancer resistance protein, 3781
- Gene therapy, apoptosis, colon carcinoma, RGD, fiber modifications, 3075
- Gene therapy, cancer, delivery systems, stem cells, 501
- Gene therapy, cochleate, macrophage, transgene, tumour cell, 483
- Gene therapy, enzyme/prodrug therapy, cytosine deaminase, 5-fluorouracil, protein secretion, 1393
- Gene therapy, Epstein-Barr virus, BZLF1, lytic replication, 67
- Gene therapy, IL-21, IL-23, esophageal tumors, 79
- Gene therapy, immunotherapy, osteosarcoma, IL-12, IL-18, IL-23, 2861
- Gene therapy, isolated perfusion, ras-oncogene, rhabdomyosarcoma, adenovirus, 2295
- Gene therapy, lung cancer, retroviral vector, herpes simplex virus thymidine kinase, 827
- Gene therapy, p53, glioma, retrovirus, VEGF, angiopoietins, 1
- Gene therapy, p75NTR, liposome, prostate xenograft tumor, 2997
- Gene therapy, transfection, acoustic energy, 2303
- Genes, esophageal neoplasms, squamous cell, 1417
- Genistein, MMPs, TIMPs, breast cancer, cell growth, invasion, 4025
- Genistein, ovarian cancer cell, daidzein, 795
- Genistein, pancreatic cancer, prevention, STAT3 transcription factor, indole-3-carbinol, 133
- Genomic aberrations, microsatellite instability, mismatch repair, ovarian carcinoma, 361
- Genomic hybridization, cartilaginous tumors, chondrosarcomas, 1721
- Genomic instability, colorectal carcinoma, prognostic markers, review, angiogenesis, invasion, circulating cells, 2519
- Genomics, microarray, cancer, across-platform, 441
- Germ-cell testicular tumors, HER-2/neu, FISH, 2219
- GFP, EpCAM, promoter, targeted gene expression, HSV1-TK, 3715
- GFP, metastasis, imaging, 5-fluorouracil, UFT, 1353
- GFP, orthotopic implantation, SCID mice, lung cancer, model, 719
- GFP, RFP, in vivo imaging, metastasis, 4067
- GIST, imatinib, (18)F-FDG PET, 3147
- GIST, immunocell therapy, molecularly-targeted therapy, Imatinib mesylate, Ph(+)ALL, 3303
- Glioblastoma multiforme, prion, doppel gene expression, 1507
- Glioblastoma, Akt, PTEN, EGFR, 2643
- Glioblastoma, apoptosis, taurolidine, 1143
- Glioblastoma, chemotherapy, primary cerebral tumor, 1249
- Glioblastoma, drug resistance, glioma, tamoxifen, 4195
- Glioblastoma, drug resistance, glioma, tamoxifen, 4205
- Glioblastoma, malignant glioma, brain tumor, local treatment, anti-angiogenic treatment, 631
- Glioblastomas, malignant glioma, extracranial metastases, astrocytomas, 2563
- Glioma therapy, brain cancer, experimental treatment, iodine-131-labelled amino acid, preclinical study, 3971
- Glioma, central nervous system, tumor progression, brain imaging, 2359
- Glioma, drug resistance, glioblastoma, tamoxifen, 4195
- Glioma, drug resistance, glioblastoma, tamoxifen, 4205
- Glioma, intracranial tumour, microglia, monocyte, lymphocyte, 37
- Glioma, neuron-specific enolase, S-100B protein, 2511
- Glioma, neuropilin 1, VEGF, Flt-1, KDR, prognosis, 547
- Glioma, p53, gene therapy, retrovirus, VEGF, angiopoietins, 1
- Glucose deprivation, oncogenes, src, ras, abl, bcr-abl, bcl-2, IL-3, apoptosis, 2503
- Glucose metabolism, 2-DG uptake, drug-resistance, 433
- Glucose transporter, prostate cancer, Glut-1, 3057
- Glufosfamide, glufosfamide, head and neck carcinoma, HNSCC, chemosensitivity, 2947
- Glufosfamide, head and neck carcinoma, HNSCC, glufosfamide, chemosensitivity, 2947
- Glut-1, prostate cancer, glucose transporter, 3057
- Glutamate transporters, MG-63 cells, ionotropic glutamate receptors, metabolotropic glutamate receptors, glutamine synthetase, 3923
- Glutamine synthetase, MG-63 cells, ionotropic glutamate receptors, metabolotropic glutamate receptors, glutamate transporters, 3923
- Glutamine, asparaginase, asparagine, deamination, 1121
- Glutathione, whey protein, cysteine, prostate, breast cancer, oxidant, antioxidant, 553
- Glutathione-S-transferase, colorectal cancer, metabolizing enzymes, cancer susceptibility, N-acetyltransferase, 3965
- GM-CSF, dendritic cell, IL-4, immunotherapy, 1609
- GM-CSF, tumor growth, immunotherapy, 2717
- Gold, anti-cancer drugs, arsenic, antimony, bismuth, vanadium, iron, rhodium, titanium, gallium, platinum, review, 1529
- Gossypol, DNA synthesis, cyclin D1, TGFβ1, PC3, 91
- GPx4, PHGPx, cyclooxygenase, colon cancer cells, 1387
- Granulosa cell tumor, ovarian cancer, prognostic factor, mitotic rate, 1223
- Green fluorescent protein, portal vein metastatic trafficking, liver, metastasis, 3699

- Green tea, (-)-EGCG, organic synthesis, proteasome inhibitors, cell cycle, growth inhibition, 943
- Green tea, gap junction, renal cell carcinoma, connexin, 3757
- Growth factor receptor, c-Met, oral squamous cell carcinoma, oral mucosa, metastasis, 1063
- Growth factor, mitogen activated protein kinase, signal transduction, migration, cell cycle, 593
- Growth factors, malignant mesothelioma, chemotaxis, chemokinesis, 1625
- Growth fraction, human tumor, Ki-67, radiation, recruitment, 107
- Growth inhibition, (-)-EGCG, green tea, organic synthesis, proteasome inhibitors, cell cycle, 943
- Growth inhibition, clodronate, bisphosphonates, thyroid cancer cells, calcium signaling, 1617
- Growth inhibition, Pura α , E2F1, cell cycle, RNA association, 2585
- Growth inhibition, sialic acid, cationic dextran, 1347
- Growth pattern, E-cadherin, breast cancer, adhesion molecule, 2237
- Growth, isoflavones, isoflavanones, mouse macrophage, activation, NO, 1481
- Guanidine alkaloid, crambescidin 800, erythroid differentiation, K562 cells, p21, Neuro 2A cells, neurite outgrowth, 2325
- Guanyldrazones, imidazo[2, 1-b]thiazole, diimidazo[1, 2-a:1, 2-c]pyrimidine, antitumor activity, 203
- Gynaecologic oncology, sedation, 4109
- Gynaecological cancer, alfa-erythropoietin, anaemia, 1287
- H19, microarray, hepatocellular carcinoma, IGF2, imprinted gene, 4085
- Haplotype, MMP1, MMP3, head and neck cancer, case control study, 2021
- α -Haptoglobin, hepatocyte growth factor, small cell lung cancer, serum tumor biomarkers, proteomics, 1031
- HBD-2, antimicrobial peptides, innate immunity, cancer, *Candida*, defensin, 1025
- HCG, Kaposi's sarcoma, AIDS, apoptosis, human eosinophil-derived neurotoxin, 1427
- HDM2, dendritic cells, melanoma, 2141
- Head and neck cancer, concurrent chemoradiation, cisplatin, docetaxel, 4135
- Head and neck cancer, induction chemotherapy, alkylating drugs, oropharyngeal cancer, 2557
- Head and neck cancer, MMP1, MMP3, case control study, haplotype, 2021
- Head and neck cancer, monoterpenes, chemo-radiation, 3089
- Head and neck cancer, platinum isomers, oncogene expression, 3997
- Head and neck cancer, tonsillar cancer, HPV, 1829
- Head and neck cancer, vascular endothelial growth factor (VEGF), angiogenesis, antisense, chemotherapy, 2179
- Head and neck carcinoma, glufosfamide, HNSCC, glufosfamide, chemosensitivity, 2947
- Head and neck carcinoma, HNSCC, chemosensitivity testing, tumor stroma, ex vivo culture, 325
- Head and neck neoplasms, *Chlamydia pneumoniae*, squamous cell carcinoma, 1207
- Head and neck squamous cell carcinoma, STAT 3, EGFR, 3881
- Head and neck squamous cell carcinoma, taxane analogues, paclitaxel, chemosensitivity, clonogenic assay, 3769
- HEC-1-A, 2-methoxyestradiol, endometrium carcinoma cells, RL-95-2, cell cycle, apoptosis, necrosis, iNOS, caspases, STAT1, 3983
- HeLaS3 cells, cervical cells, 2-methoxyestradiol, apoptosis, cell cycle, 873
- Helicobacter pylori*, E-cadherin, intestinal metaplasia, gastritis, 1603
- Helicobacter pylori*, N-acetyltransferase, 2-aminofluorene, N-acetyl-2-aminofluorene, shikonin, gastric cancer, 1587
- Hematogenous metastasis, serosa-negative advanced gastric cancer, peritoneal metastasis, lymphatic metastasis, 3169
- Hematoporphyrin, folate receptor, photodynamic therapy, targeted solid-lipid nanoparticle, 161
- Heparin affin regulatory peptide, angiogenesis, X-rays, vascular endothelial growth factor, nitric oxide synthase, 2941
- Heparin-binding epidermal growth factor, malignant fibrous histiocytoma, immunohistochemistry, betacellulin, epiregulin, 2007
- Hepatectomy, hepatocellular carcinoma, chemo-lipiodolization, 1929
- Hepatic arterial infusion chemotherapy, oxaliplatin, liver metastases from colorectal cancer, 2093
- Hepatic arterial infusion, colorectal liver metastases, interferon, 5-fluorouracil, starch microspheres, 3275
- Hepatitis B virus (HBV), viral reactivation, doxorubicin, lamivudine, 3035
- Hepatocellular carcinoma, ATP7B, cisplatin, 1045
- Hepatocellular carcinoma, chemo-lipiodolization, hepatectomy, 1929
- Hepatocellular carcinoma, portal vein thrombosis, ethanol injection, radiofrequency, thermal ablation, 2419
- Hepatocellular carcinoma, retinoic acid, tamoxifen, RAR receptors, 1255
- Hepatocellular carcinoma, microarray, IGF2, H19, imprinted gene, 4085
- Hepatocyte growth factor, α -haptoglobin, small cell lung cancer, serum tumor biomarkers, proteomics, 1031
- Hepatoma, cisplatin (CDDP), oral carcinoma, apoptosis, DNA fragmentation, caspase, 655
- Hepatoma, tocotrienol, tocopherol, apoptosis, 1683
- HER-2, Akt, EGFR, NSCLC, TGF- α , immunohistochemistry, 11

- HER-2/neu, breast neoplasms, serum, trastuzumab, 1083
 HER-2/neu, FISH, germ-cell testicular tumors, 2219
 HER-2/neu, non-Hodgkin's lymphoma, diffuse large cell lymphoma, 3233
 HER-2/neu, soft tissue sarcomas, c-Kit, VEGF, 333
 HER2, breast cancer, chemotherapy, predictive value, tumor marker, 1261
 HER2, tumor cell dissemination, breast cancer, p53, bcl-2, Ki-67, hormone receptor, 4211
 Her2-neu, breast cancer, p53, cathepsin D, survival, 2061
 Her2/neu, oncogene, archival breast cancer, chromogenic in situ hybridisation, prognostic significance, 2401
 Her2/NeuN, bamboo grass leaves, chemoprevention, mammary tumor, Sasa Health, 2879
 Herpes simplex virus thymidine kinase, lung cancer, gene therapy, retroviral vector, 827
 Hexafluorotrihydroxyvitamin D3 derivatives, differentiation, hypercalcemic activity, structure-activity relationship, log P, hydrophobicity, 683
 HHV-6, computational simulation, infection, HIV, HTLV-1, clinical course, 187
 HHV-8 genotypes, Kaposi's sarcoma, 1597
 HHV-8, interleukin-6, Kaposi's sarcoma, renal transplant recipients, 1311
 HIF1, VEGF, vascular endothelial growth factor, endothelium, angiosarcoma, retroperitoneal mass, HIF1, hypoxia inducible factor, VHL, von Hippel-Lindau, 167
 HIF2, VEGF, vascular endothelial growth factor, endothelium, angiosarcoma, retroperitoneal mass, HIF1, hypoxia inducible factor, VHL, von Hippel-Lindau, 167
 Histamine receptors, histamine, neuroblastoma, tumor, retinoic acid, 1657
 Histamine, histamine receptors, neuroblastoma, tumor, retinoic acid, 1657
 Histamine, melanoma, interleukin-2, interferon-alpha, immunotherapy, 1837
 Histological grade, chondrosarcoma, matrix metalloproteinase, tissue inhibitor of metalloproteinase, a disintegrin and metalloproteinase, immunohistochemistry, 4079
 Histone acetylation, 4-phenylbutyrate, PPAR gamma agonists and antagonists, 2765
 Histone deacetylase inhibitor, chronic myeloid leukemia, imatinib mesylate, depsipeptide, apoptosis, cyclin D1, MEK, c-Myc, 2705
 Histone deacetylase inhibitor, FK228, urinary bladder carcinogenesis, 785
 Histone deacetylase inhibitor, ovarian cancer, paclitaxel, apoptosis, p53, 539
 Histone deacetylase inhibitors, breast cancer, retinoids, 4019
 HIV infection, immune system modeling, delay differential equation, 1689
 HIV, computational simulation, infection, HHV-6, HTLV-1, clinical course, 187
 HL-60, 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone, PBMC, apoptosis, cell cycle, G2/M arrest, ERK, 1769
 HLA antibody, cancer, 3387
 HLA, immunoescape, immunotherapy, lung cancer cells, 1525
 HLA-A*2402-restricted peptide cocktail, metastatic melanoma, cytotoxic T cell (CTL), CTL epitope, HLA-A24 motif, 571
 HLA-A24 motif, metastatic melanoma, cytotoxic T cell (CTL), CTL epitope, HLA-A*2402-restricted peptide cocktail, 571
 HMAF, MiaPaCa, cytotoxic, 59
 HMGB1 expression, osteosarcoma, cisplatin, semi-quantitative RT-PCR, 707
 HMGCoA reductase, cell proliferation, apoptosis, colon cancer, 3837
 HNPCC, colorectal cancer, tumor progression, 1765
 HNSCC, glufosfamide, head and neck carcinoma, glufosfamide, chemosensitivity, 2947
 HNSCC, head and neck carcinoma, chemosensitivity testing, tumor stroma, ex vivo culture, 325
 HNSCC, ribosomal proteins, S19, mRNA expression, 2161
 Hodgkin's disease, intermediate stage HD, involved field radiotherapy, extended field radiotherapy, radiotherapy, 4045
 Hodgkin's disease, soluble adhesion molecules, prognosis, 1243
 Homeodomain, colorectal cancer, immunohistochemistry, 955
 Hormone receptor, breast cancer, CEA, CA 15-3, MIB-1, 3221
 Hormone receptor, tumor cell dissemination, breast cancer, HER2, p53, bcl-2, Ki-67, 4211
 Hormone, prostate cancer, docetaxel, estramustine, metastases, 2897
 Hormone-dependent tumors, anastrozole, breast cancer, postmenopausal, 1315
 Hormone-refractory prostate cancer, metastatic prostate cancer, anaemia, epoetin beta, 1957
 Hormone-refractory prostate cancer, radiotherapy, Patterns of care study, 3141
 Hormone-related gene, polymorphism, prostate cancer, 2431
 Hot vaporized water, tumour therapy, microtube, thermal ablation, 2757
 Hot-spot mutations, Canis familiaris, fibrosarcoma, melanoma, ras genes, 3027
 HPV, deleted E7 protein, therapeutic vaccine, tumour, Pichia pastoris, 2265
 HPV, p63, CK17, stem cell, uterine cervix, reserve cell, 771

- HPV, tonsillar cancer, head and neck cancer, 1829
 HPV16, retinoids, E7, transcription, inhibition, 807
 HSV1-TK, EpCAM, promoter, targeted gene expression, GFP, 3715
 HT-29, cyclic dipeptides, apoptosis, 1713
 HT-29, retinoids, colon cancer, CaCo-2, IIF, cell differentiation, 1779
 HTLV-1, computational simulation, infection, HHV-6, HIV, clinical course, 187
 Human breast cell extracts, apurinic sites, base excision repair, DNA adducts, DNA repair, nucleotide excision repair, 117
 Human eosinophil-derived neurotoxin, Kaposi's sarcoma, AIDS, hCG, apoptosis, 1427
 Human papillomavirus, oesophageal cancer, Barrett's oesophagus, oesophagitis, 1319
 Human tumor xenografts, imidazothioxanones, cytotoxicity, antitumor activity, murine tumors, molecular modeling-docking, 907
 Human tumor, growth fraction, Ki-67, radiation, recruitment, 107
 Human tumour cells, radiosensitization, cisplatin, ZD0473, 613
 Human, checkpoints, CDKN1A, Gadd45, oxidative stress, prostate cancer, DNA repair, 3955
 Human-like orthotopic model, anti-angiogenic gene therapy, cationic liposomes, osteosarcoma, 3977
 Humanized monoclonal antibody, epitope, parathyroid hormone-related protein, hypercalcemia, 2665
 Humoral immune response, methotrexate, lactoferrin, delayed type hypersensitivity, mice, 3831
 Hyaluronan (HA), hyaluronan synthases (HAS), malignant mesothelioma, 599
 Hyaluronan synthases (HAS), hyaluronan (HA), malignant mesothelioma, 599
 Hydrophobicity, hexafluorotrihydroxyvitamin D3 derivatives, differentiation, hypercalcemic activity, structure-activity relationship, log P, 683
 Hydroxyketones, deferiprone, maltol, cytotoxic activity, oral tumor cells, 755
 17 β -Hydroxysteroid dehydrogenase, dydrogesterone, progestins, breast cancer cells, sulfatase, 1433
 Hypercalcemia, humanized monoclonal antibody, epitope, parathyroid hormone-related protein, 2665
 Hypercalcemic activity, hexafluorotrihydroxyvitamin D3 derivatives, differentiation, structure-activity relationship, log P, hydrophobicity, 683
 Hypermethylation, gastric cancer, methylation-specific polymerase chain reaction, tumor marker, 2477
 Hypertension, metastasis, brain, small cell lung cancer, 3115
 Hyperthermia, cisplatin, intraperitoneal perfusion, 2041
 Hyperthermia, electroporation, tumour perfusion, animal tumour model, 2343
 Hypocholesterolemic agent, probucol, uterine adenomyosis, pituitary-grafted mice, 2209
 Hypofractionation, prostate cancer, radiotherapy, amifostine, 3239
 Hypomethylation, thyroid cancer, 1495
 Hypopharyngeal cancer, advanced stage, exclusive radiotherapy, 349
 Hypoxia inducible factor, VEGF, vascular endothelial growth factor, endothelium, angiosarcoma, retroperitoneal mass, HIF1, HIF2, VHL, von Hippel-Lindau, 167
 Hysterectomy, endometrial cancer, pelvic lymphadenectomy, staging, prognostic value, surgery, 2073
 ICTP, CA 125, collagen metabolism, epithelial ovarian cancer, prognosis, tumor markers, 1057
 Id, sarcoma, apoptosis, CDDP, caspase, 1519
 Id-1, gastric cancer, up-regulation, 881
 Ifosfamide, sarcoma, real-time RT-PCR, P16-CDK4-Rb pathway, P14RF-MDM2-p53-P73 pathway, 3819
 IGF-1, IGFBP-3, esophageal carcinoma, ELISA, 3029
 IGF2, microarray, hepatocellular carcinoma, H19, imprinted gene, 4085
 IGFBP-3, IGF-1, esophageal carcinoma, ELISA, 3029
 IgG oligosaccharide chains, prostate-specific antigen, prostate cancer, 3135
 I κ B- α , paclitaxel, apoptosis, NF- κ B, mitotic arrest, 27
 IIF, retinoids, colon cancer, CaCo-2, HT-29, cell differentiation, 1779
 IL-10, mantle cell lymphoma, CD40, CD40 ligand, 691
 IL-12, cyclophosphamide, ONO-4007, isolation perfusion, TNF, 1823
 IL-12, IL-23, IL-27, cytokine gene therapy, 3763
 IL-12, immunotherapy, gene therapy, osteosarcoma, IL-18, IL-23, 2861
 IL-18, immunotherapy, gene therapy, osteosarcoma, IL-12, IL-23, 2861
 IL-2, PS-K, lymphocyte proliferation, IL-2R, TGF-beta, 639
 IL-21, IL-23, esophageal tumors, gene therapy, 79
 IL-23, CD40, CD40 ligand, 2713
 IL-23, IL-12, IL-27, cytokine gene therapy, 3763
 IL-23, IL-21, esophageal tumors, gene therapy, 79
 IL-23, immunotherapy, gene therapy, osteosarcoma, IL-12, IL-18, 2861
 IL-27, IL-12, IL-23, cytokine gene therapy, 3763
 IL-2R, PS-K, IL-2, lymphocyte proliferation, TGF-beta, 639
 IL-3, glucose deprivation, oncogenes, src, ras, abl, bcr-abl, bcl-2, apoptosis, 2503
 IL-4, dendritic cell, GM-CSF, immunotherapy, 1609
 Ileum, paneth cells, adenoma, 4187
 Image analysis, Akt-1, protein kinase B, inositolphosphate-3-kinase, IP3-K, multi-stage skin carcinogenesis, epidermal keratinocytes, cell survival, mast cells, papilloma, 2773

- Image cytophotometry, ovarian tumours, CAS200, 4191
- Imaging, metastasis, GFP, 5-fluorouracil, UFT, 1353
- Imatinib mesylate, chronic myeloid leukemia, histone deacetylase inhibitor, depsipeptide, apoptosis, cyclin D1, MEK, c-Myc, 2705
- Imatinib mesylate, immunocell therapy, molecularly-targeted therapy, Ph(+)ALL, GIST, 3303
- Imatinib, GIST, (18)F-FDG PET, 3147
- Imidazothioxanthenes, cytotoxicity, antitumor activity, human tumor xenografts, murine tumors, molecular modeling-docking, 907
- Imidazo[2, 1-b]thiazole, diimidazo[1, 2-a:1, 2-c]pyrimidine, guanylhydrazones, antitumor activity, 203
- 2-a:1, Imidazo[2, 1-b]thiazole, diimidazo[1, 2-c]pyrimidine, guanylhydrazones, antitumor activity, 203
- Immune system modeling, HIV infection, delay differential equation, 1689
- Immune therapy, macrophage, lipopolysaccharide, LPS-tolerance, innate immunity, review, 3311
- Immune tolerance, immunotherapy, tumor-associated antigens, 2443
- Immuno-cell therapy, immunotherapy, adoptive immunotherapy, LAK, CD3-LAK, review, 3321
- Immuno-histochemistry, infantile gynecomastia, BRCA1, BRCA2, 321
- Immuno-histochemistry, malignant fibrous histiocytoma, soft tissue, amphiregulin, epidermal growth factor receptor, 1307
- Immunocell therapy, molecularly-targeted therapy, Imatinib mesylate, Ph(+)ALL, GIST, 3303
- Immunocompetence, non-seminomatous testicular cancer, 3251
- Immunocytochemistry, extracellular matrix, morphometry, proliferation kinetic, osteoblastic marker, 3743
- Immunocytochemistry, occult papillary carcinoma, FNAC, galectin-3, 1111
- Immunoescape, immunotherapy, HLA, lung cancer cells, 1525
- Immunohistochemistry, bone marrow micrometastases, colorectal carcinoma, cytokeratin, p53, Ki67, 2375
- Immunohistochemical expression, colorectal cancer, dihydropyrimidine dehydrogenase, enzymatic activity, disease-free survival, 273
- Immunohistochemistry, Akt, EGFR, HER-2, NSCLC, TGF- α , 11
- Immunohistochemistry, apoptosis, bcl-2, breast cancer, disease/relapse-free survival, mcl-1, overall survival, prognostic indicator, reverse-transcriptase polymerase chain reaction, 473
- Immunohistochemistry, appendix, carcinoid, catestatin, Western blot, 311
- Immunohistochemistry, chondrosarcoma, matrix metalloproteinase, tissue inhibitor of metalloproteinase, a disintegrin and metalloproteinase, histological grade, 4079
- Immunohistochemistry, E-cadherin, β -catenin, endometrium, endometrial carcinoma, 3843
- Immunohistochemistry, homeodomain, colorectal cancer, 955
- Immunohistochemistry, Kaposi's sarcoma, tongue, 1897
- Immunohistochemistry, malignant fibrous histiocytoma, betacellulin, heparin-binding epidermal growth factor, epiregulin, 2007
- Immunohistochemistry, melanoma brain metastases, brain tumors, DNA-repair, mutations, 981
- Immunohistochemistry, nuclear translocation, RelA, poor prognosis, 1071
- Immunohistochemistry, p53, gallbladder cancer, 1201
- Immunohistochemistry, papillary thyroid carcinoma, peroxisome proliferator activated receptor gamma, 1993
- Immunohistochemistry, PLK1, thyroid malignant lymphoma, cell cycle, 259
- Immunohistochemistry, Skp2, p27, esophageal squamous cell carcinoma, Western blotting, 777
- Immunohistochemistry, TGF- β , Smad6, Smad7, esophageal squamous cell carcinoma, 3703
- Immunohistochemistry, β -defensin, lung cancer, tumour marker, antimicrobial peptide, 4051
- Immunomodulation, mistletoe extract, mistletoe lectin, 1231
- Immunomodulation, mistletoe extract, mistletoe lectin, breast cancer patients, 1293
- Immunotherapy, bladder neoplasm, subcutaneous animal model, CpG-ODN, 2225
- Immunotherapy, cytolysin, cholesterol, intermedilysin, 3343
- Immunotherapy, dendritic cell, GM-CSF, IL-4, 1609
- Immunotherapy, dendritic cells, electrofusion, cancer, vaccine, 929
- Immunotherapy, gene therapy, osteosarcoma, IL-12, IL-18, IL-23, 2861
- Immunotherapy, GM-CSF, tumor growth, 2717
- Immunotherapy, immune tolerance, tumor-associated antigens, 2443
- Immunotherapy, immuno-cell therapy, adoptive immunotherapy, LAK, CD3-LAK, review, 3321
- Immunotherapy, immunoescape, HLA, lung cancer cells, 1525
- Immunotherapy, interleukin-2, interleukin-12, 2633
- Immunotherapy, intermedilysin, membrane modification, 3367
- Immunotherapy, melanoma, histamine, interleukin-2, interferon-alpha, 1837
- Immunotherapy, OK-432, toll-like receptor, dendritic cell, review, 3295
- Immunotherapy, tumor antigens, alpha 1, 3 galactosyltransferase, anti- α Gal antibodies, 605
- Immunotoxin, peritoneal mesothelioma, SS1(dsFv)PE38, mesothelin, 1327

- Imprinted gene, microarray, hepatocellular carcinoma, IGF2, H19, 4085
- In vivo imaging, GFP, RFP, metastasis, 4067
- In-silico analysis, kallikreins, pancreatic cancer, colon cancer, serine proteases, cancer genes, SAGE, tumor markers, digital differential display, X-profiler, 43
- Indole-3-carbinol, cervical cancer, estrogen, apoptosis, 2649
- Indole-3-carbinol, pancreatic cancer, prevention, STAT3 transcription factor, genistein, 133
- Induction chemotherapy, alkylating drugs, head and neck cancer, oropharyngeal cancer, 2557
- Infantile gynecomastia, BRCA1, BRCA2, immunohistochemistry, 321
- Infection, computational simulation, HHV-6, HIV, HTLV-1, clinical course, 187
- Infiltrating leucocytes, nasopharyngeal carcinoma, EBV LMP1, apoptosis, p53, 2309
- Inflammation, antitrypsin, antichymotrypsin, secretory leukocyte proteinase inhibitor, lung tumor, 241
- Inflammatory bowel diseases, ursodeoxycholic acid, ulcerative colitis, Crohn's disease, dysplasia, DNA-aneuploidy, 3121
- Inhibition rate constants, curcumin, cytotoxicity, ROS, stoichiometric factor, DPPH, PM3, 563
- Inhibition rate constants, estrogens, antiestrogens, stoichiometric factor, 3931
- Inhibition, retinoids, HPV16, E7, transcription, 807
- Innate immunity, hBD-2, antimicrobial peptides, cancer, Candida, defensin, 1025
- Innate immunity, immune therapy, macrophage, lipopolysaccharide, LPS-tolerance, review, 3311
- Inoperable, mitomycin, cisplatin, doxifluridine, gastric cancer, combination therapy, 2465
- INOS, 2-methoxyestradiol, endometrium carcinoma cells, HEC-1-A, RL-95-2, cell cycle, apoptosis, necrosis, caspases, STAT1, 3983
- INOS, azulenes, Raw 264.7 cells, NO, ESR, radical, 3939
- INOS, tropolones, Raw 264.7 cells, NO, ESR, radical, 3917
- Inositidylphosphate-3-kinase, Akt-1, protein kinase B, IP3-K, multi-stage skin carcinogenesis, epidermal keratinocytes, cell survival, mast cells, papilloma, image analysis, 2773
- Insulin-growth factor-I receptor, mammary carcinogenesis, insulin-growth factor-I, rats, diabetes, 2953
- Insulin-growth factor-I, mammary carcinogenesis, insulin-growth factor-I receptor, rats, diabetes, 2953
- Interferon alpha, biological therapy, drug toxicity, melanoma, 1947
- Interferon, colorectal liver metastases, hepatic arterial infusion, 5-fluorouracil, starch microspheres, 3275
- Interferon, PNET, maintenance, local administration, 1105
- Interferon- γ , ELISPOT, dendritic cells, melanoma, T cell, 171
- Interferon-alpha, melanoma, histamine, interleukin-2, immunotherapy, 1837
- Interferon-gamma, peptide, cytotoxic T lymphocytes, ELISA, 1193
- Interleukin-12, gastric cancer, vascular endothelial growth factor, 3289
- Interleukin-12, immunotherapy, interleukin-2, 2633
- Interleukin-2, immunotherapy, interleukin-12, 2633
- Interleukin-2, melanoma, histamine, interferon-alpha, immunotherapy, 1837
- Interleukin-6, Kaposi's sarcoma, renal transplant recipients, HHV-8, 1311
- Intermediate stage HD, Hodgkin's disease, involved field radiotherapy, extended field radiotherapy, radiotherapy, 4045
- Intermedilysin, cytolysin, cholesterol, immunotherapy, 3343
- Intermedilysin, immunotherapy, membrane modification, 3367
- Interphase cytogenetics, fluorescence in situ hybridization, chromosome 9 and 11 numerical aberrations, bladder cancer, 3857
- Interphase cytogenetics, fluorescence in situ hybridization, chromosome 8 aberrations, gastric cancer, 155
- Interventional radiology, metastases, vertebral compression fracture, radiofrequency heat ablation, vertebroplasty, 3129
- Intestinal metaplasia, E-cadherin, Helicobacter pylori, gastritis, 1603
- Intestinal metaplasia, gastric, gastrectomy, 3185
- Intracellular retention, 211At-para-astato-benzoate, 125I-para-iodo-benzoate, EGF, A-431 cells, 4035
- Intracranial tumour, glioma, microglia, monocyte, lymphocyte, 37
- Intraperitoneal perfusion, cisplatin, hyperthermia, 2041
- Intraprostatic surgical margin, prostate specific antigen, radical prostatectomy, biochemical failure, perianastomotic biopsies, 1179
- Invasion, cancer, Sp1 transcription factor, cathepsin B, matrigel, CA-074, 3887
- Invasion, colorectal carcinoma, prognostic markers, review, angiogenesis, genomic instability, circulating cells, 2519
- Invasion, MMP-9, CD44, migration, colon tumour cell lines, 489
- Invasion, MMPs, TIMPs, genistein, breast cancer, cell growth, 4025
- Invasion, resveratrol, cell signaling, chemoprevention, metastasis, transformation, tumorigenesis, apoptosis, review, 2783
- Involved field radiotherapy, Hodgkin's disease, intermediate stage HD, extended field radiotherapy, radiotherapy, 4045
- Involvement of 1p12, multiple myeloma, conventional cytogenetics, chromosomal abnormalities, prognosis, 4141

- Iodine-131-labelled amino acid, brain cancer, experimental treatment, glioma therapy, preclinical study, 3971
- Ionizing radiation, adhesion molecules, apoptosis, multiparametric flow cytometry, Ewing tumors, 1637
- Ionizing radiation, cyclin B1, NF- κ B, mitochondrial antioxidant enzyme, MnSOD, 2657
- Ionizing radiation, polo-like kinase 1, cell cycle checkpoints, breast cancer, 555
- Ionotropic glutamate receptors, MG-63 cells, metabotropic glutamate receptors, glutamate transporters, glutamine synthetase, 3923
- IP3-K, Akt-1, protein kinase B, inositolphosphate-3-kinase, multi-stage skin carcinogenesis, epidermal keratinocytes, cell survival, mast cells, papilloma, image analysis, 2773
- Irinotecan, colon cancer, topoisomerase I, carboxylesterase, clinical response, 579
- Irinotecan, rectal cancer, microsatellite instability, cell cycle proteins, neoadjuvant therapy, 3161
- Irinotecan, small cell lung cancer, drug resistance, topoisomerase, 3911
- Irinotecan, topoisomerase I, cisplatin, lung cancer, 3893
- Iron, anti-cancer drugs, arsenic, antimony, bismuth, gold, vanadium, rhodium, titanium, gallium, platinum, review, 1529
- Iron, colorectal cancer risk, Ki-ras, diet, vitamin A, thiamine, vitamin D, 2011
- Irradiated osteoarticular graft, acetabular osteosarcoma, pelvic reconstruction, vascularized fibula graft, 1889
- Irradiation, dysfunction, salivary glands, tenascin-C, 2841
- Isobologram, cancer, vitamin D, 1, 24(OH)2D2, antiproliferation, 2905
- Isoflavanones, isoflavones, mouse macrophage, growth, activation, NO, 1481
- Isoflavones, isoflavones, mouse macrophage, growth, activation, NO, 1481
- Isolated perfusion, ras-oncogene, rhabdomyosarcoma, gene therapy, adenovirus, 2295
- Isolation perfusion, cyclophosphamide, ONO-4007, IL-12, TNF, 1823
- K-ras mutation, colorectal carcinoma, liver metastases, 2471
- K-ras, microsatellite instability, p53, colorectal carcinoma, 2047
- K562 cells, crambescidin 800, erythroid differentiation, guanidine alkaloid, p21, Neuro 2A cells, neurite outgrowth, 2325
- Kallikreins, pancreatic cancer, colon cancer, serine proteases, cancer genes, SAGE, tumor markers, digital differential display, X-profiler, in-silico analysis, 43
- Kaposi's sarcoma, AIDS, hCG, apoptosis, human eosinophil-derived neurotoxin, 1427
- Kaposi's sarcoma, HHV-8 genotypes, 1597
- Kaposi's sarcoma, interleukin-6, renal transplant recipients, HHV-8, 1311
- Kaposi's sarcoma, tongue, immunohistochemistry, 1897
- KDR, neuropilin 1, glioma, VEGF, Flt-1, prognosis, 547
- KDR/Flk-1, VEGF, angiogenesis, Flt-1, endothelial cell, 3009
- Ketone body, gastric cancer, monoacetoacetin, succinyl-CoA transferase, 2213
- Ki-67 LI, thymoma, thymic carcinoma, thymoma classification, 4113
- Ki-67, growth fraction, human tumor, radiation, recruitment, 107
- Ki-67, tumor cell dissemination, breast cancer, HER2, p53, bcl-2, hormone receptor, 4211
- Ki-ras, colorectal cancer risk, diet, vitamin A, thiamine, vitamin D, iron, 2011
- Ki67 (MIB1), orbital rhabdomyosarcoma, p53, bcl2, MDR-1, DNA ploidy, prognosis, 249
- Ki67, bone marrow micrometastases, colorectal carcinoma, immunohistochemistry, cytokeratin, p53, 2375
- C-Kit, malignant fibrous histiocytoma, STI571, tyrosine kinase, platelet-derived growth factor receptor, 2675
- C-Kit, soft tissue sarcomas, HER-2/neu, VEGF, 333
- Kupffer cells, apoptosis, LPS, octreotide, 833
- Lactoferrin, methotrexate, delayed type hypersensitivity, humoral immune response, mice, 3831
- LAK, immuno-cell therapy, immunotherapy, adoptive immunotherapy, CD3-LAK, review, 3321
- Laminin-5 γ 2 chain, T1 tongue carcinoma, 3109
- Lamivudine, hepatitis B virus (HBV), viral reactivation, doxorubicin, 3035
- LAT1, oral squamous cell carcinoma, 4F2hc, 1671
- 4F2hc, LAT1, oral squamous cell carcinoma, 1671
- LEA-135, breast carcinoma, prognosis, 2391
- Left ventricular ejection fraction, anthracyclines, cardiotoxicity, cisplatin, epirubicin, gemcitabine, non-small cell lung cancer, radionuclide ventriculography, 2079
- Leucovorin, advanced colorectal cancer, chemotherapy, oxaliplatin, 5-fluorouracil, 1935
- Leucovorin, breast cancer, salvage chemotherapy, cyclophosphamide, 5-fluorouracil, vinorelbine, 4217
- Leucovorin, breast cancer, salvage chemotherapy, cyclophosphamide, 5-fluorouracil, vinorelbine, 4223
- Leucovorin, UFT, oral chemotherapy, 625
- Leukemia, 5-aza-2'-deoxycytidine, methylation, p15CDKN2B, E-cadherin, p73, 75
- Leukemia, Taxol, apoptosis, caspases, mitochondria, cytochrome c, death receptors, 123
- Leuprorelin acetate, dihydrotestosterone, cyproterone acetate, apoptosis-related genes, prostate cancer, 2729
- LFA-1, somatostatin, substance P, neuraminidase, 2331
- LHRH, luteinizing hormone-releasing hormone, apoptosis, ovarian cancer, endometrial cancer, 1727

- Lifestyle and occupational risk factors, transitional cell carcinomas, urinary bladder, RT-PCR, mRNA, retinoblastoma gene, p16 gene, cyclin D-dependent kinase 4, LOH, 1011
- Limited-sampling model, carboplatin, AUC, taxane, 1911
- Lipoma, liposarcoma, 1039
- Lipoperoxidation, cancer, vitamins, microelements, oxidative stress, free radical scavengers, 1449
- Lipoplatin, cisplatin, nephrotoxicity, 2193
- Lipopolysaccharide, immune therapy, macrophage, LPS-tolerance, innate immunity, review, 3311
- Liposarcoma cells, S100A4 protein, metalloproteinases, extracellular matrix, 967
- Liposarcoma, lipoma, 1039
- Liposome, p75NTR, gene therapy, prostate xenograft tumor, 2997
- Liposome, solid tumor, fluorescent latex microspheres, 3005
- Liposomes, drug delivery, paclitaxel, doxorubicin, physiological modeling, cancer chemotherapy, 397
- Lipoxygenase, MBT-2, baicalein, apoptosis, 733
- Liver metastases from colorectal cancer, oxaliplatin, hepatic arterial infusion chemotherapy, 2093
- Liver metastases, colorectal carcinoma, K-ras mutation, 2471
- Liver, portal vein metastatic trafficking, metastasis, green fluorescent protein, 3699
- Local administration, PNET, interferon, maintenance, 1105
- Local treatment, malignant glioma, brain tumor, glioblastoma, anti-angiogenic treatment, 631
- Locoregional chemotherapy, stealth liposomes, PEG liposomes, 5-FU, 1699
- Log P, hexafluorotrihydroxyvitamin D3 derivatives, differentiation, hypercalcemic activity, structure-activity relationship, hydrophobicity, 683
- LOH analysis, BRCA1, BRCA2, p53, long-term survival, prognostic marker, sporadic breast cancer, 281
- LOH, plasma, microsatellites, bladder, MSI, 1733
- LOH, transitional cell carcinomas, urinary bladder, RT-PCR, mRNA, retinoblastoma gene, p16 gene, cyclin D-dependent kinase 4, lifestyle and occupational risk factors, 1011
- LOH, azoxymethane, Min mice, adenomatous polyposis coli, β -catenin, 2595
- Long-term survival, BRCA1, BRCA2, p53, LOH analysis, prognostic marker, sporadic breast cancer, 281
- Loss of heterozygosity, breast cancer, BRCA1, BRCA2, 2681
- Loss of heterozygosity, non-small cell lung cancer, chromosome 3p, chromosome 17p, 4259
- Lovostatin, chemoprevention, exisulind, aberrant crypt foci, 1805
- LPS, Kupffer cells, apoptosis, octreotide, 833
- LPS-tolerance, immune therapy, macrophage, lipopolysaccharide, innate immunity, review, 3311
- LRP, multidrug resistance, flow cytometry, confocal laser scanning microscopy, fluorescence correlation spectroscopy, 725
- Lucanthone, APE1, ref-1, base excision repair, breast cancer, 2127
- Lung cancer cells, cyclooxygenase-2, antisense oligonucleotides, A-549, 3789
- Lung cancer cells, immunoescape, immunotherapy, HLA, 1525
- Lung cancer, cell proliferation, apoptosis, 4243
- Lung cancer, gemcitabine, vinorelbine, 2985
- Lung cancer, gene therapy, retroviral vector, herpes simplex virus thymidine kinase, 827
- Lung cancer, GFP, orthotopic implantation, SCID mice, model, 719
- Lung cancer, procathepsin D, 2739
- Lung cancer, topoisomerase I, cisplatin, irinotecan, 3893
- Lung cancer, UGT, CPT-11, SN-38, 2893
- Lung cancer, β -defensin, immunohistochemistry, tumour marker, antimicrobial peptide, 4051
- Lung carcinoma, bone scintigraphy, bone markers, bone metastasis, 3193
- Lung neoplasms, prognosis, angiogenesis, 2367
- Lung resistance-related protein, testicular germ cell tumor, 1097
- Lung squamous cell carcinoma, Stevens-Johnson syndrome, paclitaxel, anti-hypersensitivity prophylaxis failure, 1135
- Lung tumor, antitrypsin, antichymotrypsin, secretory leukocyte proteinase inhibitor, inflammation, 241
- Lung tumor, choriocarcinoma, chorionic gonadotropin, 1905
- Lung, fatty acid synthase, carcinoma, prognosis, 4169
- Lung, tumor, minimally invasive, radiofrequency ablation, complications, 339
- LV/5-FU, cancer chemotherapy, stomatitis, allopurinol-cryotherapy, 1131
- Lymph node invasion, apoptosis, DNA fragmentation, breast ductal carcinoma, tumor stroma, steroid hormone, 53
- Lymph node metastasis, MRI, rectal cancer, 4097
- Lymph node metastasis, VX2 carcinoma, intravenous cisplatin therapy, animal model, 1785
- Lymph node, CD3 ζ chain, gastric cancer, 2123
- Lymphadenectomy, papillary thyroid carcinoma, follicular thyroid carcinoma, 2439
- Lymphatic metastasis, serosa-negative advanced gastric cancer, peritoneal metastasis, hematogenous metastasis, 3169
- Lymphocyte proliferation, PS-K, IL-2, IL-2R, TGF-beta, 639
- Lymphocyte, intracranial tumour, glioma, microglia, monocyte, 37

- Lymphomagenesis, T cell differentiation, mathematical modeling, 1813
- Lytic replication, gene therapy, Epstein-Barr virus, BZLF1, 67
- Macrophage activating factor (MAF), vitamin D-binding protein, Gc protein, Gc typing, carbohydrate processing, GalNAc, 3361
- Macrophage, cochleate, gene therapy, transgene, tumour cell, 483
- Macrophage, immune therapy, lipopolysaccharide, LPS-tolerance, innate immunity, review, 3311
- Macrophages, apoptosis, adriamycin, caspases, p38 MAPK, 2689
- Macrophages, CXCR6, protein expression, rectal cancer, T cells, epithelial cells, 3711
- Male breast cancer, prostate cancer, anti-androgen monotherapy, 1077
- Malignant brain tumor, adoptive immunotherapy, therapeutic activity, 1861
- Malignant disease, cardiovascular tests, pancreatic polypeptide, 2515
- Malignant fibrous histiocytoma, immunohistochemistry, betacellulin, heparin-binding epidermal growth factor, epiregulin, 2007
- Malignant fibrous histiocytoma, soft tissue, immunohistochemistry, amphiregulin, epidermal growth factor receptor, 1307
- Malignant fibrous histiocytoma, STI571, tyrosine kinase, c-kit, platelet-derived growth factor receptor, 2675
- Malignant glioma, brain tumor, local treatment, glioblastoma, anti-angiogenic treatment, 631
- Malignant glioma, extracranial metastases, astrocytomas, glioblastomas, 2563
- Malignant intestinal obstruction, metallic stent, 3153
- Malignant melanoma, cytokeratin, 3203
- Malignant melanoma, Spitz nevus, BRAF gene, 2415
- Malignant mesothelioma, chemotaxis, chemokinesis, growth factors, 1625
- Malignant mesothelioma, hyaluronan synthases (HAS), hyaluronan (HA), 599
- Maltol, deferiprone, hydroxyketones, cytotoxic activity, oral tumor cells, 755
- Mammary carcinogenesis, insulin-growth factor-I, insulin-growth factor-I receptor, rats, diabetes, 2953
- Mammary tumor, bamboo grass leaves, chemoprevention, Her2/NeuN, Sasa Health, 2879
- Mammary tumor, capsaicin, denervation, sensory neurons, metastasis, 1003
- Mammography, breast cancer, technetium Tc-99m-medronate, VEGF, 1999
- Mannose receptors, scavenger receptors, monocytes, tumour cells, cytokines, 2287
- α -Mannosidase, breast cancer, MCF-7, β -galactosidase, fluorescent-lectin conjugates, membrane receptors, 139
- Mantle cell lymphoma, CD40, CD40 ligand, IL-10, 691
- MAPK, EGCG, MMP-9, AP-1, gastric cancer, 747
- Mast cells, Akt-1, protein kinase B, inositolphosphate-3-kinase, IP3-K, multi-stage skin carcinogenesis, epidermal keratinocytes, cell survival, papilloma, image analysis, 2773
- Mast cells, microvasculature, dispersed fibrous long-spacing collagen, angiogenesis, electron microscopy, advanced gastric carcinoma, 2257
- Mathematical modeling, T cell differentiation, lymphomagenesis, 1813
- Matrigel, cancer, invasion, Sp1 transcription factor, cathepsin B, CA-074, 3887
- Matrix metalloproteinase, chondrosarcoma, tissue inhibitor of metalloproteinase, a disintegrin and metalloproteinase, immunohistochemistry, histological grade, 4079
- Matrix metalloproteinases, MMP-21, polymorphism, breast cancer, 199
- MB-MDA-231, breast cancer, MCF-7, estrogen receptor (ER), estrogen, tamoxifen, VEGF, 3961
- MBT-2, lipoxygenase, baicalein, apoptosis, 733
- MCF-7, breast cancer, MB-MDA-231, estrogen receptor (ER), estrogen, tamoxifen, VEGF, 3961
- MCF-7, breast cancer, β -galactosidase, α -mannosidase, fluorescent-lectin conjugates, membrane receptors, 139
- MCF-7, multidrug resistance, breast cancer, monocyte, cytokine, 935
- Mcl-1, apoptosis, bcl-2, breast cancer, disease/relapse-free survival, immunohistochemistry, overall survival, prognostic indicator, reverse-transcriptase polymerase chain reaction, 473
- MDA-MB-231, breast cancer, MDA-MB-435, SDF-1 α , CXCR4, chemotaxis, transendothelial migration, 4011
- MDA-MB-435, breast cancer, MDA-MB-231, SDF-1 α , CXCR4, chemotaxis, transendothelial migration, 4011
- MDR, multiple drug resistance, MRP-1, sulindac, resistance modulation, resistance circumvention, combination chemotherapy, NCI H460, 457
- MDR-1, colon cancer cell, cisplatin, cyclooxygenase-2, MRP-1, 2723
- MDR-1, orbital rhabdomyosarcoma, p53, bcl2, Ki67 (MIB1), DNA ploidy, prognosis, 249
- Medicago scutellata, serine protease inhibitor, cytotoxicity, 227
- Medullary thyroid carcinoma, drug resistance, apoptosis, plant - based drugs, 495
- MEK, chronic myeloid leukemia, imatinib mesylate, histone deacetylase inhibitor, depsipeptide, apoptosis, cyclin D1, c-Myc, 2705
- Melanoma brain metastases, brain tumors, DNA-repair, mutations, immunohistochemistry, 981
- Melanoma, bacteriophages, purified bacteriophages, 3991

- Melanoma, biological therapy, drug toxicity, interferon alpha, 1947
- Melanoma, *Canis familiaris*, fibrosarcoma, hot-spot mutations, ras genes, 3027
- Melanoma, dendritic cells, HDM2, 2141
- Melanoma, ELISPOT, interferon- γ , dendritic cells, T cell, 171
- Melanoma, histamine, interleukin-2, interferon-alpha, immunotherapy, 1837
- Melanoma, VEGF, prognosis, 4255
- Membrane modification, intermedilysin, immunotherapy, 3367
- Membrane receptors, breast cancer, MCF-7, β -galactosidase, α -mannosidase, fluorescent-lectin conjugates, 139
- Meningiomas, confrontation culture, proliferation markers, 2319
- Menstrual cycle, vascular endothelial growth factor, 4237
- Mesothelin, peritoneal mesothelioma, SS1(dsFv)PE38, immunotoxin, 1327
- Mesothelioma, calretinin, calcium-binding proteins, EF-hand, tumor marker, differential expression, alternative splicing, 4003
- Mesothelioma, sarcomatoid malignant mesothelioma, cytokeratin, calretinin, 3097
- C-Met, oral squamous cell carcinoma, oral mucosa, metastasis, growth factor receptor, 1063
- C-Met, prostate cancer, angiogenesis, bFGF, VEGF, progression, 1797
- Metabolizing enzymes, colorectal cancer, cancer susceptibility, N-acetyltransferase, glutathione-S-transferase, 3965
- Metabolotropic glutamate receptors, MG-63 cells, ionotropic glutamate receptors, glutamate transporters, glutamine synthetase, 3923
- Metallic stent, malignant intestinal obstruction, 3153
- Metallic stent, self-expanding, colostomy, rectosigmoidal obstruction, 265
- Metallic stent, self-expanding, gastroenterostomy, gastric outlet obstruction, 269
- Metallo-proteinases, angiogenesis, nafoxidine, antiestrogens, 1737
- Metalloproteinases, S100A4 protein, liposarcoma cells, extracellular matrix, 967
- Metastases, colorectal cancer, raltitrexed, oxaliplatin, 1139
- Metastases, cyclooxygenase-2, breast cancer, 2349
- Metastases, prostate cancer, docetaxel, estramustine, hormone, 2897
- Metastases, vertebral compression fracture, interventional radiology, radiofrequency heat ablation, vertebroplasty, 3129
- Metastasis model, PCR, colon cancer cell line HT29, severe-combined-immunodeficient (scid) mouse, carcinoembryonic antigen (CEA), circulating tumor cells, 1421
- Metastasis, bone sialoprotein (BSP), bone, breast cancer, 1361
- Metastasis, brain, small cell lung cancer, hypertension, 3115
- Metastasis, c-Met, oral squamous cell carcinoma, oral mucosa, growth factor receptor, 1063
- Metastasis, capsaicin, denervation, sensory neurons, mammary tumor, 1003
- Metastasis, Fas, FasL, colorectal carcinoma, carcinogenesis, 1569
- Metastasis, GFP, RFP, in vivo imaging, 4067
- Metastasis, imaging, GFP, 5-fluorouracil, UFT, 1353
- Metastasis, multidrug resistance, soft-tissue sarcomas, 291
- Metastasis, portal vein metastatic trafficking, liver, green fluorescent protein, 3699
- Metastasis, resveratrol, cell signaling, chemoprevention, transformation, invasion, tumorigenesis, apoptosis, review, 2783
- Metastasis, serum HER2, CA 15-3, breast cancer, prognosis, survival, 1987
- Metastatic breast cancer, doxorubicin, docetaxel, 3257
- Metastatic breast cancer, epirubicin, docetaxel, epirubicin dose, 1963
- Metastatic breast cancer, serum HER-2/neu, fractionated paclitaxel, predictive markers, monitoring, 895
- Metastatic breast cancer, trastuzumab, bone marrow metastases, 317
- Metastatic melanoma, cytotoxic T cell (CTL), CTL epitope, HLA-A24 motif, HLA-A*2402-restricted peptide cocktail, 571
- Metastatic prostate cancer, hormone-refractory prostate cancer, anaemia, epoetin beta, 1957
- Methotrexate, lactoferrin, delayed type hypersensitivity, humoral immune response, mice, 3831
- Methotrexate, photodynamic therapy, photosensitisers, UV-vis irradiation, 2925
- 2-Methoxyestradiol, cervical cells, HeLaS3 cells, apoptosis, cell cycle, 873
- 2-Methoxyestradiol, endometrium carcinoma cells, HEC-1-A, RL-95-2, cell cycle, apoptosis, necrosis, iNOS, caspases, STAT1, 3983
- 2-Methoxyphenols, butyl-substituted phenols, orthobisphenols, 3019
- 2-(3'-Methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone, HL-60, PBMC, apoptosis, cell cycle, G2/M arrest, ERK, 1769
- N-Methyl-nitrosourea, aminopeptidase A, breast cancer, angiotensin, 801
- Methylation specific PCR, colorectal cancer, caveolin-1 gene, 1645
- Methylation, 5-aza-2'-deoxycytidine, leukemia, p15CDKN2B, E-cadherin, p73, 75
- Methylation-specific polymerase chain reaction, gastric cancer, hypermethylation, tumor marker, 2477

- Methylator phenotype, MTHFR polymorphism, DNA methylation, colorectal cancer, 649
- Mevastatin, multiple myeloma, apoptosis, caspase, 1817
- MG-63 cells, ionotropic glutamate receptors, metabotropic glutamate receptors, glutamate transporters, glutamine synthetase, 3923
- MHC class Ib, tumor-specificity, tissue-specificity, transcription, tumor antigen, nonclassical histocompatibility antigen, 3379
- MHC, CTL, SCCHN, FACS, 973
- MiaPaCa, HMAF, cytotoxic, 59
- MIB-1, breast cancer, CEA, CA 15-3, hormone receptor, 3221
- MIB1, breast cancer, mitotic index, S-phase fraction, 3283
- MIB1, CD44s, ovarian cancer, ER, PR, p53, PCNA, 1665
- Microarray, cancer screen, artificial intelligence, 1159
- Microarray, cancer, genomics, across-platform, 441
- Microarray, hepatocellular carcinoma, IGF2, H19, imprinted gene, 4085
- Microelements, cancer, vitamins, oxidative stress, lipoperoxidation, free radical scavengers, 1449
- Microglia, intracranial tumour, glioma, monocyte, lymphocyte, 37
- Micrometastases, vulva cancer, squamous cell carcinoma, sentinel lymph node, multilevel sectioning, 1281
- Microsatellite instability, colorectal cancer, thymidylate synthase, pharmacogenomic, polymorphism, molecular therapeutic, 3875
- Microsatellite instability, genomic aberrations, mismatch repair, ovarian carcinoma, 361
- Microsatellite instability, K-ras, p53, colorectal carcinoma, 2047
- Microsatellite instability, rectal cancer, cell cycle proteins, neoadjuvant therapy, irinotecan, 3161
- Microsatellites, plasma, bladder, LOH, MSI, 1733
- Microtube, tumour therapy, hot vaporized water, thermal ablation, 2757
- Microvasculature, mast cells, dispersed fibrous long-spacing collagen, angiogenesis, electron microscopy, advanced gastric carcinoma, 2257
- Microvessel density, breast cancer, core needle biopsy, vascular endothelial growth factor, 371
- Microvessel density, vascular endothelial growth factor, thymidine phosphorylase, gastric carcinoma, 1853
- Migration, mitogen activated protein kinase, growth factor, signal transduction, cell cycle, 593
- Migration, MMP-9, CD44, invasion, colon tumour cell lines, 489
- Min mice, azoxymethane, adenomatous polyposis coli, β -catenin, LOH, 2595
- Minimally invasive, lung, tumor, radiofrequency ablation, complications, 339
- Mismatch repair, microsatellite instability, genomic aberrations, ovarian carcinoma, 361
- Mistletoe extract, cancer patients, quality of life, randomized controlled trial, 303
- Mistletoe extract, mistletoe lectin, breast cancer patients, immunomodulation, 1293
- Mistletoe extract, mistletoe lectin, immunomodulation, 1231
- Mistletoe lectin, breast cancer, 1187
- Mistletoe lectin, mistletoe extract, breast cancer patients, immunomodulation, 1293
- Mistletoe lectin, mistletoe extract, immunomodulation, 1231
- Mitochondria, taxol, apoptosis, caspases, cytochrome c, leukemia, death receptors, 123
- Mitochondrial antioxidant enzyme, cyclin B1, ionizing radiation, NF- κ B, MnSOD, 2657
- Mitochondrial DNA deletion, tandem duplication, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, 1753
- Mitogen activated protein kinase, growth factor, signal transduction, migration, cell cycle, 593
- Mitomycin C (MMC), vitamin B2 (riboflavin), vitamin C, γ -radiation, 4031
- Mitomycin, cisplatin, doxifluridine, gastric cancer, inoperable, combination therapy, 2465
- Mitotic arrest, paclitaxel, apoptosis, NF- κ B, I κ B- α , 27
- Mitotic index, breast cancer, MIB1, S-phase fraction, 3283
- Mitotic rate, granulosa cell tumor, ovarian cancer, prognostic factor, 1223
- MK 886, U937 nuclear Ca²⁺, apoptosis, 2601
- MMP-21, matrix metalloproteinases, polymorphism, breast cancer, 199
- MMP-9, breast carcinoma, antiestrogen therapy, 4247
- MMP-9, CD44, invasion, migration, colon tumour cell lines, 489
- MMP-9, EGCG, AP-1, MAPK, gastric cancer, 747
- MMP-9, esophagus, dysplasia, 3245
- MMP1, MMP3, head and neck cancer, case control study, haplotype, 2021
- MMP3, MMP1, head and neck cancer, case control study, haplotype, 2021
- MMPs, TIMPs, genistein, breast cancer, cell growth, invasion, 4025
- MnSOD, cyclin B1, ionizing radiation, NF- κ B, mitochondrial antioxidant enzyme, 2657
- Model, GFP, orthotopic implantation, SCID mice, lung cancer, 719
- Modulation, multidrug resistance, P-glycoprotein, multidrug resistance protein, breast cancer resistance protein, taxane, structure-activity analysis, 409
- Molecular markers, colon cancer, RT-PCR, 4127
- Molecular modeling-docking, imidazothioxanthenes, cytotoxicity, antitumor activity, human tumor xenografts, murine tumors, 907

- Molecular target-based therapy, radiation, survival signal transduction pathway, 811
- Molecular targeting, esophageal cancer, PPAR, cell cycle regulator, apoptosis, 1409
- Molecular therapeutic, colorectal cancer, thymidylate synthase, pharmacogenomic, microsatellite instability, polymorphism, 3875
- Molecularly-targeted therapy, immunocell therapy, Imatinib mesylate, Ph(+)ALL, GIST, 3303
- MOLT-4 cells, caffeine, cell cycle, cyclin E, flow cytometry, cell proliferation, 2991
- Monitoring, serum HER-2/neu, fractionated paclitaxel, predictive markers, metastatic breast cancer, 895
- Monoacetoacetin, gastric cancer, ketone body, succinyl-CoA transferase, 2213
- Monoclonal antibody, carcinoembryonic antigen, scFv, 3355
- Monocyte, intracranial tumour, glioma, microglia, lymphocyte, 37
- Monocyte, multidrug resistance, MCF-7, breast cancer, cytokine, 935
- Monocytes, scavenger receptors, mannose receptors, tumour cells, cytokines, 2287
- Monoterpenes, head and neck cancer, chemo-radiation, 3089
- Morphometry, extracellular matrix, proliferation kinetic, osteoblastic marker, immunocytochemistry, 3743
- Mouse lymphoma cell line, cycloartane triterpenes, Euphorbia, apoptosis induction, multidrug resistance, 859
- Mouse macrophage, isoflavones, isoflavanones, growth, activation, NO, 1481
- Mouse mammary tumors, chemoimmunotherapy, 2249
- MRI, lymph node metastasis, rectal cancer, 4097
- MRI, renal diffusion-weighted MRI, renal tumours, tumour cellularity, 4175
- MRNA expression, ribosomal proteins, S19, HNSCC, 2161
- MRNA, transitional cell carcinomas, urinary bladder, RT-PCR, retinoblastoma gene, p16 gene, cyclin D-dependent kinase 4, LOH, lifestyle and occupational risk factors, 1011
- MRP-1, colon cancer cell, cisplatin, cyclooxygenase-2, MDR-1, 2723
- MRP-1, multiple drug resistance, MDR, sulindac, resistance modulation, resistance circumvention, combination chemotherapy, NCI H460, 457
- MRP1, multidrug resistance, ATP-binding cassette, ABC-signature, nucleotide trapping, ABC-ABC structure, 449
- MSI, plasma, microsatellites, bladder, LOH, 1733
- MTHFR polymorphism, DNA methylation, methylator phenotype, colorectal cancer, 649
- MTHFR, breast cancer, estrogen exposure, polymorphism, 3863
- MTHFR, breast cancer, folate, polymorphism, TS, 3215
- MTT assay, CA-4, 3, 4-diarylfuran-2-one, tumors, tubulin polymerization, cell cycle, 179
- Muc1, transcription, regulation, Yin Yang 1, 235
- Mucin, gemcitabine, tumor antigen, 821
- Mucositis, amifostine, WR-1065, cytoprotection, 3263
- Multi-stage skin carcinogenesis, Akt-1, protein kinase B, inosidylphosphate-3-kinase, IP3-K, epidermal keratinocytes, cell survival, mast cells, papilloma, image analysis, 2773
- Multicellular tumour spheroids, bispecific trivalent antibody, 887
- Multidrug resistance protein, multidrug resistance, P-glycoprotein, breast cancer resistance protein, modulation, taxane, structure-activity analysis, 409
- Multidrug resistance, ABCG2, ribozyme, 2231
- Multidrug resistance, anthracyclines, real-time reverse transcriptase polymerase chain reaction, 2931
- Multidrug resistance, cycloartane triterpenes, Euphorbia, apoptosis induction, mouse lymphoma cell line, 859
- Multidrug resistance, doxorubicin, drug encapsulation, gene expression, topoisomerase II, P-glycoprotein, breast cancer resistance protein, 3781
- Multidrug resistance, LRP, flow cytometry, confocal laser scanning microscopy, fluorescence correlation spectroscopy, 725
- Multidrug resistance, MCF-7, breast cancer, monocyte, cytokine, 935
- Multidrug resistance, MRP1, ATP-binding cassette, ABC-signature, nucleotide trapping, ABC-ABC structure, 449
- Multidrug resistance, organosilicon, reversal, 865
- Multidrug resistance, P-glycoprotein, multidrug resistance protein, breast cancer resistance protein, modulation, taxane, structure-activity analysis, 409
- Multidrug resistance, soft-tissue sarcomas, metastasis, 291
- Multidrug resistance, tetrahydroisoquinolines, P-glycoprotein, 1631
- Multilevel sectioning, vulva cancer, squamous cell carcinoma, sentinel lymph node, micrometastases, 1281
- Multiparametric flow cytometry, adhesion molecules, apoptosis, ionizing radiation, Ewing tumors, 1637
- Multiple drug resistance, MRP-1, MDR, sulindac, resistance modulation, resistance circumvention, combination chemotherapy, NCI H460, 457
- Multiple myeloma, adhesion, E-cadherin, prognosis, 2027
- Multiple myeloma, conventional cytogenetics, chromosomal abnormalities, involvement of 1p12, prognosis, 4141
- Multiple myeloma, mevastatin, apoptosis, caspase, 1817
- Multiple tumour markers, NSE, Cyfra21-1, small cell lung cancer, prognosis, 1941

- Murine tumors, imidazothioxanones, cytotoxicity, antitumor activity, human tumor xenografts, molecular modeling-docking, 907
- Mutagenicity, Salmonella typhimurium, Ames test, oxidative stress, plant phenolics, bleomycin, antioxidant, antimutagenicity, caffeic acid, 743
- Mutations, melanoma brain metastases, brain tumors, DNA-repair, immunohistochemistry, 981
- Myc, Bcl-2, p53, p21waf1, drug resistance, radiation resistance, paclitaxel, SCLC cells, 465
- C-Myc, chronic myeloid leukemia, imatinib mesylate, histone deacetylase inhibitor, depsipeptide, apoptosis, cyclin D1, MEK, 2705
- Myelodysplastic syndrome, persistent cytopenia, chromosome aberrations, conventional, cytogenetic analysis, fluorescence in situ hybridization, childhood, 3945
- Nafoxidine, angiogenesis, antiestrogens, metallo-proteinases, 1737
- Nasopharyngeal carcinoma, EBV LMP1, infiltrating leucocytes, apoptosis, p53, 2309
- Nasopharyngeal carcinoma, Real-time PCR, Epstein-Barr virus, 4059
- NCI H460, multiple drug resistance, MRP-1, MDR, sulindac, resistance modulation, resistance circumvention, combination chemotherapy, 457
- Necrosis, 2-methoxyestradiol, endometrium carcinoma cells, HEC-1-A, RL-95-2, cell cycle, apoptosis, iNOS, caspases, STAT1, 3983
- Necrosis, pancreatic carcinoma cells, paclitaxel, daunorubicin, apoptosis, 2617
- Neoadjuvant chemotherapy, esophageal cancer, 2385
- Neoadjuvant chemotherapy, gastric cancer, UFT, randomized consent design trial, 1879
- Neoadjuvant therapy, esophageal carcinoma, chemoradiotherapy, esophagectomy, 4091
- Neoadjuvant therapy, rectal cancer, microsatellite instability, cell cycle proteins, irinotecan, 3161
- Nephrotoxicity, cisplatin, lipoplatin, 2193
- Nephroureterectomy, urothelial tumors, 1921
- Neuraminidase, somatostatin, substance P, LFA-1, 2331
- Neurite outgrowth, crambescidin 800, erythroid differentiation, K562 cells, guanidine alkaloid, p21, Neuro 2A cells, 2325
- Neuro 2A cells, crambescidin 800, erythroid differentiation, K562 cells, guanidine alkaloid, p21, neurite outgrowth, 2325
- Neuroblastoma, histamine, histamine receptors, tumor, retinoic acid, 1657
- Neuroblastoma, p53, curcumin, resveratrol, apoptosis, 987
- Neuroendocrine tumors, second primary malignancy, 1049
- Neuron-specific enolase, glioma, S-100B protein, 2511
- Neuropilin 1, glioma, VEGF, Flt-1, KDR, prognosis, 547
- Neurotoxicity, chemotherapy, amifostine, in vitro study, 2337
- NF- κ B, cyclin B1, ionizing radiation, mitochondrial antioxidant enzyme, MnSOD, 2657
- NF- κ B, paclitaxel, apoptosis, I κ B- α , mitotic arrest, 27
- NHANES, aspirin, NSAIDs, cancer, cardiovascular disease, cohort study, 3177
- Nitric oxide synthase, angiogenesis, X-rays, vascular endothelial growth factor, heparin affin regulatory peptide, 2941
- 2-Nitroimidazole, boron neutron capture therapy, sodium borocaptate-10B, quiescent cell, thermal neutrons, γ -rays, 2975
- NO, azulenes, Raw 264.7 cells, iNOS, ESR, radical, 3939
- NO, isoflavones, isoflavanones, mouse macrophage, growth, activation, 1481
- NO, tropolones, Raw 264.7 cells, iNOS, ESR, radical, 3917
- Non-genomic cell growth inhibition, progesterone, cell cycle, 3749
- Non-Hodgkin's lymphoma, diffuse large cell lymphoma, HER-2/neu, 3233
- Non-seminomatous testicular cancer, immunocompetence, 3251
- Non-small cell lung cancer (NSCLC), cathepsin B (cath B), plasminogen activator-inhibitor (PAI-1), plasminogen activator-receptor (uPAR), prognosis, 4147
- Non-small cell lung cancer, anthracyclines, cardiotoxicity, cisplatin, epirubicin, gemcitabine, left ventricular ejection fraction, radionuclide ventriculography, 2079
- Non-small cell lung cancer, Bcl-2, p53, 1925
- Non-small cell lung cancer, chemotherapy, docetaxel, second-line, taxane, 1211
- Non-small cell lung cancer, cisplatin, vinorelbine, 4227
- Non-small cell lung cancer, docetaxel, carboplatin, 1239
- Non-small cell lung cancer, gemcitabine, weekly paclitaxel, second-line chemotherapy, 2567
- Non-small cell lung cancer, loss of heterozygosity, chromosome 3p, chromosome 17p, 4259
- Nonclassical histocompatibility antigen, tumor-specificity, tissue-specificity, transcription, tumor antigen, MHC class Ib, 3379
- NSAIDs, aspirin, cancer, cardiovascular disease, NHANES, cohort study, 3177
- NSAIDs, UDP-glucuronosyltransferases, anticarcinogens, chemoprevention, Wistar rat, 843
- NSCLC, Akt, EGFR, HER-2, TGF- α , immunohistochemistry, 11
- NSCLC, CYFRA 21-1, CEA, 1953
- NSCLC, gefitinib, salvage therapy, 1873
- NSCLC, squamous, EGFR, EGFR-TKI, gefitinib, ZD1839, 393
- NSE, Cyfra21-1, multiple tumour markers, small cell lung cancer, prognosis, 1941

- Nuclear factor-kB, colorectal carcinoma, electrophoretic mobility shift assay, tumor progression, 675
- Nuclear translocation, RelA, immunohistochemistry, poor prognosis, 1071
- Nucleolin, estrogen receptor, nucleolus, breast carcinoma, 963
- Nucleolus, nucleolin, estrogen receptor, breast carcinoma, 963
- Nucleotide excision repair, apurinic sites, base excision repair, DNA adducts, DNA repair, human breast cell extracts, 117
- Nucleotide trapping, MRP1, multidrug resistance, ATP-binding cassette, ABC-signature, ABC-ABC structure, 449
- Nude mouse, TZT-1027, breast cancer, vascular flow, 2201
- Occult cancer, testicular metastasis, gastrointestinal cancer, 1093
- Occult papillary carcinoma, FNAC, immunocytochemistry, galectin-3, 1111
- Octreotide, Kupffer cells, apoptosis, LPS, 833
- Oesophageal cancer, human papillomavirus, Barrett's oesophagus, oesophagitis, 1319
- Oesophageal carcinoma, survival, predictive factors, 1915
- Oesophageal, quality of life, gastrointestinal, gastric, pancreatic, colorectal cancer, 2117
- Oesophagitis, human papillomavirus, oesophageal cancer, Barrett's oesophagus, 1319
- OK-432, immunotherapy, toll-like receptor, dendritic cell, review, 3295
- Onco-protein, endometrioid adenocarcinoma, endometriosis, ovary, comparative genomic hybridisation, 151
- Oncogene expression, head and neck cancer, platinum isomers, 3997
- Oncogene, Her2/neu, archival breast cancer, chromogenic in situ hybridisation, prognostic significance, 2401
- Oncogenes, glucose deprivation, src, ras, abl, bcr-abl, bcl-2, IL-3, apoptosis, 2503
- ONO-4007, cyclophosphamide, IL-12, isolation perfusion, TNF, 1823
- Oral carcinoma cell lines, confluence, gene expression, 2627
- Oral carcinoma, cisplatin (CDDP), hepatoma, apoptosis, DNA fragmentation, caspase, 655
- Oral carcinomas, xerostomia, tea, EGCG, salivary gland, 3065
- Oral chemotherapy, UFT, leucovorin, 625
- Oral mucosa, c-Met, oral squamous cell carcinoma, metastasis, growth factor receptor, 1063
- Oral squamous cell carcinoma, artemisinin, 2153
- Oral squamous cell carcinoma, c-Met, oral mucosa, metastasis, growth factor receptor, 1063
- Oral squamous cell carcinoma, LAT1, 4F2hc, 1671
- Oral tumor cells, deferiprone, maltol, hydroxyketones, cytotoxic activity, 755
- Oral tumor cells, α , β -unsaturated ketone, cytotoxic activity, structure-activity, 737
- Oral tumor cells, β -diketone, apoptosis, cytotoxic activity, 711
- Orbital rhabdomyosarcoma, p53, bcl2, MDR-1, Ki67 (MIB1), DNA ploidy, prognosis, 249
- Organosilicon, multidrug resistance, reversal, 865
- Oropharyngeal cancer, induction chemotherapy, alkylating drugs, head and neck cancer, 2557
- Orthobisphenols, 2-methoxyphenols, butyl-substituted phenols, 3019
- Orthotopic implantation, GFP, SCID mice, lung cancer, model, 719
- Osseous neoplasms, actinium, thorium, α -particles, 101
- Osteoblastic marker, extracellular matrix, morphometry, proliferation kinetic, immunocytochemistry, 3743
- Osteogenic sarcoma, paclitaxel, N-acetyltransferase, 2-aminofluorene-DNA adduct, 83
- Osteolysis, bone metastasis, renal cell carcinoma, angiogenesis, 1705
- Osteosarcoma, anti-angiogenic gene therapy, cationic liposomes, human-like orthotopic model, 3977
- Osteosarcoma, cisplatin, HMGB1 expression, semi-quantitative RT-PCR, 707
- Osteosarcoma, immunotherapy, gene therapy, IL-12, IL-18, IL-23, 2861
- Ovarian cancer cell, genistein, daidzein, 795
- Ovarian cancer, CD44s, ER, PR, p53, PCNA, MIB1, 1665
- Ovarian cancer, granulosa cell tumor, prognostic factor, mitotic rate, 1223
- Ovarian cancer, luteinizing hormone-releasing hormone, LHRH, apoptosis, endometrial cancer, 1727
- Ovarian cancer, paclitaxel, histone deacetylase inhibitor, apoptosis, p53, 539
- Ovarian cancer, platelet count, thrombocytosis, cervical carcinoma, endometrial carcinoma, 2053
- Ovarian cancer, suPAR, prognostic factors, ELISA, 1981
- Ovarian cancer, topotecan, 1267
- Ovarian cancer, VEGF, 1973
- Ovarian carcinoma, microsatellite instability, genomic aberrations, mismatch repair, 361
- Ovarian carcinoma, VEGF, cyst fluid, ascites, 1149
- Ovarian tumours, CAS200, image cytophotometry, 4191
- Ovary, endometrioid adenocarcinoma, endometriosis, onco-protein, comparative genomic hybridisation, 151
- Ovary, FHL2, focal adhesion kinase (pp125FAK), protein interaction, epithelial ovarian cancer, 921
- Overall survival, apoptosis, bcl-2, breast cancer, disease/relapse-free survival, immunohistochemistry, mcl-1, prognostic indicator, reverse-transcriptase polymerase chain reaction, 473

- Oxaliplatin, 5-fluorouracil, tomudex, CPT-11, cDNA microarray, 417
- Oxaliplatin, 5FU, DPD deficiency, 1969
- Oxaliplatin, advanced colorectal cancer, chemotherapy, leucovorin, 5-fluorouracil, 1935
- Oxaliplatin, colon cancer cells, apoptosis, 219
- Oxaliplatin, colorectal cancer, metastases, raltitrexed, 1139
- Oxaliplatin, colorectal cancer, palliative first- and second-line treatment, weekly high-dose 5-FU as 24-hour infusion and folinic acid, 385
- Oxaliplatin, colorectal cancer, phase II, dose-intensity, 5-fluorouracil, 355
- Oxaliplatin, hepatic arterial infusion chemotherapy, liver metastases from colorectal cancer, 2093
- Oxidant, whey protein, cysteine, glutathione, prostate, breast cancer, antioxidant, 553
- Oxidative DNA damage, *Drosophila melanogaster* S3, ribosomal/repair protein, bladder cells, dS3, 3811
- Oxidative stress, cancer, vitamins, microelements, lipoperoxidation, free radical scavengers, 1449
- Oxidative stress, checkpoints, CDKN1A, Gadd45, human, prostate cancer, DNA repair, 3955
- Oxidative stress, *Salmonella typhimurium*, Ames test, mutagenicity, plant phenolics, bleomycin, antioxidant, antimutagenicity, caffeic acid, 743
- P-glycoprotein, multidrug resistance, doxorubicin, drug encapsulation, gene expression, topoisomerase II, breast cancer resistance protein, 3781
- P-glycoprotein, multidrug resistance, multidrug resistance protein, breast cancer resistance protein, modulation, taxane, structure-activity analysis, 409
- P-glycoprotein, tetrahydroisoquinolines, multidrug resistance, 1631
- P14RF-MDM2-p53-P73 pathway, sarcoma, ifosfamide, real-time RT-PCR, P16-CDK4-Rb pathway, 3819
- P15CDKN2B, 5-aza-2'-deoxycytidine, leukemia, methylation, E-cadherin, p73, 75
- P16 gene, transitional cell carcinomas, urinary bladder, RT-PCR, mRNA, retinoblastoma gene, cyclin D-dependent kinase 4, LOH, lifestyle and occupational risk factors, 1011
- P16-CDK4-Rb pathway, sarcoma, ifosfamide, real-time RT-PCR, P14RF-MDM2-p53-P73 pathway, 3819
- P2-purinoceptor-mediated cell growth, purinergic receptors, prostate cancer cells, 2853
- P21, crambescidin 800, erythroid differentiation, K562 cells, guanidine alkaloid, Neuro 2A cells, neurite outgrowth, 2325
- P21, rectal cancer, radiochemotherapy, 1217
- P21waf1, Bcl-2, p53, myc, drug resistance, radiation resistance, paclitaxel, SCLC cells, 465
- P21waf1/cip1, tongue cancer, prognosis, 3225
- P27, Skp2, esophageal squamous cell carcinoma, immunohistochemistry, Western blotting, 777
- P27kip, tumor marker, squamous cell carcinoma, CD26, TGF- β 1, 619
- P38 MAPK, apoptosis, macrophages, adriamycin, caspases, 2689
- P53 locus, small hepatocellular carcinoma, chromosome 17, dual-color fluorescence in situ hybridization, 111
- P53, Bcl-2, non-small cell lung cancer, 1925
- P53, Bcl-2, p21waf1, myc, drug resistance, radiation resistance, paclitaxel, SCLC cells, 465
- P53, bone marrow micrometastases, colorectal carcinoma, immunohistochemistry, cytokeratin, Ki67, 2375
- P53, BRCA1, BRCA2, LOH analysis, long-term survival, prognostic marker, sporadic breast cancer, 281
- P53, breast cancer, Her2-neu, cathepsin D, survival, 2061
- P53, CD44s, ovarian cancer, ER, PR, PCNA, MIB1, 1665
- P53, gene therapy, glioma, retrovirus, VEGF, angiopoietins, 1
- P53, immunohistochemistry, gallbladder cancer, 1201
- P53, microsatellite instability, K-ras, colorectal carcinoma, 2047
- P53, nasopharyngeal carcinoma, EBV LMP1, infiltrating leucocytes, apoptosis, 2309
- P53, neuroblastoma, curcumin, resveratrol, apoptosis, 987
- P53, orbital rhabdomyosarcoma, bcl2, MDR-1, Ki67 (MIB1), DNA ploidy, prognosis, 249
- P53, ovarian cancer, paclitaxel, histone deacetylase inhibitor, apoptosis, 539
- P53, tumor cell dissemination, breast cancer, HER2, bcl-2, Ki-67, hormone receptor, 4211
- P63, CK17, stem cell, uterine cervix, reserve cell, HPV, 771
- P70 S6 kinase, Akt, PKB, phosphatidylinositol 3-kinase, rapamycin, 2697
- P73, 5-aza-2'-deoxycytidine, leukemia, methylation, p15CDKN2B, E-cadherin, 75
- P75NTR, gene therapy, liposome, prostate xenograft tumor, 2997
- Paclitaxel, carboplatin, cervical carcinoma, chemoradiation, 345
- Paclitaxel, apoptosis, NF- κ B, I κ B- α , mitotic arrest, 27
- Paclitaxel, Bcl-2, p53, p21waf1, myc, drug resistance, radiation resistance, SCLC cells, 465
- Paclitaxel, drug delivery, doxorubicin, liposomes, physiological modeling, cancer chemotherapy, 397
- Paclitaxel, endothelial cell proliferation, anthracyclines, 5-FU, etoposide, 1759
- Paclitaxel, N-acetyltransferase, 2-aminofluorene-DNA adduct, osteogenic sarcoma, 83
- Paclitaxel, N-acetyltransferase, bladder cancer cell line (T24), 2-aminofluorene, flow cytometry, cDNA microarray, 1501

- Paclitaxel, ovarian cancer, histone deacetylase inhibitor, apoptosis, p53, 539
- Paclitaxel, pancreatic carcinoma cells, daunorubicin, apoptosis, necrosis, 2617
- Paclitaxel, Stevens-Johnson syndrome, anti-hypersensitivity prophylaxis failure, lung squamous cell carcinoma, 1135
- Paclitaxel, taxane analogues, head and neck squamous cell carcinoma, chemosensitivity, clonogenic assay, 3769
- Palliative first- and second-line treatment, colorectal cancer, weekly high-dose 5-FU as 24-hour infusion and folinic acid, oxaliplatin, 385
- Pancreatic cancer, gemcitabine, 5-fluorouracil, 2107
- Pancreatic cancer, kallikreins, colon cancer, serine proteases, cancer genes, SAGE, tumor markers, digital differential display, X-profiler, in-silico analysis, 43
- Pancreatic cancer, prevention, STAT3 transcription factor, indole-3-carbinol, genistein, 133
- Pancreatic cancer, SMAD-4, adjuvant chemotherapy, DPC4, 1173
- Pancreatic carcinoma cells, paclitaxel, daunorubicin, apoptosis, necrosis, 2617
- Pancreatic ductal adenocarcinoma, PDPK FA, 1489
- Pancreatic polypeptide, malignant disease, cardiovascular tests, 2515
- Pancreatic, quality of life, gastrointestinal, oesophageal, gastric, colorectal cancer, 2117
- Pancreaticobiliary maljunction, cyclooxygenase-2, bile duct cancer, 671
- Paneth cells, adenoma, ileum, 4187
- Papillary thyroid carcinoma, follicular thyroid carcinoma, lymphadenectomy, 2439
- Papillary thyroid carcinoma, peroxisome proliferator activated receptor gamma, immunohistochemistry, 1993
- Papilloma, Akt-1, protein kinase B, inositolphosphate-3-kinase, IP3-K, multi-stage skin carcinogenesis, epidermal keratinocytes, cell survival, mast cells, image analysis, 2773
- 125I-Para-iodo-benzoate, 211At-para-astato-benzoate, EGF, A-431 cells, intracellular retention, 4035
- Parathyroid hormone-related protein, humanized monoclonal antibody, epitope, hypercalcemia, 2665
- α -Particles, actinium, thorium, osseous neoplasms, 101
- Pasteurized bone graft, autograft, chondrosarcoma, 1893
- Patterns of care study, radiotherapy, hormone-refractory prostate cancer, 3141
- PBMC, 2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone, HL-60, apoptosis, cell cycle, G2/M arrest, ERK, 1769
- PC3, gossypol, DNA synthesis, cyclin D1, TGF β 1, 91
- PCNA, CD44s, ovarian cancer, ER, PR, p53, MIB1, 1665
- PCR, metastasis model, colon cancer cell line HT29, severe-combined-immunodeficient (scid) mouse, carcinoembryonic antigen (CEA), circulating tumor cells, 1421
- PDPK FA, pancreatic ductal adenocarcinoma, 1489
- PEG liposomes, stealth liposomes, 5-FU, locoregional chemotherapy, 1699
- PEHG, cAMP, Ca²⁺, colonic epithelial cells, 1465
- PEHG, proliferation, apoptosis, cell cycle, colonic epithelial cells, 587
- Pelvic lymphadenectomy, endometrial cancer, staging, prognostic value, surgery, hysterectomy, 2073
- Pelvic reconstruction, acetabular osteosarcoma, vascularized fibula graft, irradiated osteoarticular graft, 1889
- Peptide, cytotoxic T lymphocytes, interferon-gamma, ELISA, 1193
- Perianastomotic biopsies, prostate specific antigen, radical prostatectomy, biochemical failure, intraprostatic surgical margin, 1179
- Peritoneal dissemination, gastric cancer, real-time RT-PCR, 1113
- Peritoneal mesothelioma, SS1(dsFv)PE38, mesothelin, immunotoxin, 1327
- Peritoneal metastasis, serosa-negative advanced gastric cancer, hematogenous metastasis, lymphatic metastasis, 3169
- Peroxisome proliferator activated receptor gamma, papillary thyroid carcinoma, immunohistochemistry, 1993
- Persistent cytopenia, myelodysplastic syndrome, chromosome aberrations, conventional, cytogenetic analysis, fluorescence in situ hybridization, childhood, 3945
- PET, cancer screening, FDG, PET/CT, 4103
- PET/CT, cancer screening, FDG, PET, 4103
- PGP9.5, plasminogen activator inhibitor-1, esophageal squamous cell carcinoma, 3731
- Ph(+)ALL, immunocell therapy, molecularly-targeted therapy, imatinib mesylate, GIST, 3303
- Phagocytosis, apoptosis, breast cancer cells, 1455
- Pharmacogenomic, colorectal cancer, thymidylate synthase, microsatellite instability, polymorphism, molecular therapeutic, 3875
- 4-Phenylbutyrate, histone acetylation, PPAR gamma agonists and antagonists, 2765
- PHGPx, GPx4, cyclooxygenase, colon cancer cells, 1387
- Phosphatidylinositol 3-kinase, Akt, PKB, p70 S6 kinase, rapamycin, 2697
- Photodynamic therapy, hematoporphyrin, folate receptor, targeted solid-lipid nanoparticle, 161
- Photodynamic therapy, methotrexate, photosensitisers, UV-vis irradiation, 2925
- Photosensitisers, methotrexate, photodynamic therapy, UV-vis irradiation, 2925
- Physiological modeling, drug delivery, paclitaxel, doxorubicin, liposomes, cancer chemotherapy, 397
- Pichia pastoris, HPV, deleted E7 protein, therapeutic vaccine, tumour, 2265

- Pituitary-grafted mice, hypocholesterolemic agent, probucol, uterine adenomyosis, 2209
- PKB, Akt, p70 S6 kinase, phosphatidylinositol 3-kinase, rapamycin, 2697
- Plant - based drugs, medullary thyroid carcinoma, drug resistance, apoptosis, 495
- Plant phenolics, Salmonella typhimurium, Ames test, oxidative stress, mutagenicity, bleomycin, antioxidant, antimutagenicity, caffeic acid, 743
- Plasma, microsattellites, bladder, LOH, MSI, 1733
- Plasma, tissue inhibitor of matrix metalloproteinase-1, colorectal carcinoma, prognostic value, 2101
- Plasminogen activator inhibitor-1, PGP9.5, esophageal squamous cell carcinoma, 3731
- Plasminogen activator-inhibitor (PAI-1), cathepsin B (cath B), plasminogen activator-receptor (uPAR), prognosis, non-small cell lung cancer (NSCLC), 4147
- Plasminogen activator-receptor (uPAR), cathepsin B (cath B), plasminogen activator-inhibitor (PAI-1), prognosis, non-small cell lung cancer (NSCLC), 4147
- Platelet count, thrombocytosis, cervical carcinoma, endometrial carcinoma, ovarian cancer, 2053
- Platelet-derived growth factor receptor, malignant fibrous histiocytoma, STI571, tyrosine kinase, c-kit, 2675
- Platinum isomers, head and neck cancer, oncogene expression, 3997
- Platinum, anti-cancer drugs, arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, gallium, review, 1529
- Pleomorphic lipoma, 3157
- Pleomorphic malignant fibrous histiocytoma, atypical fibroxanthoma, undifferentiated high grade pleomorphic sarcoma, comparative genomic hybridization, 19
- PLK1, thyroid malignant lymphoma, cell cycle, immunohistochemistry, 259
- PM3, curcumin, cytotoxicity, ROS, stoichiometric factor, inhibition rate constants, DPPH, 563
- PNET, interferon, maintenance, local administration, 1105
- Polo-like kinase 1, cell cycle checkpoints, ionizing radiation, breast cancer, 555
- Polyacetylenes, capillin, Artemisia species, 2281
- Polymorphism, breast cancer, estrogen exposure, MTHFR, 3863
- Polymorphism, breast cancer, folate, MTHFR, TS, 3215
- Polymorphism, colorectal cancer, thymidylate synthase, pharmacogenomic, microsattelite instability, molecular therapeutic, 3875
- Polymorphism, hormone-related gene, prostate cancer, 2431
- Polymorphism, matrix metalloproteinases, MMP-21, breast cancer, 199
- Polyomavirus, viral infection, telomerase activity, apoptosis, 791
- Portal vein metastatic trafficking, liver, metastasis, green fluorescent protein, 3699
- Portal vein thrombosis, hepatocellular carcinoma, ethanol injection, radiofrequency, thermal ablation, 2419
- Postmenopausal, anastrozole, breast cancer, hormone-dependent tumors, 1315
- Postoperative survival, 5-fluorouracil, adjuvant chemotherapy, dihydropyrimidine dehydrogenase, gastric carcinoma, 2495
- PPAR gamma agonists and antagonists, 4-phenylbutyrate, histone acetylation, 2765
- PPAR, esophageal cancer, molecular targeting, cell cycle regulator, apoptosis, 1409
- PR, CD44s, ovarian cancer, ER, p53, PCNA, MIB1, 1665
- Preclinical study, brain cancer, experimental treatment, glioma therapy, iodine-131-labelled amino acid, 3971
- Predictive factors, oesophageal carcinoma, survival, 1915
- Predictive markers, serum HER-2/neu, fractionated paclitaxel, monitoring, metastatic breast cancer, 895
- Predictive value, breast cancer, chemotherapy, HER2, tumor marker, 1261
- Prevention, pancreatic cancer, STAT3 transcription factor, indole-3-carbinol, genistein, 133
- Primary cerebral tumor, chemotherapy, glioblastoma, 1249
- Prion, doppel gene expression, glioblastoma multiforme, 1507
- Probucol, hypocholesterolemic agent, uterine adenomyosis, pituitary-grafted mice, 2209
- Procarbazine, radiolysis, 1593
- Procathepsin D, lung cancer, 2739
- Progesterone, non-genomic cell growth inhibition, cell cycle, 3749
- Progestins, dydrogesterone, breast cancer cells, sulfatase, 17 β -hydroxysteroid dehydrogenase, 1433
- Prognosis, adhesion, E-cadherin, multiple myeloma, 2027
- Prognosis, breast carcinoma, LEA-135, 2391
- Prognosis, CA 125, collagen metabolism, epithelial ovarian cancer, ICTP, tumor markers, 1057
- Prognosis, cathepsin B (cath B), plasminogenactivator-inhibitor (PAI-1), plasminogenactivator-receptor (uPAR), non-small cell lung cancer (NSCLC), 4147
- Prognosis, fatty acid synthase, lung, carcinoma, 4169
- Prognosis, Hodgkin's disease, soluble adhesion molecules, 1243
- Prognosis, lung neoplasms, angiogenesis, 2367
- Prognosis, multiple myeloma, conventional cytogenetics, chromosomal abnormalities, involvement of 1p12, 4141
- Prognosis, neuropilin 1, glioma, VEGF, Flt-1, KDR, 547
- Prognosis, NSE, Cyfra21-1, multiple tumour markers, small cell lung cancer, 1941
- Prognosis, orbital rhabdomyosarcoma, p53, bcl2, MDR-1, Ki67 (MIB1), DNA ploidy, 249
- Prognosis, p21waf1/cip1, tongue cancer, 3225

- Prognosis, serum HER2, CA 15-3, breast cancer, survival, metastasis, 1987
- Prognosis, VEGF, melanoma, 4255
- Prognostic factor, granulosa cell tumor, ovarian cancer, mitotic rate, 1223
- Prognostic factors, gastric cancer, 377
- Prognostic factors, suPAR, ovarian cancer, ELISA, 1981
- Prognostic factors, UPT, adenocarcinoma, 297
- Prognostic indicator, apoptosis, bcl-2, breast cancer, disease/relapse-free survival, immunohistochemistry, mcl-1, overall survival, reverse-transcriptase polymerase chain reaction, 473
- Prognostic marker, BRCA1, BRCA2, p53, LOH analysis, long-term survival, sporadic breast cancer, 281
- Prognostic markers, colorectal carcinoma, review, angiogenesis, genomic instability, invasion, circulating cells, 2519
- Prognostic significance, Her2/neu, oncogene, archival breast cancer, chromogenic in situ hybridisation, 2401
- Prognostic value, endometrial cancer, pelvic lymphadenectomy, staging, surgery, hysterectomy, 2073
- Prognostic value, tissue inhibitor of matrix metalloproteinase-1, colorectal carcinoma, plasma, 2101
- Progression, prostate cancer, angiogenesis, bFGF, VEGF, c-met, 1797
- Proliferation kinetic, extracellular matrix, morphometry, osteoblastic marker, immunocytochemistry, 3743
- Proliferation markers, meningiomas, confrontation culture, 2319
- Proliferation, CDK1, enhancer, transcription, cell cycle, gene expression, 1469
- Proliferation, E2F-1, apoptosis, colon cancer, 3041
- Proliferation, pEHG, apoptosis, cell cycle, colonic epithelial cells, 587
- Promoter, EpCAM, targeted gene expression, HSV1-TK, GFP, 3715
- Prostate cancer cell lines, rhodium ferrocene complexes, apoptosis, 763
- Prostate cancer cells, purinergic receptors, P2-purinoceptor-mediated cell growth, 2853
- Prostate cancer, angiogenesis, bFGF, VEGF, c-met, progression, 1797
- Prostate cancer, anti-androgen monotherapy, male breast cancer, 1077
- Prostate cancer, caspase-1, apoptosis, radiation, 1377
- Prostate cancer, cathepsin B, serum, prostate volume, 2573
- Prostate cancer, checkpoints, CDKN1A, Gadd45, human, oxidative stress, DNA repair, 3955
- Prostate cancer, docetaxel, estramustine, hormone, metastases, 2897
- Prostate cancer, ethnic differences, diet, 2551
- Prostate cancer, glucose transporter, Glut-1, 3057
- Prostate cancer, IgG oligosaccharide chains, prostate-specific antigen, 3135
- Prostate cancer, leuprorelin acetate, dihydrotestosterone, cyproterone acetate, apoptosis-related genes, 2729
- Prostate cancer, polymorphism, hormone-related gene, 2431
- Prostate cancer, PSA, free PSA, cPSA, 4181
- Prostate cancer, radiotherapy, hypofractionation, amifostine, 3239
- Prostate cancer, stromal cells, tumor-stromal cell interaction, antitumor drugs, fibroblast, 1561
- Prostate cancer, α -tocopheryloxybutyrate, α -tocopheryl succinate, apoptosis, Akt, 3795
- Prostate carcinoma, prostate specific antigen, 2069
- Prostate specific antigen, prostate carcinoma, 2069
- Prostate specific antigen, radical prostatectomy, biochemical failure, perianastomotic biopsies, intraprostatic surgical margin, 1179
- Prostate volume, prostate cancer, cathepsin B, serum, 2573
- Prostate xenograft tumor, p75NTR, gene therapy, liposome, 2997
- Prostate, animal models, CWR22, androgen independent, angiogenesis, VEGF, 2135
- Prostate, whey protein, cysteine, glutathione, breast cancer, oxidant, antioxidant, 553
- Prostate-specific antigen, IgG oligosaccharide chains, prostate cancer, 3135
- Prostatic neoplasms, angiogenesis, von Willebrand factor, CD34, CD31, endothelial cells, endothelial marker, 1651
- Proteasome inhibitors, (-)-EGCG, green tea, organic synthesis, cell cycle, growth inhibition, 943
- Protein expression, CXCR6, rectal cancer, macrophages, T cells, epithelial cells, 3711
- Protein interaction, FHL2, focal adhesion kinase (pp125FAK), ovary, epithelial ovarian cancer, 921
- Protein kinase B, Akt-1, inositol diphosphate-3-kinase, IP3-K, multi-stage skin carcinogenesis, epidermal keratinocytes, cell survival, mast cells, papilloma, image analysis, 2773
- Protein secretion, enzyme/prodrug therapy, cytosine deaminase, 5-fluorouracil, gene therapy, 1393
- Protein, SELDI, proteinChip, proteome, array, colorectal cancer, carcinoma, 1791
- ProteinChip, SELDI, proteome, protein, array, colorectal cancer, carcinoma, 1791
- Proteome, SELDI, proteinChip, protein, array, colorectal cancer, carcinoma, 1791
- Proteomics, α -haptoglobin, hepatocyte growth factor, small cell lung cancer, serum tumor biomarkers, 1031
- PS-K, IL-2, lymphocyte proliferation, IL-2R, TGF-beta, 639
- PSA, free PSA, cPSA, prostate cancer, 4181
- PTEN, glioblastoma, Akt, EGFR, 2643

- Purified bacteriophages, bacteriophages, melanoma, 3991
- Purinergic receptors, prostate cancer cells, P2-purinoceptor-mediated cell growth, 2853
- Pur α , E2F1, growth inhibition, cell cycle, RNA association, 2585
- 2-c]Pyrimidine, imidazo[2, 1-b]thiazole, diimidazo[1, 2-a:1, guanylhydrazones, antitumor activity, 203
- Quality of life, gastrointestinal, oesophageal, gastric, pancreatic, colorectal cancer, 2117
- Quality of life, mistletoe extract, cancer patients, randomized controlled trial, 303
- Quiescent cell, boron neutron capture therapy, sodium borocaptate-10B, 2-nitroimidazole, thermal neutrons, γ -rays, 2975
- Radiation resistance, Bcl-2, p53, p21waf1, myc, drug resistance, paclitaxel, SCLC cells, 465
- Radiation therapy, central nervous system, brain, spinal cord, amifostine, 3803
- Radiation therapy, small cell lung cancer, brain metastasis, chemotherapy, 2097
- Radiation, caspase-1, apoptosis, prostate cancer, 1377
- Radiation, growth fraction, human tumor, Ki-67, recruitment, 107
- Radiation, molecular target-based therapy, survival signal transduction pathway, 811
- γ -Radiation, vitamin B2 (riboflavin), vitamin C, mitomycin C (MMC), 4031
- Radical prostatectomy, prostate specific antigen, biochemical failure, perianastomotic biopsies, intraprostatic surgical margin, 1179
- Radical, azulenes, Raw 264.7 cells, NO, iNOS, ESR, 3939
- Radical, tropolones, Raw 264.7 cells, NO, iNOS, ESR, 3917
- Radiochemotherapy, rectal cancer, p21, 1217
- Radiofrequency ablation, lung, tumor, minimally invasive, complications, 339
- Radiofrequency heat ablation, metastases, vertebral compression fracture, interventional radiology, vertebroplasty, 3129
- Radiofrequency, hepatocellular carcinoma, portal vein thrombosis, ethanol injection, thermal ablation, 2419
- Radioimmunoguided surgery (RIGS), gastric carcinoma, carcinoembryonic antigen (CEA), T84.66, F(ab')₂, Fab', 663
- Radiolysis, procarbazine, 1593
- Radionuclide ventriculography, anthracyclines, cardiotoxicity, cisplatin, epirubicin, gemcitabine, left ventricular ejection fraction, non-small cell lung cancer, 2079
- Radiosensitivity, trace elements, selenium, radiotherapy, 2913
- Radiosensitization, cisplatin, ZD0473, human tumour cells, 613
- Radiotherapy, breast cancer, 1303
- Radiotherapy, esophageal cancer, elderly, chemotherapy, 2483
- Radiotherapy, Hodgkin's disease, intermediate stage HD, involved field radiotherapy, extended field radiotherapy, 4045
- Radiotherapy, hormone-refractory prostate cancer, patterns of care study, 3141
- Radiotherapy, prostate cancer, hypofractionation, amifostine, 3239
- Radiotherapy, trace elements, selenium, radiosensitivity, 2913
- Raltitrexed, colorectal cancer, cross-resistance, 5-fluorouracil, 2037
- Raltitrexed, colorectal cancer, metastases, oxaliplatin, 1139
- Randomized consent design trial, neoadjuvant chemotherapy, gastric cancer, UFT, 1879
- Randomized controlled trial, mistletoe extract, cancer patients, quality of life, 303
- Rapamycin, Akt, PKB, p70 S6 kinase, phosphatidylinositol 3-kinase, 2697
- RAR receptors, hepatocellular carcinoma, retinoic acid, tamoxifen, 1255
- Ras genes, Canis familiaris, fibrosarcoma, hot-spot mutations, melanoma, 3027
- Ras, glucose deprivation, oncogenes, src, abl, bcr-abl, bcl-2, IL-3, apoptosis, 2503
- Ras-oncogene, isolated perfusion, rhabdomyosarcoma, gene therapy, adenovirus, 2295
- Rats, mammary carcinogenesis, insulin-growth factor-I, insulin-growth factor-I receptor, diabetes, 2953
- Raw 264.7 cells, azulenes, NO, iNOS, ESR, radical, 3939
- Raw 264.7 cells, tropolones, NO, iNOS, ESR, radical, 3917
- γ -Rays, boron neutron capture therapy, sodium borocaptate-10B, 2-nitroimidazole, quiescent cell, thermal neutrons, 2975
- Real-time PCR, nasopharyngeal carcinoma, Epstein-Barr virus, 4059
- Real-time reverse transcriptase polymerase chain reaction, anthracyclines, multidrug resistance, 2931
- Real-time RT-PCR, peritoneal dissemination, gastric cancer, 1113
- Real-time RT-PCR, sarcoma, ifosfamide, P16-CDK4-Rb pathway, P14RF-MDM2-p53-P73 pathway, 3819
- Real-time RT-PCR, urinary bladder, transitional cell carcinomas, angiogenesis, vascular endothelial growth factor, angiopoietins-1 and -2, 2745
- Receptor tyrosine kinase inhibitor, vascular endothelial growth factor, angiogenesis, antisense oligodeoxynucleotides, renal cell carcinoma, 213
- Recruitment, growth fraction, human tumor, Ki-67, radiation, 107
- Rectal cancer, adjuvant therapy, transanal endoscopic microsurgery, 1167

- Rectal cancer, CXCR6, protein expression, macrophages, T cells, epithelial cells, 3711
- Rectal cancer, microsatellite instability, cell cycle proteins, neoadjuvant therapy, Irinotecan, 3161
- Rectal cancer, MRI, lymph node metastasis, 4097
- Rectal cancer, radiochemotherapy, p21, 1217
- Rectosigmoidal obstruction, self-expanding, metallic stent, colostomy, 265
- Recurrence, adrenal cortical carcinoma, repeat surgical resection, survival, 1901
- Recurrent, docetaxel, doxifluridine, 2085
- Ref-1, APE1, base excision repair, lucanthone, breast cancer, 2127
- Regulation, transcription, Muc1, Yin Yang 1, 235
- Regulatory T cells, DCs, DC maturation, tumor-antigen specific CTL, 3327
- RelA, nuclear translocation, immunohistochemistry, poor prognosis, 1071
- Renal cell carcinoma, bone metastasis, osteolysis, angiogenesis, 1705
- Renal cell carcinoma, catenin, 2407
- Renal cell carcinoma, green tea, gap junction, connexin, 3757
- Renal cell carcinoma, vascular endothelial growth factor, angiogenesis, antisense oligodeoxynucleotides, receptor tyrosine kinase inhibitor, 213
- Renal diffusion-weighted MRI, renal tumours, MRI, tumour cellularity, 4175
- Renal transplant recipients, interleukin-6, Kaposi's sarcoma, HHV-8, 1311
- Renal tumours, renal diffusion-weighted MRI, MRI, tumour cellularity, 4175
- Repeat surgical resection, adrenal cortical carcinoma, recurrence, survival, 1901
- Reserve cell, p63, CK17, stem cell, uterine cervix, HPV, 771
- Resistance circumvention, multiple drug resistance, MRP-1, MDR, sulindac, resistance modulation, combination chemotherapy, NCI H460, 457
- Resistance modulation, multiple drug resistance, MRP-1, MDR, sulindac, resistance circumvention, combination chemotherapy, NCI H460, 457
- Resveratrol, antioxidant, apoptosis, 999
- Resveratrol, cell signaling, chemoprevention, metastasis, transformation, invasion, tumorigenesis, apoptosis, review, 2783
- Resveratrol, neuroblastoma, p53, curcumin, apoptosis, 987
- Retinoblastoma gene, transitional cell carcinomas, urinary bladder, RT-PCR, mRNA, p16 gene, cyclin D-dependent kinase 4, LOH, lifestyle and occupational risk factors, 1011
- Retinoic acid, hepatocellular carcinoma, tamoxifen, RAR receptors, 1255
- Retinoic acid, histamine, histamine receptors, neuroblastoma, tumor, 1657
- Retinoids, breast cancer, histone deacetylase inhibitors, 4019
- Retinoids, colon cancer, CaCo-2, HT-29, IIF, cell differentiation, 1779
- Retinoids, HPV16, E7, transcription, inhibition, 807
- Retroperitoneal mass, VEGF, vascular endothelial growth factor, endothelium, angiosarcoma, HIF1, HIF2, hypoxia inducible factor, VHL, von Hippel-Lindau, 167
- Retroviral vector, lung cancer, gene therapy, herpes simplex virus thymidine kinase, 827
- Retrovirus, p53, gene therapy, glioma, VEGF, angiopoietins, 1
- Reversal, organosilicon, multidrug resistance, 865
- Reverse-transcriptase polymerase chain reaction, apoptosis, bcl-2, breast cancer, disease/relapse-free survival, immunohistochemistry, mcl-1, overall survival, prognostic indicator, 473
- Review, anti-cancer drugs, arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, gallium, platinum, 1529
- Review, chromosomal instability, aneuploidy, centriole, aurora A, tumorigenesis, 3269
- Review, colorectal carcinoma, prognostic markers, angiogenesis, genomic instability, invasion, circulating cells, 2519
- Review, endothelial monocyte activating polypeptide II (EMAP II), tumor necrosis factor-alpha, 2243
- Review, immune therapy, macrophage, lipopolysaccharide, LPS-tolerance, innate immunity, 3311
- Review, immuno-cell therapy, immunotherapy, adoptive immunotherapy, LAK, CD3-LAK, 3321
- Review, OK-432, immunotherapy, toll-like receptor, dendritic cell, 3295
- Review, resveratrol, cell signaling, chemoprevention, metastasis, transformation, invasion, tumorigenesis, apoptosis, 2783
- Review, RNA helicases, cancer, 3951
- RFP, GFP, in vivo imaging, metastasis, 4067
- RGD, apoptosis, gene therapy, colon carcinoma, fiber modifications, 3075
- Rhabdomyosarcoma, isolated perfusion, ras-oncogene, gene therapy, adenovirus, 2295
- Rheumatoid factor, adoptive immunotherapy, autologous activated lymphocyte, antinuclear antibody, autoimmune disease, 2423
- Rhodium ferrocene complexes, prostate cancer cell lines, apoptosis, 763
- Rhodium, anti-cancer drugs, arsenic, antimony, bismuth, gold, vanadium, iron, titanium, gallium, platinum, review, 1529
- Ribosomal proteins, S19, mRNA expression, HNSCC, 2161

- Ribosomal/repair protein, *Drosophila melanogaster* S3, bladder cells, dS3, oxidative DNA damage, 3811
- Ribozyme, ABCG2, multidrug resistance, 2231
- Ribozyme, caspase-3, 425
- RL-95-2, 2-methoxyestradiol, endometrium carcinoma cells, HEC-1-A, cell cycle, apoptosis, necrosis, iNOS, caspases, STAT1, 3983
- RNA association, Pur α , E2F1, growth inhibition, cell cycle, 2585
- RNA helicases, cancer, review, 3951
- RNASEL, breast cancer, 2547
- ROS, curcumin, cytotoxicity, stoichiometric factor, inhibition rate constants, DPPH, PM3, 563
- RT-PCR, molecular markers, colon cancer, 4127
- RT-PCR, transitional cell carcinomas, urinary bladder, mRNA, retinoblastoma gene, p16 gene, cyclin D-dependent kinase 4, LOH, lifestyle and occupational risk factors, 1011
- S-1, gastric carcinoma, chemotherapy, phase I study, docetaxel, 1843
- S-100B protein, glioma, neuron-specific enolase, 2511
- S-phase fraction, breast cancer, MIB1, mitotic index, 3283
- S100A4 protein, metalloproteinases, liposarcoma cells, extracellular matrix, 967
- S19, ribosomal proteins, mRNA expression, HNSCC, 2161
- SAGE, kallikreins, pancreatic cancer, colon cancer, serine proteases, cancer genes, tumor markers, digital differential display, X-profiler, in-silico analysis, 43
- Salivary gland, xerostomia, tea, EGCG, oral carcinomas, 3065
- Salivary glands, dysfunction, irradiation, tenascin-C, 2841
- Salmonella typhimurium, Ames test, oxidative stress, mutagenicity, plant phenolics, bleomycin, antioxidant, antimutagenicity, caffeic acid, 743
- Salvage chemotherapy, breast cancer, cyclophosphamide, 5-fluorouracil, leucovorin, vinorelbine, 4217
- Salvage chemotherapy, breast cancer, cyclophosphamide, 5-fluorouracil, leucovorin, vinorelbine, 4223
- Salvage therapy, gefitinib, NSCLC, 1873
- Sarcoma 180 cell ultrastructure, Sparfloxacin, ultrasound irradiation, 1553
- Sarcoma, apoptosis, CDDP, Id, caspase, 1519
- Sarcoma, ifosfamide, real-time RT-PCR, P16-CDK4-Rb pathway, P14RF-MDM2-p53-P73 pathway, 3819
- Sarcomatoid malignant mesothelioma, cytokeratin, calretinin, mesothelioma, 3097
- Sasa Health, bamboo grass leaves, chemoprevention, Her2/NeuN, mammary tumor, 2879
- Scavenger receptors, mannose receptors, monocytes, tumour cells, cytokines, 2287
- SCCHN, MHC, CTL, FACS, 973
- ScFv, monoclonal antibody, carcinoembryonic antigen, 3355
- SCID mice, GFP, orthotopic implantation, lung cancer, model, 719
- Scid mouse tumor xenograft, epidermal growth factor receptor, colon cancer, ERRP, apoptosis, 2885
- SCLC cells, Bcl-2, p53, p21waf1, myc, drug resistance, radiation resistance, paclitaxel, 465
- SDF-1 α , breast cancer, MDA-MB-231, MDA-MB-435, CXCR4, chemotaxis, transendothelial migration, 4011
- Second primary malignancy, neuroendocrine tumors, 1049
- Secretory leukocyte proteinase inhibitor, antitrypsin, antichymotrypsin, lung tumor, inflammation, 241
- Sedation, gynaecologic oncology, 4109
- SELDI, proteinChip, proteome, protein, array, colorectal cancer, carcinoma, 1791
- Selenium compounds, DNA repair, cancer-chemoprevention, field-effect, 1401
- Selenium, trace elements, radiosensitivity, radiotherapy, 2913
- Self-expanding, metallic stent, colostomy, rectosigmoidal obstruction, 265
- Self-expanding, metallic stent, gastroenterostomy, gastric outlet obstruction, 269
- Semi-quantitative RT-PCR, osteosarcoma, cisplatin, HMGB1 expression, 707
- Sensory neurons, capsaicin, denervation, mammary tumor, metastasis, 1003
- Sentinel lymph node, vulva cancer, squamous cell carcinoma, micrometastases, multilevel sectioning, 1281
- Serine protease inhibitor, medicago scutellata, cytotoxicity, 227
- Serine proteases, kallikreins, pancreatic cancer, colon cancer, cancer genes, SAGE, tumor markers, digital differential display, X-profiler, in-silico analysis, 43
- Serosa-negative advanced gastric cancer, peritoneal metastasis, hematogenous metastasis, lymphatic metastasis, 3169
- Serrated, adenoma, gastric, 2113
- Serum HER-2/neu, fractionated paclitaxel, predictive markers, monitoring, metastatic breast cancer, 895
- Serum HER2, CA 15-3, breast cancer, prognosis, survival, metastasis, 1987
- Serum tumor biomarkers, α -haptoglobin, hepatocyte growth factor, small cell lung cancer, proteomics, 1031
- Serum, breast neoplasms, HER-2/neu, trastuzumab, 1083
- Serum, prostate cancer, cathepsin B, prostate volume, 2573
- Severe-combined-immunodeficient (scid) mouse, metastasis model, PCR, colon cancer cell line HT29, carcinoembryonic antigen (CEA), circulating tumor cells, 1421
- Shikonin, N-acetyltransferase, 2-aminofluorene, N-acetyl-2-aminofluorene, *Helicobacter pylori*, gastric cancer, 1587
- Sialic acid, cationic dextran, growth inhibition, 1347
- Sialic acid, cationic dextran, growth inhibition, 1347

- Signal transduction inhibition, bladder cancer, carboxyamido-triazole (CAI), apoptosis, bcl-2, calcium, 2869
- Signal transduction, mitogen activated protein kinase, growth factor, migration, cell cycle, 593
- Skp2, p27, esophageal squamous cell carcinoma, immunohistochemistry, Western blotting, 777
- Smad, CD105, endoglin, TGF- β 1, 1337
- SMAD-4, pancreatic cancer, adjuvant chemotherapy, DPC4, 1173
- Smad6, TGF- β , Smad7, esophageal squamous cell carcinoma, immunohistochemistry, 3703
- Smad7, TGF- β , Smad6, esophageal squamous cell carcinoma, immunohistochemistry, 3703
- Small cell lung cancer, brain metastasis, radiation therapy, chemotherapy, 2097
- Small cell lung cancer, irinotecan, drug resistance, topoisomerase, 3911
- Small cell lung cancer, metastasis, brain, hypertension, 3115
- Small cell lung cancer, NSE, Cyfra21-1, multiple tumour markers, prognosis, 1941
- Small cell lung cancer, α -haptoglobin, hepatocyte growth factor, serum tumor biomarkers, proteomics, 1031
- Small hepatocellular carcinoma, p53 locus, chromosome 17, dual-color fluorescence in situ hybridization, 111
- SN-38, UGT, CPT-11, lung cancer, 2893
- Sodium borocaptate-10B, boron neutron capture therapy, 2-nitroimidazole, quiescent cell, thermal neutrons, γ -rays, 2975
- Soft tissue sarcoma, tumor prognosis, survival, CD44s, 1053
- Soft tissue sarcomas, HER-2/neu, c-Kit, VEGF, 333
- Soft tissue, malignant fibrous histiocytoma, immunohistochemistry, amphiregulin, epidermal growth factor receptor, 1307
- Soft-tissue sarcomas, multidrug resistance, metastasis, 291
- Solid tumor cell lines, DNA topoisomerase I, topotecan, down-regulation, 1745
- Solid tumor, liposome, fluorescent latex microspheres, 3005
- Soluble adhesion molecules, Hodgkin's disease, prognosis, 1243
- Somatostatin, substance P, LFA-1, neuraminidase, 2331
- Soybean flour, colon cancer, garbanzo beans, ACF, CF-1 mice, 3049
- Sp1 transcription factor, cancer, invasion, cathepsin B, matrigel, CA-074, 3887
- Sparfloxacin, ultrasound irradiation, sarcoma 180 cell ultrastructure, 1553
- Spinal cord, central nervous system, brain, radiation therapy, amifostine, 3803
- Spitz nevus, malignant melanoma, BRAF gene, 2415
- Sporadic breast cancer, BRCA1, BRCA2, p53, LOH analysis, long-term survival, prognostic marker, 281
- Squamous cell carcinoma, Chlamydia pneumoniae, head and neck neoplasms, 1207
- Squamous cell carcinoma, mitochondrial DNA deletion, tandem duplication, actinic keratosis, basal cell carcinoma, 1753
- Squamous cell carcinoma, tumor marker, CD26, TGF- β 1, p27kip, 619
- Squamous cell carcinoma, vulva cancer, sentinel lymph node, micrometastases, multilevel sectioning, 1281
- Squamous cell, genes, esophageal neoplasms, 1417
- Squamous, NSCLC, EGFR, EGFR-TKI, gefitinib, ZD1839, 393
- Src, glucose deprivation, oncogenes, ras, abl, bcr-abl, bcl-2, IL-3, apoptosis, 2503
- SS1(dsFv)PE38, peritoneal mesothelioma, mesothelin, immunotoxin, 1327
- Staging, endometrial cancer, pelvic lymphadenectomy, prognostic value, surgery, hysterectomy, 2073
- Starch microspheres, colorectal liver metastases, hepatic arterial infusion, interferon, 5-fluorouracil, 3275
- STAT 3, EGFR, head and neck squamous cell carcinoma, 3881
- STAT1, 2-methoxyestradiol, endometrium carcinoma cells, HEC-1-A, RL-95-2, cell cycle, apoptosis, necrosis, iNOS, caspases, 3983
- STAT3 transcription factor, pancreatic cancer, prevention, indole-3-carbinol, genistein, 133
- Stealth liposomes, PEG liposomes, 5-FU, locoregional chemotherapy, 1699
- Stem cell, p63, CK17, uterine cervix, reserve cell, HPV, 771
- Stem cells, cancer, gene therapy, delivery systems, 501
- Steroid hormone, apoptosis, DNA fragmentation, breast ductal carcinoma, tumor stroma, lymph node invasion, 53
- Stevens-Johnson syndrome, paclitaxel, anti-hypersensitivity prophylaxis failure, lung squamous cell carcinoma, 1135
- STI571 (Glivec®), breast cancer, cells, 1445
- STI571, malignant fibrous histiocytoma, tyrosine kinase, c-kit, platelet-derived growth factor receptor, 2675
- Stoichiometric factor, curcumin, cytotoxicity, ROS, inhibition rate constants, DPPH, PM3, 563
- Stoichiometric factor, estrogens, antiestrogens, inhibition rate constants, 3931
- Stomatitis, cancer chemotherapy, allopurinol-cryotherapy, LV/5-FU, 1131
- Stromal cells, prostate cancer, tumor-stromal cell interaction, antitumor drugs, fibroblast, 1561
- Structure-activity analysis, multidrug resistance, P-glycoprotein, multidrug resistance protein, breast cancer resistance protein, modulation, taxane, 409
- Structure-activity relationship, hexafluorotrihydroxyvitamin D3 derivatives, differentiation, hypercalcemic activity, log P, hydrophobicity, 683

- Structure-activity, α , β -unsaturated ketone, cytotoxic activity, oral tumor cells, 737
- Subcutaneous animal model, immunotherapy, bladder neoplasm, CpG-ODN, 2225
- Substance P, somatostatin, LFA-1, neuraminidase, 2331
- Succinyl-CoA transferase, gastric cancer, ketone body, monoacetoacetin, 2213
- Sulfatase, dydrogesterone, progestins, breast cancer cells, 17 β -hydroxysteroid dehydrogenase, 1433
- Sulindac, multiple drug resistance, MRP-1, MDR, resistance modulation, resistance circumvention, combination chemotherapy, NCI H460, 457
- SuPAR, ovarian cancer, prognostic factors, ELISA, 1981
- Surgery, early gastric cancer, endoscopic clipping, 4163
- Surgery, endometrial cancer, pelvic lymphadenectomy, staging, prognostic value, hysterectomy, 2073
- Survival signal transduction pathway, molecular target-based therapy, radiation, 811
- Survival, adrenal cortical carcinoma, recurrence, repeat surgical resection, 1901
- Survival, breast cancer, p53, Her2-neu, cathepsin D, 2061
- Survival, oesophageal carcinoma, predictive factors, 1915
- Survival, serum HER2, CA 15-3, breast cancer, prognosis, metastasis, 1987
- Survival, soft tissue sarcoma, tumor prognosis, CD44s, 1053
- T cell differentiation, mathematical modeling, lymphomagenesis, 1813
- T cell, ELISPOT, interferon- γ , dendritic cells, melanoma, 171
- T cells, CXCR6, protein expression, rectal cancer, macrophages, epithelial cells, 3711
- T84.66, radioimmunoguided surgery (RIGS), gastric carcinoma, carcinoembryonic antigen (CEA), F(ab')₂, Fab', 663
- Tamoxifen, breast cancer, MCF-7, MB-MDA-231, estrogen receptor (ER), estrogen, VEGF, 3961
- Tamoxifen, drug resistance, glioblastoma, glioma, 4195
- Tamoxifen, drug resistance, glioblastoma, glioma, 4205
- Tamoxifen, hepatocellular carcinoma, retinoic acid, RAR receptors, 1255
- Tandem duplication, mitochondrial DNA deletion, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, 1753
- Tandem repeat, 5-fluorouracil, chemosensitivity, thymidylate synthetase, dihydropyrimidine dehydrogenase, gastric cancer, 2455
- Targeted gene expression, EpCAM, promoter, HSV1-TK, GFP, 3715
- Targeted solid-lipid nanoparticle, hematoporphyrin, folate receptor, photodynamic therapy, 161
- Taurolidine, glioblastoma, apoptosis, 1143
- Taxane analogues, paclitaxel, head and neck squamous cell carcinoma, chemosensitivity, clonogenic assay, 3769
- Taxane, carboplatin, AUC, limited-sampling model, 1911
- Taxane, chemotherapy, docetaxel, second-line, non-small cell lung cancer, 1211
- Taxane, multidrug resistance, P-glycoprotein, multidrug resistance protein, breast cancer resistance protein, modulation, structure-activity analysis, 409
- Taxol, apoptosis, caspases, mitochondria, cytochrome c, leukemia, death receptors, 123
- Tea, xerostomia, EGCG, salivary gland, oral carcinomas, 3065
- Technetium Tc-99m-medronate, breast cancer, mammography, VEGF, 1999
- Telomerase activity, viral infection, apoptosis, polyomavirus, 791
- Temozolomide, CSF, CNS-lymphoma, 4121
- Tenascin-C, dysfunction, irradiation, salivary glands, 2841
- Testicular germ cell tumor, lung resistance-related protein, 1097
- Testicular metastasis, gastrointestinal cancer, occult cancer, 1093
- Tetrahydroisoquinolines, multidrug resistance, P-glycoprotein, 1631
- TGF- β , PS-K, IL-2, lymphocyte proliferation, IL-2R, 639
- TGF- α , Akt, EGFR, HER-2, NSCLC, immunohistochemistry, 11
- TGF- β , Smad6, Smad7, esophageal squamous cell carcinoma, immunohistochemistry, 3703
- TGF- β 1, CD105, Smad, endoglin, 1337
- TGF- β 1, tumor marker, squamous cell carcinoma, CD26, p27kip, 619
- TGF β 1, gossypol, DNA synthesis, cyclin D1, PC3, 91
- Therapeutic activity, adoptive immunotherapy, malignant brain tumor, 1861
- Therapeutic vaccine, HPV, deleted E7 protein, tumour, *Pichia pastoris*, 2265
- Thermal ablation, hepatocellular carcinoma, portal vein thrombosis, ethanol injection, radiofrequency, 2419
- Thermal ablation, tumour therapy, microtube, hot vaporized water, 2757
- Thermal neutrons, boron neutron capture therapy, sodium borocaptate-10B, 2-nitroimidazole, quiescent cell, γ -rays, 2975
- Thiamine, colorectal cancer risk, Ki-ras, diet, vitamin A, vitamin D, iron, 2011
- 1-b]Thiazole, imidazo[2, diimidazo[1, 2-a:1, 2-c]pyrimidine, guanylhydrazones, antitumor activity, 203
- Thorium, actinium, α -particles, osseous neoplasms, 101
- Thrombocytosis, platelet count, cervical carcinoma, endometrial carcinoma, ovarian cancer, 2053
- Thymic carcinoma, thymoma, thymoma classification, Ki-67 LI, 4113
- Thymidine phosphorylase, vascular endothelial growth factor, microvessel density, gastric carcinoma, 1853

- Thymidylate synthase, colorectal cancer, pharmacogenomic, microsatellite instability, polymorphism, molecular therapeutic, 3875
- Thymidylate synthetase, 5-fluorouracil, chemosensitivity, dihydropyrimidine dehydrogenase, tandem repeat, gastric cancer, 2455
- Thymoma classification, thymoma, thymic carcinoma, Ki-67 LI, 4113
- Thymoma, thymic carcinoma, thymoma classification, Ki-67 LI, 4113
- Thyroid cancer cells, clodronate, bisphosphonates, growth inhibition, calcium signaling, 1617
- Thyroid cancer, hypomethylation, 1495
- Thyroid cancer, thyroid nodule, thyroid scintigraphy, fine-needle aspiration cytology, FNAB, 2531
- Thyroid malignant lymphoma, PLK1, cell cycle, immunohistochemistry, 259
- Thyroid nodule, thyroid cancer, thyroid scintigraphy, fine-needle aspiration cytology, FNAB, 2531
- Thyroid scintigraphy, thyroid cancer, thyroid nodule, fine-needle aspiration cytology, FNAB, 2531
- TIMPs, MMPs, genistein, breast cancer, cell growth, invasion, 4025
- Tissue inhibitor of matrix metalloproteinase-1, colorectal carcinoma, plasma, prognostic value, 2101
- Tissue inhibitor of metalloproteinase, chondrosarcoma, matrix metalloproteinase, a disintegrin and metalloproteinase, immunohistochemistry, histological grade, 4079
- Tissue-specificity, tumor-specificity, transcription, tumor antigen, MHC class Ib, nonclassical histocompatibility antigen, 3379
- Titanium, anti-cancer drugs, arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, gallium, platinum, review, 1529
- TNF, cyclophosphamide, ONO-4007, IL-12, isolation perfusion, 1823
- Tocopherol, tocotrienol, hepatoma, apoptosis, 1683
- α -Tocopheryl succinate, α -tocopheryloxybutyrate, prostate cancer, apoptosis, Akt, 3795
- α -Tocopheryloxybutyrate, α -tocopheryl succinate, prostate cancer, apoptosis, Akt, 3795
- Tocotrienol, tocopherol, hepatoma, apoptosis, 1683
- Toll-like receptor, OK-432, immunotherapy, dendritic cell, review, 3295
- Tomudex, 5-fluorouracil, oxaliplatin, CPT-11, cDNA microarray, 417
- Tongue cancer, p21waf1/cip1, prognosis, 3225
- Tongue carcinoma, laminin-5 γ 2 chain, 3109
- Tongue, Kaposi's sarcoma, immunohistochemistry, 1897
- Tonsillar cancer, head and neck cancer, HPV, 1829
- Topoisomerase I, cisplatin, irinotecan, lung cancer, 3893
- Topoisomerase I, irinotecan, colon cancer, carboxylesterase, clinical response, 579
- Topoisomerase II, multidrug resistance, doxorubicin, drug encapsulation, gene expression, P-glycoprotein, breast cancer resistance protein, 3781
- Topoisomerase, irinotecan, small cell lung cancer, drug resistance, 3911
- Topotecan, DNA topoisomerase I, down-regulation, solid tumor cell lines, 1745
- Topotecan, ovarian cancer, 1267
- Trace elements, selenium, radiosensitivity, radiotherapy, 2913
- Transanal endoscopic microsurgery, rectal cancer, adjuvant therapy, 1167
- Transcription, CDK1, enhancer, cell cycle, proliferation, gene expression, 1469
- Transcription, regulation, Muc1, Yin Yang 1, 235
- Transcription, retinoids, HPV16, E7, inhibition, 807
- Transcription, tumor-specificity, tissue-specificity, tumor antigen, MHC class Ib, nonclassical histocompatibility antigen, 3379
- Transendothelial migration, breast cancer, MDA-MB-231, MDA-MB-435, SDF-1 α , CXCR4, chemotaxis, 4011
- Transfection, gene therapy, acoustic energy, 2303
- Transformation, resveratrol, cell signaling, chemoprevention, metastasis, invasion, tumorigenesis, apoptosis, review, 2783
- Transgene, cochleate, gene therapy, macrophage, tumour cell, 483
- Transitional cell carcinomas, urinary bladder, angiogenesis, real-time RT-PCR, vascular endothelial growth factor, angiopoietins-1 and -2, 2745
- Transitional cell carcinomas, urinary bladder, RT-PCR, mRNA, retinoblastoma gene, p16 gene, cyclin D-dependent kinase 4, LOH, lifestyle and occupational risk factors, 1011
- Trastuzumab, bone marrow metastases, metastatic breast cancer, 317
- Trastuzumab, breast neoplasms, HER-2/neu, serum, 1083
- Trastuzumab, extracellular domain, c-erbB2, breast cancer, 1127
- Triazinoindoles, 2-diazoindoles, antiproliferative activity, 3775
- Tropolones, Raw 264.7 cells, NO, iNOS, ESR, radical, 3917
- TS, breast cancer, folate, polymorphism, MTHFR, 3215
- Tubular adenoma, COX-2, gastric carcinoma, angiogenesis, apoptosis, 1439
- Tubulin polymerization, CA-4, 3, 4-diarylfuran-2-one, tumors, MTT assay, cell cycle, 179
- Tumor antigen, gemcitabine, mucin, 821
- Tumor antigen, tumor-specificity, tissue-specificity, transcription, MHC class Ib, nonclassical histocompatibility antigen, 3379
- Tumor antigens, immunotherapy, alpha 1, 3 galactosyltransferase, anti- α Gal antibodies, 605

- Tumor cell dissemination, breast cancer, HER2, p53, bcl-2, Ki-67, hormone receptor, 4211
- Tumor growth, GM-CSF, immunotherapy, 2717
- Tumor imaging, zinc, apoptosis, 3869
- Tumor marker, breast cancer, chemotherapy, HER2, predictive value, 1261
- Tumor marker, calretinin, calcium-binding proteins, EF-hand, mesothelioma, differential expression, alternative splicing, 4003
- Tumor marker, gastric cancer, hypermethylation, methylation-specific polymerase chain reaction, 2477
- Tumor marker, squamous cell carcinoma, CD26, TGF- β 1, p27kip, 619
- Tumor markers, CA 125, collagen metabolism, epithelial ovarian cancer, ICTP, prognosis, 1057
- Tumor markers, kallikreins, pancreatic cancer, colon cancer, serine proteases, cancer genes, SAGE, digital differential display, X-profiler, in-silico analysis, 43
- Tumor necrosis factor-alpha, endothelial monocyte activating polypeptide II (EMAP II), review, 2243
- Tumor prognosis, soft tissue sarcoma, survival, CD44s, 1053
- Tumor progression, adenomas, colon, 2033
- Tumor progression, colorectal cancer, HNPCC, 1765
- Tumor progression, glioma, central nervous system, brain imaging, 2359
- Tumor progression, nuclear factor-kB, colorectal carcinoma, electrophoretic mobility shift assay, 675
- Tumor stroma, apoptosis, DNA fragmentation, breast ductal carcinoma, lymph node invasion, steroid hormone, 53
- Tumor stroma, head and neck carcinoma, HNSCC, chemosensitivity testing, ex vivo culture, 325
- Tumor, histamine, histamine receptors, neuroblastoma, retinoic acid, 1657
- Tumor, lung, minimally invasive, radiofrequency ablation, complications, 339
- Tumor-antigen specific CTL, DCs, DC maturation, regulatory T cells, 3327
- Tumor-associated antigen, cancer gene therapy, viral vector, tumor-targeting, 3373
- Tumor-associated antigens, immune tolerance, immunotherapy, 2443
- Tumor-associated macrophage, endometrial cancer, 3335
- Tumor-specificity, tissue-specificity, transcription, tumor antigen, MHC class Ib, nonclassical histocompatibility antigen, 3379
- Tumor-stromal cell interaction, prostate cancer, stromal cells, antitumor drugs, fibroblast, 1561
- Tumor-targeting, cancer gene therapy, viral vector, tumor-associated antigen, 3373
- Tumorigenesis, chromosomal instability, aneuploidy, centriole, aurora A, review, 3269
- Tumorigenesis, resveratrol, cell signaling, chemoprevention, metastasis, transformation, invasion, apoptosis, review, 2783
- Tumors, CA-4, 3, 4-diarylfuran-2-one, tubulin polymerization, MTT assay, cell cycle, 179
- Tumour budding, cathepsin D, cathepsin B, colorectal cancer, 2847
- Tumour cell, cochleate, gene therapy, macrophage, transgene, 483
- Tumour cells, scavenger receptors, mannose receptors, monocytes, cytokines, 2287
- Tumour cellularity, renal diffusion-weighted MRI, renal tumours, MRI, 4175
- Tumour marker, colorectal cancer, 2353
- Tumour marker, β -defensin, lung cancer, immunohistochemistry, antimicrobial peptide, 4051
- Tumour perfusion, electroporation, hyperthermia, animal tumour model, 2343
- Tumour therapy, microtube, hot vaporized water, thermal ablation, 2757
- Tumour, HPV, deleted E7 protein, therapeutic vaccine, *Pichia pastoris*, 2265
- Twist, breast cancer, Wnt, 3851
- Tyrosine kinase, malignant fibrous histiocytoma, STI571, c-kit, platelet-derived growth factor receptor, 2675
- TZT-1027, breast cancer, nude mouse, vascular flow, 2201
- U937 nuclear Ca²⁺, MK 886, apoptosis, 2601
- UDP-glucuronosyltransferases, NSAIDs, anticarcinogens, chemoprevention, Wistar rat, 843
- UFT, leucovorin, oral chemotherapy, 625
- UFT, metastasis, imaging, GFP, 5-fluorouracil, 1353
- UFT, neoadjuvant chemotherapy, gastric cancer, randomized consent design trial, 1879
- UGT, CPT-11, SN-38, lung cancer, 2893
- Ulcerative colitis, ursodeoxycholic acid, inflammatory bowel diseases, Crohn's disease, dysplasia, DNA-aneuploidy, 3121
- Ultrasound irradiation, sparfloxacin, sarcoma 180 cell ultrastructure, 1553
- Undifferentiated high grade pleomorphic sarcoma, atypical fibroxanthoma, pleomorphic malignant fibrous histiocytoma, comparative genomic hybridization, 19
- α , β -Unsaturated ketone, cytotoxic activity, oral tumor cells, structure-activity, 737
- β -Unsaturated ketone, α , cytotoxic activity, oral tumor cells, structure-activity, 737
- Up-regulation, Id-1, gastric cancer, 881
- UPT, adenocarcinoma, prognostic factors, 297
- Urinary bladder carcinogenesis, FK228, histone deacetylase inhibitor, 785
- Urinary bladder, transitional cell carcinomas, angiogenesis, real-time RT-PCR, vascular endothelial growth factor, angiopoietins-1 and -2, 2745

- Urinary bladder, transitional cell carcinomas, RT-PCR, mRNA, retinoblastoma gene, p16 gene, cyclin D-dependent kinase 4, LOH, lifestyle and occupational risk factors, 1011
- Urothelial tumors, nephroureterectomy, 1921
- Ursodeoxycholic acid, inflammatory bowel diseases, ulcerative colitis, Crohn's disease, dysplasia, DNA-aneuploidy, 3121
- Uterine adenomyosis, hypocholesterolemic agent, probuticol, pituitary-grafted mice, 2209
- Uterine cervix, p63, CK17, stem cell, reserve cell, HPV, 771
- UV-vis irradiation, methotrexate, photodynamic therapy, photosensitisers, 2925
- Vaccine, dendritic cells, electrofusion, cancer, immunotherapy, 929
- Vanadium, anti-cancer drugs, arsenic, antimony, bismuth, gold, iron, rhodium, titanium, gallium, platinum, review, 1529
- Vascular endothelial growth factor (VEGF), angiogenesis, antisense, chemotherapy, head and neck cancer, 2179
- Vascular endothelial growth factor, angiogenesis, antisense oligodeoxynucleotides, receptor tyrosine kinase inhibitor, renal cell carcinoma, 213
- Vascular endothelial growth factor, angiogenesis, X-rays, heparin affini regulatory peptide, nitric oxide synthase, 2941
- Vascular endothelial growth factor, breast cancer, core needle biopsy, microvessel density, 371
- Vascular endothelial growth factor, interleukin-12, gastric cancer, 3289
- Vascular endothelial growth factor, menstrual cycle, 4237
- Vascular endothelial growth factor, thymidine phosphorylase, microvessel density, gastric carcinoma, 1853
- Vascular endothelial growth factor, urinary bladder, transitional cell carcinomas, angiogenesis, real-time RT-PCR, angiopoietins-1 and -2, 2745
- Vascular endothelial growth factor, VEGF, endothelium, angiosarcoma, retroperitoneal mass, HIF1, HIF2, hypoxia inducible factor, VHL, von Hippel-Lindau, 167
- Vascular flow, TZT-1027, breast cancer, nude mouse, 2201
- Vascularized fibula graft, acetabular osteosarcoma, pelvic reconstruction, irradiated osteoarticular graft, 1889
- VEGF, breast cancer, CD105, endoglin, angiogenesis, 1581
- VEGF, breast cancer, mammography, technetium Tc-99m-medronate, 1999
- VEGF, breast cancer, MCF-7, MB-MDA-231, estrogen receptor (ER), estrogen, tamoxifen, 3961
- VEGF, cyst fluid, ascites, ovarian carcinoma, 1149
- VEGF, melanoma, prognosis, 4255
- VEGF, neuropilin 1, glioma, Flt-1, KDR, prognosis, 547
- VEGF, ovarian cancer, 1973
- VEGF, p53, gene therapy, glioma, retrovirus, angiopoietins, 1
- VEGF, prostate cancer, angiogenesis, bFGF, c-met, progression, 1797
- VEGF, prostate, animal models, CWR22, androgen independent, angiogenesis, 2135
- VEGF, soft tissue sarcomas, HER-2/neu, c-Kit, 333
- VEGF, vascular endothelial growth factor, endothelium, angiosarcoma, retroperitoneal mass, HIF1, HIF2, hypoxia inducible factor, VHL, von Hippel-Lindau, 167
- VEGF, VEGA1155, angiogenesis, KDR/Flk-1, Flt-1, endothelial cell, 3009
- Vertebral compression fracture, metastases, interventional radiology, radiofrequency heat ablation, vertebroplasty, 3129
- Vertebroplasty, metastases, vertebral compression fracture, interventional radiology, radiofrequency heat ablation, 3129
- VGA1155, VEGF, angiogenesis, KDR/Flk-1, Flt-1, endothelial cell, 3009
- VHL, VEGF, vascular endothelial growth factor, endothelium, angiosarcoma, retroperitoneal mass, HIF1, HIF2, hypoxia inducible factor, von Hippel-Lindau, 167
- Vinorelbine, breast cancer, salvage chemotherapy, cyclophosphamide, 5-fluorouracil, leucovorin, 4217
- Vinorelbine, breast cancer, salvage chemotherapy, cyclophosphamide, 5-fluorouracil, leucovorin, 4223
- Vinorelbine, lung cancer, gemcitabine, 2985
- Vinorelbine, non-small cell lung cancer, cisplatin, 4227
- Viral infection, telomerase activity, apoptosis, polyomavirus, 791
- Viral reactivation, hepatitis B virus (HBV), doxorubicin, lamivudine, 3035
- Viral vector, cancer gene therapy, tumor-targeting, tumor-associated antigen, 3373
- Vitamin A, colorectal cancer risk, Ki-ras, diet, thiamine, vitamin D, iron, 2011
- Vitamin B2 (riboflavin), vitamin C, mitomycin C (MMC), γ -radiation, 4031
- Vitamin C, vitamin B2 (riboflavin), mitomycin C (MMC), γ -radiation, 4031
- Vitamin D, cancer, 1, 24(OH)2D2, antiproliferation, isobologram, 2905
- Vitamin D, colorectal cancer risk, Ki-ras, diet, vitamin A, thiamine, iron, 2011
- Vitamin D-binding protein, Gc protein, macrophage activating factor (MAF), Gc typing, carbohydrate processing, GalNAc, 3361
- Vitamins, cancer, microelements, oxidative stress, lipoperoxidation, free radical scavengers, 1449
- Von Hippel-Lindau, VEGF, vascular endothelial growth factor, endothelium, angiosarcoma, retroperitoneal mass, HIF1, HIF2, hypoxia inducible factor, VHL, 167

- Von Willebrand factor, prostatic neoplasms, angiogenesis, CD34, CD31, endothelial cells, endothelial marker, 1651
- Vulva cancer, squamous cell carcinoma, sentinel lymph node, micrometastases, multilevel sectioning, 1281
- VX2 carcinoma, lymph node metastasis, intravenous cisplatin therapy, animal model, 1785
- Western blot, appendix, carcinoid, catestatin, immunohistochemistry, 311
- Western blotting, Skp2, p27, esophageal squamous cell carcinoma, immunohistochemistry, 777
- Whey protein, cysteine, glutathione, prostate, breast cancer, oxidant, antioxidant, 553
- Wilms' tumor gene, WT1, esophageal cancer, esophageal dysplasia, 3103
- Wistar rat, UDP-glucuronosyltransferases, NSAIDs, anticarcinogens, chemoprevention, 843
- Wnt, twist, breast cancer, 3851
- WR-1065, mucositis, amifostine, cytoprotection, 3263
- WT1, Wilms' tumor gene, esophageal cancer, esophageal dysplasia, 3103
- X-profiler, Kallikreins, pancreatic cancer, colon cancer, serine proteases, cancer genes, SAGE, tumor markers, digital differential display, in-silico analysis, 43
- X-rays, angiogenesis, vascular endothelial growth factor, heparin affn regulatory peptide, nitric oxide synthase, 2941
- Xerostomia, tea, EGCG, salivary gland, oral carcinomas, 3065
- Yin Yang 1, transcription, regulation, Muc1, 235
- ZD0473, radiosensitization, cisplatin, human tumour cells, 613
- ZD1839, NSCLC, squamous, EGFR, EGFR-TKI, gefitinib, 393
- Zinc, apoptosis, tumor imaging, 3869

Authors Index

(Figures refer to page numbers)

- Aaltomaa S, 2407
 Aasebo U, 2515
 Abatzoglou I, 3239
 Abdelhaleem M, 3951
 Abe K, 4051
 Abe Y, 547
 Abeno S, 3103
 Abgrall JF, 2535
 Abiodun Elegbede J, 3089
 Abnet CC, 3245
 Aboukameel A, 2885
 Abreu PM, 859
 Acevedo-Nuño E, 1319
 Acs G, 167
 Addeo A, 2567
 Adlassnig C, 311
 Adunka O, 3881
 Affara NI, 2773
 Agelaki S, 4217
 Aggarwal BB, 2783
 Aggarwal RS, 2783
 Agnantis NJ, 1665, 3081
 Agnarsson BA, 2681
 Agostara B, 1139
 Agudo D, 1581
 Ahmed FE, 4127
 Ahmed Y, 3887
 Ahn BW, 747
 Ahn SG, 1671
 Aiba M, 671, 2385, 3851
 Aikou T, 2123
 Airoma G, 1873
 Akagi T, 691
 Akahani S, 4135
 Akahoshi T, 3135
 Akaike M, 2101
 Akamine S, 2541
 Akimoto T, 811
 Akisue T, 1307, 2007, 2675
 Akiya T, 2465
 Akiyama H, 377, 3169
 Akiyama M, 2705
 Akiyama S, 3731
 Akiyama Y, 571
 Akouaouach H, 2037
 Akrivakis C, 895
 Akyerli C, 2547
 Al Ghuzlan A, 3283
 Albert P, 935
 Alboni C, 2073
 Albrecht CA, 2141
 Alcover J, 4181
 Alexander EP, 1417
 Alexander J, 2595
 Alfo' M, 4045
 Alken P, 1651, 2303
 Allen J, 2997
 Almerico AM, 3775
 Alo PL, 4169
 Alonso DF, 1737
 Alrefai WA, 2601
 Al-Timimi A, 441
 Altomare DF, 3837
 Amadori S, 4045
 Amano O, 711
 Amato I, 1705
 Ambagtsheer G, 2295
 Ames IH, 2249
 Amini S, 2585
 Amirkhan RH, 2367
 Ammar K, 1779
 Anderson KM, 2601
 Andersson LC, 1427
 Ando K, 107
 Ando S, 1941
 Andratschke NH, 3803
 Andreani A, 203
 Androulakis N, 4217
 Angelucci C, 2729
 Anne P, 3161
 Anselmo AP, 4045
 Aoe K, 1135, 1525, 1905, 3893
 Aoki S, 2325
 Aoyama H, 2085
 Aozasa K, 3103
 Aozuka Y, 3009
 Appalla L, 441
 Aprile G, 2487
 Araki T, 2431
 Arany I, 807, 3997
 Arapadoni-Dadioti P, 1597
 Arason A, 2681
 Aravantinos G, 1947
 Arcaro KF, 139
 Ardizzoia A, 4223
 Ardyanto TD, 1439
 Arends J, 771
 Arihiro K, 1893
 Arimura Y, 4051
 Arnold N, 929
 Arnold RD, 397
 Aronen HJ, 2359
 Artym J, 3831
 Asaga T, 2085
 Ascaso C, 2011
 Ascierio PA, 4255
 Ashitani J-I, 4051
 Asimacopoulos P, 2061
 Aspenblad U, 3109
 Atomi Y, 4097
 Atsumi T, 563, 3019
 Auburn KJ, 2649
 Auer G, 3109
 Aurilio C, 4109
 Avgerinos A, 155
 Avnet S, 1705
 Avramis IA, 1121
 Avramis VI, 1121
 Baba S, 3135
 Babanaraki A, 3857
 Bäckstrom T, 873
 Badran A, 3355, 3373
 Bae JY, 3961
 Baer A, 19
 Baer MR, 409
 Bafaloukos D, 1947
 Baghi M, 3881
 Bähr M, 4121
 Bahra M, 3075
 Bai M, 3081
 Baibas N, 2027
 Bak M, 1097, 2219
 Bakos É, 449
 Balderas-Peña Luz Ma A, 1319
 Baldet P, 53
 Baldi A, 3157
 Baldini N, 1705
 Baldoni M, 1255
 Balkanli-Kaplan P, 2053
 Ballardelli A, 967
 Ballesta AM, 2011, 4181
 Balletta A, 3257
 Baltzer AWA, 2861
 Bamba K, 2423
 Banelli E, 1303
 Barana D, 2107
 Barkardottir RB, 2681
 Barna G, 1817
 Barnett B, 1361
 Barone C, 2567
 Barraja P, 3775
 Barrière G, 1387
 Bartel F, 3819
 Barth P, 2225
 Bartolini G, 1779
 Bartsch G, 1797
 Barzelloni ML, 1873
 Bascones A, 3225
 Basile G, 1449, 2257
 Bassi C, 2107
 Basso SMM, 3221
 Bastounis E, 3041
 Battistelli L, 1705
 Bauer JA, 2773
 Bazzocchi M, 2487
 Becker H, 1091
 Becker S, 4211
 Beckurts KTE, 4113
 Beer D, 553
 Begum FD, 1981
 Behrend M, 1901
 Beilby J, 3215
 Belenger J, 2757
 Benassi M, 967
 Bendardaf R, 2519
 Benes P, 2739
 Beniers AJ, 3057
 Benoit D, 2319
 Bentel J, 955
 Berard M, 4011
 Berger G, 1699, 3275
 Bergoc R, 2953
 Bergqvist M, 1915
 Bergström S, 1915
 Bernabeu C, 1337
 Bernacki RJ, 409
 Bernardeschi P, 2093
 Bernard-Gallon DJ, 321
 Bernardo G, 2419
 Berndt A, 2841
 Bernstein M, 75
 Beró A, 3997
 Berridge MV, 2503

- Berruti A, 2567
 Bertaccini A, 3955
 Bertelsen EL, 3749
 Bertetto O, 2567
 Berthou C, 2535
 Bessho A, 393
 Bethune-Volters A, 1083
 Beuth J, 303
 Bhardwaj A, 2783
 Bharti A, 1031
 Bibby MC, 907
 Biberfeld P, 1427, 2309
 Bignon Y-J, 321
 Bing G, 1759
 Binzoni T, 2757
 Biondi E, 1935
 Bisonni R, 3257
 Blaakaer J, 1981
 Blankenstein MA, 2511
 Bloigu R, 4247
 Blons H, 2021
 Boca M, 2729
 Boccardo F, 4019
 Bock JE, 1981
 Bocker Edmonston T, 3161
 Böcker W, 1721
 Bocsi J, 1817
 Bodrogi I, 1097, 2219
 Boehle AS, 827
 Boenicke L, 827
 Boese-Landgraf J, 3275
 Bogdanos J, 1957
 Bogner B, 3965
 Bohm L, 763
 Boiesen P, 371
 Bojar H, 2861
 Boletis J, 1311, 1597
 Bollen A, 2265
 Bölling T, 1637
 Boman B, 3161
 Bonavolontà G, 249
 Bonechi F, 2093
 Bonneau RH, 1003
 Bonnerot C, 171
 Bonnet J, 3781
 Bononi M, 265, 1495, 1921, 2439
 Boratynski J, 3991
 Borg Å, 2681
 Borgono CA, 43
 Borrini F, 1603
 Borsato S, 2531
 Borsellino N, 1139
 Bos AME, 345
 Bossert S, 3209
 Bossone G, 1287
 Böttcher B, 1727
 Botti C, 4169
 Bouchier-Hayes DJ, 483
 Bouillet P, 1249
 Boulikas T, 2193
 Bounous G, 553
 Bourquard P, 2535
 Boutonnat J, 725
 Bouton-Verville H, 2717
 Bovicelli A, 2073
 Bovicelli L, 2073
 Boyer J, 417
 Boyer PJ, 1003
 Bozkurt B, 2547
 Bramis J, 3041
 Brandes AA, 3221
 Brandi ML, 1705
 Brandt ME, 187
 Brasnu D, 2021
 Bratland Å, 555
 Brattström D, 1915
 Brauns SC, 1713
 Braunschweig T, 1791
 Bravo Cuellar A, 2689
 Bravo-Perez M, 3225
 Breier M, 1231
 Brem B, 495
 Bremnes RM, 2515
 Brenna A, 4169
 Brezeanu M, 2925
 Briasoulis E, 1665
 Brichard V, 171
 Brinck U, 981, 2237, 3203, 3819, 4191
 Brismar K, 1427
 Brock M, 1143
 Brodowicz T, 1127
 Broll R, 3789
 Brooks TA, 409
 Brozzetti S, 2439
 Bruch H-P, 3789
 Brückl V, 385
 Brückl WM, 385
 Bruland ØS, 101
 Bulet J-M, 2265
 Bu S, 873
 Buccheri G, 4227
 Buchegger F, 2757
 Buchweitz O, 151
 Buffoni L, 2567
 Bufo P, 249
 Buhr HJ, 1699, 3275
 Bui F, 2531
 Buja LM, 187, 1689, 1813
 Bujdoso L, 3997
 Bullerdiel J, 707, 3027
 Burgerhof JGM, 3263
 Burgin KE, 2717
 Burkholder S, 3161
 Burnstock G, 2853
 Burza A, 269, 3153
 Butler C, 3907
 Cabibi D, 3875
 Cagli B, 3157
 Cai Y-J, 999
 Cakalagaoglu F, 1999
 Calabria C, 1139
 Calascibetta A, 3875
 Calvert RC, 2853
 Calvo N, 1315
 Caly M, 3283
 Camacho E, 1239
 Cangemi V, 265, 269, 1495, 1921, 2439, 3153
 Cantonetti M, 4045
 Cantore M, 2093
 Cantore N, 317
 Cao Y, 67
 Cappelletti C, 3257
 Capucci S, 2729
 Carapella C, 2563
 Carbone M, 3097
 Carlier A, 935
 Carlini P, 1963, 2653
 Carlsson G, 2391
 Carlsson J, 4035
 Carney W, 1083
 Caroli F, 2563
 Carrera MP, 801
 Carstocea B, 2925
 Carter TH, 2649
 Caruso MG, 3837
 Caruso RA, 2257
 Casanovas JM, 1315
 Case LD, 3115
 Cassandro R, 3157
 Castellani D, 1255
 Castelli M, 791
 Castello G, 4255
 Casterad X, 2011
 Casula G, 1167
 Catalano M, 227
 Catrina SB, 1427
 Cattel L, 2041
 Cavaliere E, 4045
 Cavaliere EL, 117
 Cavallaro A, 265, 1495, 1921, 2439
 Cavallaro G, 269, 1921, 3153
 Cavallini G, 2107
 Ceccarini M, 2073
 Ceccaroni M, 2073
 Cecchin D, 2531
 Cedolini C, 2487
 Celio MR, 4003
 Cemazar M, 2343
 Cenni E, 1705
 Ceribelli A, 3147
 Ceroni M, 1507
 Cervantes-Munguia R, 2689
 Cetto GL, 2107
 Chaiwun B, 2391
 Chalabi N, 321
 Chambonniere ML, 1993
 Chan T-H, 943
 Chandhoke V, 441
 Chang H-L, 91
 Chang H-M, 1617
 Chang J-G, 1645
 Chaparro-Huerta V, 2689
 Chapman KA, 117
 Chapman RD, 3715
 Charara M, 3161
 Charasson V, 579
 Chavour S, 3115
 Chemler S, 3795
 Chen C-J, 3863
 Chen D, 2649
 Chen H-C, 1645
 Chen H-L, 3035
 Chen J, 1361
 Chen L-K, 4103
 Chen P-J, 3035
 Chen Shou-Tung, 1645
 Chen S-Y, 1501
 Chen Szu-Tah, 1617
 Chen W, 3245
 Chen WT-L, 1645
 Chen Xiaoxi, 2991
 Chen Xinqiu, 1973
 Chen Y-K, 4103
 Chen Y-S, 83
 Chen Z-W, 483
 Cheng A-L, 3035
 Cheng G, 4059

- Cheng L, 2135
 Chetrite GS, 1433
 Chi C-W, 1617
 Chiara S, 355
 Chieco P, 3955
 Chikamori M, 3893, 3911
 Chin K-F, 2353
 Chirala M, 2919
 Chiyo M, 3763
 Chloraki-Bobota A, 1957
 Chmara M, 4259
 Chobanian NH, 539
 Choi JK, 3049
 Chou M-C, 83
 Chou Y-C, 3863
 Christensen A, 441
 Christensen L, 1981
 Chu T-Y, 3863
 Chuang Y-C, 1587
 Chung J-G, 83, 1501, 1587, 1677, 1753
 Chung K-W, 3961
 Ciardi A, 1495
 Ciccarese M, 1287
 Cifone MG, 219
 Cirrincione G, 3775
 Clavere P, 1249
 Clawson GA, 1003
 Clerici C, 1255
 Clynes M, 425, 433, 457, 473
 Coca F, 4181
 Cocca C, 2953
 Cognetti F, 1093, 1287, 1963, 2563, 3147
 çolak T, 2547
 çolakoglu G, 2547
 Colantuoni G, 317, 1873
 Colella G, 1897
 Colleoni M, 1261
 Comincini S, 1507
 Coninx P, 1207
 Connolly L, 457
 Constantinou AI, 3049
 Cook AC, 2773
 Cooke RR, 2069
 Cook-Moreau J, 1387
 Cooper J, 441
 Cordon-Cardo C, 981, 3203
 Corona W, 1417
 Costa M, 2757
 Cova M, 4175
 Coy DH, 179
 Crawley S, 1281
 Crepin M, 4011
 Cricco G, 2953
 Cristante L, 4195
 Cronin D, 425, 473
 Crowe DL, 593
 Csejtey A, 807, 3965, 3997
 Csuka O, 1097
 Csuka O, 2219
 Cui N-J, 4059
 Cuny M, 53
 Curran W, 3161
 Curtis Bird R, 1469
 Cusimano MP, 1139
 Dabrowska K, 3991
 Daga H, 1911
 Dagnaes-Hansen F, 3735
 Dahlgren L, 1829
 Dahlstrand H, 1829
 D'Alessandro S, 851
 Dalianis T, 1829
 Dalpke A, 2225
 Daly C, 425
 Dam WA, 4237
 Danbara M, 3135
 Dandachi N, 2401
 Dane F, 1999
 Dannhardt G, 1545
 Darbinian N, 2585
 Dardanoni G, 3875
 Darvas Zs, 1657
 Darzynkiewicz Z, 1525
 Date H, 393
 Dattolo G, 3775
 Davey MW, 465
 Davey RA, 465
 Davis MA, 1393
 Dawsey SM, 3245
 De Angelis PM, 587
 De Boer BAG, 771
 De Braekeleer M, 2535
 De Capoa A, 1495
 De Cesare A, 265, 2439
 De Chiara G, 317
 De Filippis S, 1935
 De Gre Ve JLP, 2037
 De Joannon BC, 4169
 De Jong R, 2697
 De La Pena AS, 1417
 De Lorenzo MS, 1737
 De Luca A, 2985
 De Maio E, 2985
 De Ridder L, 2319
 De Rosa G, 249, 1063
 De Sanctis V, 1303, 4045
 De Simone M, 2041, 2093
 De Vos FYFL, 345
 De Vries EGE, 345
 De Witte PAM, 1631
 Decesare A, 1921
 Dechelotte PJ, 321
 Decoster L, 2037
 Dede F, 1999
 Degan P, 3811
 Deinnocentes P, 1469
 Del Giacco L, 441
 Del Vecchio I, 1507
 Delahunt B, 2069
 Delipetar-Grudl A, 1593
 Dell'Atti L, 1179
 Della Rovere F, 1449
 Dellas A, 361
 Delmonte D, 2419
 Delprino L, 2041
 Den Otter W, 2633
 Denes SL, 1249
 Denschlag D, 1267
 Dentico P, 2093
 Derežić D, 3251
 Desbordes C, 2765
 Desimone CP, 539
 Desoize B, 1529
 Devarajan P, 2193
 Devy J, 935, 1745
 Dhellin O, 171
 Di Cocco B, 1093, 1287
 Di Cosimo S, 1963
 Di Lella F, 3157
 Di Loreto C, 2487
 Di Lullo L, 1935
 Di Maio M, 2985
 Di Roma M, 4175
 Diallo R, 1637
 Diamandis EP, 43
 Diana P, 3775
 Dickinson D, 3065
 Dickson J, 1361
 Dienemann H, 1953
 Dietel M, 1223, 3233
 Dietz A, 325, 2947
 Dietze O, 2401
 Dimberg J, 3711
 Ding H, 1973
 Ding H-J, 4103
 Dinjens WNM, 1369
 Diodoro MG, 4169
 Dippon J, 1187
 Djakiew D, 2997
 Dobra K, 599
 Dockhorn-Dworniczak B, 1721
 Doglioni C, 4003
 Dohmen W, 1231
 Dohrmann P, 827
 Doi K, 785
 Doillon CJ, 2169
 Doleschall Z, 1097
 Dollner R, 325, 2947
 Domagala W, 963
 Domínguez-Rodríguez J, 2689
 Donato V, 349, 1303
 Dongiovanni D, 2567
 Dongiovanni V, 2567
 Donovan J, 441
 Dorn DC, 821
 Dornfeld K, 1393
 Dorval T, 171
 Double JA, 907
 Douet-Guilbert N, 2535
 Dougaz A, 3283
 Dowell JE, 2367
 Dreilich M, 1915
 Drescher FS, 1223
 Drevs J, 1759
 Dricu A, 1427
 Duan H, 3735
 Duchrow M, 3789
 Dudeja P, 2601
 Dudov A, 1293
 Duffy AM, 483
 Dumollard JM, 1993
 Dünne AA, 1785
 Dupuy D, 339
 Durdux M, 725
 Dusonchet L, 851
 Dutour A, 3977
 Dziadyk JM, 27
 Dziadziuszko R, 4259
 Eb F, 1207
 Ebert W, 1953, 3193, 4147
 Eble JN, 2135
 Eda R, 1135
 Eerola H, 2681
 Effert P, 1797, 3057
 Efferth T, 495
 Efird J, 2359

- Egawa K, 3303, 3321, 3327, 3379, 3387
 Egawa S, 3135
 Eggermont AMM, 2243, 2295
 Egilsson V, 2681
 Einarsson C, 3121
 Einarsson R, 1149
 Eisele S, 1759
 Eisenberger C, 1053
 El-Deeb A, 67
 Elgjo K, 587, 1465
 Elie C, 3283
 Elling D, 1223
 Ember A, 3997
 Ember I, 2557, 3965, 3997
 Ember IA, 807
 Emdin SO, 2375
 Emionite L, 4019
 Emons G, 1727
 Endo Y, 2047
 Endou H, 1671
 Endresen PC, 3749
 Ensinger C, 311, 1049
 Erben P, 2303
 Eriguchi M, 3303
 Erin N, 1003
 Ermani M, 3221
 Ernberg I, 2309, 4059
 Errico ME, 249
 Esaki K, 2665
 Escobar HM, 3027
 Escot C, 53
 Esposito V, 3157
 Esser N, 1759
 Esteban F, 3225
 Estep M, 441
 Estour B, 1993
 Eto H, 2573
 Everse LA, 2633

 Fabi A, 1093, 1287, 1963, 2563
 Fabiano V, 2257
 Facchetti A, 1507
 Fakler J, 1759
 Falconi M, 2107
 Falsetti SC, 943
 Faluhelyi Z, 807, 3965, 3997
 Falus A, 1657
 Familiari D, 1449
 Fan W, 27
 Faneyte IF, 2931

 Fang B, 3075
 Fang J-G, 999
 Faried A, 4091
 Farina A, 2073
 Farina HG, 1737
 Farinha NJ, 75
 Farley KM, 2231
 Faucher K, 1387
 Fayyazi A, 2141, 3819
 Fehm T, 1987, 4205, 4211
 Feiden W, 3971
 Feitelson AK, 795
 Feng H, 881
 Feng H-X, 4059
 Feng Y, 2991
 Feng Y-Z, 3843
 Feo S, 3875
 Ferbo U, 317
 Fernández Martínez JA, 3225
 Ferrara G, 249
 Ferraresi V, 3147
 Ferrari F, 1063
 Ferreira M-JU, 859
 Ferreri AM, 1779
 Ferretti A, 349
 Ferretti G, 1287, 1963
 Ferretti L, 1507
 Ferri M, 1167
 Ferrieres G, 53
 Ferrigno D, 4227
 Ferti AD, 155, 2967, 4141
 Fiano V, 2643
 Fichtner I, 907
 Ficorella C, 219
 Fiebig HH, 907
 Fiehn W, 4147
 Filella X, 4181
 Filipits M, 1201
 Fingert HJ, 1121
 Fiorentini G, 2093
 Fiorenza F, 3977
 Fiori E, 265, 269, 791, 1921, 2439, 3153
 Fiori R, 3129
 Fiorica JF, 1281
 Fiorillo A, 249
 Fiorucci S, 1255
 Fischer G, 3203, 4191
 Fischman AJ, 2359
 Fishel R, 3161
 Fissore C, 2567
 Fitzek M, 2359

 Fizazi K, 2897
 Flath B, 895
 Flati V, 219
 Flohr AM, 707
 Florentin L, 2547
 Flyvbjerg A, 3735
 Fodstad Ø, 555
 Fogt F, 1791
 Fontaine C, 2037
 Fornari D, 1733
 Fortney A, 441
 Fossile E, 3129
 Foster H, 333
 Fountzilias G, 1947
 Fouskakis D, 2061
 Fowles JR, 2069, 2551
 Franco R, 249
 Frangia K, 1947
 Frankfater A, 3887
 Frawley WH, 2367
 Fréneaux P, 3283
 Friedmann W, 1223
 Friedrich D, 1651
 Friend KE, 3735
 Fritz P, 1187
 Frödin J-E, 2375
 Frontini L, 4223
 Frosina G, 3811
 Fry R, 3161
 Fu H-H, 1489
 Fu S, 881
 Fu Xiaoli, 1159
 Fu Xin, 873, 3983
 Fuga L, 4031
 Fujii D, 1409
 Fujii N, 1525
 Fujimoto T, 1131
 Fujino H, 719
 Fujisawa S, 563, 3019, 3931
 Fujisawa T, 2185, 3763
 Fujita I, 1307, 2007, 2675
 Fujita S, 3103
 Fujita Y, 1113
 Fujitaka K, 1911
 Fujiwara Y, 1911
 Fujiwara Y, 2893, 3103
 Fujiyama J, 1113
 Fukai Y, 777, 3029, 4091
 Fukatsu T, 2431
 Fukuchi M, 777, 3029, 3703, 4091
 Fukuda K, 1113, 2495
 Fukuda T, 2465

 Fukushima S, 11, 785
 Fukushima T, 1045, 2047
 Fukuyama Y, 2465
 Fulden Yumuk P, 1999
 Fülöp F, 1631
 Furukawa Y, 2705
 Furusawa K, 619
 Fuselier JA, 179
 Füzési L, 2237

 Gaal D, 865
 Gabriel B, 921
 Gabriëlsson S, 171
 Gabriëljelic-Geiger D, 4147
 Gagnon E, 2169
 Galati G, 791, 1921
 Galla DAP, 219
 Gallia GL, 2585
 Gallkowski U, 3275
 Galmozzi F, 4019
 Galosi AB, 1179
 Galusca B, 1993
 Gamberi G, 967
 Gangl S, 2141
 Ganti AK, 333
 Gao H-Y, 4059
 Gao M, 3035
 Garaliene V, 203
 Garcíá MJ, 801
 Gardani G, 4223
 Gardiner E, 2353
 Gardner TA, 2135
 Garrett C, 441
 Gáspár R, 1631
 Gass JM, 539
 Gatti C, 2419
 Gautier T, 725
 Gaynon PS, 1121
 Gazdaru D, 2925
 Gazouli M, 1311, 1597
 Gebauer G, 1987, 4205
 Gebbia V, 1139
 Géczi L, 1097, 2219
 Geldof AA, 2337
 Gelibter A, 3147
 Genet D, 1249
 Genin P, 3283
 Gentile G, 2487
 Gentili G, 1255
 Genvresse I, 3233
 Georas S, 235
 Georgoulías V, 4217
 Geppert R, 895, 3233

- Gercel-Taylor C, 795
 Germain N, 1993
 Germer CT, 3275
 Geroldi A, 3811
 Gervasoni Jr JE, 2617
 Getoff N, 1593, 4031
 Ghimenti C, 2643
 Ghoneum M, 1455
 Giannarelli D, 1963
 Giannopoulos D, 2061
 Giaslakitotis K, 1597
 Gibson B, 483
 Giese A, 4195
 Gietema JA, 345
 Gikas E, 907
 Gil-Montoya JA, 3225
 Giordano C, 4227
 Giorgi G, 203
 Giovagnoli MR, 1111, 2439
 Giovannini C, 3955
 Giranda VL, 2697, 3899, 3907
 Gires O, 887, 3715
 Gitsch G, 921, 1267
 Giuliani A, 791
 Giuliano V, 1255
 Giunti A, 1705
 Glaser F, 2745
 Glenn DW, 339
 Gligoris T, 2941
 Glud E, 1981
 Glynn S, 473
 Gminski R, 631
 Godlewska J, 3991
 Goessler U, 2179
 Gogas H, 1947
 Göhl J, 385
 Gollapudi S, 1455
 Gomez DE, 1737
 Gómez-Contreras PC, 2689
 Gómez-Esquer F, 1581
 Gong J, 2991
 González-Moles MA, 3225
 González-Moles S, 3225
 González-Ojeda A, 1319
 Gorgoulis VG, 2061, 3041
 Görögh T, 929, 1025, 2161
 Gorreta F, 441
 Gorski A, 3991
 Goto S, 3303, 3379, 3387
 Götte K, 2179
 Gould Fogerite S, 483
 Gozza A, 355
 Gramantieri L, 3955
 Granaiola M, 203
 Granata A, 1449
 Granchi D, 1705
 Grant GM, 441
 Granzow C, 325, 2947
 Grappelli C, 1495
 Grassi M, 2985
 Grattarola M, 4019
 Graubard BI, 3177
 Grawé J, 3983
 Gray MA, 2069, 2551
 Graziano F, 3257
 Greco I, 249
 Greenberg VL, 539
 Greenman J, 2353
 Greger H, 495
 Grendys E, 1281
 Grenier J, 53
 Grenman R, 2627
 Grénman R, 3769
 Gridelli C, 317, 1873, 2985
 Griesinger C, 2141
 Grieu F, 3215
 Griffioen AW, 297
 Grigoryan RS, 1121
 Grimaudo M, 851
 Grobholz R, 1651
 Groeger AM, 3157
 Groen HJM, 2079, 3263
 Groshen SL, 2391
 Gruber I, 4211
 Gruenberger T, 1201
 Gründker C, 1727
 Grundmann R, 3209
 Grunwald D, 725
 Gruol DJ, 409
 Grybos M, 1149
 Gstöttner W, 3881
 Guadagni S, 2093
 Gücer F, 2053
 Guepratte S, 1083
 Guerra V, 3837
 Guerriero C, 1873
 Gulluoglu B, 1999
 Gumus M, 1999
 Günthert AR, 1727
 Guo B, 1337
 Gustavsson B, 2391
 Gutiérrez A, 2953
 Gutierrez R, 4181
 Guzińska-Ustymowicz K, 2847
 Gyémánt N, 865
 Gýnther K, 3027
 Haas M, 1
 Haasper C, 3789
 Habte T, 2153
 Hacene K, 1083
 Hachimine K, 3355, 3373
 Hachiya J, 4097
 Hagiwara A, 1113
 Hahn EG, 385
 Hahsimoto N, 1361
 Haisch CE, 605
 Hajto B, 2287
 Hakam A, 1281
 Hakim SG, 2841
 Hallez S, 2265
 Hamaguchi K, 2385
 Hamamoto Y, 4085
 Hamazaki S, 393
 Hambek M, 3881
 Hammons GJ, 133
 Hampl JA, 281
 Hampl M, 281
 Hamstra DA, 1393
 Han EK-H, 3899, 3907
 Han W, 3961
 Han Z, 999
 Handt S, 3057
 Hans S, 2021
 Hansen AB, 1733
 Happich K, 385
 Hara I, 2573
 Harada H, 1861
 Harada M, 1525, 3893
 Harashima K, 811
 Harbeck N, 4147
 Harder J, 1025
 Harlozińska A, 1149
 Harmey JH, 483
 Harms-Schirra B, 145
 Harnack U, 821
 Harrington JK, 2027
 Harris A, 2551
 Harris JE, 2601
 Harsh Iv G, 1
 Harvie RM, 465
 Haseba M, 111
 Hasegawa A, 2047
 Hasegawa K, 2465
 Hashiba K, 3917, 3939
 Hashiguchi N, 2201
 Hashimoto K, 655, 711, 737, 755, 1173, 1481, 1879, 3917, 3939
 Hashimoto M, 1131
 Hassan C, 1603
 Hassan R, 1327
 Hata K, 1519
 Hatakeyama Y, 2047
 Hatanaka H, 547
 Hatano H, 1039
 Hauke S, 707
 Hauser-Kronberger C, 2401
 Hauzenberger D, 599
 Hawk E, 3177
 Hayakawa K, 2097
 Hayashi K, 691
 Hayashizaki Y, 1113
 Haye S, 827
 Hebert BJ, 333
 Heeg K, 2225
 Heenan M, 425, 457
 Heeren PAM, 2579
 Hegele A, 2225
 Hegyes P, 865
 Hegyesi H, 1657
 Heiden T, 2309
 Heidenreich J, 1143
 Heikkilä P, 2681
 Heilmann V, 3209
 Heimann A, 3971
 Heimans JJ, 2337, 2511
 Heinderickx M, 2265
 Heinecke A, 1053
 Heiser A, 929
 Heitz PU, 19, 2415
 Helbig M, 2947
 Heldin N-E, 3983
 Hellstrand K, 1837
 Hellwig D, 3971
 Helmberger T, 339
 Helmerhorst TJM, 771
 Helmke BM, 325
 Hendriks HR, 907
 Henke C, 1011
 Henness S, 465
 Henriksen G, 101
 Henschke P, 895
 Heouaine A, 355
 Herb KP, 3193
 Hernández-Flores G, 2689
 Herrmann PC, 1791
 Herry A, 2535

- Herve M-A, 4011
Hesselmann S, 1637
Hevér A, 865
Hibi K, 3731
Hibi T, 3723
Hidaka S, 111, 1925, 2541
Higami T, 1173, 1879
Higashimoto M, 1045
Hihara J, 1409
Hikino H, 1609
Hill AD, 473
Hillen HFP, 297
Hilpert F, 929
Hiltbrand E, 2757
Hindenburg AA, 2617
Hino M, 3311
Hioki T, 2431
Hirabayashi N, 1843
Hirai K, 4163
Hirakawa K, 2213
Hiraki A, 1135, 1525, 1905
Hirano A, 3851
Hiraoka M, 2975
Hirata K, 11, 3239
Hirayama N, 3009
Hirokawa Y, 2431
Hirota T, 3185
Hirsch R, 1239
Hirschberg K, 1657
Hisamitsu K, 2495
Hisanaga M, 1569
Hisatsune A, 235
Hitora T, 1307, 2007, 2675
Hjalmarsen A, 2515
Hoekstra HJ, 291
Hoelscher AH, 4113
Hoffman RM, 1353, 3699, 4067
Hofmann R, 2225
Høgdall CK, 1981
Høgdall EVS, 1981
Högmo A, 3109
Hohenberger W, 385
Hokita S, 2123
Hollema H, 2579
Hollington P, 955
Holmberg AR, 1347
Holmes LM, 2717
Hong HK, 663
Honjo S, 1439
Honma K, 1039
Hori H, 2975, 3311, 3361
Horig K, 1267
Horiguchi-Yamada J, 2705
Hörmann K, 2179
Horn T, 1733
Horny H-P, 151
Horvat R, 1127
Hosch S, 1053
Hosen N, 3103
Hospers GAP, 1217, 1969, 3263, 4237
Hotta T, 1039
Hou D-X, 2657
Houllier A-M, 2021
Hour M-J, 1769
Høyer-Hansen G, 1981
Hsia T-C, 1587
Hsiao M, 1
Hsiao Y-M, 83
Hsu C-H, 3035
Hsu H-C, 3035
Hsu S, 3065
Hu B, 4059
Hu F-L, 4103
Hu G, 1159
Hu J, 2991
Hu L-F, 2309, 4059
Huang D, 1553
Huang H-B, 3863
Huang L-J, 1677, 1769
Huet S, 3781
Hung T-Z, 4103
Hurtuk MG, 3097
Husoy T, 587
Hwang YS, 747
Hyun SW, 235
Iacoangeli A, 791
Iacopetta B, 3215
Iacopino F, 2729
Iakovou K, 907
Iannotti M, 4109
Ibuki Y, 3869
Ichikawa D, 2477
Ichikawa T, 2431
Ide H, 2385
Ieni A, 2257
Ientile R, 1449
Iida T, 1941
Iijima T, 2471
Iizasa T, 3763
Iizuka N, 4085
Ikawa N, 1105
Ikeba A, 3103
Ikeda D, 1561
Ikeda N, 1569
Ikeda T, 2085
Ikeguchi M, 273
Ikemoto S, 733
Ikeya H, 3009
Ikoma D, 2477
Ikoma H, 2477
Imada T, 2101
Imai A, 3141
Imakiire A, 1519
Imam SA, 2391
Imamura H, 3851
Imarisio S, 2643
Imawari M, 699
Imperatori L, 3257
Inagawa H, 1823, 3311, 3335
Inaji H, 1275
Inferrera C, 2257
Inohara H, 4135
Inoue K, 11
Inoue M, 3335
Inoue N, 1045, 2047
Inoue T, 3141, 4135
Inoue Y, 3239
Ioannovich J, 1947
Ip C, 1401, 3795
Irjala KA, 1271
Ishibashi K, 1131
Ishigami S, 2123
Ishiguro K, 649
Ishihara M, 563, 683, 1481, 3019
Ishii H, 3723
Ishii K, 2665
Ishikawa E, 1861
Ishikawa H, 811
Ishikawa K, 625
Ishikura H, 719
Ishizuka M, 1561
Isobe K, 2483
Isobe T, 1911, 2893
Isogai M, 3387
Isohashi F, 4135
Isshiki S, 2723
Itabashi M, 3185
Itakura M, 1879
Ito H, 1439, 2483
Ito K, 3103, 3731
Ito S, 3019
Ito Y, 259
Itoh H, 3239
Itoi E, 1553
Itokawa T, 3009
Iversen J-GH, 1465
Iwase H, 2085
Iwase S, 2705
Izbicki JR, 1421
Izzo L, 791, 3153
Jacob AL, 339
Jacob D, 3075
Jacob S, 4121
Jacobs S, 2237
Jacquet A, 2265
Jäger C, 3209
Jäger W, 1987, 4205
Jahanzeb M, 1239
Jakesz R, 1127, 1201
Jakse G, 3057
Jakubchak S, 2717
James NS, 3795
Jamison C, 441
Janciauskiene S, 241
Janisch W, 1143
Janke K, 1637
Jánosi J, 1817
Jansen RLH, 297
Janssen D, 1025
Jassem E, 4259
Jassem J, 4259
Jeanteur P, 53
Jeng Y-L, 3863
Jeong K-S, 2331
Jeong M, 747
Jepsen JV, 1733
Jewell A, 2349
Jiang J, 91
Jiang P, 4067
Jin G, 691
Jin Z, 691
Jobo T, 2185
Johannesdottir G, 2681
Johannsdottir HK, 2681
Johannsson OT, 2681
Johansson B, 2627
Johansson H, 1261
Johnston PG, 417
Jomgeow T, 3103
Jönsson P-E, 371
Jorde R, 2515
Jose Lafuente M, 2011
Juan D, 1
Jukkola A, 4247
Jung W, 4121
Jung YD, 747
Jüngert B, 385

- Ka IH, 663
 Kabelitz D, 929
 Kachel M, 145
 Kadoma Y, 563, 3019, 3931
 Kafka A, 3209
 Kahle L, 3177
 Kai T, 1609
 Kaibara N, 273, 1439, 1853, 2495
 Kaibori M, 1929
 Kailajärvi MEH, 1271
 Kaiser HE, 1281
 Kakudo K, 259
 Kalala J-P, 2319
 Kalariti N, 3923
 Kalbakis K, 4217
 Kaletta C, 3977
 Kalionis B, 955
 Kalofonos HP, 1947
 Kalthoff H, 827
 Kamata Y, 2185
 Kamatani T, 3065
 Kamei T, 3335
 Kamijo A, 625
 Kamina S, 3081
 Kamiyama Y, 1929
 Kamp S, 2869
 Kanai Y, 1671
 Kanato K, 3103
 Kanavaros P, 3081
 Kanaya I, 3295
 Kanazawa H, 11
 Kanda K, 2085
 Kandioler D, 1201
 Kanehiro H, 1569
 Kaneko T, 3303
 Kanetake H, 3757
 Kano Y, 2705
 Kanoh Y, 3135
 Kansara M, 2503
 Kanzaki A, 1045
 Kanzaki M, 1609
 Kao C, 2135
 Kao C-H, 4103
 Kaplan H, 935
 Karakaya AE, 2547
 Karaman M, 1999
 Karamanakos P, 1077
 Karamanolakis D, 1957
 Karamanos NK, 1445, 4025
 Karasawa K, 2097
 Karavasilis B, 1665
 Karayiannakis AJ, 1243, 2027
 Kardamakis D, 2941
 Kareem S, 3115
 Kargas S, 333
 Kärjä V, 2407
 Karkera DJ, 1417
 Karner KB, 2343
 Karreman C, 2861
 Karrenbeld A, 1217
 Kasacka I, 2847
 Kase S, 1439
 Kashima H, 3843
 Kasi D, 3795
 Kásler M, 1097, 2219
 Kasono K, 1609
 Kaštelan M, 3251
 Kaštelan M, 3251
 Katada N, 4163
 Katano M, 675, 1071
 Käthe N, 2745
 Katirtzoglou N, 1243, 2027
 Kato H, 777, 3029, 3703, 4091
 Kato N, 2185
 Kato Y, 3185
 Katoh M, 1421
 Katoh R, 1045
 Katoh T, 2431
 Katšube T, 2385
 Katsuki T, 3239
 Kaufmann O, 1797, 3233
 Kauppila A, 1057
 Kavanagh K, 405
 Kawabuchi Y, 639, 1193
 Kawada M, 1561
 Kawai H, 4073
 Kawakami H, 2483
 Kawakami K, 649
 Kawakami M, 1609, 3103
 Kawamoto T, 1307, 2007, 2675
 Kawamura K, 1553
 Kawano T, 2705
 Kawase M, 711, 737, 755
 Kawashima I, 571
 Kawata T, 2483
 Kazi A, 943
 Kee ST, 339
 Keenan J, 433
 Keil F, 2053
 Kelland LR, 907
 Kelley MR, 2127
 Kempfski O, 3971
 Kennedy DN, 2359
 Kennedy DR, 409
 Kennedy SM, 473
 Khalili K, 2585
 Khan E, 1031
 Khwaja F, 2997
 Kiamouris C, 1445
 Kierschke T, 1187
 Kiessig ST, 865
 Kievit E, 1393
 Kijima H, 547
 Kikuchi H, 711, 737, 755, 1481
 Kikuchi S, 4163
 Kim DK, 1671
 Kim HC, 663
 Kim H-J, 2331
 Kim HS, 747
 Kim J, 2897
 Kim JC, 663
 Kim JS, 663
 Kim KC, 235
 Kim KP, 1805
 Kim MH, 747
 Kim Seok Won, 3961
 Kim S-H, 2331
 Kim S-R, 2331
 Kim Sung-Won, 3961
 Kim T-H, 2331
 Kimura H, 1941
 Kimura M, 2085
 Kimura T, 11
 Kin S, 1113
 Kinashi Y, 2975
 King J, 339
 Kinoshita A, 785
 Kinoshita J, 3851
 Kinugasa T, 3355, 3373
 Királyfalvi L, 2557
 Kirsch C-M, 3971
 Kiss I, 3965
 Kissel C, 1267
 Kitagawa T, 3185
 Kitajima M, 2201, 2455, 2723
 Kitamura K, 2477
 Kitayama A, 2423
 Kitsoulis P, 3081
 Kittas C, 3041
 Kitze B, 4121
 Kiura K, 393, 1525, 3893, 3911
 Kjaer SK, 1981
 Klare P, 1223
 Klein-Vehne A, 145
 Kletsas D, 1445
 Klijanienko J, 3283
 Klominek J, 599, 1625
 Kloppenberg FWH, 2579
 Knecht R, 3881
 Knoefel WT, 1053
 Knoll T, 1651, 2303
 Knox S, 333
 Knutsen HK, 587
 Knutson JC, 2905
 Ko S, 1569
 Kobayashi H, 1039, 2483
 Kobayashi M, 2201, 2325
 Kobayashi N, 4163
 Kobierska G, 4259
 Kocabas NA, 2547
 Koch M, 333
 Koch R, 281
 Kodali U, 2885
 Kodera Y, 3731
 Koga T, 2085
 Koh J-I, 2201
 Kohara H, 3893
 Kohchi C, 1823, 3311, 3335
 Kohn EC, 2869
 Kohno N, 1911, 2893
 Koike H, 2477
 Koike K, 3335
 Koike M, 1879
 Koizumi M, 3141
 Koizumi W, 2465
 Kojima M, 675
 Kojima Y, 2465
 Koletsky A, 1239
 Kolialexi A, 3945
 Koliou G, 833
 Kolk A, 3743
 Kolkmeier A, 1637
 Komdeur R, 291
 Komminoth P, 19, 2415
 Komori C, 1553
 Kondo A, 1853
 Kondo K, 719
 Könemann S, 1637
 Kong D, 2325
 König F, 981
 Konishi F, 1609
 Konishi I, 2495, 3843
 Konno S, 2385, 3851
 Konstantopoulou I, 2547
 Kontogianni E, 2547
 Kontos M, 1077

- Koo KH, 663
 Koopmans P, 3263
 Kopper L, 1817
 Kopun M, 2947
 Korabiowska M, 981, 1011, 2745, 3203, 3819, 4191
 Körholz D, 145
 Korkolis DP, 2061, 3041
 Korman LY, 1417
 Kos J, 4147
 Kosma V-M, 2407
 Kosmehl H, 2841
 Kostakis A, 1311, 1597
 Kostler WJ, 1127
 Kotsaki E, 2941
 Kotsinas A, 3041
 Kotzsch M, 4147
 Koukourakis IM, 3239
 Koullias GJ, 2061
 Kourai H, 3343, 3367
 Kouretas D, 743
 Kouris S, 743
 Kouroumalis E, 833
 Kouroussis C, 4217
 Kourvetaris A, 2193
 Kousidou OCH, 4025
 Koutsilieris M, 1077, 1957, 2169, 2443, 3923
 Kovács P, 1657
 Kowalski P, 2231
 Koyama T, 1519
 Koyama Y, 1045, 2047
 Kozuki T, 393
 Kraemer S, 4205
 Kragl M, 4031
 Krainer M, 1127
 Kramer B, 4211
 Krämer S, 1987
 Krause-Elsmore S, 483
 Kreienberg R, 3209
 Krieg RC, 1791
 Kristel PMP, 2931
 Kronish L, 1239
 Krueger GRF, 187, 1689, 1813
 Krüger C, 929
 Kruglyak E, 1239
 Kruzal ML, 3831
 Kubo M, 1071
 Kubo S, 3361
 Kubo T, 1889, 1893, 4135
 Kubota T, 2201, 2209, 2455, 2723
 Kucuk O, 2885
 Kudoh S, 11
 Kühn W, 1223
 Kulle B, 2237
 Kulmala J, 3769
 Kulp SK, 91
 Kulpa J, 1149
 Kuma K, 259
 Kumagai H, 1561
 Kumai K, 2201, 2455, 2723
 Kumar N, 943
 Kumar P, 1337
 Kumar S, 1337
 Kunisaki C, 377, 3169
 Kunze E, 1011, 2745
 Kuo H-M, 1587
 Kuo S-C, 1677, 1769
 Kurai M, 3843
 Kuramoto H, 2185
 Kurata T, 1911
 Kuratukuri K, 733
 Kurdow R, 827
 Kurek R, 4205, 4211
 Kurihara M, 2465
 Kurihara T, 3917, 3939
 Kuriyama T, 2713
 Kuroiwa Y, 2423
 Kuroki Masahide, 3373, 3355
 Kuroki Motomu, 3373, 3355
 Kuropkat C, 1785
 Kurosaka M, 1307, 2007, 2675
 Kuroyama S, 4163
 Kusano M, 2471
 Kusayanagi S, 699
 Kushima Y, 3303
 Kusić Z, 3251
 Kusumanto YH, 4237
 Kuwada E, 3379, 3387
 Kuwano H, 777, 3029, 3703, 4091
 Kvarda A, 3997
 Kwon A-H, 1929
 Kyprianou N, 1377
 La Rocca A, 1449
 Labourey JL, 1249
 Labroquere M, 1083
 Labrousse F, 1249
 Lacchini M, 3955
 Laccourreye O, 2021
 Laengle F, 1201
 Lafontaine JS, 53
 Lafuente A, 2011
 Lage H, 865, 2231
 Lagergren J, 2113
 Lah TT, 4147
 Lai HC, 2277
 Lai WS, 2367
 Laici G, 3257
 Lalli A, 1935
 Lama G, 2729
 Lamazza A, 265, 269, 3153
 Lamlum H, 2519
 Lancia JK, 1401
 Landström M, 873
 Lans TE, 2243
 Lanza A, 227
 Laplanche J-L, 1507
 Lappi J, 2407
 Larkin A, 457, 473
 Laroche-Clary A, 579, 3781
 Larrue A, 3781
 Larsen RH, 101
 Larsson L, 2391
 Lasagni RP, 4169
 Laso N, 2011
 László V, 1657
 Laudani A, 1139
 Laudisi A, 3129
 Lauer I, 2841
 Laurand A, 3781
 Laurent-Puig P, 2021
 Lauria A, 3775
 Lawrence TS, 1393
 Lázár L, 1631
 Le Bris M-J, 2535
 Le Charpentier T, 2535
 Le Corre L, 321
 Le Naour R, 935
 Lea MA, 2765
 Lebeda O, 4035
 Lebon T, 2657
 Lechertier T, 4011
 Lee C-H, 1617
 Lee H-C, 1753
 Lee IJ, 235
 Lee JE, 3961
 Lee KH, 663
 Lee M-R, 1769
 Lee RJ, 161, 3005
 Lee T-K, 1617
 Lefebvre J-F, 1207
 Lehmacher W, 1293
 Leino AE, 1271
 Lemaire M, 75
 Lembessis P, 1077, 3923
 Lencioni R, 339
 Lennartsson L, 1347
 Leonardi E, 4255
 Leonardi R, 1063
 Leonardi V, 1139
 Leoni A, 203
 Lerma-Díaz JM, 2689
 Lesnicar H, 2343
 Levi E, 2885
 Lewis J, 3065
 Li C, 1337
 Li J, 2717
 Li JJ, 67, 2657
 Li L, 873, 1973, 3983
 Li LF, 613
 Li Qian, 1327
 Li Qiaoxia, 79
 Li QQ, 1973, 2991
 Li X, 1973
 Li Y-H, 4059
 Lian JP, 133
 Liang Y, 433
 Liao CA, 4103
 Liautaud-Roger F, 1207
 Lichtenegger W, 1223
 Liebau C, 2861
 Lieder A, 973
 Liljefors ML, 2375
 Lim SH, 747
 Limon J, 4259
 Lin HS, 303
 Lin J-D, 1617
 Lin Shuw-Yun, 1501, 1587
 Lin Shyr-Yi, 1645
 Lin W-C, 1677
 Lin W-Y, 3863
 Lin YC, 91
 Lindblom A, 1765
 Lindholm J, 3109
 Lindner H, 2869
 Lindner N, 1721
 Lindner P, 1837
 Lindquist D, 1829
 Linehan R, 473
 Link K, 385
 Lionetto R, 355
 Liontas A, 987
 Lippe P, 3257
 Lipponen P, 2407
 Lissoni P, 4223

- Liu B, 1417
 Liu D, 1337
 Liu F, 1159
 Liu L, 2919
 Liu S, 91
 Liu X, 2697
 Liu Y-X, 691
 Liu Zhaoxu, 1347
 Liu Zhiwen, 599, 1625
 Liu Z-L, 999
 Lo Muzio L, 249, 1063
 Locatelli A, 203
 Locke VL, 465
 Lockwood P, 3065
 Loddenkemper C, 1143
 Loddenkemper R, 1211
 Löfberg R, 3121
 Logothetis CJ, 2897
 Lohmann F, 4195
 Lombardi G, 4169
 Londero V, 2487
 Longley DB, 417
 Loriot M-A, 2021
 Lu H-F, 1501, 1587
 Lu K-H, 83
 Lu N, 3245
 Lu R, 483
 Lucandri G, 1167
 Ludwig C, 1201
 Lue K-H, 83
 Luebke T, 4113
 Lüftner D, 895, 3233
 Lukač J, 3251
 Lukas JC, 1311
 Lüleci G, 2547
 Lumachi F, 2531, 3221
 Lundqvist H, 4035
 Lundstedt S, 2407
 Luo M, 2127
 Luo X-M, 3245
 Luo Y, 2697, 3899, 3907
 Luther T, 4147
 Lyn-Cook BD, 133

 Ma PC, 1031
 Ma Q, 2193
 Ma W, 1361
 Macdonald JR, 59
 Mack B, 887
 Mackenzie PI, 2893
 Macura-Biegun A, 2287
 Madoulet C, 935
 Madureira AM, 859

 Maeda K, 649
 Maeda T, 1135, 1525, 1905
 Maeta Y, 1853
 Magagnoli Giorgia, 967
 Magagnoli Giovanna, 967
 Magdolen V, 4147
 Magrassi L, 1507
 Mahata SK, 311
 Maiello MR, 2985
 Maione P, 1873
 Majed H, 1957
 Majumdar APN, 2885
 Makino K, 3311
 Makino M, 273
 Makrydimas G, 1665
 Makuuchi H, 625
 Malas K, 4217
 Malath J, 1637
 Malianga E, 3857
 Malik E, 151
 Malkhosyan SR, 199
 Mallery SR, 2773
 Malone S, 613
 Manavis J, 3239
 Mancino M, 2985
 Manda R, 3029, 4091
 Mandai K, 3185
 Mandic R, 973
 Mándoky L, 1097, 2219
 Manenti G, 4175
 Manguoglu E, 2547
 Mannino RJ, 483
 Männlein G, 385
 Manno P, 2107
 Mansmann U, 303, 3275
 Mansueto G, 249
 Mansutti M, 2487
 Mantovani B, 1779
 Mantovani G, 1935
 Marandino F, 1093
 Marangi GF, 3157
 Marcelo AB, 1417
 Marchenko GN, 199
 Marchetti P, 219
 Marciniak D, 2885
 Margreiter R, 311, 1049
 Marksteiner J, 311
 Marmé D, 1759, 2353
 Martens F, 2511
 Martens JE, 771
 Martín G, 2953
 Martin J, 1249
 Martinez LA, 2897

 Martinez M, 1239
 Martínez-Arribas F, 1581
 Martínez-Martos JM, 801
 Martini ME, 1603
 Martorana A, 3875
 Martorana G, 3955
 Maruhashi A, 2975
 Marui T, 1307, 2007, 2675
 Maruyama I, 2123
 Maruyama K, 571
 Maruyama R, 1173, 1879
 Marzola MC, 2531
 Mas S, 2011
 Masaki T, 4097
 Masala S, 3129
 Masaoka T, 3723
 Mashiko M, 2047
 Mashiko T, 3135
 Masiuk M, 963
 Massa E, 1935
 Massacesi C, 3257
 Massari F, 3129
 Mastubara H, 2483
 Masuda C, 785
 Masuda K, 1525
 Masuda N, 777, 3029, 4091
 Masuda T, 1561
 Masunaga S-I, 2975
 Masztalerz A, 2633
 Mathieu NT, 1249
 Matsuda E, 1905
 Matsuda G, 377, 3169
 Matsui K, 2325
 Matsui Y, 1929
 Matsumoto K, 1307, 2007, 3239
 Matsumoto M, 2123
 Matsuo M, 3757
 Matsuoka H, 4097
 Matsuura K, 11
 Matsuura N, 259
 Matsuzuka F, 259
 Mattern J, 4243
 Matthes H, 303
 Mattioli R, 3257
 Mattsson J, 1837
 Maudoux F, 2265
 Maulik G, 1031
 Maune S, 929, 1025
 Maurizi Enrici R, 349, 1303, 4045
 Mauz-Körholz C, 145
 Mavrou A, 3945

 Maxwell PJ, 417
 May A, 3881
 Mayas MD, 801
 Mazurchuk R, 397
 McDermott EW, 473
 McDonnell S, 489
 Mcgonigal T, 3899
 Medina V, 2953
 Medinger M, 1759
 Mehier H, 2757
 Mehta RG, 3049
 Mehta S, 2617
 Meijer C, 4237
 Meli M, 851
 Melkko J, 4247
 Mellstedt HT, 2375
 Mendoza J, 1327
 Meng X, 881
 Mengs U, 1231, 1293
 Menichetti ET, 3257
 Mercer TI, 1401
 Merk H, 2861
 Merkel S, 385
 Merol J-C, 1207
 Messa C, 3837
 Messina F, 1303
 Messineo D, 1303
 Metaxa-Mariatou V, 1597
 Metzger E, 921
 Meucci F, 2093
 Meucci M, 2439, 3153
 Meyer A, 1901
 Meyer B, 707
 Meyer JE, 929, 1025
 Meyermann R, 37
 Mezza E, 249
 Miano R, 4175
 Mibu R, 675
 Michaelis U, 3977
 Michel MS, 1651, 2303
 Michie J, 763
 Micke O, 2913
 Mignogna MD, 1063
 Mihályi A, 1631
 Mihatsch MJ, 361
 Mihic-Probst D, 19, 2415
 Mihm MJ, 2773
 Mikami T, 4163
 Mikhailidis DP, 2853
 Milathianakis K, 1957
 Mildenerger S, 921
 Milella M, 3147
 Milla L, 1315

- Milla-Santos A, 1315
 Milne P, 1713
 Milz S, 3743
 Minagawa K, 1481
 Minami K, 639, 1193
 Minamiguchi K, 1561
 Minardi D, 1179
 Mingazzini P, 1603
 Minisini AM, 2487
 Minna JD, 2367
 Mirri A, 2563
 Mishra J, 2193
 Mitamura K, 699
 Mitchell E, 3161
 Mitomi H, 4163
 Mitropoulou TN, 1445
 Mitsiades CS, 1077
 Mitsuhashi M, 785
 Mitsuhashi N, 811, 3141
 Mitsuyama S, 2085
 Miyagawa K, 1113
 Miyaguchi T, 3757
 Miyake H, 2573
 Miyaki M, 2471
 Miyamoto T, 3843
 Miyamoto Y, 3303
 Miyauchi A, 259
 Miyazaki M, 1911, 2893
 Miyazaki T, 777, 3029, 4091
 Miyazono F, 2123
 Miyoshi T, 719
 Mizobuchi H, 1105
 Mizuguchi J, 1519
 Moch H, 361
 Mochizuki T, 571
 Moenig SP, 4113
 Mohamad N, 2953
 Mohammad R, 2885
 Möhler H, 631
 Mohring A, 1187
 Moisa A, 1187
 Mokbel K, 2349
 Moku M, 785
 Molema G, 2633
 Molenaar WM, 291
 Molina R, 2011, 4181
 Møllersen L, 2595
 Molls M, 3803
 Molnár A, 859
 Molnár J, 865, 859
 Momparder L, 75
 Momparder RL, 75
 Monaco A, 1303
 Monaco F, 1449
 Monaco M, 1449
 Mondello B, 1449
 Monden M, 3103
 Monden Y, 719
 Monson J, 2353
 Montalbano A, 3775
 Montemurro S, 3837
 Montoya-Fuentes H, 1319
 Moossa AR, 4067
 Moreau JJ, 1249
 Morel F, 2535
 Morelli A, 1255
 Morelli O, 1255
 Moreno-Villa H, 1319
 Morgan RJ, 2853
 Mori K-I, 3757
 Mori T, 2209
 Morice P, 2535
 Morigi R, 203
 Morimura K, 785
 Morini S, 1603
 Morisaki T, 675, 1071
 Morishita T, 3723
 Morita T, 1039
 Moriya Y, 3295
 Morrin M, 489
 Morris C, 1275
 Morris DL, 339
 Moschovi M, 3945
 Motl S, 1239
 Motohashi N, 1481, 3917, 3939
 Mougel L, 935
 Moutel K, 1207
 Mouzas I, 833, 2117
 Mrazovac D, 3251
 Mucsi I, 865
 Mukae H, 4051
 Mukohara T, 11
 Mulder NH, 1217, 1969, 2579, 4237
 Muley T, 1953
 Muley Th, 3193
 Müller JM, 921
 Munck-Wikland E, 1829, 3109
 Münz M, 3715
 Murakami T, 1135, 1525, 1905
 Murata T, 2431
 Murayama C, 625
 Murdter TE, 1187
 Murillo G, 3049
 Murray D, 489
 Murua Escobar H, 707
 Musolino A, 1495
 Mustea A, 1223
 Mutschler W, 3743
 Muzzonigro G, 1179
 Mýller SC, 2869
 Mytar B, 2287
 Myrquez M, 1347
 Nabeya Y, 2483
 Nabiev I, 1745
 Nacciarriti D, 3257
 Nacey JN, 2069
 Nacsá J, 865
 Nádasi E, 3997
 Nadrowitz R, 2841
 Nagamune H, 3367
 Nagamyune H, 3343
 Nagao M, 1569
 Nagasawa H, 2209, 2975, 3361
 Nagashima N, 3239
 Nagasue N, 1823
 Nagata K, 2975
 Nagata N, 3239
 Nagayasu T, 111, 1925, 2541
 Nagel H, 4121
 Nagengast FM, 843
 Nagira K, 1307, 2007
 Nagy K, 1817
 Nakabayashi H, 1105
 Nakagawa T, 4135
 Nakagoe T, 111, 2541
 Nakai E, 1105
 Nakaike S, 3009
 Nakajima M, 777, 1911, 3029, 3703, 4091
 Nakajima Y, 1569
 Nakajo A, 2123
 Nakamine H, 259
 Nakamoto T, 1823
 Nakamura A, 4097
 Nakamura K, 3141
 Nakamura M, 547
 Nakamura S, 273
 Nakamura T, 625
 Nakamura Y, 259
 Nakanishi M, 1113
 Nakano K, 675, 711, 737, 755, 2047
 Nakano T, 107
 Nakano Y, 3103
 Nakao A, 3731
 Nakao K, 2471
 Nakase Y, 1113
 Nakashima H, 1071
 Nakashima S, 2123
 Nakata K, 3311
 Nakatani T, 733, 1307, 2007, 2675
 Nakatsuka S-I, 3103
 Nakayachi T, 711, 737, 755
 Nakayama T, 2209
 Nakayama Y, 3239
 Nakazato M, 4051
 Namgung H, 663
 Nanashima A, 111, 2541
 Nano R, 1507
 Naouar C, 441
 Nap RE, 2579
 Napolitano M, 4255
 Nara N, 571
 Nardoni C, 1287, 1963
 Naredi P, 1837
 Naritaka Y, 2385
 Naritoku WY, 2391
 Nasioulas G, 1597, 2547
 Nasir A, 1281
 Natsugoe S, 2123
 Naudé R, 1713
 Navone NM, 2897
 Nehmzow M, 1223
 Németh A, 2557, 3965, 3997
 Nemoto N, 4079
 Neth P, 3743
 Neufing P, 955
 Neuhaus P, 3075
 Neumaier M, 1421
 Neumann R, 1083
 Neuss M, 2237
 Nevanlinna H, 2681
 Neyns B, 2037
 Nezam R, 1421
 Ng EY, 1393
 Ng S-C, 3907
 Nguyen TP, 1637
 Ni J, 3795
 Nieda M, 3303, 3327
 Nieder C, 3803
 Niibe Y, 2097
 Nikiteas N, 2061, 3041
 Nilsson S, 1347

- Ninomiya M, 1843
 Nio Y, 1173, 1879
 Nishi M, 547
 Nishida S, 3103
 Nishiguchi Y, 2213
 Nishikawa H, 711, 737, 755, 1481
 Nishimura R, 1275, 2085
 Nishimura Y, 2185
 Nishiyama M, 1843
 Nishizawa T, 1823
 Nitta Y, 1045
 Noack F, 151
 Nobile MT, 355
 Nobuto H, 1889, 1893
 Noguchi A, 3387
 Noguchi K, 3379, 3387
 Noguchi M, 3757
 Noguchi Y, 2101
 Noh D-Y, 3961
 Nolte I, 707, 3027
 Noma K, 639
 Nomata K, 3757
 Nomura M, 377, 3169
 Nomura Y, 1275
 Nonaka T, 811
 Normanno N, 2985
 Nose T, 1861
 Noshiro H, 1071
 Notarbartolo G, 851
 Notarnicola M, 3837
 Notas G, 833
 Novikova IA, 199
 Nukaya I, 571
 Nuñez M, 2953
 Nuñez-Villar M-J, 1581
 Nuzzo A, 1935
 Nyárády Z, 2557

 Occhipinti E, 2563
 Ochi M, 1889, 1893
 Ochiai T, 2483
 Ochman K, 4259
 O'Connor R, 457
 Oda D, 2153
 Oda M, 3311
 O'Doherty T, 425
 O'Driscoll L, 473
 Oehlschlegel C, 19
 Ogata E, 2665
 Ogawa J, 4073
 Ogawa K, 671, 1045, 1131, 2385, 2423, 3851
 Ogawa S, 1569
 Ogose A, 1039
 Ogura Y, 1045
 Oguri T, 1911, 2893
 Oh SJ, 663
 Ohara T, 3723
 Ohgaki M, 1113
 O'Higgins NJ, 473
 Ohira M, 2213
 Ohki S, 2047
 Ohkura K, 3343, 3367
 Ohno N, 2465
 Ohno S, 1275, 2085, 3335
 Ohno T, 1861
 Ohno Y, 3335
 Ohnoshi T, 3911
 Ohshita A, 639, 1193
 Ohtani S, 3135
 Oi K, 273
 Oji Y, 3103
 Ojima I, 409
 Oka K, 107
 Oka M, 4085
 Oka T, 691
 Oka Y, 3103
 Okabe M, 1683
 Okabe T, 3851
 Okada K, 1553
 Okamoto M, 3295
 Okamura M, 655
 Okazaki Y, 1113
 Okazumi S, 2483
 O'Keefe J, 405
 Okumura H, 2123
 Okuyama N, 2085
 Olasz L, 2557, 3997
 Olbert P, 2225
 Oleksijew AX, 2697
 Oliani C, 2107
 Olive MC, 2897
 Olsson H, 2681
 Oltersdorf T, 2697
 Omori H, 1879
 Ono H, 377, 699, 3169
 Ono K, 2975
 Ono M, 3009
 Onuma E, 2665
 Opolski A, 3991
 Opri F, 1223
 Orbach Arbouys S, 2689
 Ørbo A, 3749
 Orino K, 4073
 Orlandi M, 1779
 Orlando L, 1261
 Orlova A, 4035
 Orsós Z, 3965
 Ortiz-Lazareno PC, 2689
 Osada H, 547
 Osaka E, 4079
 Osaka S, 4079
 Osaki M, 1439
 Osaki T, 3065
 Osawa H, 3703
 Oshibe N, 671
 Öst Å, 3121
 Osti FM, 4045
 Otani Y, 2201, 2455, 2723
 Otis CN, 139
 Otsuji E, 2477
 Otsuka Y, 377, 3169
 Ottaiano A, 4255
 Oxelmark L, 3121
 Oyama K, 649
 Ozaki M, 273
 Ozaki T, 1721
 Özcelik T, 2547
 Ozeki M, 2657

 Paavo P, 4247
 Pace A, 2563
 Pace L, 4109
 Pace MC, 4109
 Pacetti U, 1963
 Padovani M, 2107
 Pagalou-Thoua E, 1957
 Pagano D, 3221
 Pageau S, 1361
 Paija OMM, 1271
 Pajkos G, 3965
 Palagianio A, 4109
 Palazzo J, 3161
 Pállinger É, 1657
 Pallis AG, 2117
 Palmieri G, 4175
 Pan O, 3049
 Pan Q-J, 3245
 Pan XQ, 3005
 Panagiotou P, 1947
 Panani AD, 155, 2967, 3857, 4141
 Panico L, 317
 Pannone G, 1063
 Panosyan EH, 1121
 Papaconstantinou I, 1311, 1597, 3041
 Papadimitriou E, 2941
 Papadopoulos S, 1445
 Papadopoulou E, 2547
 Papalambros E, 2061
 Papaldo P, 1963
 Paparelli C, 269, 1921
 Papaxoinis C, 4141
 Papoff G, 851
 Paradis R, 2169
 Parameshwar S, 1337
 Pardo FS, 2359
 Paredes B, 19
 Park JC, 1671
 Park KC, 1105
 Park K-Y, 91
 Park S-J, 123
 Park S-J, 2331
 Parkinson M, 473
 Pascu ML, 2925
 Pascu R, 2925
 Pasini J, 3251
 Pasqualini JR, 1433
 Passavanti MB, 4109
 Passera R, 2041
 Passerini R, 1261
 Pastore D, 791
 Pastrone I, 355
 Patsouris E, 2061
 Patterson RH, 1417
 Paulsen JE, 1465, 2595
 Pautke C, 3743
 Pavia R, 1449
 Pavillard V, 579
 Pazaiti A, 3041
 Pazzaglia L, 967
 Pecher G, 821
 Pectasides D, 1947
 Pederzoli P, 2107
 Pei P, 2773
 Peifer C, 1545
 Peiper M, 1053
 Peldszus R, 973
 Peoc'h K, 1507
 Péoc'h M, 1993
 Perabo FGE, 2869
 Percivale PL, 355
 Perego MS, 4223
 Pergola-Becker G, 4211
 Perren A, 2415
 Perrone Donnorso R, 4169
 Perrone F, 2985
 Persichetti P, 3157
 Perut F, 1705
 Pescia S, 4223

- Peters WHM, 843
 Petrakopoulou T, 1947
 Pfisterer J, 929
 Pfragner R, 495
 Philippe J-C, 1433
 Piao BK, 303
 Piazza G, 1805
 Picci P, 967
 Pichon M-F, 1083
 Picht T, 1143
 Piekarska B, 2287
 Pieramici T, 1063
 Piga A, 2487
 Pignatelli M, 1369
 Piitulainen E, 241
 Ping Dou Q, 943
 Pino MS, 1963
 Piotrowski Z, 2847
 Pisani T, 1111
 Pistilli A, 2729
 Pittman HK, 605
 Pizzi G, 1093
 Pizzolitto S, 2487
 Plukker JTM, 1217, 2579
 Pluot M, 1745
 Pöckl S, 3715
 Poggi A, 3811
 Poggi G, 2419
 Pohlen U, 1699, 3275
 Polimeni MA, 2567
 Polychronopoulou S, 3945
 Polymeris M-E, 43
 Polytarchou C, 2941
 Polyzos A, 1947
 Pons M, 1315
 Ponticelli F, 967
 Popalis C, 43
 Poremba C, 1721
 Portella J, 1315
 Porwit A, 2375
 Porzio G, 219
 Pós Z, 1657
 Posekany KJ, 605
 Possinger K, 895, 3233
 Postma TJ, 2337, 2511
 Potti A, 333
 Poulsen AL, 1733
 Powell B, 3215
 Powlas J, 2697
 Prades JM, 1993
 Pras E, 345
 Prevost A, 1207
 Pricci M, 3837
 Prinz B, 895
 Prisack JB, 2861
 Profanter C, 1049
 Prommegger R, 311, 1049
 Puchner MJA, 4195
 Puettmann S, 2913
 Puglisi F, 2487
 Puhalla H, 1201
 Puhl A, 361
 Pulkkinen J, 3769
 Purcell R, 473
 Pürstner P, 495
 Pyrhönen S, 2519
 Qiao Y-L, 3245
 Qin J, 2991
 Qiu D, 2431
 Quentin T, 1011, 2745
 Raaphorst GP, 613
 Rabinovich-Chable H, 1387, 3977
 Rabitti C, 3157
 Radice P, 1239
 Raffetto N, 349
 Raffo P, 1255
 Ragazzini P, 967
 Raghuwanshi R, 1281
 Ragona L, 227
 Rahko E, 4247
 Raitanen M, 1347, 3769
 Rallo L, 1315
 Ramaswamy A, 1785
 Rambaldi M, 203
 Ramírez-Expósito MJ, 801
 Ranger GS, 2349
 Rao S, 3065
 Rappaport J, 2585
 Raptis SA, 155, 2967, 4141
 Rasmussen LM, 3735
 Rath W, 2237
 Rathcke IO, 2161
 Rathmell WK, 167
 Ratnam M, 3005
 Ratnasinghe LD, 3177
 Rausa L, 851, 3875
 Rea S, 1935
 Recchia F, 1935
 Reddy S, 2885
 Ree AH, 555
 Reed E, 1973, 2991
 Reerink O, 1217, 1969
 Rehemtulla A, 1393
 Reichel WH, 587
 Reichelt KL, 587, 1465
 Reichelt WH, 1465
 Reilly RT, 2879
 Reiß G, 281
 Ren M, 2879
 Repousis P, 1957
 Reszka R, 1699
 Reusch P, 2353
 Reza MD Morshed S, 711, 737, 755
 Rhee JG, 1377
 Ricevuto E, 219
 Richter A, 707, 3027
 Riedel F, 2179
 Riesenbeck D, 1637
 Rigaud M, 1387, 3977
 Ring-Larsen H, 1981
 Rinner B, 495
 Rishi AK, 2885
 Risteli J, 1057
 Risuleo G, 791
 Rivera E, 2953
 Rizell M, 1837
 Ro S, 3269
 Robert J, 579, 3781
 Roberts C, 1797
 Robertson FM, 2773
 Robustelli Della Cuna FS, 227
 Robustelli Della Cuna G, 227
 Rocchi P, 1779
 Rodes J, 1315
 Rodler I, 807, 3965
 Roelofs HMJ, 843
 Roesel C, 2861
 Rogalla P, 707
 Rogan EG, 117
 Roh SA, 663
 Romagnoli F, 4169
 Romeike BFM, 981, 3971
 Romiti A, 1603
 Ronot X, 725
 Ropolo M, 3811
 Rose D, 3161
 Roselli M, 3129
 Rosen BR, 2359
 Rosenau A, 929
 Rosenberg S, 3907
 Rossi A, 317, 1873
 Rossi O, 3811
 Rossi S, 2093
 Rossiello L, 1897
 Rossiello R, 1897
 Rössing C, 1797
 Rosso R, 355
 Rost T, 2161
 Rosty C, 3283
 Roth MJ, 3245
 Roth S, 59
 Rouanet P, 53
 Rouleau-Dubois C, 53
 Roussidis AE, 1445, 4025
 Roussos C, 2967
 Roussos CH, 3857, 4141
 Roussou P, 1243, 2027
 Rubenstein M, 2601
 Ruberti L, 851
 Rubini C, 1063
 Rubio CA, 1765, 2033, 2113, 3185, 4187
 Ruess A, 325
 Ruggiero I, 2287
 Ruiz-Avila I, 3225
 Rüschoff J, 361
 Russo FP, 219
 Russo G, 1255
 Ruutu M, 2627
 Ryan MF, 2281
 Rydén L, 371
 Ryoma Y, 3295
 Ryu J, 4079
 Ryu JH, 663
 Ryu JS, 663
 Ryu S-Y, 2331
 Sabatino G, 1255
 Sacchi I, 1963
 Sacchi N, 2879
 Sadahiro S, 625
 Sadick H, 2179
 Sadowski M, 973
 Saeger H-D, 281
 Safa AR, 123
 Sager G, 3749
 Saggio G, 1935
 Saguchi T, 625
 Saha B, 2391
 Sahmoun AE, 3115
 Saijo K, 1861
 Saikawa Y, 2201, 2455, 2723
 Saiki I, 3009
 Saini N, 1417
 Saito H, 1853, 2665

- Saito M, 3295
 Sakagami H, 655, 683, 711, 737, 755, 1481, 3917, 3939,
 Sakai M, 1683
 Sakakura C, 1113
 Sakamoto J, 1843
 Sakamoto S, 2209
 Sako T, 3239
 Sakurai H, 811
 Sakurai Y, 2975
 Sakuramoto S, 4163
 Salas J, 2011
 Salesi N, 1093, 1287
 Salgami E, 1243
 Salgia R, 1031
 Salim EI, 785
 Salminen EK, 1271
 Samaila D, 3089
 Samata K, 3009
 Samnick S, 3971
 Sándor J, 3965
 Sandri MT, 1261
 Sanguedolce G, 3875
 Sanguedolce R, 3875
 Sanguineti O, 355
 Sano M, 1275, 4079
 Santala M, 1057
 Santarelli JG, 1
 Santarelli M, 349
 Sapundzhiev N, 1785
 Sarcina I, 1603
 Saremaslani P, 19, 2415
 Sarkadi B, 449
 Sarkar FH, 2885
 Sarna G, 1239
 Sasaki H, 3361
 Sasaki N, 675, 1071
 Sastre-Garau X, 3283
 Sato K, 2665
 Sato M, 3295
 Sato T, 1053
 Sato Y, 1045
 Satoh K, 1481, 3917, 3939
 Satriano RA, 1897
 Sattler B, 4191
 Sauper T, 1049
 Savarese A, 1287
 Savci D, 1999
 Savelli L, 2073
 Savio G, 1139
 Sawada S, 1929
 Sawai M, 2213
 Sawai T, 2541
 Sayek I, 2547
 Scala S, 4255
 Scanabissi F, 1779
 Scanlon KJ, 425, 473, 501
 Schaaf A, 2303
 Schackert HK, 281
 Schad A, 325
 Schaefer U, 2913
 Schäfer K-L, 1721
 Schallier D, 2037
 Schanbacher BL, 2773
 Scheurer L, 631
 Schieker M, 3743
 Schiffer D, 2643
 Schillaci A, 265, 269, 3153
 Schilling A, 1143
 Schirner I, 385
 Schirren J, 4147
 Schlatterer K, 631
 Schlott T, 981, 1011, 2141, 2745, 3819
 Schmid S, 2415
 Schmidt DH, 2869
 Schmidt H, 151
 Schmidt S, 2861
 Schmidt-Gayk H, 3193
 Schmitt B, 887
 Schmitt M, 4147
 Schnabel S, 895
 Schneider E, 2231
 Schneider HB, 1091
 Schneider J, 1581
 Schneider P, 1699, 4113
 Schniewind B, 827
 Schoenfel N, 1211
 Schoenlein P, 3065
 Schraml P, 361
 Schubert S, 1025
 Schuck A, 1637
 Schueller P, 2913
 Schüle R, 921
 Schulz S, 1785
 Schulze S, 2617
 Schumacher G, 3075
 Schumacher U, 1421
 Schuster G, 3065
 Schwab B, 1127
 Schwaller B, 4003
 Schwartz GG, 3115
 Schwartz M, 1733
 Schweyer S, 3819
 Scott-Algara D, 2689
 Scozzafava S, 2439
 Sebastiani V, 4169
 Sebestyén A, 1817
 Sedlaczek P, 1149
 Seeram NP, 2783
 Segawa Y, 3911
 Sehoul J, 1223
 Seibel NL, 1121
 Sekara E, 1243
 Sekido M, 161
 Sekikawa K, 1045, 2047
 Sekine T, 2423
 Semiglasov VF, 1293
 Sengpiel V, 2161
 Senner V, 2913
 Serafin A, 763
 Serke M, 1211
 Serpico R, 1063
 Sersa G, 2343
 Sesterhenn A, 1785
 Sevinç A, 2547
 Sewell PE, 339
 Shabbir M, 2853
 Shagisultanova EI, 199
 Shaker S, 75
 Shan B, 79
 Shang G, 483
 Shao J-Y, 2309, 4059
 Shen J, 785
 Shen Y-Y, 4103
 Shetye JD, 2375
 Shi W, 213
 Shi Y, 2697
 Shiba E, 2085
 Shibaguchi H, 3355, 3373
 Shibao K, 3239
 Shibasaki S-I, 2541
 Shibata Y, 1925
 Shibayama T, 3911
 Shibukawa G, 1045
 Shih H-C, 3843
 Shimada H, 377, 2483, 3169
 Shimada J, 655
 Shimakawa T, 2385, 2423
 Shimao H, 4163
 Shimizu K, 1105
 Shimizu N, 2423
 Shimizu T, 3851
 Shimomura K, 1113
 Shimose S, 1889, 1893
 Shimozato O, 79, 2713, 3763
 Shin BA, 747
 Shin E, 1275
 Shin HJ, 3961
 Shioyama Y, 3141
 Shiozawa S, 671
 Shiozawa T, 3843
 Shiraishi T, 2431
 Shirakata T, 3103
 Shirane M, 1113, 3731
 Shirataki Y, 1481
 Shiratori T, 2483
 Shishodia S, 2783
 Shoemaker AR, 2697
 Sholes K, 333
 Shouji H, 3367
 Shun C, 1677
 Sica G, 2729
 Sidorenko YS, 199
 Sieg P, 2841
 Siegel SE, 1121
 Siegl V, 495
 Siegle I, 1187
 Siemann DW, 213
 Sigala F, 3041
 Sigal-Zafrani B, 3283
 Sikes CR, 2897
 Silberman S, 3887
 Silengo L, 2643
 Silva RR, 3257
 Silverberg G, 1
 Simon MC, 167
 Simone P, 3157
 Simonetti G, 3129, 4175
 Singer CF, 1127
 Singh NP, 2277
 Singh R, 1031
 Singuaroli I, 227
 Sismanidou K, 3239
 Sivridis L, 3239
 Sjöqvist U, 3121
 Sjöström A, 4035
 Skarin AT, 1031
 Skarlos D, 1947
 Skokowski J, 4259
 Skrzydlewska E, 2847
 Skubis J, 4191
 Skyrlas A, 3081
 Slack JE,
 Slaney DP, 2551
 Slevin M, 1337
 Slotman BJ, 2511
 Sluiter WJ, 1217, 4237
 Smith ML, 1401
 Smith PV, 1281

- Sobrero A, 2487
 Sohda M, 3029, 4091
 Sohn C, 1987, 4205
 Solberg Landsverk K, 555
 Soleiman A, 1127
 Soller JT, 3027
 Solomayer E, 1987, 4205, 4211
 Solomayer-Meyberg G, 4205
 Soma E, 3781
 Soma G-I, 1823, 3311, 3335
 Someno T, 1561
 Somma P, 249
 Son H-Y, 2331
 Song H, 1973
 Soosaipillai A, 43
 Sorrentino R, 4109
 Soruri A, 2141
 Šošić H, 3251
 Sosinska-Mielcarek K, 4259
 Sotlar K, 4211
 Soubeyran I, 579
 Souglakos J, 4217
 Spengler G, 859
 Spiess E, 4147
 Spijkervet FKL, 3263
 Spitz DR, 2657
 Spreer A, 4121
 Squillaci E, 4175
 Stachura J, 3203
 Stagos D, 743
 Staibano S, 249, 1063
 Staicu A, 2925
 Staples J, 3065
 Stefano R, 1139
 Stefanou D, 1665
 Steger GG, 1127
 Steinacker A, 3203
 Steiner P, 1049
 Steinke K, 339
 Stella F, 1603
 Stendel R, 631, 1143
 Stepula VV, 1293
 Steven K, 1733
 Stevens PJ, 161
 Stipa F, 1167
 Stokman MA, 3263
 Stoll M, 37
 Stoltzfus P, 3109
 Straubinger RM, 397
 Strauß F, 1797
 Strebhard K, 3881
 Strianes D, 249
 Strigård K, 2375
 Strik HM, 37, 4121
 Strohmeyer D, 1797
 Strongin AY, 199
 Strugnell SA, 2905
 Stucker I, 2021
 Sturtz F, 1387, 3977
 Su C-T, 4103
 Sugano H, 3185
 Suganuma K, 2723
 Sugeno H, 1045
 Sugi K, 1525
 Sugimasa Y, 2101
 Sugimoto Y, 91
 Sugimura K, 733
 Sugimura Y, 2431
 Sugita H, 4079
 Sugita T, 1889, 1893
 Sugitani M, 4079
 Sugiura T, 2723
 Sugiyama H, 3103
 Sugiyama K, 711
 Sugiyama M, 4097
 Sugiyama T, 1045
 Sui M, 27
 Sukhanova A, 1745
 Sun C-A, 3863
 Sun L, 179
 Sun Z, 1159
 Sura M, 2765
 Suzuki H, 1519, 2431, 3723
 Suzuki M, 1941, 2975
 Suzuki N, 3335
 Suzuki S, 2047
 Suzuki Toshio, 1553
 Suzuki Toshiyuki, 625
 Swanson MS, 605
 Swarts JC, 763
 Sweeney CJ, 2135
 Switala-Jelen K, 3991
 Syper D, 3991
 Syrigos KN, 1243, 2027
 Syrjänen K, 2627
 Syrjänen S, 2627
 Szabo BG, 1217, 1969
 Szentpétery Zs, 449
 Szpaderska AM, 3887
 Tabata M, 393, 3893, 3911
 Tachibana H, 1683
 Tada Y, 2713
 Tagawa M, 79, 2713, 3763
 Tagawa Y, 111, 1925
 Takada Y, 2783
 Takagi T, 1113
 Takahara M, 3327
 Takahashi H, 3757
 Takahashi K, 691
 Takahashi Takeo, 107
 Takahashi Toshiaki, 1911, 2893
 Takahashi Y, 719, 3141
 Takakura N, 1843
 Takano S, 1861
 Takayama Y, 3135
 Takebayashi Y, 1045, 2047
 Takeda A, 3869
 Takemiya S, 2101
 Takemoto H, 273
 Takemura M, 1113
 Takenaka Y, 4135
 Takenoshita S, 1045, 2047
 Takesako K, 571
 Takeuchi Y, 699
 Takeyama H, 1135, 1905
 Takigawa N, 3911
 Takiguchi K, 1823, 3311
 Takiguchi S, 3103
 Takiguchi Y, 2713
 Takita J, 4091
 Takiyama W, 1843
 Talvensaari-Mattila A, 4247
 Tamae D, 2657
 Tamano H, 3869
 Tamesa T, 4085
 Tamimi Y, 3057
 Tammela T, 1347
 Tamussino K, 2053
 Tanabe K, 1409
 Tanaka Haruyuki, 1889, 1893
 Tanaka Hitoshi, 619
 Tanaka Kenji, 111, 2541
 Tanaka Kumi, 1889, 1893
 Tanaka Makoto, 3009
 Tanaka Masao, 675, 1071
 Tang B, 1973
 Tang J, 1361
 Tang M, 67
 Tang Y, 1973
 Tangrea JA, 3177
 Tani N, 2477
 Tanigawa N, 1929
 Tanimoto M, 393, 1525, 3893, 3911
 Tao D, 2991
 Tarabishi R, 2193
 Tarpin M, 935
 Tasaki A, 1071
 Tatebe S, 1853
 Tatsumi K, 2713
 Taubert H, 3819
 Tava A, 227
 Taveggia P, 355
 Taylor CR, 2391
 Taylor DD, 795
 Taylor PR, 3177, 3245
 Taylor S, 133
 Tempfer C, 1267
 Ten Hagen TLM, 2243, 2295
 Tendulkar K, 333
 Tenna S, 3157
 Terada H, 3311
 Terada K, 1045
 Teragni C, 2419
 Teramoto N, 691
 Teshima T, 3141
 Testa E, 3257
 Testa N, 1063
 Tez M, 2547
 Theocharis AD, 1445, 4025
 Thole HH, 1433
 Thomas D, 1651
 Thomas S, 2265
 Thomas V, 2349
 Thomke SE, 361
 Thompson CS, 2853
 Thyphronitis G, 2443
 Tilanus HW, 1369
 Tilley WD, 955
 Tischer T, 3743
 Tiziano G, 1921
 Tocchi A, 2439
 Toga T, 1173
 Toge T, 639, 1193, 1409, 1843
 Tokojima M, 4051
 Tokuda K, 2123
 Tokunaga T, 547
 Tolmachev V, 4035
 Tolomeo N, 851
 Toma S, 1255, 4019
 Tomaino A, 1449
 Tomao S, 1603
 Tombolini V, 349
 Tomek S, 1127
 Tominaga T, 2085
 Tomita K, 4067

- Tomiyama M, 3327
 Toriumi F, 2455, 2723
 Toriyama M, 4079
 Tory K, 2237
 Tóth J, 2219
 Touliatou V, 3945
 Touloupidis S, 3239
 Toy BJ, 3089
 Toyonaga S, 1105
 Trachiotis DG, 1417
 Trafalis D, 1077
 Tranfa F, 249
 Tregnaghi A, 2531
 Tregouet D-A, 2021
 Trempus CS, 2773
 Trevisiol L, 1063
 Trias M, 2011
 Tribukait B, 3121
 Trojan L, 1651, 2303
 Truan D, 4181
 Tsangaris GTH, 3945
 Tsao SW, 881
 Tsao-Wei DD, 2391
 Tse V, 1
 Tsintavis A, 1957
 Tsoli E, 2061
 Tsoutsos D, 1947
 Tsuboi A, 3103
 Tsuboi K, 1861
 Tsuchiya A, 671
 Tsuchiya H, 4067
 Tsugu A, 547
 Tsui P, 2601
 Tsuji T, 2541
 Tsujitani S, 1853, 2495
 Tsukada K, 4091
 Tsukino H, 2431
 Tsunenari T, 2665
 Tsuneyoshi M, 1071
 Tsunoda A, 2471
 Tsunoda Y, 2471
 Tsurudome K, 3239
 Tucker ET, 1369
 Tunn P-U, 145
 Turgut Turoglu H, 1999
 Turhal NS, 1999
 Turley ML, 2551
 Turpeenniemi-Hujanen T, 4247
 Tyring S K, 807
 Ueda Y, 3009
 Uematsu T, 619
 Ueno N, 2483
 Ueoka H, 393, 3893, 3911
 Ueyama Y, 547
 Uges DRA, 3263
 Ugocsai K, 865
 Uitdehaag BMJ, 2511
 Ukegawa J-I, 699
 Ulmsten U, 873, 3983
 Umehara A, 1131
 Umemori Y, 1905
 Umezu K, 3367
 Unger C, 1759
 Uno T, 2483
 Unten S, 683
 Urasinska E, 963
 Urben CM, 2905
 Ursone A, 3129
 Uto Y, 2975, 3361
 Vaghi M, 4223
 Vaingankar S, 311
 Valatas V, 833
 Valenzuela MT, 801
 Valeriani M, 349
 Vályi-Nagy I, 1817
 Vamvakas L, 4217
 Van Dalen A, 1149
 Van De Venter M, 1713
 Van De Vijver MJ, 2931
 Van De Wouw AJ, 297
 Van Den Berg E, 291
 Van Der Graaf WTA, 291, 2079
 Van Der Linden PJQ, 771
 Van Der Logt EMJ, 843
 Van Der Zee AGJ, 345
 Van Etten B, 2295
 Van Horssen R, 2243
 Van Laar ES, 59
 Van Lieshout EMM, 843
 Van Luyn M, 2633
 Van Meter A, 441
 Van Nagell JR, 539
 Van Rensburg C, 763
 Van Tiel ST, 2295
 Vandertop WP, 2511
 Vandooren C, 2265
 Váradi A, 449
 Vardakis N, 4217
 Varga A, 859, 865
 Varga Z, 2225
 Varotto L, 2531
 Varvaesou A, 907
 Vasilevich NI, 179
 Vassy R, 4011
 Vaughn DJ, 167
 Vázquez-Camacho G, 1319
 Vecchione A, 1093, 1111, 1287, 2439, 3147
 Venat L, 1249
 Ventéo L, 935
 Verbanac KM, 605
 Vergani L, 4019
 Verheggen R, 981
 Verlengo MC, 2041
 Verschraegen CF, 1327
 Verschueren RCJ, 1217
 Verstappen CCP, 2337
 Vetvicka V, 2739
 Vetvickova J, 2739
 Zezeridis MP, 2617
 Viale G, 1261
 Vibits H, 1733
 Vidiri A, 2563
 Vincent-Salomon A, 3283
 Virtanen AM, 1271
 Visca P, 4169
 Vissac-Sabatier C, 321
 Voicu L, 2925
 Volm M, 4243
 Volpino P, 265, 269, 1495, 2439
 Vormoor J, 1637
 Vos MJ, 2511
 Vos P, 4127
 Vougiouka M, 2193
 Voutsinas G, 2547
 Vozza A, 1897
 Wachtters FM, 2079, 3263
 Wada A, 2713
 Wadleigh R, 1417
 Wagatsuma Y, 2385
 Wagenius G, 1915
 Wagner TE, 2717
 Wågsäter D, 3711
 Wai D, 1721
 Wakabayashi H, 3917, 3939
 Wakae M, 1481
 Wakahara Y, 2665
 Wallmark A, 241
 Wallner F, 2947
 Wallwiener D, 1987, 4205, 4211
 Walters R, 3161
 Walz A, 887
 Wanebo HJ, 2617
 Wang D-Y, 83
 Wang Gangduo, 1973
 Wang Guanyu, 187, 1689, 1813
 Wang H, 67
 Wang J, 1361
 Wang Jieyi, 3899
 Wang Jinwei, 1353, 3699
 Wang Joann, 139
 Wang L, 1973
 Wang Q, 881
 Wang RC, 3089
 Wang T, 2657
 Wang X, 881
 Wang YX, 303
 Wang Z, 943
 Wanibuchi H, 11, 785
 Wargnier R, 1745
 Wargovich MJ, 1805
 Waring P, 955
 Wataha J, 3065
 Watanabe G, 649
 Watanabe J, 2185
 Watanabe J-I, 2201
 Watanabe Kiyo, 1131
 Watanabe Kumiko, 1045
 Watanabe Masahiko, 2201, 2455, 4163
 Watanabe Masatoshi, 2431
 Watanabe O, 671, 3851
 Watanabe T, 1275
 Watermann D, 1267
 Waters SJ, 59
 Wattchow D, 955
 Wattiez R, 2265
 Weber B, 763
 Weber-Dabrowska B, 3991
 Wei M, 785
 Wei Q-Y, 999
 Wei W-Q, 3245
 Wei Y, 2717
 Wei YH, 1753
 Weimer J, 929
 Wein A, 385
 Weinstein P, 2069, 2551
 Weise JB, 929, 1025
 Weisser CW, 921
 Weitman S, 59
 Welch DR, 1003
 Wellmann A, 1791
 Werle B, 4147
 Wernecke K-D, 895

- Werner JA, 1785
Werner JA, 973, 2161
Werner N, 2633
Westin U, 241
Whelan LC, 2281
White MK, 2585
Whitehead C, 1805
Wickenhauser C, 4113
Wieckhorst W, 929
Wiedenmann N, 3803
Wiencke JK, 2011
Wietrzyk J, 3991
Wigington DP, 2905
Wijnhoven BPL, 1369
Willemse PHB, 345
Williams P, 1361
Willich N, 1637, 2913
Wiltshcke C, 1127
Windhövel U, 3789
Windisch J, 3209
Winkelmann W, 1721
Winkler S, 707, 3027
Winter RN, 1377
Wirger A, 2869
Wójcik E, 1149
Wolfram N, 2861
Wolin E, 1239
Wollenberg B, 887
Wollscheidt V, 1791
Woloszyn M, 2287
Wong YC, 881
Word B, 133
Wozniak A, 4259
Wrba F, 1201
Wu C-C, 3863
Wu C-H, 123
Wu L-H, 1617
Wu M-H, 3863
Wu Q-L, 4059
Wu Y, 3795
Wyche JH, 999

Xidakis C, 833
Xie GR, 303
Xu M, 4067
Xue W, 881

Yabuta N, 2665
Yacoub GM, 43

Yagawa H, 2385
Yagi S, 1353
Yamachika E, 2153
Yamada H, 2705
Yamada K, 1683
Yamada Y, 2201
Yamada-Okabe H, 2665, 4085
Yamagishi H, 1113, 2477
Yamagishi T, 3009
Yamaguchi H, 111, 2541
Yamaguchi K, 571, 1853, 2495
Yamaguchi T, 1193, 2423
Yamaguchi Y, 639
Yamamoto A, 571
Yamamoto H, 3103
Yamamoto K, 2423
Yamamoto Naoyoshi, 1941
Yamamoto Norio, 4067
Yamamoto Tetsuji, 1307, 2007, 2675
Yamamoto Tetsuya, 3065
Yamamoto Yoshifumi, 4135
Yamamoto Yukiyo, 1481
Yamanaka N, 1071
Yamane H, 1525
Yamane N, 273
Yamaoka M, 619
Yamasaki M, 1683
Yamauchi K, 4067
Yamauchi S, 11
Yamazaki H, 547
Yamazaki N, 571
Yanagi S, 4051
Yanagisawa A, 3185
Yanase N, 1519
Yang C-C, 1501
Yang D-M, 1617
Yang DP, 613
Yang J, 2897
Yang J-H, 1501, 1753
Yang J-S, 1769
Yang L, 999
Yang L-X, 3269
Yang M, 1353, 3699, 4067
Yang S-D, 1489
Yang X, 1159

Yang Z, 1973
Yannoukakos D, 2547
Yano H, 111
Yano M, 3103
Yano S, 1879
Yanoma S, 2101
Yao D, 1973
Yao T, 1071
Yashiro M, 2213
Yasuda S, 625
Yasuda T, 3103
Yasumoto E, 711, 737, 755
Yasutake T, 2541
Yatani R, 2431
Yeger H, 987
Yeh K-T, 1645
Yeh P-Y, 3035
Yeh S, 3795
Yehia M, 1179
Yiotis J, 2061
Yokoe I, 3019
Yokomizo H, 1131
Yokoyama K, 3917, 3939
Yoneda T, 1361
Yoon JH, 1671
Yoon W-K, 2331
Yoshida A, 3311
Yoshida H, 259
Yoshida K, 1131, 1409
Yoshida M, 2455
Yoshida Y, 1843, 4079
Yoshikawa J, 11
Yoshikawa T, 2101
Yoshimatsu K, 671, 1131, 2423, 3851
Yoshimoto Y, 1561
Yoshimura N, 11
Yoshino T, 691
You S-L, 3863
Younes M, 2919
Yousef GM, 43
Yu C-P, 3863
Yu C-S, 1677
Yu CS, 663
Yu J-C, 3863
Yu L, 79
Yu X, 2717
Yüce MA, 2053
Yukawa N, 2101

Yulug IG, 2547
Yung Y, 1

Zacharatos P, 3041
Zagorianakou N, 1665
Zagorianakou P, 1665
Zalán Z, 1631
Zalewski B, 2847
Zavos G, 1311, 1597
Zeidler R, 887
Zelano G, 2729
Zelvyte I, 241
Zembala M, 2287
Zeng L, 67
Zeng Y-X, 2309, 4059
Zeuli M, 3147
Zhang H, 3907
Zhang J, 1973
Zhang JH, 1361
Zhang L, 1159
Zhang N, 2391
Zhang S, 2135
Zhang W, 1973
Zhang Y, 4059
Zhao J, 19, 1973
Zhao Y, 67
Zheng S, 2011
Zheng W, 1361
Zhou R, 397
Zhou Y-F, 2209
Zhu X, 27
Zidane M, 3283
Zielinski CC, 1127
Zimecki M, 3831
Zimmer SG, 539
Zimmerman B, 1011
Zinzindohoué F, 2021
Ziparo V, 1167
Zirilli A, 1449
Zografidis A, 1311, 1597
Zöller G, 2745
Zorzino L, 1261
Zu K, 3795
Zucchetta P, 2531
Zuckerman BM, 139
Zullo A, 1603
Zupo S, 3811
Zurakowski D, 1053
Zwart N, 291

Errata Volume 22, 2002

Volume 22 (2002), page 2275: The name and address of the 6th author should read:

A. ASTERIOU-DIONYSSIOU,
³*Department of Biological Chemistry.*

Errata, Volume 23, 2003

Page 1014: The legend of Figure 2 should read:

Figure 2. *Agarose gel electrophoresis of PCR products showing specificity of real-time RT-PCR. M = molecular weight standard.*

Left column, line 3 should read:

from four PCR reactions containing 0.01, 0.1, 1.0, 10 and 100 attomol.

Left column, line 20 should read:

for generating the standard curves, elongated primers (sense 5'-GGA

Left column, line 31 should read:

x reaction buffer [Tris-HCl (pH 8.7), KCl, (NH₄)₂SO₄, 15 mM MgCl₂],


Page 1022: Left column, line 10 should read:

in an epidemiological case-control study (23). Albeit the number

Contents of issue No. 3C, page 3073: The third author should read: F. D'ANGELO

Errata, Volume 24, 2004


Page 389: Figure 2 should be replaced by:



Pages 649-654: MTHFR C667T should be corrected to MTHFR C677T throughout this article.

Page 1427: The name of the second author should read:
SERGIU-BOGDAN CATRINA (family name: CATRINA).

Page 1497: Figure 1 should be replaced by:



Page 2547: The name of the 11th author should read:
G. VOUSINAS.

Page 3367: The name of the author should read:
KAZUNORI UMETSU.

Page 3561, Abstract no. 314: The authors' names should read:
S. STAIBANO, M. MASCOLO, L. LO MUZIO, G. SALVATORE,
M. DI BENEDETTO, C. MIGNOGNA, E. MEZZA, G. DE ROSA

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy advises that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 1200 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts regarding grammar and style.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods, or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements, and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in «Chemical Abstracts». Standard abbreviations are preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of «Index Medicus» and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216,1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones* (O' Malley BW and Chamnes GC, eds). New York, Plenum Publ Corp. 1973, pp 113-136.

Submission of Manuscripts. An original and two copies of the manuscript (including all photographs and graphs) should be sent to: Dr. J. G. Delinassios, Managing Editor, Anticancer Research, Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.Box 22, Attiki 19014, Greece. A floppy disc should also be submitted indicating the computer-processing program using the text form ASCII FILE. Authors are invited to submit along with their manuscripts a short list of possible reviewers and any previous publications which could facilitate reviewing. Manuscripts should be accompanied by six adhesive labels with the name and address of the Author to whom correspondence should be sent. Only the original copy of the submitted manuscript will be returned to Authors upon rejection. The number of recently accepted manuscripts will be entered in the Anticancer Research page "Author's Service" as soon as a decision has been reached.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Editorial Staff

Managing Editor and Executive Publisher: J.G. DELINASSIOS, Athens, Greece

Assistant Managing Editor: S. AZOUDIS

Production Editor: E. ILIADIS, Athens, Greece

Editorial Office

International Institute of Anticancer Research,

1st km Kapandritiou-Kalamou Rd.,

Kapandriti, P.O.Box 22, Attiki 19014, Greece.

Telephone and Fax: 0030-22950-53389.

Please visit the IAR website: www.iar-anticancer.org

e-mails:

Editor: editor@iar-anticancer.org

Journals: journals@iar-anticancer.org

IAR website: iar@iar-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Annual Subscription Rates 1981, 1982, 1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005: Institutional subscription for Europe: Euro 1530 per volume. Institutional subscription for all other continents: Euro 1630 per volume. Personal subscription for Europe: Euro 740 per volume. Personal subscription for all other continents: Euro 800 per volume. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-23, 1981-2004) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece and should be sent to the Editorial Office.

Correspondence: (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, and general editorial matters) should be directed to Dr. J. G. Delinassios, Executive Publisher and Managing Editor, Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents (Life*

Sciences), *Science Citation Index*, *Index Medicus*, *Biological Abstracts*, *Chemical Abstracts*, *Excerpta Medica*, *University of Sheffield Biomedical Information Service*, *Current Clinical Cancer*, *AIDS Abstracts*, *Progress in Palliative Care*, *Cambridge Scientific Abstracts*, *Cancergram (International Cancer Research Data Bank)*, *MEDLINE*, *Reference Update - RIS Inc.*, *PASCAL-CNRS*, *Inpharma-Reactions (Datastar, BRS)*, *CABS*, *Immunology Abstracts*, *Telegen Abstracts*, *Genetics Abstracts*, *Nutrition Research Newsletter*, *Dairy Science Abstracts*, *Current Titles in Dentistry*, *Inpharma Weekly*, *BioBase*, *MedBase* and *Investigational Drugs Database*.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2005 \$2.00 +0.40.

The Editors and Publishers of the journal ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Editorial Office

International Institute of Anticancer Research,

1st km Kapandritiou-Kalamou Rd.,

Kapandriti, P.O.Box 22, Attiki 19014, Greece.

Telephone and Fax: 0030-22950-53389.

PHOTOCOMPOSITION BY IAR

PRINTED BY A. ELEFTHEROS - ATHENS - GREECE

PRINTED ON ACID - FREE PAPER